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 Abstract 
 
The knowledge that unbound gadolinium was responsible for NSF highlighted the need for 
alternative and safer imaging agents for MRI applications.  Nanoparticles (used in conjunction 
with MRI) were identified as offering the potential and promise, to be safer across a multitude 
of applications; some dedicated for the investigation of specific disease processes.  In 
particular, iron oxide nanoparticles have been considered as offering the greatest possibility as 
an MRI contrast (imaging) agent in both the research and clinical arenas. 
Advantages offered by T10 dextran coated iron oxide nanoparticles include human 
biocompatibility with a safe and known excretion pathway.  The dextran coating can be 
functionalised, thus providing opportunities for creative compounds to be created.  For 
example, experimental work contributing to this thesis has resulted in T10 dextran coated iron 
oxide nanoparticles being radiolabelled with 68Ga – and this is being presented for 
consideration as a potential imaging agent for PET/MRI; that is, 68Ga providing an imaging 
agent effect on PET imaging while the iron oxide component provides simultaneous imaging 
contrast with MRI.  68Ga itself provides an advantage over 99mTc (the most commonly used 
PET imaging agent); it has an improved imaging sensitivity over 99mTc and is less costly to 
generate, requiring 68Ge (a radio-isotope of germainium) and a gallium generator.  The 
clinical benefit to developing iron oxide nanoparticles radio-labelled with 68Ga is also to 
improve the imaging of lymph nodes in oncology patients (as well as a PET/MRI contrast 
agent).  Also presented here are the PET imaging findings, identifying the prostate draining 
lymph nodes, from four prostate cancer patients having had these nanoparticle preparations 
directly injected into their prostate glands.   
xxxix 
 
 Iron oxide nanoparticles can also be loaded into immune cells, in vitro; for this thesis, murine 
dendritic cells (bone marrow derived) and human dendritic cells (monocyte derived) were 
used, as dendritic cells are known to migrate to lymph nodes.   
The combination of iron oxide nanoparticles radiolabelled with 68Ga, and in vitro cell loading, 
offer the potential to re-visit cellular MRI to determine if imaging advances can be made in 
this area. 
To support these achievements and claims, this thesis includes in vitro murine dendritic cell 
and in vitro human dendritic cell studies and also in vivo murine and in vivo human imaging 
studies. 
Chapter 1 provides a review of the literature, identifying; the advantages of iron oxide 
nanoparticles over the limitations of gadolinium based contrast agents; their relevance to MRI 
and also their capabilities of being internalised by certain cells for targeting imaging 
applications.  The overall aims of the thesis are presented. 
Chapter 2 explains in detail the materials used, the methods employed and the physical and 
chemical processes that underpin all of the in vitro and in vivo experiments.  The processes 
used draw upon knowledge from a range of disciplines, including cell biology, immunology, 
chemistry, physics, medical imaging, nuclear medicine and radiopharmaceuticals. This 
chapter describes how the iron oxide nanoparticles were prepared and the radiolabelling 
process used.  The functionalised method used for the T10 dextran coating is explained, thus 
providing attachment sites for either 68Ga or fluorescent markers such as FITC or R-PE for in 
vitro (murine and human) and in vivo (murine) experiments.  Also described are the in vitro 
cellular (murine and human) experimental process with dendritic cells and iron oxide 
nanoparticles, investigating dose dependent and time dependent uptake. 
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 Chapter 3 provides an analysis of the physical characteristics of the laboratory produced T10 
dextran coated iron oxide nanoparticles (using TEM and SEM) and an important assessment 
of how these nanoparticles behaved in a magnetic environment, namely at 1.5T and 3.0T 
clinical MRI environment; calculating and graphing the R2 and T2 relaxivity rate values of 
nanoparticle concentration at a specific TE value and magnetic field strength.  The 
methodology of radiolabelling these nanoparticles with 68Ga is described and the results of 
TLC are provided, demonstrating the levels of bound and unbound 68Ga.  Any effects T10 
dextran coated iron oxide nanoparticles could cause on cell proliferation was assessed with 
PBMC using the MTS assay technique and compared with the effect that Dotarem® (safest 
gadolinium based contrast agent) may have  on these same cells. 
Chapter 4 investigates the characterisation of nanoparticle uptake by murine bone marrow 
derived dendritic cells (GM-CSF and Flt3) in vitro, with dose (concentration) dependent and 
time dependent uptake studies.  These same BM-DCs were observed for apoptotic effects, in 
vitro, using various nanoparticle concentrations over a 24 hour incubation period.  A murine 
CBA kit was used to also ascertain any inflammatory response in these BM-DCs to the 
presence of nanoparticles; assessed using the supernatant from in vitro experiments 
Chapter 5 reports on the characterisation of nanoparticle uptake by human monocyte derived 
DCs, in vitro.  Dose (concentration) dependent and time dependent uptake in CD14+ and 
CD11+ cells were identified.  In vitro supernatant assessment for an inflammatory response 
using a human CBA kit was used.  Dose dependent uptake, in vitro, was also quantified in 
other cells that play varying roles in an immune response; namely PBMC, lymphocytes, 
granulocytes/monocytes.   
Chapter 6 examines in vivo applications of nanoparticle preparations; murine and human.  
Lymphatic drainage to the popliteal and inguinal lymph nodes in C57/BL6 female mice were 
assessed using flow cytometry; following local subcutaneous injection of T10 dextran coated 
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 iron oxide nanoparticles tagged with FITC.  To observe any systemic effects of these 
nanoparticles in these mice, biochemical analysis of blood serum was conducted and 
histopathological assessment performed, using H&E and Perls Prussian Blue, of the heart, 
lungs, liver, spleen and kidneys and PAS staining of the kidneys (to observe the basement 
membrane).  Following footpad injections of T10 dextran coated IONPs tagged with FITC 
and radiolabelled with 68Ga, separate PET and MRI imaging of mice was conducted and on 
both imaging modalities, image contrast effects due to 68Ga (PET) and iron oxide 
nanoparticles (MRI) were identified.  Most importantly, PET imaging results from patients 
(positive for prostate cancer) undergoing insertion of gold seeds (for later radiotherapy 
treatment) having T10 dextran coated IONPs radiolabelled with 68Ga demonstrated observed 
drainage to lymph nodes with the PET component of a PET/CT scanner.  
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1.0 Chapter 1 – Introduction to MRI and nanoparticles 
 
Ever since MRI emerged as a clinical utility in the mid 1980’s, it has continued to be 
exploited in so many ways, creatively, to encounter new clinical frontiers and research 
applications.  What was new and experimental even ten years ago, is now mainstream and 
common place.  MRI has continued to evolve to meet emerging challenges and has 
persistently proven its imaging flexibility in novel approaches to scanning, data collection and 
image reconstruction techniques.  In Australia, from the mid 1990’s, MRI started to become a 
mainstream imaging modality in radiology departments.  This also co-incided with the 
emergence of a new era of medicine; that of patient tailored treatment and therapies.   
MRI scanning often involves the use of contrast media to improve diagnostic capabilities.  
The most commonly used agents are based upon a gadolinium chelation, however, 
alternatives do exist.  Specifically relevant to this thesis, iron oxide nanoparticles have been 
explored as one alternative – not only as an imaging agent for MRI.  Iron oxide nanoparticles, 
coated with dextran, can provide avenues beyond standard MRI imaging.  These include 
radiolabelling with 68Ga as a potential PET/MRI dual modality or bimodal contrast agent.  
Such a radiolabelled nanoparticle could be used to perform an MRI imaging procedure 
analogous to lymphoscintigraphy; thus providing a non-ionising radiation alternative with 
superior spatial resolution.  This thesis will also report that these specific iron oxide 
nanoparticles with a dextran surface layer, are well tolerated by MD-DC; thus opening up 
further imaging possibilities which include targeted imaging. 
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1.1 Magnetic resonance imaging 
 
A typical MRI scanner is comprised of a cylindrical magnet and the most common field 
strengths used currently are either 1.5 T or 3.0 T(1).  Each cylindrical magnet has a bore of 
approximately 60 cm wide and 2.0 m long, for a patient to be positioned within.  This magnet 
is surrounded by gradients coils or bands.  These gradients are immersed in a cryogen bath 
(filled with liquid helium) to reduce electrical impedance, permitting the gradients to carry 
powerful electrical currents to perform functions such as delivering rf energy to the required 
imaging volume, slice selection (axial, coronal, sagittal or oblique) and the encoding of the 
phase and frequency of the emitted rf energy from the imaging volume(1-3).  The rf energy that 
is delivered into the imaging volume has a specific frequency and wavelength to resonate the 
hydrogen nuclei, found in abundance in the human body, in the form of water, fat, proteins 
and carbohydrates.  The MRI scanner also needs to fill k-space creatively so that imaging 
times can be kept to a minimum, while maintaining acceptable imaging quality with spatial 
and contrast resolution appropriate to the anatomy and pathology located within the imaging 
volume – all this is co-ordinated with pulse sequences(3, 4).   
A summary of the fundamental physics of Nuclear Magnetic Resonance (NMR) now follows.  
There are three known types of motion present with respect to the atom.  These are; the 
motion of electrons spinning about their axis; the motion of electrons orbiting the atom’s 
nucleus; and the nucleus itself spinning about its own axis(3-5).  The physics and imaging 
principles of MRI depend upon this third motion – the motion of certain nuclei spinning about 
their own axis and present within biological tissue.  Such nuclei are referred to as being MR 
active nuclei or NMR nuclei(2, 3, 5).  Only nuclei having an odd mass number are NMR nuclei; 
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 where the number of neutrons within the atomic nucleus is greater or lesser than the number 
of protons; thus, such atoms have a net charge.   
Therefore, the motion of the nucleus spinning about its own axis, results in a net spin or 
angular momentum, when compared with the motion of the electrons(3, 6).  Faraday’s law of 
electromagnetic induction associates the three forces of charge, motion and magnetism; and 
clearly defines that when any two of these are present, the third is automatically induced(1-3).  
Hence, MRI active nuclei, possessing net charge and also (spinning) motion; will have 
magnetism referred to as a magnetic moment and this magnetic moment allows such nuclei to 
align themselves with an applied magnetic field(1, 3, 6).  In the clinical setting, this occurs with 
hydrogen nuclei aligning themselves with the main magnetic field of the MRI scanner.  
Hydrogen nuclei have an odd mass number of one, and are abundant in biological tissue. 
Ordinarily, in biological tissue, hydrogen nuclei are randomly oriented.  When placed in an 
MRI scanner, or a strong external magnetic field is applied to the biological tissue, the net 
population of the hydrogen nuclei are aligned with the direction of the applied magnetic 
field(3, 6).  It is the magnetic moments of the hydrogen nuclei that actually align parallel to the 
applied magnetic field(1, 2) and this net alignment results in the net magnetic vector (NMV) 
and is the starting point for the MRI imaging signal(3, 4).  Any pulse sequence used in MRI 
imaging, always firstly interacts with the NMV.  The externally applied magnetic field is 
denoted by Bo on diagrams and in equations(2, 3).   
As each hydrogen nuclei has its own angular momentum and the externally present main 
magnetic field, Bo, induces a further spin on the magnetic moment of the hydrogen nuclei.  
This further spin is termed precession(1, 2, 4, 5) and results in the magnetic moment of hydrogen 
nuclei to form a circular path(2, 3) around, or about, the direction of Bo.  The precessional 
frequency is the speed of the magnetic moment following its precessional path about Bo.     
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The Larmor equation(1-6) is used to calculate the precessional frequency.  The Larmor 
equation is stated as: 
ω0 = Bo x λ      Equation 1.1 
           
  
where: ω0 is the precessional frequency 
 Bo is the main magnetic field strength 
 λ is the gyromagnetic ratio    
The gyromagnetic ratio is specific for a MR active nuclei and defines the relationship between 
the nuclei’s angular momentum and the magnetic moment(1, 5).  The gyromagnetic ratio of 
hydrogen nuclei is 42.57 MHz/T (2, 4).  Therefore, in a standard 1.5 T (value of Bo) MRI 
scanner, the precessional frequency, ω0, of hydrogen nuclei is 63.86 MHz.  This then means 
that for the hydrogen nuclei in the NMV, to be incorporated into an imaging pulse sequence, 
the rf energy from either a Gradient Echo or Spin Echo pulse sequence that is sent into the 
imaging volume, would need to be transmitted with a an equivalent frequency in order to 
cause resonance of these nuclei.  Graphically, Bo, is represented as being in the longitudinal 
plane(1-3).   
The duration of the transmitted rf energy determines the degree of tip or flip of the NMV from 
the longitudinal axis(1, 3, 4).  A Spin Echo pulse sequence always commences with the NMV 
being tipped or flipped exactly 90 degrees from the longitudinal plane to the transverse plane; 
whereas; a Gradient Echo pulse sequence commences with an rf energy pulse that can tip or 
flip the NMV 90 degrees or less (commonly, less than 90 degrees) from the longitudinal 
plane(1-5).         
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 Regardless of whether the initial transmitted rf energy pulse results in a flip angle of 90 
degrees or less, and also regardless if this initial rf energy pulse was delivered by a Spin Echo 
or Gradient Echo pulse sequence; when the rf energy pulse is switched off, the NMV 
(comprised of the net magnetic moments of the net hydrogen nuclei), effected by the main 
magnetic field, Bo, commences to re-align itself with the main magnetic field, Bo (1-6).  For this 
to occur, the hydrogen nuclei need to release the rf energy they have received from the 
transmitted rf pulse; in a process called relaxation(1-3, 5).  As this relaxation process occurs, the 
magnetisation in the longitudinal increases and is referred to as recovery, or longitudinal 
recovery or T1 recovery(1-3).  Simultaneously, the magnetisation in the transverse plane 
decreases and is referred to as decay or transverse decay or T2 decay(1-3).  Longitudinal 
recovery and transverse decay are said to take place independent of each other and this 
independence is due to inhomogeneities or non-uniformities in the magnetic field, T2* 
(pronounced as “T2 star”)(1, 2, 5, 6).  As transverse decay takes place, that is, the transverse 
magnetisation is reduced in magnitude, so too is the signal (induced voltage) in the signal 
receiver coil.  The detection of this signal decaying is the Free Induction Decay (FID)(1-6).  
The echoes generated by this FID is what is measured in MRI imaging.                  
Longitudinal recovery, or T1 recovery, results from nuclei transferring their rf energy to their 
immediate environment lattice and can thus also be referred to as spin-lattice relaxation(1-3, 5).  
The nuclei in the surrounding lattice absorb this rf energy and their magnetic moments 
recover to align with the longitudinal plane, re-forming the NMV.  This recovery rate is an 
exponential process(1, 3, 5).  The T1 relaxation time, is the recovery time constant, which is 
defined as the time taken for 63 %(1-6) of the longitudinal magnetisation in biological tissue to 
recover.      
Transverse decay, or T2 decay, results from the magnetic fields of adjacent nuclei interacting 
with one another and thus, termed spin-spin relaxation(1-3, 5).  The decay or loss in transverse 
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 magnetisation not only is reduced in magnitude, but also results in a loss of coherence of 
nuclei; as magnetic fields of hydrogen nuclei spins within water and within fat, for example, 
with interact with each other differently, even though together, they comprised the NMV 
(along with other biological tissue).  T2 decay is also an exponential process(1, 3, 5).  The T2 
relaxation time of a specific biological tissue, is also a time constant (of decay) and is defined 
as the time taken for 63 % reduction of the transverse magnetisation and only 37 % magnitude 
of transverse magnetisation remaining(1-6).  Only the coherent component of magnetisation in 
the transvers plane is capable of inducing a voltage signal in the receiver coil, however(1-3). 
 
 
1.1.1 Pulse sequences 
 
What exactly is an MRI pulse sequence?  It is effectively a set of instructions, carefully 
designed, to co-ordinate equipment involved with the generation, delivery, detection and 
reconstruction of rf energy signals.  Crucially, pulse sequences contain instructions for 
carefully controlling the duration and timing of rf pulses and gradient pulses. 
There are two main types of pulse sequences; Gradient Echo and Spin Echo(1-4).  All clinically 
used pulsed sequences are based on these two types of pulse sequences, and from each of 
these, come further pulse sequences where the variations or modifications are designed for 
specific clinical applications and/or body regions; such as the 3D Time of Flight Gradient 
Echo(1, 2) pulse sequence to image the Circle of Willis.  
Regardless of sequence type, all have timing values which can be modified to alter the image 
contrast or image weighting(1-3).  These timing values are the repetition time, or TR(1-4), which 
co-ordinates the application of rf energy into the imaging volume; and; the echo time, or TE(1-
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4), which listens to, or detects and receives, the resonating rf energy signal from the imaging 
volume.  Both TE and TR are measured in milliseconds. 
 
The TR period is the time from one excitation rf pulse to the next(1-6).  This determines the 
amount of relaxation allowed to occur from one excitation rf pulse to the next and thus, the 
TR determines the amount of T1 relaxation that has occurred during the pulse sequence(1-3).  
The TE is the time from the application of the excitation rf pulse to the peak signal strength as 
detected by rf receiver coil(1-6).  This controls the amount of T2 relaxation and therefore 
determines the level of T2 decay along the transverse plane is allowed to occur before the rf 
signal is read(1-3). 
T1 recovery and T2 decay are intrinsic contrast parameters specific to a particular tissue and 
cannot be changed.  At the MRI operating console, parameters that can be altered, and that 
can also alter resulting image contrast and appearances include TR, TE and flip angle.  
Depending on the variation in pulse sequences, additional parameters that can be manipulated 
include; Time from Inversion, TI; Echo Train Length, ETL (also known as Turbo Factor, TF) 
and b-values(1). 
In biological tissue, hydrogen nuclei is abundant; due to their presence in fat and water.  
These two tissues will be used as examples to demonstrate T1 weighted and T2 weighted 
image contrast(1-3).  Firstly, before proceeding; an explanation of T1 recovery and T2 decay in 
fat tissue and likewise with water.   
Fat or adipose or lipid molecules contain hydrogen bonded with oxygen and carbon.  These 
are comparatively large molecules and are arranged very close together(1, 2).  Their molecular 
tumbling rate are considered to be slow(3, 6).   
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 With water molecules, hydrogen is only bonded with oxygen.  Water molecules are further 
apart and their molecular tumbling rate is regarded as fast (compared to fat molecules)(1-3, 6).  
The way that hydrogen is arranged in water, results in it having a greater Larmor frequency 
compared to the arrangement of hydrogen in fat(1, 2).   
Therefore, compared to hydrogen in water; the hydrogen in fat has a quicker longitudinal 
recovery (or T1 recovery or spin-lattice relaxation or T1 relaxation time) and its loss of 
transverse magnetisation (or T2 decay or spin-spin relaxation or T2 relaxation time) is more 
rapid(1-4, 6).  Due to these time differences, the arising MRI signal from water and fat will 
mean that they will appear different on the resulting MRI images. 
The MRI operator’s selection of specific TE and TR values, weights an image to demonstrate 
either mostly T1 values and contrast mechanisms or alternatively, to have T2 characteristics, 
dominate a resulting image.  
 
 
1.1.2 T1 weighted imaging 
 
The T1 relaxation time of fat is shorter than the T1 relaxation time of water(1-4).  Once the rf 
pulse is switched off (after the NMV has been flipped from the longitudinal plane), the NMV 
begins to re-align itself with the longitudinal plane, Bo,(1-6) and the vector from each tissue (in 
this example we will only consider fat and water) will commence to de-phase or become 
incoherent from the transverse plane(2, 3).  The shorter T1 relaxation time of fat will allow it 
(the fat vector) to re-align with the longitudinal plane, Bo, sooner than the water vector(1-3).  
Thus, more of the fat signal has recovered (compared to water) and is ready to be excited, 
again.  Following the expiration of the TR period (and this TR period will be less than the 
total relaxation times of the biological tissues being imaged), the pulse sequences commences 
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 again, sending an rf excitation pulse into the biological tissue.  Compared to water, as there is 
a greater vector from fat contributing to the NMV in the longitudinal plane; after the RF 
excitation pulse has flipped the NMV into the transverse plane, the recovery signal from fat 
will be greater (compared to water) and therefore contribute more to the FID(2-4).  The signal 
from fat will be higher compared with the signal from water and therefore fat will appear as a 
hyperintense signal on the resulting T1 MRI image.  The comparatively lower water vector 
and resulting signal, leads to water appearing hypo-intense in the same image. 
As the TR duration of a pulse sequence determines the extent of vectors recovering to re-align 
in the longitudinal plane(1, 3); to allow for T1 weighted images to be created, the TR value 
needs to be of a short duration; thus not allowing the fat and water vectors to fully recover in 
their longitudinal plane and re-align with Bo(1-4).  A TR value longer than the T1 recover times 
of fat and water will mean that both tissues would fully recover their longitudinal 
megnetisations and when the next rf excitation energy pulse is applied, the MRI signal 
differences related to their T1 relaxation times cannot be demonstrated nor imaged(1, 2).   
Overall therefore, the TR value of a pulse sequence provides control over the degree of T1 
weighting; and for T1 weighted images to be generated, the TR must be short – shorter than 
the longitudinal recovery times of the biological tissues needing to be imaged(1-4). 
 
 
1.1.3 T2 weighted imaging 
 
The T2 relaxation time of fat is also shorter than the T2 relaxation time of water(1-4).  As T2 
relaxation or decay, is indicative of T2 signal;(1, 2) this means that at the point in the pulse 
sequence when the FID is recorded, there will be a greater signal component from the water 
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 vector(3, 4).  Hence, compared to fat, water will contribute a larger signal and appear relatively 
hyperintense on the resulting T2 image(2, 3).  
An image that has been generated containing T2 influences, results from the contrast 
mechanisms being dependent on the T2 relaxation times of fat and water, along with other 
biological tissue from the imaging volume.  From a pulse sequence, the duration of the TE 
determines the degree of T2 decay that is permitted to occur before the FID signal is identified 
and read(1-4).  To generate an image that is considered to be T2 weighted, the TE value needs 
to be sufficiently long, allowing both fat and water to decay via their spin-spin lattice 
interactions(1-3).  If, however, the TE value is too short, and fat and water are unable to 
demonstrate sufficient T2 decay, their T2 signal characteristic differences will not be able to be 
detected and not imaged.   
 Overall therefore, the TE value of a pulse sequence provides control over the degree of T2 
weighting(1-4); and for T2 weighted images to be generated, the TE must be of sufficient 
duration – allowing T2 decay in the transverse plane to be detected.  This is designed to take 
advantage of fat having a short T2 decay time and water having a longer T2 decay time.  
 
 
1.1.4 T2* weighted imaging 
 
T2* results from either inhomogeneities in the main magnetic field(1-6), or, from susceptibility 
effects within the imaging volume(1-3); which, in effect, is a local magnetic field disturbance(1, 
3).  Local susceptibility imaging effects, due to iron deposits in an imaging volume, can be 
seen in patients suffering from a number of health conditions; including; haemorrhagic stroke 
(iron rich components of blood products such as met-haemoglobin or haemosiderin)(1), 
neuroferritinopathy (iron in the basal ganglia)(7-9), genetic conditions such as 
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 haemochromatosis (inherited iron overload disorder)(10-12), haemosiderosis (iron overloads in 
the RES organs)(13-15) and neurodegeneration with brain iron accumulation (NBIA)(16, 17).   
These local susceptibility imaging effects can be used by radiologists and clinicians to narrow 
the differential diagnosis. 
Whether due to main magnetic field inhomogeneities or from local susceptibility effects, T2* 
arises from molecular interactions (spin-spin relaxation)(1-3).  The MRI active nuclei 
experiencing these field variations will precess at slightly different frequencies(1-4) because 
these spins are oriented at a slightly different angle(1) to the main magnetic field.  This T2* 
effect leads to a rapid loss in phase coherence and transverse magnetisation(1-4).  T2* time is 
less than T2 time(1-6) and is observed in the FID(1, 3).  Thus, the spins within the biological 
tissue being imaged experiencing such inhomogeneities will also experience different local 
magnetic fields(1, 3).  This, in turn, affect the relaxation of the spins after an rf pulse; speeding 
up the apparent spin-spin relaxation T2* time(1).  Relative to the T2 decay time of the same 
spins in a uniform magnetic field, the T2* transverse magnetisation decay is quicker – but 
spin-lattice relaxation is not affected(1).  SE pulse sequence can correct for this effect by 
having 180 degree rephrasing rf pulses written into their pulse sequences; but GE pulse 
sequences cannot, as they use a gradient in an attempt to re-phase the magnetic moments(1-4).  
The gradient used by GE pulse sequences is essentially a reversal of current direction in the 
coils (or gradients) surrounding the main magnet(1, 3).  This gradient cannot re-set any phase 
differences between the spins and thus cannot compensate for magnetic field 
inhomogeneities(1-3).  GE images therefore result from the apparent spin-spin relaxation time, 
T2* time.  For a given tissue, the T2* time closely approximates its T2 time; therefore, GE T2* 
images can be similar in appearance to images generated with a SE T2 pulse sequence(1, 3, 4).   
It is also said that the T2* is a reflection of the quality of the main magnet within the MRI 
scanner.  As a magnet in the Tesla strength range required for clinical and research purposes 
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 cannot be produced with a perfectly uniform magnetic field; T2* therefore, are effects due to a 
non-uniform magnetic field(1, 3).   
Specifically to iron oxide nanoparticles, the local susceptibility imaging effects can be 
exploited with MRI imaging to introduce obvious image contrast and characteristics.  Iron 
oxide nanoparticles will induce local susceptibility effects and therefore T2* weighted images 
should be used to best demonstrate their effects on MRI images(1, 2) or contribution to image 
contrast and diagnosis.  There are two most likely ways this can be achieved.  Firstly, cells 
can be removed from a patient, then loaded with iron oxide nanoparticles in safe medical 
laboratory conditions and then administered to the same patient(18-20).  Secondly, the iron 
oxide nanoparticles themselves can be directly administered to the patient(21).  In both 
instances, MRI can be used to track their progress or movement from injection site to their 
final destination (an organ or site of pathology).   
 
 
1.1.5 Contrast media and MRI 
 
Broadly defined, a contrast agent or medium is any substance that can be used together with 
an imaging technique to provide additional and useful information.  Contrast media can be 
either exogenous or endogenous.  Endogenous material which can be used include water 
molecules inherent within the blood stream when performing Arterial Spin Labelling (ASL) 
or Tagging (AST).  Exogenous substances include the already well known paramagnetic 
gadolinium-based agents and now emerging from literature, we are noting an increasing 
experimental usage of superparamagnetic iron oxide nanoparticle. 
When MRI first became a clinical reality, it was thought that no contrast media would ever be 
needed because of MRI’s superior contrast and spatial (isotropic voxels) resolution compared 
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 with other modalities(3).  It was soon realised that a contrast media was needed to improve the 
specificity of MRI(1).   
In 1988 the first MRI-specific contrast media preparation was approved by the Food and Drug 
Administration (FDA) for intravascular administration in clinical use(22, 23).  This was needed 
to define a pattern of contrast enhancement so that a characteristic enhancement pattern of a 
particular disease process could be recognised and also to narrow the differential diagnosis.  
This contrast media preparation contained gadolinium as its base.  There have always been 
some concerns in relation to this preparation. These include its expense (cost per millilitre and 
patents are strongly held and continually renewed) and its degradation with exposure to 
ambient light.  The way that such gadolinium-based contrast media is chemically altered and 
eliminated by the body is not entirely understood(24).  For some time now, a condition known 
as “cross reactivity” has existed.  It cannot be entirely explained, however, it is thought to 
result either from the chelated molecules or elements, or the chelated structure themselves(25).  
Within the last decade or so, a more serious condition has been attributed to gadolinium-based 
preparations.  This condition is referred to as nephrogenic systemic fibrosis (NSF) and can 
lead to eventual death.  NSF is almost always seen in patients with reduced renal function 
(less than normal glomeruli filtration rate, GFR) and there have been a number of deaths 
recorded and attributed to NSF.  In early 2008, the Royal Australian and New Zealand 
College of Radiologists (RANZCR) has recommended that all clinical centres offering 
gadolinium-based contrast media for MRI scanning examinations to establish a new policy 
concerning intravascular administration and, in particular, with respect to NSF and patients 
with impaired renal function(26).  Due to these trends, anecdotal reports suggest more caution 
and less reliance upon gadolinium-based contrast media even though no alternative currently 
exists in Australia.  The current commercially available contrast media is gadolinium-based 
and also referred to as para- magnetic and only benefits T1-weighted MR imaging.  No 
mainstream commercially available contrast media for T2-weighted imaging is currently 
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 available in Australia.  There are benefits attributed to contrast media if it can be prepared for 
T2-weighted MR imaging(24).  Coincidently, an increasing trend is underway towards clinical 
MRI scanners with higher field strengths such as 3.0 Tesla.  The main drivers are improved 
capital and running costs and increased signal-to-noise (SNR) ratio.  However, at higher field 
strengths such as 3.0 Tesla, T1 and T2 relaxation times of human tissue are altered compared 
to 1.5 Tesla.  Gadolinium-based contrast media results in shortening T1 tissue relaxivity 
values and therefore only T1 optimised sequences can be used (T2 relaxivity values are not 
altered significantly for MR imaging practicality).  It is proposed that contrast media 
preparations based on nanoparticles can overcome all of the abovementioned challenges 
related to MRI scanning while simultaneously addressing the current medical safety 
concerns(24, 27).  More specifically, iron oxide nanoparticles have the following attractive 
attributes: 
• it can offer T2-weighted imaging opportunities 
• it has a well-recognised and understood pathway for breakdown and excretion from 
the human body 
o Degradation causes iron to enter plasma, where it is processed by the body 
o Risk of iron overload is minimal 
o Average dose of iron in contrast agent is comparable to iron contained in less 
than one unit of blood 
• It provides “negative” enhancement  
Depending on the physio-chemical property of the coating (surrounding the iron oxide 
nanoparticle), both generalised and specific contrast media can be created(27, 28).  The term 
“specific” means that contrast media preparations can be targeted to a particular organ within 
the body or a particular disease process.  If this can be achieved, then it follows that not only 
can diagnostic imaging be successful, but also therapeutic drugs/medication can be tagged to 
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 the preparation so that it can reach and work on the target tissue.  At one point, it was 
estimated that 30 % to 40 % of MR examinations were performed with intravascular contrast 
media(25).  With the awareness of NSF, no hard data currently exists to determine if the use of 
intravascular contrast media has decreased or remains at the same level.  The most commonly 
available intravenous contrast media contains gadolinium.  A gadolinium ion has seven 
unpaired electrons in its outer shell(2) and is considered a paramagnetic substance because it 
has an overall positive effect on the local magnetic field(3).  In brief, when placed within a 
magnetic field, the negatively charged gadolinium ion demonstrates characteristics such as a 
magnetic moment, producing a large time-varying magnetic field in its vicinity, allowing 
rapid exchange of bulk water, altering the relaxation rates (both T1 and T2, or longitudinal and 
horizontal) of adjacent water protons(2, 3, 25).  Gadolinium is referred to as a T1 enhancement 
contrast agent as it affects T1 to a greater extent than it does T2.  The act of molecular 
tumbling and local magnetic field alterations occur near the Larmor frequency value.  This 
leads to a reduction of the T1 relaxation value of adjacent water protons, which in turn, leads 
to an increased signal strength on T1 weighted images(2).  This is due to an increased rate of 
longitudinal magnetisation recovery(1, 25).  For acceptable biocompatibility, gadolinium is 
chelated to other molecules.  This reduces any acute toxicity effects, and also allows the 
gadolinium-based agent to remain circulating within the body for a relatively longer period 
(than without chelation)(1) with an elimination half-life of between 1 hour to 2 hours(2, 3).  
Currently available paramagnetic contrast agents are commonly administered intravenously.  
Its biodistribution is into the blood stream and then into the extra cellular space.   It is 
therefore not taken up by any specific body organ, tissue type or pathologic lesion.  Hence, 
gadolinium compounds are also regarded as non-specific contrast agents(3).  Enhancement 
patterns, however, are known to be characteristic of certain pathology groups.  For example, a 
hyperintense circular rim with a hypointense centre may be representative of a cystic lesion.   
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1.1.5.1 Gadolinium and current concerns 
 
Up until about ten or twelve years ago, gadolinium-based contrast agents had been regarded 
as having a relatively excellent safety record(29).  NSF was originally referred to as 
nephrogenic fibrosing dermopathy by Cowper et al. in 2000(30).  It was described as being 
scleromyxoedema-like cutaneous disorder and thought to only affect the skin or dermis.  It 
was noted in patients undergoing renal dialysis(30, 31).  As additional cases became recorded 
and further understanding of the pathology grew, the currently used term of NSF has become 
accepted.  This is due to the now recognised systemic nature of the pathology(32, 33).  
Commonly, NSF commences with swelling at the distal aspects of the extremities.  This may 
then resolve, however, leaving behind thick, firm plaques over the affected skin.  In the 
majority of patients, initial skin lesions appear on the legs, then the arms and lastly on the 
trunk of the body.  It has also been reported that the skin lesions are often symmetrical and 
bilateral.  It may then progress to a point where the patient has significantly reduced range of 
motion of their extremities and joints(34).  In addition to the flexion and joint contractures 
accompanying extremity skin lesions(35, 36), fibrotic effects may also be widespread and 
penetrating; involving organs including the liver, lungs and heart, among others(36, 37).  Today, 
the only successful approach in treating NSF is to restore the normal renal function.  This can 
only be achieved by renal transplant surgery(34, 36).  NSF is almost always seen in patients with 
less than normal renal function or patients requiring ongoing renal dialysis.  Therefore, NSF 
may be a resulting consequence in patients with renal impairment because the contrast media 
excretion half-life is markedly increased(38).  This situation then permits disassociated or de-
chelated gadolinium ions an increased circulation time.  Some authors consider NSF to be an, 
“adverse reaction to gadolinium contrast agents in particular the less stable gadodiamide”(39).  
Even though all gadolinium-based preparations carry a level of risk, there is published 
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 evidence to suggest that some gadolimium-based contrast agents offer a greater risk than 
others in inducing NSF(39).  This variation in risk is linked to the overall molecular structure 
of the gadolinium-based contrast agent and in particular, its level of chemical stability within 
the human body(40).  Gadodiamide has been associated with the greatest incidence of induced 
NSF(39, 40).  On its own, gadolinium is highly toxic; and not only can it cause injury to the liver 
and spleen, but it can also inhibit secretions of certain enzymes and it can induce 
haematological ailments(40-42).  To minimise such toxic consequences, the gadolinium ion is 
chelated to other chemical elements and compounds(40).  This improves its biocompatibility.  
The molecule or atom that is bonded to the gadolinium can be referred to as a ligand.  The 
gadolinium ion is chelated in either a linear or macrocyclic fashion and prepared as either 
ionic or non-ionic formulations(25, 40).  Published data reflect that the least stable preparations 
are non-ionic linear chelate formulations such as gadodiamide (Omniscan, GE healthcare, 
Chalfort, ST Giles, UK) and Gadoversetamide (OptiMark, Covidien, St Louis, USA).  
Gadodiamide has been reported to have a kinetic stability of 35 seconds; that is, at a pH of 
1.0, half of the preparation will shed the linearly chelated material; thus leaving free 
gadolinium ions to search for other metals (body cations) to bind to within the body.  These 
would include iron, copper, zinc and calcium.  This process is referred to as transmetallation.  
Of the above body cations, zinc has the highest relative concentration (55- 125 micromole per 
litre) within the blood stream(40).  The most stable gadolinium-based preparation is the ionic, 
macrocyclic chelate formulation; namely, gadoterate.  Public communications by the FDA in 
2009 and 2011 (no later public notices or communications can be found), state that no cases 
of NSF linked to any macrocyclic formulation has been reported (40) or confirmed by the 
International Centre for Nephrogenic Fibrosing Dermopathy Research(43) in the USA.  It is 
suggested that this is due to a macrocyclic structure providing a relatively superior protection 
of the gadolinium ion; that is, the gadolinium ion is caged by the chelating agent(25, 40, 44, 45).  
Conversely, a linear chelate is referred to as being a flexible open chain and thus not 
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 providing a strong bond to the gadolinium ion.  Gadoterate is documented to have kinetic 
stability of greater than one month(40).  High et al. (29) obtained paraffin embedded tissue 
samples from the NSF registry (the International Centre for Nephrogenic Fibrosing 
Dermopathy Research).  These tissue samples had histopathologic diagnosis of NSF.  This 
research group demonstrated with energy dispersive spectroscopy (EDS), a device used to 
characterise chemical elements, that in four of seven patients, gadolinium was able to be 
identified and all detectable gadolinium particles were less than 1 micrometre in size.  Further 
analysis with field emission scanning electron microscope (FESEM) demonstrated that in all 
of the positive tissue samples, gadolinium particles were present within the intracellular space 
and most probably located within, or adjacent to, the lysosome structures.  Also noteworthy 
was an excessive amount of iron deposition within the tissue samples.  While the exact cause 
of NSF has not been conclusively established(36, 37, 45-49) and precise pathologic pathways are 
yet to be determined(31), there is however, convincing evidence that gadolinium may be 
responsible somehow(48, 50).  The most probable theory is that de-chelation occurs(51), resulting 
in the release of free gadolinium ions, which in turn may or may not lead to 
transmetallation(52, 53).   
 
 
1.2 What are Nanoparticles 
 
Nanotechnology is the manufacture and manipulation of materials in the nanoscale range of 1 
nm to 1,000 nm(54).  Nanoparticles are defined as particulate matter and being less than 100 
nm in one of their dimension, they are most likely to be spherical, but can also be shaped as 
rods, cages or stars(55).  In broad terms, a colloidal system is comprised of a dispersing 
medium and a dispersed medium.  Both of these media can be gas, liquid or solid.  Solid 
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 particles in a liquid are termed dispersions; a liquid medium in another liquid medium is 
referred to as emulsions; and solid particles in a gas are known as aerosols(55). 
For biomedical applications, a nanoparticle often has at least two components(56-58).  The core 
material and a surface layer.  A nanoparticle is often referred to by its core material.  For 
example, an iron oxide nanoparticle with have an iron oxide core, however, its surface layer 
may be dextran, silica or another material.  The core material provides the fundamental 
properties of the nanoparticle, while the surface layer can be designed to provide added 
benefits such as preventing agglomeration and also being capable of functionalisation to 
improve imaging capabilities or drug delivery or other intended benefits such as increased 
blood circulation time(59).  Another layer, known as a shell, can be incorporated between the 
core material and the surface layer.   
Iron oxide, as a material for the nanoparticle core, demonstrates the required characteristics 
necessary for MRI imaging; as the iron oxide core behaves as a single magnetic domains (just 
like NMR active nuclei)  in the presence of an external magnetic field. 
Dextran, as the surface layer material provides the interface between the iron oxide core and 
its immediate environment(28).  Dextran acts as a physical barrier between the iron oxide and 
its surroundings, to protect and stabilise the core and prevent oxidation(24, 28).  Further, dextran 
is capable of being functionalised to allow it to be tagged with FITC; meaning that in addition 
to MRI imaging detail, further data can be obtained with FACS flow cytometry and also 
confocal microscopy can be performed. 
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 1.3 Nanoparticles and imaging 
 
In medical imaging, the development of nanoparticles has attracted a phenomenal amount of 
research, particularly for applications in molecular imaging.  Nanoparticles can be tailored 
with unique characteristics providing them with capabilities to maximise imaging signals and 
increase image contrast for improved visualisation, detection and diagnosis(27, 60).   
In the Nuclear Medicine field, nano-scale sulphur colloids were first popularised in the 1970’s 
for imaging lymph nodes in lymphoscintigraphy by being radiolabelled with 99mTechnetium 
(99mTc)(61, 62). 
For a brief period in the 1980’s, some serious research was conducted with iron oxide 
nanoparticles as a possible patient administrable contrast agent in MRI scanning(63, 64).  The 
technological capabilities were not available at the time to reduce the nanoparticle size below 
200nm.  The ability for nanoparticles to improve MRI imaging flexibility was first noticed 
and reported in the late 1970s(65). 
With the incorporation of nanoparticles, various imaging modalities have transitions from 
simply imaging anatomy and pathology towards more sophisticated capabilities to include 
cell tracking and targeted imaging; with improved sensitivity and specificity(27).  For example, 
with iron oxide nanoparticles less than 100 nm in diameter and having a surface layer capable 
of being conjugated to biomarkers; these two factors can facilitate cellular uptake while the 
superparamagnetic properties of the iron will allow the target site to be identified on an MRI 
image.  Nanoparticles can potentially be incorporated with many conventional imaging 
modalities and techniques(66).  Some conventional imaging modalities, such as x-ray imaging, 
ultrasound and CT, on their own, lack dual benefits of high sensitivity and high spatial 
resolution needed for molecular imaging.  The benefits of MRI include having high spatial 
resolution, does not use ionising radiation, provides multi-planar imaging capabilities and is 
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 non-invasive.  PET and SPECT imaging, both nuclear medicine modalities offer greater 
sensitivity to molecular processes but have significantly reduced spatial resolution capabilities 
(when compared to MRI).  Hybrid imaging, such as PET/MRI, merges the benefits of both 
modalities and each modality overcomes the drawbacks of the other.  A radio-labelled iron 
oxide nanoparticle, thus, provides the promise of one contrast agent serving the purposes of 
both imaging modalities. 
There are a number of examples in the literature of innovative uses of various types of 
nanoparticles being used together with common imaging modalities of planar x-ray, CT and 
Ultrasound.    
X-ray imaging has traditionally incorporated iodinated contrast media to improve conspicuity 
and sensitivity in images; however, iodine has been associated with severe adverse events; 
ranging from allergy-type responses, respiratory arrest, laryngeal oedema, cardiovascular 
responses and nephrotoxicity.  These adverse events can also be attributed to large and 
repeated doses being necessary.   
De La Vega et al(67) has explored alternatives to iodine by way of a review of the literature.  
Elements with high atomic numbers are required in order to exhibit high absorption of x-rays 
photons on the generated images.  Nanoparticles synthesised from elements with atomic 
numbers greater than iodine have been reported to have superior imaging properties, longer 
blood circulation times and lower toxicity than the conventional iodine based contrast agents.  
A study performed by Hainfield et al(68) focussed on nanoparticles containing a gold core; as 
gold has an atomic number of 79 (iodine has an atomic number of 53) providing it (gold) with 
a higher mass x-ray absorption (or attenuation) co-efficient; 5.16 cm2/g (at 100 keV) 
compared to iodine’s 1.94 cm2/g (at 100 keV).  Using these figures, gold can provide 2.7 
times greater imaging contrast compared to iodine (5.16 cm2/g ÷ 1.94 cm2/g = 2.7).  To 
observe and asses the biodistribution and contrast enhancement, these same investigators 
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 injected these gold nanoparticles into the tail vein of Balb/C mice containing EMT-6 
subcutaneous mammary tumours.  Their results showed that the gold nanoparticles allowed 
high contrast visualisation of angiogenic and hypervascularised areas pertaining to tumours 
for approximately one hour following peak opacification.  The detailed imaging of the 
vasculature were also attributed to the size of the gold nanoparticles, being approximately 2 
nm.  The gold nanoparticles were then eliminated via the urinary system, as noted by the 
image enhancement of the kidneys and urinary bladder.  Standard planar x-ray imaging was 
used to image mice in this study. 
Chien et al(69) also used gold nanoparticles to assess tumour related micro-vasculature in 
tumour bearing mice; however, their aim was to measure the dimension of the smallest 
identifiable vessel.  Their results were achieved using gold nanoparticles conjugated with 
heparin and were able to image in vivo blood vessels as small as 3-5 μm.  They achieved this 
imaging with the use of synchrotron assisted microradiology imaging techniques.   
Kobayashi et al(70) demonstrated that gold nanoparticles with a silica outer layer can be 
retained within a mouse for 6 hours and allowing imaging of internal organs (such as heart, 
liver and spleen).  Kobayashi et al concluded that the 54.8 nm sized silica coated gold 
nanoparticles provided contrast enhancement greater than currently commercially available 
iodine based contrast media.  This was assessed by CT imaging and observing the CT 
numbers or Hounsfield Units of the enhancing organs. 
Cormode et al(71) successfully used gold nanoparticles coated with a high density lipoprotein 
to identify calcification and stenosis of atherosclerotic plaques via macrophage uptake.  
Apolipoprotein E knockout (apo E–KO) mice were used as the animal model for 
atherosclerosis.  The imaging capabilities of the high density lipoprotein coated gold 
nanoparticles were compared with a commercially available iodine based contrast agent and 
also compared with calcium phosphate; in phantom studies.  In vivo, multi-colour spectral CT 
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 successfully imaged the gold nanoparticles being deposited in the aortas of the subject mice.  
Post mortem microscopy assessment of the aortas demonstrated that the nanoparticles were 
contained within the macrophages.  These investigators concluded that such nanoparticles, 
together with spectral CT, can demonstrate atherosclerotic plaque composition due to uptake 
of these nanoparticles by macrophages. 
Gold nanoparticles were also used by Lie et al(72) for in vitro and in vivo targeted CT imaging 
of the KB cancer cell line (human epilthelial carcinoma).  Their nanoparticles were 
functionalised with folic acid, which allowed them to target the KB cancer cell line in vitro 
and in vivo with xenograft tumour bearing rats; via their over expressing folic acid receptors.   
CT imaging and contrast enhancement assessment (CT number or Hounsfield Units) of the 
tumour in vivo was used to compared the contrast enhancement produced by these gold 
nanoparticles to that produced by a clinically available contrast agent.  Identical 
concentrations of both contrast agents were used.  Their results demonstrated that the gold 
nanoparticles functionalised with folic acid provided the tumour with greater enhancement or 
contrast, compared to that induced by the commercially available iodine based contrast agent.  
The greatest difference in image contrast was noted at 1 hour post administration. 
Titanium dioxide nanoparticples have also been successfully used with ultrasound in vitro by 
Ninomiya et al(73) to perform sonodynamic cancer therapy.  Such therapy is not dependent 
upon the thermal effects of oscilating or reverberating molecules due to the ultrasound 
frequency waves, but rather, based on sonochemical effects of low frequency ultrasound 
waves and sonosensitzer (cancer fighting drugs).  The titanium dioxide nanoparticles are 
preferentially internalised and accumulated in cancerous tissue and low frequency ultrasound 
then used to activate the drug.  It was discovered by these investigators (in an earlier study) 
that titanium dioxide, when activated with ultrasound, can act as a sonocatalyst; enhancing 
hydroxyl radical generation.  The titanium oxide then produced reactive oxygen species 
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 capable of killing cancerous cells.  Prior to this, it was thought that titanium dioxide could 
only induce reactice oxygen species in the presence of ultraviolet irradiation.  In their in vitro 
study, Ninomiya et al identified that 80 % of the human breast cancer cells (MCF-7) ingested 
the titanium oxide and one day following treatment with 1 MHz ultrasound, the cell viability 
of MCF-7 cells was at 68 %. 
 
 
1.4 Iron Oxide Nanoparticles and MRI 
 
The most common form of iron oxides used in nanoparticle preparations are magnetite 
(Fe3O4) and maghemite (γFe2O3)(74, 75), and research with these has intensified over the past 
decade.  They are both insoluble in water and because of their size, these superparamagnetic 
substances only exhibit their magnetic properties when placed within a magnetic field(3, 18).  
The hydrodynamic size of a nanoparticle preparation is the term used to describe its overall 
size, that is, the iron oxide core plus the coating plus any additional ligand attachments and 
the thin electric dipole layer of the solvent layer attached to the particle as it moves under the 
influence of brownian motion.  If the overall hydrodynamic size is greater than 50 nm, then 
the preparation is referred to as a superparamagnetic iron oxide nanoparticle (SPION).   
Iron oxide nanoparticle preparations are highly complex.  There are numerous production 
methods which can be used to generate them.  Each method can result in iron oxide 
nanoparticles having specific dimensions, as well as unique imaging and therapeutic 
characteristics.  Each manufacturing method is undertaken in a strict controlled environment 
to ensure consistency of dimensions, characteristics and biostability.   
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 The physiochemical properties of iron oxide nanoparticles are determined by the size of the 
iron oxide core, its overall charge and the zeta charges between coatings and the overall 
hydrodynamic size.  With respect to magnetic resonance imaging, the above factors also play 
a fundamental role in determining their efficacy (or imaging efficacy), stability within the 
body’s environment, biodistribution, opsonisation, metabolism, clearance from vascular 
system and then excretion from the body(56).  
 
 
1.4.1 Nanoparticle coating 
 
An understanding of the bonding and the geometry of the coating will help us appreciate the 
pharmokinetic pathways and biodistribution of contrast agents composed with iron oxide 
nanoparticles(18, 76-78).  From a chemical perspective, the iron oxide core is coated for four 
main reasons.  Firstly, to prevent destabilisation; secondly, to prevent agglomeration 
(aggregation or sedimentation) as it will be a colloidal suspension; thirdly, it allows for the 
iron oxide nanoparticle formulation to be soluble in an aqueous solution or a biological 
medium; fourthly, it determines either the role it performs within the body (diagnostic 
magnetic resonance imaging, cell tracking or therapeutic purposes such as tailored drug 
delivery) or the ligand that can be bonded to it to support the imaging, tracking or therapeutic 
roles.  The coating used can also facilitate the method of endocytosis(79).  For example, it has 
been shown that IONP coated with monomer citrate (overall hydrodynamic size of 8nm) 
demonstrated cell entry via phagocytosis.  When the same iron oxide nanoparticles were 
coated with polymer carboxydextran (overall hydrodynamic size of 31 nm), cell entry or 
penetration was demonstrated by pinocytosis.  In both examples, the same cell line was 
used(76, 78).   
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 A new field of nanoparticle research is emerging, termed theranostic, whereby either the core 
material or the surface layer can be loaded with drugs or nucleic acid; providing the 
nanoparticle with both therapeutic and diagnostic imaging capabilities – ‘thera’ from therapy 
and ‘nostic’ from diagnostic(59). 
 
 
1.4.2 Stabilisation 
 
High density coatings have been reported to be effective in stabilising iron oxide 
nanoparticles(18, 80-82).  Such high density coatings are commonly polymeric and monomeric 
materials or species.  Polymeric coatings include dextran, carboxymethylated dextran, 
carboxy dextran and starch.  Whereas monomeric coatings include dimercaptosuccinic acid 
(DMSA), amino acids and α-hydroxamates (such as citric, tartaric or gluconic acids).  
 
1.4.3 Hydrodynamic size 
 
There is evidence to suggest that USPION is less prone to phagocytosis by the liver; whereas 
SPION greater than 50 nm are rapidly phagocytosed(18).  Therefore, hydrodynamic size can 
affect biodistribution and blood half life in a time dependent manner(83).  Eventually, USPIO 
will actually be processed by the liver. 
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 1.4.4 Biodistribution 
 
Iron oxide nanoparticles greater than 50 nm are readily macrophaged by the reticulo-
endothelial system (RES).  This namely refers to the Kuppfer cells of the liver, the spleen and 
bone marrow(18).  Iron oxide nanoparticles less than 50 nm have been used to demonstrate 
uptake by lymph nodes(18, 56, 84-87).  Of the available iron oxide-based contrast agents which are 
currently on the market and also undergoing clinical trials, the blood half-life values can vary 
considerably from 40 mins to up to 36 hours.  There is thus a link between the hydrodynamic 
size and the biodistribution and blood half-life.  As has been established, particles greater than 
50nm are readily taken up by the liver in a matter of minutes.  USPION are not readily 
phagocytosed by the liver and can have a longer blood half-life and thus reach other structures 
within the body(18).  It must also be emphasised that the coating itself can be responsible for 
aspects of biodistribution as well as ligands; for example the targeting of specific cells or 
organs(18, 56, 85).  
 
 
1.4.5 Metabolism and excretion 
 
The manner in which the body metabolises iron oxide nanoparticles is determined by their 
overall chemical composition.  In particular the immediate coating and any ligands are strong 
determinants as to the site (that is, which particular organ or body system) of metabolism and 
thus also the rate of metabolism and excretory pathways.  The commonly used dextran 
coating should ideally be of low molecular weight.  This is vital as higher molecular weight 
dextrans, such as those used as plasma substitutes, have a reported association with adverse 
reactions.  Immunoglobulin G (IgG) antibodies have been reported to be reactive to such high 
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 molecular weight dextrans(88).  Low molecular weight dextrans will initially undergo 
dextranases which is an intracellular level breakdown process.  The majority of the 
breakdown components are excreted with urine over a period of nearly 2 months(18).  Once the 
low molecular dextran has metabolised in this manner, the iron oxide core has been found to 
enter the normal iron store of the body.  Such iron elements can also be found as haemoglobin 
with the body’s red blood cells(89).  This iron then follows the same excretory pathway as 
endogenous iron.  That is, approximately one-fifth is eliminated mostly with the faeces and 
over a three-month period.  Therefore, as both dextran and iron from iron oxide nanoparticles 
are incorporated into the body’s normal metabolic pathways, without raising these levels 
noticeably, and with the evidence available today, it can thus be stated that these substances 
do not trigger any long-term toxicity.  In the average healthy adult, normal total human iron 
stores is about 3500 mg with the liver containing an average of 0.2 mg of iron per gram(89).  
From the currently approved iron oxide nanoparticles for diagnostic MR imaging, a regular 
adult dose can contain 50-200 mg of iron.  This value can be considered relatively small 
compared to the human body’s iron store.  Chronic iron toxicity is known to occur when the 
concentration of iron within the liver reaches a level of 4mg of iron per gram of liver(74). 
 
   
1.4.6 Phenomenon of superparamagnetism  
 
From a physics perspective, there are four variations of magnetic susceptibility.  In order of 
weaker magnetism to stronger, these are diamagnetic, paramagnetic, superparamagnetic and 
ferromagnetic.  Materials identified as diamagnetic demonstrate very weak magnetic 
susceptibility effects and in fact, produce a magnetic field in the opposite direction to the 
externally applied magnetic field.  Paramagnetic items demonstrate a relatively stronger 
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 susceptibility effect as their own magnetic field is in the same direction as the externally 
applied magnetic field.  Biological tissue components that are paramagnetic and their 
paramagnetic nature can be exploited to improve image contrast, through the use of pulse 
sequences, include met-haemoglobin and deoxy-haemoglobin.  The gadolinium incorporated 
into MRI contrast media is also a known paramagnetic substance.  Superparamagnetic 
describes material that induce a susceptibility effect in magnitude somewhere between 
paramagnetic and ferromagnetic substances.  Ferritin and haemosiderin are naturally 
occurring (in the body) superparamagnetic substances and are also capable of being exploited 
through creative pulse sequences to aide in diagnosis.  Items referred to as being 
ferromagnetic are material that experience introduced into an external magnetic field and thus 
demonstrate the strongest magnetism.  Iron, and materials embedded with iron are highly 
magnetic – introducing ferromagnetic items into an MRI scanning facility is prohibited.    
Iron oxide nanoparticles, as discussed here, are referred to as being superparamagnetic.  The 
superparamagnetic phenomenon is observed when the thermal energy of the medium is 
sufficient to alter the crystallite or nanoparticles’s magnetisation direction by overcoming 
coupling forces.  When crystallite or nanoparticles are placed within an external magnetic 
field, its magnetic moment will align with the externally applied magnetic field.  At least two 
points distinguish superparamagnetism from paramagnetism.  Firstly, with paramagnetism, it 
is each individual atom or ion that becomes aligned with an externally applied magnetic field.  
Secondly, superparamagnetism will occur when the crystal or hydrodynamic size is less than 
its ferromagnetic domain.  Authors report this size to be less than 30 nm(18), with the “critical 
size” being about 15 nm(77, 90, 91).   
When not in the presence of an externally applied magnetic field, superparamagnetic particles 
are not magnetised, nor do they demonstrate any remnants of magnetism once removed from 
the magnetic field.  When the crystals or particles are under the influence of an applied 
29 
 
 magnetic field, their magnetic spins are considered to be in perfect alignment and very high 
local magnetic field gradients are generated.  These gradients then cause spin dephasing of the 
surrounding water protons; thus reducing their T1 and T2 relaxivity(3, 90, 92).  It must also be 
noted that there is a relationship between the iron oxide nanoparticle size and the level of 
superparamagnetic saturation.  As the particle size decreases, so too does the 
superparamagnetic saturation.  This then has an effect on reducing the observed relaxivity or 
further reducing T1 and T2 relaxation.  
Gadolinium based contrast agents are the most widely used paramagnetic contrast agents.  
They are designed to demonstrate pathology as a hyper-intense signal on T1 weighted images.  
Commercially available brand names include containing gadolinium in their formulation 
include Magnevist®, Optimark™, Prohance® and MultiHance® (93).  
Concerns have arisen relating to gadolinium dissociating from its chelating agents once 
administered into patients.  Deaths have resulted due to dissociated gadolinium inducing 
nephrogenic systemic fibrosis (37, 94-97).  
Among the superparamagnetic agents, iron-based particles have been the most widely used 
and researched(77). There are also commercially available iron-based particles, such as 
Revosist®, Feridex®, Gastromark® and Abdoscan® (98).  These commercial iron-based 
nanoparticles are marketed for with MRI in imaging the liver, spleen and gastrointestinal 
lumen.  
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 1.4.7 IONP Influence on magnetic resonance image characteristics  
 
Compared to a paramagnetic material such as gadolinium, the relatively high magnetic 
moment of superparamagnetic species, such as iron oxides, are sometimes referred to as super 
spins(18, 99).  The dipolar interactions between the super spins and adjacent water protons result 
in both high longitudinal (R1) and transverse (R2) relaxation values.  IONPs therefore increase 
T2* relaxation rates through the susceptibility effect and thus have their greatest visual impact 
on T2* weighted images produced with gradient echo-based pulsed sequences(81, 82, 100, 101).  
The accelerated phase loss due to local field gradients generated by super spins, all stem from 
the (induced magnetisation) high susceptibility level of iron oxide.  At the common clinically 
available field strengths of 1.5 T and 3.0 T, published literature(18) indicate that any 
aggregation of SPION will only slightly decrease R1 (longitudinal relaxation) and 
dramatically increase R2 (horizontal relaxation).  
 
 
1.4.8 Magnetic resonance imaging with iron oxide nanoparticles  
 
Even though images composed with gradient echo pulse sequences possess lower signal-to-
noise ratio and spatial resolution compared to spin echo pulse sequences, they are currently 
the most appropriate imaging sequence to use with SPIONs.  This is often termed magnetic 
susceptibility imaging(1, 3, 82, 102).  The contrast enhancement captured on an MR image is 
dependent upon a number of factors.  Most notable are the biodistribution and opsonisation of 
SPIONs.  
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 1.4.9 Iron oxide nanoparticles as contrast agents for MRI  
 
In addition to their superior biocompatibility, IONP MRI contrast agents have been 
documented to increase diagnostic sensitivity and specificity(56, 79, 103-105) in both animal model 
experimentation and in human trials.  This improved accuracy has been attributed to their 
superparamagnetic effects and relaxation times(103, 105, 106).  Efficacy of IONPs as MRI 
dedicated contrast media also largely depends upon their physiochemical properties(56).  Such 
attributes include: size (both of the iron oxide core and the overall hydrodynamic 
dimensions); coating (dextran derivative or other); and the zeta surface charges.  Their 
efficacy can be further increased with complex surface modifications.  This is achieved by 
bonding or attaching active material such as monoclonal antibodies, receptor ligands and also 
proteins(56).  For intravascular administration, the hydrodynamic diameter of IONPs are very 
rarely greater than 150 nm.  The iron oxide core itself is usually no more than about 15 
nm(107).  The coating itself is preferably composed of dextran, or a derivative, of a low 
molecular weight.  These are positive properties, as the dextran is biodegradable and its low 
molecular weight minimises possibilities of adverse reactions(88).  IONPs have also been 
incorporated into oral contrast media(56).  
 
 
1.4.10 Imaging challenges to consider and overcome   
 
There are a few imaging challenges with the use of IONPs(108).  They are in relation to 
commonly encountered artefacts in MRI imaging.  On their own, they can be frustrating to 
deal with in everyday imaging, however, when IONPs are included in the imaging regime, a 
further layer of complication is added.  The first criticism is that it is difficult to determine or 
32 
 
 differentiate a signal void induced by IONPs compared to signal voids generated as artefacts 
by materials such as metal (susceptibility artefact).  The second artefact is that of partial 
volume averaging.  IONPs are capable of being involved in processes occurring at a cellular 
level.  Hence, signal voids induced by IONPs that are smaller than the spatial resolution of the 
MRI image will not be represented as distinct and within a voxel; as individual signal 
intensities within a voxel are averaged together (1-3, 108).   
 
 
1.4.11 Emerging trends: Applications of iron oxide nanoparticles and 
the role of MRI  
 
Where possible and practicable, medical investigators and clinicians would prefer an 
investigation means that is non-invasive or minimally invasive.  This approach is safer for 
patients, it expedites the medical management of patients, and can negate morbidity and 
mortality consequences.  IONP preparations, combined with MRI, have the potential to 
revolutionise a number of investigative and treatment procedures.  This would be achieved by 
combining the advantages provided by IONP together with MRI, leading to safer and superior 
imaging alternatives.  IONPs as MRI contrast agents have already been discussed in this 
thesis.  To re-iterate, they promise improved levels of toxicity and increased diagnostic 
sensitivity and specificity.  These are achieved through careful chemical preparations, leading 
to IONPs having the required characteristics for biocompatibility and MRI image 
enhancement.  It is recognised that further research is required to overcome the challenges 
mentioned.  A discussion on the innovative uses of IONPs combined with MR techniques will 
now follow.  These promise to revolutionise clinical therapies and improve patient outcomes.  
Molecular imaging is a broad term concerning the imaging of biological events at the cellular 
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 or molecular level.  It should also be non-invasive and the imaging characteristics 
representing the biological activity should be quantifiable(109).  MRI is seen as having an 
emerging and innovative role.  Molecular imaging can be possible with MRI when IONPs are 
conjugated with biologically active materials such as antibodies.  The near future looks 
promising for MRI, together with IONPs, to have a positive impact in leading non- invasive 
imaging of biological and biochemical processes.  Not only can such processes be diagnosed; 
but also progression and treatment can be imaged over time.  
 
 
1.4.11.1 Angiogenesis  
 
Angiogenesis, the growth of new blood vessels (for development, wound repair or tissue 
reproduction), is related to tumour growth and progression(66).  There are several known 
molecular markers associated with angiogenesis.  That is, endothelial cells active in 
angiogenesis express known surface receptors compared to endothelial cells not partaking in 
angiogenesis(110).  The commonly occurring receptors include integrins and vascular 
endothelial growth factor receptors.  Antibodies or drugs to seek out angiogenic markers, can 
be conjugated to IONPs and imaged with MRI.  Thus, the angiogenic process can be 
identified and any success in treatment can be accurately monitored.  This can be achieved by 
exploiting the increased permeability of newly formed tumour vessels compared to normal 
healthy vessels(111).   
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 1.4.11.2 Apoptosis  
 
Apoptosis is the self destruction of cells.  When determined by cell age or cell health status, 
the nucleus triggers this process. It requires metabolic activity by the dying cell and is 
commonly characterised by a redistribution of phosphatidylsenine in the cell membrane(66).  It 
can even be associated with tissue development and homeostasis(110).  The degree of apoptosis 
can determine how successful chemotherapy and radiation therapy can be.  Identifying 
apoptotic events in vivo would hence further evaluate treatment regimes and progression of 
pathology(110).  It is known that apoptotic cells express lipid phospatidylserine (a 
phospholipid) on their cell membrane.  Synaptotagmin I is a protein that is used to detect this 
phospholipid.  When this protein was conjugated to IONPs, apoptosis was demonstrated in 
vivo with mice(112).  The capability to image apoptosis can allow for almost real-time 
monitoring of efficacy of drug therapies(90).   
 
 
1.4.11.3 Targeted drug delivery with IONP and MRI  
 
Many therapeutic drugs that are available, can be considered non-specific in nature.  By non-
specific, it is meant that such drugs are administered intravascularly and are thus distributed 
randomly.  This can lead to unwanted effects on healthy tissue(113).  Specificity for target 
tissue or cells can be achieved by conjugating IONPs with ligands(110).  Such ligands include 
antibodies (in particular for targeting cancerous tissue or cells), proteins, peptides and other 
biological markers.  Targeted drug delivery, as provided by superparamagnetic colloid 
suspensions, can be guided by an external magnetic field to the site of interest(56), thus, having 
the capability to minimise both side effects and required dose(113-115).  Therefore, 
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 pharmaceutical drugs can be bound to IONPs designed to reach a specific, or target, organ, 
and then be released there(56, 77).  The emerging breakthroughs that make magnetic drug 
targeting possible and promising are the new classes of IONPs less than 50nm.  This allows 
for improved circulation time, thereby permitting delivery to the target site without the 
likelihood of being sequestrated by the RES before this can occur(56).  With the original 
classes of IONPs that became commercially available over ten years ago, RES uptake 
occurred within a few minutes following intravascular administration (hence, their original 
application as dedicated contrast agents for the liver)(56).  Drug targeting can be achieved by 
passive, active or physical means(56).  Magnetic drug targeting falls into the category of 
physical means; as the pharmaceutical is attached to a carrier system (the IONP) and its 
distribution is facilitated with an external influence (the magnetic field).  Not all therapeutic 
drugs can be conjugated to one single variety of IONP.  Characteristics of IONPs that can 
determine attachment of therapeutic drugs include their size, surface charges (zeta charges) 
and capacity for protein absorption(56).  The process of cell uptake is determined by the overall 
size of the nano-system (IONP, surface coating/s and pharmaceutical); phagocytosis or 
pinocytosis.  Pinocytosis occurs for items less than 150 nm(56, 113).  The condition under which 
a cell finds itself in, may alter its susceptibility to a nano-system.  For example, under normal 
conditions, walls of endothelial cells are permeable to objects 10nm or smaller.  However, 
when involved in pathologic processes such as tumour infiltration and inflammation, the 
endothelial wall can be permeable to objects up to as large as 700 nm(56).  Zeta charges need 
to be carefully managed.  They determine whether or not nanoparticles aggregate or if they 
remain suspended in its medium.  More importantly, they also play a part in endocytosis.  It is 
noted that the likelihood of phagocytosis increases with a higher zeta charge(56, 116), while time 
spent within the circulatory system is reduced.  There is an electrostatic process involved 
when particles and substances are absorbed by a cell’s outer membrane(117).  Understanding 
nanosystem interaction with proteins is vital, as when they are injected into the vascular 
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 system, their first interaction is with the plasma proteins.  Therefore, the manner in which 
nanosystems are capable of interacting with opsonins (proteins that encourage phagocytosis 
such as IgG) and dysopsonins (proteins inhibiting phagocytosis) also determine if they are 
readily phagocytosed by the RES or if they can reach their intended target and release their 
pharmaceuticals.  Hence, protein repulsive molecules such as polyethylene glycol (PEG) can 
be used to modify the surface of nano- systems to reduce their recognition by the RES(113) and 
reduce non-specific cellular uptake(118).  A phase I/II clinical trial of IONPs combined with 
epirubicin designed to image and treat solid tumours (such as sarcomas), showed that these 
nanosystems were reasonably well tolerated by the fourteen patients involved.  No organ 
toxicity attributable to iron oxide was noted; however, toxicity responses to epirubicin were 
recorded at doses greater than 50 mg/m2(119).   
 
 
1.4.11.4 Thermal applications for cancer cells: magnetocytolysis and 
hyperthermia with IONP and MRI  
 
Compared to normal healthy cells, cancer cells are known to be sensitive to temperatures 
above 42 oC.  Normal cells can survive at higher temperatures(77).  In cancer cells, at 
temperatures above 42 oC, protein function is disrupted which can lead to apoptosis(114).  
Thus, hyperthermia is a proposed treatment regime for certain cancers.  Until recently, 
hyperthermic approaches have included irradiation with radiofrequency, ultrasound and 
microwaves.  One known criticism of these approaches is the likelihood of hyperthermic 
injury extending to healthy tissue.  The term, magnetic induction hyperthermia, now refers to 
cancer tissue being exposed to an alternating magnetic field(77).   
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 Hyperthermia using IONPs together with MRI has demonstrated positive results in pre-
clinical evaluation studies.  With this combined approach, magnetic nanoparticles can be 
either directly injected into a tumour volume or designed to be selectively uptaken by a 
tumour site.  This target-selective capability improves local heating treatment to the tumour 
while dramatically minimising potential for injury to surrounding healthy tissue(120).  
Furthermore, the alternating magnetic field (not absorbed by tissue), together with 
appropriately prepared IONP, can allow hyperthermia treatment(56) to be applied to areas deep 
within the body(77).  Radiofrequency pulses provided by MRI can be designed to provide 
frequencies and amplitudes to increase local cell temperature up to 55 oC(114), thereby 
inducing cytolysis.  This process, therefore, can be used to generate heat to target cells(121).  
For magnetic hyperthermia to be successful, it requires accurate delivery of magnetic 
nanoparticles to the tumour site.  A number of experiments report successful use of magnetic 
induction hyperthermia in cancerous cell models and also in animal models(77, 120, 122).  Salado 
et al.(123) successfully demonstrated in a rat model, with in vivo MRI imaging, that the IONPs 
which they developed were capable of providing positive contrast enhancement of induced 
liver tumour and also successfully treated these liver tumours with MRI-induced 
hyperthermia; thereby, demonstrating that IONPs can have both a diagnostic and therapeutic 
use.  Analysis of the rats following the experimental study demonstrated no vascular 
embolisms (the IONP preparation was injected through the ileo-colic vein) and specimens of 
the liver demonstrated insignificant inflammatory changes.  Xu et al.(124) have produced 
nanoparticles containing a core composed of iron and cobalt and a gold shell.  These 
nanoparticles demonstrated a specific magnetisation value far greater (226 emu/g) than that 
achievable with commercially available iron oxides (78.8 emu/g).  This higher magnetic 
moment is claimed to improve heating efficiency in hyperthermia applications; however, their 
publication did not mention any results or discussion of toxicity or biocompatibility studies.   
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 Initial success of magnetic hyperthermia with small groups of human patients provides a 
promising outlook for future clinical applications.  Plotkin et al.(125) reports a study on eleven 
consecutive patients (mean age 44 years), each with recurrent supratentorial glioblastoma.  
All patients had previously undergone surgery, nine patients also had radiation therapy and 
eight patients also had chemotherapy.  Based on the prognosis following these treatments, 
these eleven patients were eligible as candidates for hyperthermia using nanoparticles and 
MRI.  Nanoparticles were then administered directly into the tumour volume.  MRI 
hyperthermia, or nano cancer therapy, followed and in ten patients, the mean reduction in 
gross tumour volume (GTV) was 74 % as indicated with PET/CT fusion imaging.   
 
 
 
 
1.4.11.5 Cancer imaging with IONP and MRI  
 
Diagnosing cancer in its early stages significantly improves patient outcomes and survival 
rates.  The initial use for IONPs was directed at imaging liver tumours(126).  This was due to 
the nanoparticles being greater than 60nm and therefore readily phagocytosed by the liver.  
This has been occurring for several years now and there are a few commercially available 
preparations for this specific purpose.  This author will therefore discuss IONPs in relation to 
other cancers.  Current MRI techniques allow for the detection of tumour sizes in the order of 
one centimetre cubed.  By conjugating known cancer antibodies with IONPs, then MRI can 
be used to identify cancerous tissue of smaller dimensions through molecular interactions.  
This is an improved sensitivity for cancer markers, compared with current cancer marker 
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 detection probes(127).  IONP can be coated with DMSA, a bi-functional chelating agent and 
ligand.  Herceptin, a monoclonal antibody, uses elements from within the immune system to 
stop tumour progression by binding to HER2 receptor and triggering a response by natural 
killer (NK) cells(128).  With a 1.5 Tesla clinical MRI scanner, Lee et al.(127) successfully 
demonstrated how to identify cancer sizes as small as 50mg in mice using IONPs conjugated 
with Herceptin.  The above approach improves patient outcomes compared with just 
chemotherapy alone.  This principle has also been used to target other tumour antigens. 
IONPs conjugated with EPPT1 (a synthetic peptide) are able to target under-glycosylated 
MUC-1 (mucin 1); which is a tumour antigen expressed by many epithelial cell 
adenocarcinomas such as pancreatic, colorectal, gastric and prostate(90).  The role that lymph 
nodes play in cancer staging has not gone unnoticed by researchers in this field. IONPs and 
MRI can be used to image the condition of lymph nodes and more accurately determine the 
extent of metastatic spread(109).  Oghabian et al.(129) demonstrated 98% detection sensitivity 
with in vivo imaging of a rat model at 1.5 Tesla.  They also concluded that the type of surface 
coating and its thickness were factors in determining MRI signal intensity.  Today, prostate 
cancer is still a leading cause of death in men.  Current treatment, among others, involves 
brachytherapy, and as a procedure, it has its own level of invasiveness, morbidity and 
mortality.  Wang et al.(130) have conjugated IONPs with prostate specific membrane antigen 
(PSMA) and also with doxorubicin, a chemotherapy drug.  By performing whole cell assays 
on human cell lines, Wang et al. demonstrated that their conjugate can detect, with high 
sensitivity, prostate cancer cells expressing PSMA, thereby, promising the possibility of a 
multifunctional (diagnostic and therapeutic) nanoparticle system.  IONPs can also be used to 
better identify tumour boundaries within the brain(109, 126, 131, 132).  This leads to improved 
quantification of tumour volumes.  Compared with gadolinium-based contrast agents for MRI 
and also taking into consideration oedema surrounding a tumour volume, IONPs can define 
tumour margins for longer time periods(109, 131, 133).  This is as a result of the IONPs being 
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 endocytosed by tumour cells.  Thus being internalised, their elimination rate from the tumour 
is longer compared to extracellular gadolinium-based contrast media.  
 
 
1.4.11.6 Cell labelling and tracking; including stem cell therapies  
 
MRI imaging of cells labelled or endocytosed with IONPs is considered an indirect imaging 
technique.  This is because changes in MRI signal intensity is in relation to the amount of 
IONPs and not due to the number of cells.  One concern is the MRI signal characteristic and 
change over a time period.  As stem cells rapidly divide, the fixed amount of IONPs is spread 
throughout the volume of newly divided daughter cells(108, 115).  This will be a relative 
decrease in MRI signal not accurately reflecting the activity of cells.  The second noteworthy 
concern is the possibility of false positive signal findings.  This is a result of iron presented 
from cells undergoing apoptosis or lysis(108).  Despite these challenges, possibilities are being 
created for many biomedical applications(117).  The possibility of imaging stem cells in 
therapeutic applications with MRI is becoming an ever increasing area of active research.  
Published research so far indicates that IONPs combined with peptides or transfection agents 
can be used for stem cell uptake(115).  A study using stem cells with IONPs injected into the 
infarcted myocardium of pigs was able to be successfully imaged at 1.5 Tesla in vivo(134).  
Following this, histological analysis revealed that the MRI signal appearance attributed to 
IONPs corresponded with stem cells that had taken up IONPs.  Heymer et al.(135) combined 
human mesenchymal stem cells (hMSCs) with IONPs; placed these in collage type I hydrogel 
(clinically approved for the repair of articular cartilage) and imaged them in an 11.7 Tesla 
MRI scanner.  Iron uptake was confirmed by histological analysis and correlated with hypo-
intense regions demonstrated on the MRI images.  Their technique offers the possibility to use 
41 
 
 MRI to track the migration of IONPs loaded with hMSCs following implantation for articular 
cartilage repair.  Stem cell research is highly regarded as offering possible treatment solutions 
for patients with neuronal pathologies and injuries.  Guzman et al.(136) proved that IONPs 
themselves do not alter survival rates, migration patterns or differentiation capabilities of stem 
cells from the human central nervous system (CNS), compared with unlabelled human CNS 
stem cells.  They demonstrated this by administering the combined human CNS stem cells 
and IONPs into neonatal, adult and injured rodent brains.  MRI was then used to track the 
migration of stem cells and confirmed the image findings histologically.  Stem cells labelled 
with IONPs have been widely used in animal models (mice, rats and pigs) to demonstrate 
regeneration of the myocardium following infarction(137).  The limitation of this technique is 
that the conjugation of IONPs and stem cells need to be injected directly into the 
myocardium.  This introduces an element of invasiveness, however, the region of infarct can 
be clearly delineated(138).  So far, administration of stem cell and IONP conjugations for 
myocardial regeneration via a vascular route (intravenous or intracoronary), has not been as 
successful as direct injection into the infarcted myocardium.  Furthermore, comparative high 
volumes are needed(137, 139).   
 
 
1.4.11.7 Cardiovascular imaging with IONP and MRI  
 
IONPs have also demonstrated capabilities in imaging cardiovascular pathologies including 
atherosclerosis, thrombosis and myocardial infarcts(90, 140).  Atherosclerosis is considered both 
a progressive disease and chronic inflammation.  The endothelial cells of the vascular wall 
express receptors from their cell membrane to attract monocytes.  Monocytes establish 
themselves in the sub-endothelial space and then differentiate into macrophages.  The 
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 macrophages then take up oxidised low density lipoproteins and this lipoprotein can be 
conjugated to IONPs and used to identify active regions of atherosclerosis with MRI.  This 
approach has been often used in studies involving animal models(141).  Furthermore, apoptosis 
leads to plaque instability and is known to occur before plaque rupture(141).  Identifying 
apoptic plaques in vivo with MRI is seen as advantageous in improving patient outcomes, as 
inflammatory activity of atherosclerotic plaques may be associated with an increased risk of 
rupture(137).  Aortic valve disease is also an inflammatory response with macrophage 
involvement(115).  Ruehm et al successfully used commercially available IONPs to 
demonstrate (with MR imaging) in hyper-lipidemic rabbits that atherosclerotic plaques 
containing macrophages take up these nanoparticles(142).  This was confirmed with 
histopathogical evaluation techniques on samples removed from the aorta.  The MRI 
appearance demonstrated an aorta with irregular pattern where the signal dropout occurred at 
plaque sites containing macrophages endocytosing the IONPs.   
IONPs can also be used to target fibrin containing thrombi.  This approach may be considered 
a sensitive method of identifying patients at risk of more serious cardiovascular 
consequences(143).  A study by Winter et al.(144) demonstrated that by using anti-fibrin 
antibodies together with nanoparticles, clots in canine plasma in vitro could be identified with 
MRI (at 4.7 Tesla).   
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 1.4.11.8 Blood pool contrast agent  
 
There has been a high level of success in using IONPs as blood pool agents; in both animal 
models and in human subjects.  One study(145) investigated size and dose of IONPs as a blood 
pool agent for MR angiography in New Zealand White rabbits.  The rabbits were divided into 
a control group (administered with gadopentate dimeglumine), and three other groups (each 
receiving a different concentration of IONPs).  MR angiography was performed at varying 
time points; ranging from first pass to 24 hours post-intravascular administration.  Assessment 
included signal enhancement of the abdominal aorta, renal arteries and the iliac arteries.  
Results demonstrated that the highest level of signal enhancement was identified during the 
first pass imaging strategy.  It was also noted that enhancement in the abdominal aorta was 
greatest with the smallest nanoparticle size of 21 nm.  In addition to this, a concentration of 
40micromole of iron per kilogram was recognised as the dose providing signal enhancement 
comparable to gadopentate dimeglumine.  The size and dose of IONPs provided sufficient 
signal changes to allow imaging from first pass time-point up to 25 minutes post-intravascular 
administration.  In this 25-minute window, multiple imaging acquisitions and measurements 
are possible.  Another study(146) successfully demonstrated the use of IONPs as a blood pool 
agent in rats with induced myocardial injuries.  Here, a commercially available blood pool 
agent, Clariscan, was used with an MRA technique.  The image findings were also compared 
with post-mortem histochemical stains of the infarcted rat myocardium.  It was found that the 
Clariscan-enhanced MR angiogram images over-estimated the infarcted myocardial regions 
when compared with histology inspection.  The use of Clariscan identified the presence and 
dimensions of both transmural and non-transmural microvasculature insults.  The peri-
infarcted zone was seen to be over-estimated to a greater extent in rats with non-transmural 
ischaemic injuries.  Overall, there was an over-estimation of the size of the true infarct but an 
under-estimation of the region at risk.   
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 Another commercially available IONP preparation (Resovist) has been used to assess the 
abdominal aorta and the inferior vena cava in a human pilot study(147).  With a 3D MRA (T1-
weighted) acquisition technique at 1.5 Tesla, first pass imaging was achievable with results 
being comparable to those obtained by MRA with conventional Gadolinium based contrast 
agents.  Ferumoxytol has also been used for first pass enhanced 3D MRA of blood vessels of 
varying dimensions in 12 human subjects.  The following vessels were investigated: the 
carotid arteries, thoracic aorta, abdominal aorta and peripheral arteries(148).  With delayed 
MRA imaging it was noted that both arterial and venous structures displayed enhancement 
characteristics. 
 
 
1.4.11.9 Nanosensor  
 
A critical and relatively new-found application of IONPs is to include them in preparations to 
produce what is now termed “nanosensors”.  Nanosensors, in their broadest definition, are 
IONP preparations that have been designed to detect the presence of a specific biological 
interaction.  Protease specific nanosensors have been developed for in vivo detection of 
enzyme activity with MRI(149).  In particular, T2* MRI together with nanosensors of 25 nm 
(hydrodynamic size) have demonstrated the involvement of the metalloproteinase 9 (MMP-9) 
enzyme in processes including inflammation, atherosclerosis and tumour spread.  This opens 
the potential for early diagnosis of pathologies with altered protease activity and also the 
monitoring of treatment and therapies that act on protease enzymes.  Protein functionalised 
nanosensors have also demonstrated capabilities in identifying and measuring the 
concentration of anti-human serum albumin antibodies(150).  One of the additional benefits of 
the combined approach of MRI with nanosensors is that the NMR capabilities can allow for 
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 detection in natural human substances such as blood and urine.  Nanosensors have also been 
developed with the capability to detect single human alveolar cancer cells (A549) within 15 
mins, in blood, in vitro(151).  High density folic acid, when conjugated to polyacrylic acid 
coated IONPs were designed to interact with A549 cancer cells expressing the folate receptor.  
 
 
1.4.11.10 Metal doped IONPs  
 
Metal doping of IONPs is designed to provide a comparatively higher level of magnetism at 
the nano scale and also allow successful magnetic tuning(152).  Such metal doped IONPs can 
increase MRI signal contrast by as much as 14 times compared to conventional IONPs.  The 
implication of this is that a lower dose or lower concentration can be administered to the 
patient.  Their magneto-thermic effects can also increase by a factor of 4.  Lanthanide metals 
have also been used to dope IONPs(153).  The advantages that lanthanide metals can offer 
include optical imaging properties, detection by neutron activation, utilised in neutron capture 
therapy procedures and also being detectable by time resolved fluorescence.  IONPs doped 
with manganese have shown to improve the quality of contrast-enhanced MR imaging of the 
liver(154).  These nano systems have a mean diameter of 80nm.  The highest level or change in 
signal intensity occurs at 5 mins post-intravascular administration.  However, unlike early 
IONPs, the imaging window for IONPs doped with manganese can last for approximately 36 
hours.  
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 1.5 Targeted imaging 
 
Targeted imaging is the term used to describe the directing of a nanoparticle to an intended 
site or destination within the body; such as an organ or a tumour.  A site can be targeted for 
imaging purposes only, or for drug delivery or both.  Such features are introduced at the 
design or synthesis stage of manufacturing nanoparticles, or, alternatively, prior to 
administering nanoparticles, the surface layer is functionalise such that the nanoparticle can 
carry out such tasks.   
Targeting can also be performed by loading nanoparticles into cells.  This can be performed 
by simple incubation.  The cells that are selected to be carriers are cells that are known to 
migrate to the organ of interest or cells involved in the pathological process under 
investigation.   
In the field of nuclear medicine, it has been known for decades that certain radio-active 
tracers or labels can be used to identify pathology via biochemical pathways.  For example, a 
radio-active form of fluorine, 18F, is used to make fluorodeoxyglucose (FDG) for PET 
imaging to assess glucose metabolism in the brain.  FDG is also used in PET imaging of many 
forms of cancer, as it accumulates in cancerous tissue with high metabolic activity. 
Monitoring the location, distribution and long-term engraftment of administered cells is 
critical for demonstrating the success of a cell therapy. 
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 1.5.1 Targeted imaging with cells loaded with IONP and MRI 
 
Nanoparticles can be tracked with MRI, as they migrate from their administered site to their 
destination.  In particular, stem cells have been used together with MRI to monitor 
experimental treatments.   
Jendelova et al(155) used IONP loaded the bone marrow stromal cells from rats and also loaded 
into the embryonic stem cells from mice.  They were implanted into animals having been 
deliberately given either a spinal cord compression or a cortical lesion; the implantation was 
on the contralateral side.  Migration towards the injury site was imaged.  Migration took 
approximately one week.  MRI was used to track their path.  The cells with IONPs deposited 
in intracerebrally were capable of providing a hypo-intense MRI signal for over 50 days. 
McFadden et al(156) successfully labelled 231BR‐Her2 cells with IONP and administered these 
into female nude mice via a left ventricle injection.  One day later, these loaded cells were 
detectable in the brain of these mice with 3T MRI, in vivo.  The particles used were 35 nm in 
diameter and labelled with Rhodamine-B.  Such a particle was not only capable of providing 
MRI signal, and thus being capable of being tracked over time, but the Rhodamine-B allowed 
the particle to be identified and confirmed in tissue samples with a fluorescent microscope. 
 
 
1.5.2 Targeted imaging with radio-labelled IONP and MRI 
 
With the introduction PET/MRI, superparamagnetic IONP radio-labelled with radio-active 
tracers can potentially provide capabilities for high spatial resolution imaging (MRI), high 
contrast resolution imaging with high sensitivity and biochemical assessment (PET).  Studies 
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 have already been conducted, attempting to use the well-known targeting capabilities certain 
radio-tracers labelled with IONP. 
Wong et al(157) has demonstrated a proof of principle that 64Cu can be labelled to IONP and 
postulates their use with PET/MRI.  They focussed on rapid production techniques using 
microwave techniques (while minimally impacting on the radio-active decay time of 64Cu) 
while delivering consistently uniformly size nanoparticles.  Pombo-Garcia et al(158) also used 
64Cu to radio-label ultrasmall IONP and conducted in vitro assessment with human serum, 
noting time dependent internalisation with human umbilical vein endothelial cells.  These 
investigators also postulate the potential for their use in tumour imaging with PET/MRI. 
99mTc is a standard SPECT radio-active label.  Madru et al(159) has successfully radio-labelled 
99mTc to IONP (with a surface layer of polyethylene glycol) with the intention of imaging the 
sentinel lymph node, in vivo, in Wistar rats after they received sub-cutaneous injections of 
their right paw.  Imaging was performed at 4 hours post injection, initially with SPECT , then 
followed with 3.0 T MRI. 
Madru et al   has also experimented with radiolabelling 68Ga to IONP with polyethylene 
glycol as its surface layer, and successfully demonstrated their capabilities in imaging the 
sentinel lymph node in white Wistar rats(159).   
 
 
1.6 Sentinel Lymph Node Imaging 
 
The sentinel lymph node (SLN) is recognised as the first lymph node to be reached by 
metastatic cancer cells.  The mechanism of which, is directly related to the anatomical 
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 arrangement of the lymphatic system and also its function; relative to the tumour.  From a 
broad physiological perspective, the entire lymphatic system is designed to monitor fluid 
homeostasis and immune competence (160).  Further to this, the lymphatic system acts as a 
physical pathway for dendritic cells to facilitate their role in an immune response.  The entire 
lymphatic system has been considered to be a unidirectional and open ended system (161) that 
serves to drain excess interstitial fluid, large molecules, or cells that cannot re-enter the 
cardiovascular system.  Lymphatic vessels can be detected in almost all organs and interstitial 
tissue throughout the human body (162).  A tumour can transmit cells to its SLN either through 
afferent lymphatic vessels (which surround the tumour itself) or through the new development 
of lymph vessels originating from the tumour (163).  Hence, the realistic likelihood of 
metastatic cancer cells being present in the SLN. 
The identification of the SLN is of paramount importance in a patient’s diagnosis with certain 
cancers, in particular, cancers which are solid tumours and are in close proximity to lymph 
node clusters.  The establishment of malignant cancer cells in the SLN determines the 
subsequent prognostic pathway for a patient (164).  Clinicians can then make appropriate 
decisions relating to treatment, therapy and overall medical management (165).  Such decisions 
need to be made and acted upon in a precise, safe and timely manner.  The clinical intent is to 
have improved outcomes for such patients. 
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 1.6.1 Current methods 
 
The two most popular, current and valid imaging techniques are lymphoscintigraphy and 
computed tomography (CT).  They each have their own advantages and disadvantages in 
determining the SLN.  Once the SLN is identified, it will be either biopsied or surgically 
excised; then followed with histopathology assessment.  Hemotoxylin and eosin staining 
(H&E) and also cytokeratin immunohistochemical staining (IHC) are performed to determine 
the presence of cancer cells (166, 167).  If no cancer cells are identified, then the likelihood of 
other lymph nodes (other than the SLN) being infiltrated by cancer cells is less than 0.1% (166).  
If cancer cells are present within the SLN, then the treatment and therapy that a patient 
receives would be more intense and aggressive.  In melanoma patients, following metastatic 
lymph node removal, the five year survival rate is in the range of 44 % to 60 %, whereas 
delaying surgical removal of lymph nodes has an associated five year survival rate of 25 %  
(167). 
From a medical radiations perspective, both lymphoscintigraphy and CT are imaging 
modalities with their own disadvantages, when attempting to identify the SLN.  
Lymphoscintigraphy has very low spatial resolution (168).  CT requires a high volume of 
iodine based contrast media and also needs a number of volume data acquisitions to be made, 
thus, delivering a high dose of ionising radiation to the patient (169, 170).  Pre-operative imaging 
with either CT or Magnetic Resonance Imaging (MRI), without contrast agents, does not 
provide adequate sensitivity for clinicians to decide whether or not to surgically remove 
lymph nodes (171).  MRI, combined with iron oxide nanoparticles (IONP) as a contrast agent, 
has the potential to overcome the negatives associated with both lymphoscintigraphy and CT; 
and also MRI scanning without a contrast agent (172-175).   
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1.6.1.1 Lymphoscintigraphy and its role in current clinical practice 
 
In broad terms, lymphoscintigraphy can be defined as the imaging of the lymphatic pathways 
and lymph nodes by using radio-active material.  It is an established and routine nuclear 
medicine imaging procedure that captures information about lymphatic drainage (166) and the 
SLN (160). 
There are a variety of radio-active colloids and agents that are in current use.  These include 
99mTc labelled sulphur colloid (161), 99mTc labelled human serum albumin, 99mTc labelled 
dextran (166) and also 99mTc trisulfidecolloid (163).  Collectively, these are also referred to as 
99mTc nanocolloids .(171)  To improve detection sensitivity rates to higher than 90% (176), 
medical blue dyes can be used such as isosulfan blue, patent blue V or Evans blue (EB)  (160) 
in combination with 99mTc nanocolloids.  These blue dyes aid macroscopic identification of 
lymphatic pathways (177).  These radio-active agents emit gamma rays.  Thus, standard nuclear 
medicine gamma cameras and equipment are used to image their level of radio-activity.  As 
they become localised in the SLN, the gamma activity level is imaged as being representative 
of the SLN.   
The fundamental concept that underpins SLN imaging by lymphoscintigraphy is that the 
radio-active material that has been injected in close proximity to the primary tumour will then 
be taken up by adjacent lymph vessels and carried to the SLN.  In the current clinical setting, 
there are two approaches of injecting radio-active agents into patients for lymphoscintigraphy.  
Both are valid, can be complimentary and are still subject to ongoing debate (163, 178). 
The first is deep tissue injection such as subcutaneous, parenchymal, peri-tumoural and intra-
tumoural injections; commonly, by a single injection of radio-active material (171).  The second 
method is by superficial injection into the epidermal or dermal regions.  This includes 
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 intradermal and subdermal injections, as well as peri-areolar and sub-areolar injections in 
breast cancer patients.  Here, a clinician will most likely perform four intradermal injections 
surrounding the tumour mass (179).  The usual range of radio-active dose per injection is 
between 7 MBq and 10 MBq (180). 
The passage followed by the injected imaging agents is identical to that of malignant cells 
extending from the tumour mass to the SLN.  Such imaging agents can be either the medical 
blue dyes or radio-active agents previously discussed, or, as will be proposed here, iron oxide 
nanoparticles.  Tumour cells are transported to the SLN by the afferent lymph.  They arrive 
either as individual cells or as emboli of cell agglomerations (163).  These malignant cells 
initially settle in the sub-capsular sinus and the cortex of the SLN.  These regions of a lymph 
node are located in close proximity to afferent lymph vessels, thus, providing an explanation 
for being the usual commencement sites of neoplastic tumour growth (181).  The lymphatic 
communication, from tumour mass to SLN, can occur along existing afferent vessels, or along 
new peri-tumoural lymphatic vessels. 
 
 
1.6.1.2 Clinical concerns and limitations of lymphoscintigraphy 
 
Even though identifying the SLN with lymphoscintigraphy is vitally important in cancer 
patients, the procedure of lymphoscintigraphy itself has a number of significant drawbacks.  
Firstly, the resulting lymphoscintigraphy images have poor quality spatial resolution.  From 
the images, the exact location of the SLN cannot be confidently ascertained (166) and as a 
result, a hand-held gamma probe (or nuclear stethoscope) must be used intra-operatively to 
locate the SLN immediately prior to surgical removal.  Secondly, lymphoscintigraphy lacks 
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 specificity, as it relies on natural uptake of the radio-active agents from the interstitial spaces 
by the lymphatic vessels (182).   
There is also a significant level of operator dependency when using the gamma probe and the 
technique and experience of the operator is linked to the successful identification of the SLN 
(161). 
Ionising radiation is used and while the radiation dose that the patient receives may be 
considered low, the repeated radiation dose to the fingers received by staff that handle the 
resected SLN (such as the surgeon and the histopathologist) can accumulate over many years 
(161). 
Finally, proper injection technique must be observed when administering the radio-active 
imaging agent, or there may be focal contamination or pooling of the radio-active agent.  This 
can mimic the appearance of a SLN and lead to false positive assessments (179). 
 
 
1.6.1.3 The role of computed tomography (CT) 
 
Computed tomography (CT) provides improved spatial resolution as an imaging modality 
compared to lymphoscintigraphy.  CT is readily available and imaging examinations are 
relatively straight forward with minimal discomfort for patients. 
Identifying lymph nodes with CT imaging can, however, become complex, particularly when 
they are involved with a pathologic process.  On CT imaging, normal healthy lymph nodes 
have an oval or eliptical shape.  As they become involved in a pathologic process (such as 
malignancy, infection, inflammation), lymph nodes take on a circular shape.  Their short axis 
dimension also increases to over one centimetre.  The challenge for CT is to distinguish such 
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 lymph nodes from nearby blood vessels.  Both arteries and veins have a circular appearance in 
their short axis.  The challenge for CT becomes even greater when blood vessels have a short 
axis of just over one centimetre (183). 
Current clinical practice for CT imaging is to scan the anatomical area of interest dynamically 
with iodine based intravascular contrast media.  CT images are taken of the anatomical area of 
interest without intravascular contrast media; then the same area is imaged with iodine based 
contrast media in the arterial phase (contrast media flowing through arteries); next, the same 
anatomy is scanned with the contrast media flowing through the veins (venous phase); finally, 
after approximately 10 minutes, the same anatomical area is scanned again.  This last 
acquisition is referred to as a delayed post contrast phase.  It is in this phase that 
pathologically affected lymph nodes may demonstrate positive enhancement (appear hyper-
dense or bright).  The arterial phase will demonstrate contrast filled arteries, while the venous 
phase will show veins filled with contrast media.  Lymph nodes will not enhance with 
contrast media during the arterial and venous phases. 
CT imaging of lymph nodes also has inherent disadvantages.  First, it uses ionising radiation.  
Considering that up to four acquisitions can be needed (non-contrast, arterial, venous and 
delayed post-contrast), the radiation dose received by the patient can be large – significantly 
greater than the radiation levels used with lymphoscintigrahy.  Second, iodine based contrast 
media is required, which, in certain patient groups, can lead to contrast induced nephropathy 
(CIN).  Also, patients may experience adverse events ranging from minor events such as a 
warm flush or sensation throughout their body to more severe and serious events such as 
anaphylaxis.  Third, the identification of a suspect lymph node is made, based upon its shape 
and short axis measurement (163, 183).  This, of course, cannot account for normal variants or 
anomalies.  Thus, lymph node size is an ineffective parameter for attempting to diagnose 
metastatic progression to lymph nodes (184) 
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 Fourth, with the recent clinical introduction of PET/CT (positron emission tomography 
combined with computed tomography), the combination of a radio-active agent for lymph 
node imaging with PET followed by CT imaging acquisitions for lymph node; will further 
compound the radiation dose received by the patient.   
 
 
1.6.1.4 Magnetic resonance imaging 
 
As an imaging modality, magnetic resonance imaging (MRI) offers a number of advantages 
compared to nuclear medicine imaging with radio-active tracers and also when placed 
alongside CT.  MRI uses pulse sequences composed of radio-frequency pulses and also time 
varying magnetic (or gradient) fields, to generate images, thus, MRI does not image with 
ionising radiation (185).  In addition, MRI has superior spatial resolution, compared to both 
lymphoscintigraphy and CT (3).  This is due to the capability of image voxels having 
dimensions of less than one millimetre on all sides.  In fact, volume or 3D acquisitions can be 
achieved with isotropic voxels.  Therefore, the same level of spatial resolution can be 
maintained when reformations are performed from volume or 3D data sets (186). Reformations 
in a variety of planes (non-orthogonal) can be achieved, to help locate the SLN and such 
reformations would be tailored to an individual patient’s anatomy. 
As the magnetic field strength of an MRI scanner increases, so too does its signal-to-noise 
ratio, which leads to an improved contrast resolution (186).  Even with the higher level of 
spatial resolution offered by MRI, it does not seem to have the contrast resolution to identify a 
metastatic lymph node from a healthy one.  In a study conducted by Kortewegg et al(187), 114 
lymph nodes that had been surgically removed from positively diagnosed cancer patients; 
were scanned with a 7.0 Tesla MRI scanner.  The 7.0 T MRI image findings were compared 
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 with the definitive histopathologic assessments.  The findings were that, even with spatial 
resolution and signal-to-noise ratio offered by a 7.0 Tesla MRI scanner, there was poor 
discrimination between healthy and diseased lymph nodes.  Morphological aspects that were 
scrutinised on MRI images were: the fatty centre, the volume, the length-width ratio, and the 
cortical thickness of the lymph nodes (188).  It should be noted that as this study only scanned 
dissected lymph nodes, there was no opportunity to incorporate a contrast agent into the 
experiment.  Also noteworthy, is that 7.0 Tesla is an extremely high field strength for an MRI 
scanner – most current clinical MRI scanners are either 1.5 Tesla or 3.0 Tesla.     
MRI also has its own specific contrast media, based on gadolinium, however, it is not used for 
identifying the SLN.  It has an established clinical role for imaging a variety of disease 
processes such as infection and oncology (primary tumours and metastases), however, not the 
SLN.  A meta-analysis of data published over a 20 year period concluded that the accuracy of 
MRI with gadolinium contrast media in detecting lymph node metastases is considered 
moderate (189) compared to MRI imaging of lymph nodes without gadolinium contrast media.   
In recent years, concern has arisen over the use of gadolinium (190) as it is now recognised as 
the trigger for nephrogenic systemic fibrosis (NSF) in a variety of patient groups, including 
patients with Type 1 diabetes and patients with an estimated glomerular filtration rate (eGFR) 
of less than 60 ml/min (26). 
Gadolinium based contrast media is categorised as an extracellular contrast media as it 
circulates through the extracellular spaces and should not enter cells.  When placed within the 
imaging environment of an MRI scanner, gadolinium shortens the T1 recovery (or 
longitudinal relaxation) of the surrounding tissue.  Therefore, gadolinium appears hyper-
intense (or bright) on MRI images produced with T1 weighted pulse sequences.  Gadolinium 
has negligible effect on T2 decay (transverse relaxation) and thus, no intensity changes are 
able to be detected by the human eye (or observer). 
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 Iron oxide nanoparticles (IONP) behave in the opposite manner to gadolinium.  Their effect 
on T1 signal intensity cannot be observed by the human eye, however, they have magnetic 
susceptibility effects on T2 weighted and T2* (T2 star) weighted pulse sequences.  The 
resultant image will demonstrate marked areas of hypo-intensity (or dark) where the IONP 
have accumulated (186, 190). 
A review of the literature confirms that there has been some interest in imaging lymph nodes 
with MRI together with IONP.  Lymph nodes less than 8 mm in size have been detected in 
humans (175).  The commonly reported method is to administer the IONP by intravenous 
infusion.  The type of IONP used in these instances, are referred to as ultra small 
superparamagentic iron oxide (USPIO).  The brand most commonly used is feumoxtran-10 
(Combidex, Advanced Magnetics, Boston, MA, USA) (166, 191, 192).  Feumoxtran-10 is 
presented in a dry, powder type form and needs to be suspended in saline for intravenous 
infusion over a time period of 30 minutes, with a recommended dose of 2.6 mg/kg of body 
weight (165, 166).  Following entry into the venous system, the USPIO then extravasates into the 
interstitial space (191, 193).  From here, they are transported through lymphatic vessels to the 
lymph nodes (160).  Due to their dimensions (20 nm), USPIO are also capable of traversing 
capillary walls into the medullary sinuses of lymph nodes.  When the nanoparticles reach a 
normal healthy lymph node, they become phagocytosed by macrophages (160, 163, 190, 191, 193).  
The resulting accumulation of nanoparticles within macrophages leads to the magnetic 
susceptibility effect responsible for reduced signal intensity, or hypo-intense appearance of 
lymph nodes, seen on T2 weighted and T2* weighted MRI images.  In lymph nodes containing 
cancer cells, macrophages are unable to phagocytose the nanoparticles (160, 163, 190, 191).  
Therefore, cancer affected lymph nodes do not contain nanoparticles and so, do not display 
any change in signal intensity on T2 weighted and T2* weighted images.   
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 The case for IONP as a worth-while contrast agent for detecting lymph nodes is supported by 
Harisinghani et al(21) who scanned 58 male and 19 female (a total of 77) patients with MRI, 
24 hours following drip infusion of ferumoxtran-10.  In these patients, they were able to 
image collectively, 169 lymph nodes.  The findings of reporting radiologists were compared 
to that of the histopatholgy findings.  The diagnosis made by an experienced radiologist was 
noted to be not statistically different (p=0.88) to the histopathology results (21).  
Further, McCauley et al(194) investigated 9 healthy volunteers who received interstitial 
injections of ferumoxtran-10.  The interstitial dose used to visualise the lymph nodes was one-
tenth that of the dose used with an intravenous drip infusion.  Thus, McCauley et al concluded 
that an interstitial administration route would allow identification of lymph nodes at a 
significantly lower dose.  The researchers also noted the limitations of their study, which 
included a small number of subjects, and there was no independent confirmation of the 
number of lymph nodes in each patient (195).   
There are some disadvantages to imaging cancer affected lymph nodes following intravenous 
infusion of ferumoxtran-10.  The first is that USPIO are very slowly transported to the SLN, 
delaying MRI imaging to 24 to 36 hours following administration of USPIO (160, 163).  Second, 
MRI and USPIO can be referred to as an indirect method of identifying cancer affected lymph 
nodes, as it is the absence of USPIO uptake that is used to diagnose metastatic involvement of 
lymph nodes (163).  Third, image interpretation can also be time consuming.  This is due to the 
low contrast ratio between lymph nodes and their surrounding anatomy.  Fourth; the Food and 
Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) have 
not approved USPIO for human clinical use for the detection of lymph nodes because of 
concerns surrounding the high dose of USPIO used to detect a signal change in healthy lymph 
nodes(163).   
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 In the management of patients with cancer (in particular tumours such as prostate, breast, 
head and neck cancers, and melanoma), identifying the SLN will allow patient tailored 
treatment options to be considered.  Even though the current imaging method of 
lymphocintigraphy has been widely used, it has a number of negative aspects; some of which 
can be overcome by MRI (without IONP). The combination of MRI imaging with IONP may 
prove to be a more effective avenue for SLN detection, as it provides improved spatial 
resolution and does not involve ionising radiation. 
 
 
1.7 Cellular MRI (cMRI) 
 
Cellular magnetic resonance imaging (cMRI) is a method of imaging cells in vivo, and prior 
to administration, these cells would have been labelled with a contrast agent ex vivo.  Such a 
methodology has been experimented with in assessing the utility of cell-based therapies in 
vivo.  A promising branch of cancer immunotherapy that is gaining attention by researchers is 
DC-based vaccines; whereby, DCs are required to migrate to secondary lymphoid organs 
(such as lymph nodes) and interact with T cells to initiate tumour specific immune 
responses(196), thus, potentially, a patient’s own immune system can be used to battle cancer.  
DCs, and possible other antigen presenting immune cells, can be utilised as cell-based 
vaccine, due to their abilities to trigger immune responses.  cMRI can be used to non-
invasively observe the migration of DCs (loaded with an imaging agent) from their 
administration site to their destination.   
The most promising attempts made, and widely used in experimental studies, has been an ex 
vivo approach to generate DCs in vitro from hematopoietic precursor cells; which are then 
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 loaded with suitable antigen and then administered to their original cancer patient.  The added 
benefit is that DCs are prepared in a non-immunosuppressive environment.   
For DC-based immunotherapy to be successful and genuinely offer effective treatment, the ex 
vivo prepared and in vivo generated DCs and loaded with antigen material; must reach lymph 
nodes.  Initial publications reporting their results identified between 3% and 5% of 
administered DCs were capable of migration to lymph node; thus resulting in minimal 
success.  This can be explained by the tumour antigen specific response (by T cells), the 
magnitude of which is proportional to the quantity of DCs that reach the paracortices and T-
cell zones of lymph nodes (and interact with T cells).  cMRI may not only provide data about 
DC migration from administration site to lymph node; but also which other sites they are 
capable of reaching and the length of time taken.   
To date, a variety of contrast agents have been used in attempts to image the DC migratory 
path.  These included nanoparticles (of varying compositions) and also radioactive materials 
such as 19Fluorine-based perfluorcarbon nano-emulsioncombined with PET imaging but to 
date, have been found to be less sensitive, and its utility to detect DC migration in humans 
remains to be demonstrated using clinical scanners presently available.  Iron oxide 
nanoparticles can provided the imaging sensitivity needed for cMR. 
Of vital importance is the need to load DCs and other immune cells safely, ex vivo, with 
sufficient IONPs (or suitable imaging agent) so that their in vivo migration can be imaged and 
assessed quantitatively and qualitatively.  This can provide insight to DC activation and 
maturation, which in turn, may help with immunotherapy in cancer patients.  
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 1.8  Dendritic Cells 
 
Dendritic cells (DCs) were first identified in mice and described by Steinmen and Cohn in 
1973(197).  Since then, our understanding of DCs has increased to the point where DCs are 
being used for cancer immunotherapy experiments with potential translational possibilities.  
The commonly accepted definition of DCs is based on their function; that is, DCs have the 
unique capabilities to internalise, process and present antigens(198) to naïve T cell 
lymphocytes(199) (and B cell lymphocytes) and prime an immune response(200, 201).  Further, 
DCs are also defined by phenotype as being lacking in certain lineage specific markers (Lin-) 
and expressing elevated levels of Major Histocompatibility Complex (MHC) molecules (class 
II); this phenotype is represented as -HLA-DR+ (198).   
From a progenitor cell perspective, DCs can be categorised into two main groups or 
originating from either one of two lineages: conventional DCs (cDC) and plasmacytoid DC 
(pDC)(202).  cDC are also referred to as myeloid DC (mDC)(203).  DC progenitor cells originate 
in the bone marrow and are carried by blood to lymphoid organs and peripheral tissue; where, 
in situ; they develop into mDC(202).  pDC develop or differentiate in the bone marrow first and 
then subsequently colonise lymphoid organs(202).  pDC precursors produce significant 
quantities of type I interferons, such as IFN-α and IFN-β(204).  A further distinction is that 
mDCs are progressively migrating from their peripheral tissue base to the corresponding 
region’s draining lymph node (LN), while DCs originating from lymphoid organs remain 
localised there throughout their cell life cycle.    
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 DCs can also be categorised as either immature DCs or mature DCs.  Commencing from their 
progenitor cell origins, the presence of GM-CSF and the Flt3 ligand, allow these progenitor 
cells to initially become immature DCs.   
Immature DCs (iDCs) continually sample their immediate environment and have a high 
phagocytic capacity.  If iDCs ingest a pathogen, or in the presence of other relevant 
stimulants, iDC enter a phase of developing maturity.  This triggers a maturity signal and a 
complex interplay of chemicals is orchestrated.  Prior to this maturity signal, however, iDC 
(murine) are identified as having the following phenotype and attributes(203, 205):  
• High intracellular levels of MHC II (and FcR)  
• Low expression levels of costimulatory markers: CD80, CD86, CD40 and CD83 
• Low expression levels of IL-12 cytokine 
CD, or cluster of differentiation, are proteins found on cells and these proteins provide a 
costimulatory signal necessary for T cell activation.  Low expression levels of certain CD 
signify that iDC have not been activated or have not received a maturation signal.  IL-12 is a 
cytokine, a small protein; affecting the migration of iDCs to its destination, as it matures and 
affecting the subsequent behaviour of T cells (once the iDCs become mDCs and meet with T 
cells).  Chemokines, interferons and interleukins are classified as cytokines. 
As DCs mature, their physical chemotaxic transition into, and through, afferent lymphatic 
vessels requires cytokine stimulation and induction of the CCR7 chemokine receptor(201).  The 
expression of CCR7 is triggered when immature DCs become activated.  Activation of DCs 
result in up regulation of CCR7 and down regulation of inflammatory cytokine receptors to 
facilitate chemotaxis migration to draining lymph nodes(200). 
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 Following the maturation signal and as iDCs evolve to mDCs, they will migrate to their 
destination site (such as lymph nodes or sites of infection).  mDCs (murine) have been 
identified with the following phenotype and expression levels(20, 203, 206): 
• High intracellular levels of MHC II (and FcR) 
• High expression levels of  CD80, CD86, CD40, CD25 and CD83 
• High expression levels of IL-12 cytokine 
 
Mature DCs that have migrated to secondary lymphoid organs (such as the lymph nodes or 
spleen) are also characterised has having a very minimal capacity for phagocytosis, 
(compared to iDC), thus, alternatively, a lower capacity to capture antigens; however, they 
develop capability to efficiently present antigen material to naïve T cells to stimulate an 
immune response – hence, their potential pivotal role in immunotherapy(20).  
DCs can also be triggered to migrate to lymph nodes by indirect methods. Firstly, under 
normal physiological conditions and in the immunological steady state, the normal movement 
of lymph fluid along afferent lymphatic vessels is by gentle pulsatile motion(200); secondly, 
signals originating from B-cells located from within activated lymph nodes can initiate a 
migration of DCs(200).    
 
 
1.8.1 Fundamental principles of DC migration 
 
The migration(207) of iDCs from their initial environment to the high endothelial venules 
(HEV) and the T cell zone (within lymph nodes), together with the simultaneous transition 
from immature to mature; is a rather complex series of events.  pDC enter lymph nodes 
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 directly with the blood supply, whereas other types of DCs enter lymph nodes via the afferent 
lymphatic vessel(201).  It is this afferent lymphatic vessel that drains nearby tissue and thus 
providing the physical migratory pathway.   
DC precursor cells originate in bone marrow and migrate to all areas of the body where they 
can exist in an immature state, sampling their immediate environment and awaiting 
antigens(200).  Upon stimulation with a suitable antigen, iDCs commence a sentinel function to 
home to secondary lymphoid organs and structures, especially lymph nodes, where they 
interact with naïve T cells and also central memory T cells(200).   
Chemokines are mediators of iDC migration, whereby, intracellular signalling pathways are 
triggered to commence cell migration and activation to maturity(200).  Chemokine and 
chemokine receptors are pivotal in shifting DCs to LNs through afferent lymphatic vessels 
and also from blood(200).  Via afferent lymphatic vessels, DCs enter the subcapsular sinus and 
then migrate to the T-cell zone of the LN cortex.  DCs from the blood stream enter the HEV 
and then migrate from the HEV, through the endothelial wall, and into the T-cell zone for 
efficient and effective interaction with naïve T cells.   
 
 
1.8.2 The importance of DCs in an immune response and potential 
immunotherapy with cMRI 
 
Along with DCs antigen presenting characteristics, comes their unique talent to encourage an 
immune response from T cells.  This is the broad and guiding principle of Dendritic Cell 
Immunotherapy (DCI)(207).  DCs also provide a link between the innate (non-specific) and 
adaptive (acquired) immune systems.  
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 Cellular MRI is a method of detecting cells in vivo, after they have been labelled ex vivo with 
a contrast agent, commonly IONP.  This technology and methodology has been applied by 
researchers to generate iDC from bone marrow progenitor cells, incubate iDC with IONP 
preparations, then administer these loaded cells into a live specimen and observe their 
migration and subsequent fate with MRI, in vivo.  The advantages offered by cellular MRI 
include that it is non-invasive imaging to live specimens, it uses non-ionising radiation and 
produces images of exquisite image quality.   
DCs and cellular MRI are both central in experimental techniques for cancer immunotherapy 
– where an individual’s immune cells and system can be activated to combat cancer cells.  
Tumours can be targeted with the use of antigen-specific vaccine; that is, DCs are loaded with 
cancer vaccines with tumour specific antigen (peptides or proteins) and used to initiate an 
anti-tumour response(20).  For DC-based cancer immunotherapy to be considered effective, 
DCs would need to migrate to secondary lymph organs such as lymph nodes and the spleen.  
Early attempts were not wholly successful; as the methodology used to attempt to load 
antigens into DCs and have them try to migrate to secondary lymph organs to commence and 
immune reaction were not efficient.  Essentially, tumour antigen and adjuvant were 
introduced in vivo by either intradermal, subcutaneous or intramuscular injection; from here, 
local DCs were supposed to internalise the antigen, process it and migrate to lymph nodes.  
This was not successful because tumours can release immunosuppressive substances and also 
self-tolerance to the tumour antigen can exist; combined together, these can inhibit an 
effective immune response.  At present, researchers are overcoming this is with an ex vivo 
approach – iDCs are generated in vitro from haematopoietic precursor cells in non-
immunosuppressed conditions, then loaded with antigen and then administered into the live 
specimen.   
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 1.8.3 The behaviour of DCs in an immune response 
 
Upon activation, DCs commence a migratory progression to lymph nodes and during this 
migration process, DCs process uptaken antigens, place these on their cell surface (along with 
MHC molecules) for presentation to T cell lymphocytes and upregulate costimulatory 
markers.  These costimulatory markers are expressed as the DCs transition from an immature 
to mature state and also facilitate interaction with T cell lymphocytes(204); as only mature DCs 
are capable of activating T cell lymphocytes.  T cells require three different signals in order to 
be effectively and efficiently activated.  Firstly, the T cell receptors must recognise and accept 
the antigen presented by the DC (together with MHC molecules).  Secondly, T cells require 
the costimulatory molecules that have been upregulated and presented with mature DCs.  
Thirdly, a paracrine (cell-to-cell) signal from soluble molecules in the form of cytokines 
and/or chemokines produced by the mature DCs(204).   
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 1.9 The aims of this PhD research and thesis 
 
The preceding discussion allows an informed opinion to be formed; that from the current 
clinical status quo, a new path or direction can be taken to widen the capabilities of MRI 
through improvements in contrast agents.  These may include introducing safer alternatives to 
ionising radiation imaging procedures being eventually established; and with the advent of 
PET/MRI, providing a dual modality contrast agent from one injection.  All this can improve 
diagnostic precision and, importantly, better serve patients. 
The over-arching hypothesis is that iron oxide nanoparticles (IONP) will enhance magnetic 
resonance imaging (MRI images), to enable identification of the sentinel lymph node (SLN). 
The main research aims of this thesis are to: 
1. Manufacture and characterise prototype iron oxide nanoparticles (IONP). 
2. Characterise IONP uptake and toxicity in murine cells in vitro. 
3. Characterise the migration of IONP in vivo with C57BL/6 mice. 
4. Characterise IONP uptake and toxicity in human cells in vitro. 
5. Radio-label the IONP with 68Ga. 
6. Perform in vivo studies with IONP radio-labelled with 68Ga. 
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 2.0 Chapter 2 – Materials and Methods 
 
 
 
2.1 Chemicals and reagents 
 
 
Chemical or Reagent  Catalogue Number Supplier or Manufacturer 
   
(3-Aminopropyl) triethoxy-
silane (minimum 98%) 
A-3648 Sigma-Aldrich (St. Louis, 
USA) 
10% Neutral Buffered Formalin 
(NBF) 
NBF-5L Amber Scientific (Midvale, 
WV, Australia) 
25% Ammonia Solution 
(aqueous ammonia) 
4.10011.2500 Merk (Hohenbrunn, Germany) 
Acrylamide 814349 ICN Biomedicals (Irvine, 
USA) 
Ammonium Acetate 1112914 33504101 FlukaChemme GmbH 
(Germany) 
D-Glucose 101805 Univar Ajax Chemicals 
(N.S.W., Australia) 
Gelatine (G-2500) 2500-500G Sigma-Aldrich (St. Louis, 
USA) 
N’N-methylenebisacrylamide 
(BIS) 
 Sigma-Aldrich (St. Louis, 
USA) 
Paraformaldehyde or PFA 8.18715.10000 Merck-Schuchardt 
(Hohenbrunn, Germany) 
Sodium Azide 0313620 BDH Ltd., (England) 
Table 2.1: List of chemicals and reagents used. 
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 2.2 Kits used in in vitro experiments 
 
Kit Catalogue Number Supplier 
   
BD Pharmingen™Annexin V-PE 
Apoptosis Detector Kit I 
559763 BD Biosciences (San Diego, 
USA) 
CellTiter 96 Aqueous One 
Solution Cell Proliferation kit 
G3580 Promega (Madison, USA) 
FluoroTagTM FITC Conjugation 
Kit 
FITC1-1KT Sigma-Aldrich (San Diego, 
USA) 
Human Inflammatory Cytokine 
Kit 
BD™ Cytometric Bead Array 
(CBA) 
551811 BD Biosciences (San Diego, 
USA) 
Mouse Inflammation Kit  
BD™ Cytometric Bead Array 
(CBA) 
552364 BD Biosciences (San Diego, 
USA) 
Table 2.2: A list of kits purchased and used in in vitro experiments. 
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 2.3 Antibodies and conjugates 
 
Antibody or Conjugate Catalogue Number Supplier 
   
Recombinant Murine 
Antibodies 
  
   
CD11c (APC) 550261 BD Pharmingen™ (BD 
Biosciences, San Diego, USA) 
CD197(CCR7) (PE) 560682 BD Pharmingen™ (BD 
Biosciences, San Diego, USA) 
CD86 (PE) 553692) BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
   
Recombinant Human 
Antibodies 
  
   
Lineage Cocktail 1 (FITC) 340546 BD Biosciences (San Diego, 
USA) 
HLA-DR (APC-Cy™7) 335831 BD Biosciences (San Diego, 
USA) 
CD123 (APC) 560087 BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
CD14 (V500) 562693 BD Biosciences (San Diego, 
USA) 
CD11c (PE-Cy™7) 561356 BD Biosciences (San Diego, 
USA) 
CD80 (FITC) 557226 BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
CD83 (FITC) 556910 BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
CD83 (PE-Cy™5) 551058 BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
CD86 (APC) 555660 BD Pharmingen™ (BD 
Biosciences, (San Diego, USA) 
Fluorescein Isothiocyanate 
Isomer I (FITC) 
F7250-250MG Sigma-Aldrich (St. Louis, 
USA) 
R-Phycoerythrin (R-PE) P801 Life Technologies (Carlsbad, 
USA) 
 
Table 2.3: A list of antibodies and conjugates used. 
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 2.4 Tissue culture reagents, drugs and equipment 
 
Tissue culture media, 
reagents, drugs or equipment 
Catalogue or serial or 
model number 
Supplier or manufacturer 
   
1.5 ml microtube 72.690.001 Sarstedt (Numbrecht, Germany) 
1.5 Telsa Whole Body 
Clinical MRI Scanner 
Siemens Trio Magnetom Siemens Medical Solutions 
(Erlangen, Germany) 
15 ml sterile tube 
Corning®CentriStar™ 
430791 Corning Incorporated (NY, 
USA) 
3ml Pasteur Pipette 200CS01 Copan S.p.A. (Brescia, Italy) 
3.0 Telsa Whole Body 
Clinical MRI Scanner 
Siemens Trio Magnetom Siemens Medical Solutions 
(Erlangen, Germany) 
50 ml sterile tube 
Corning®CentriStar™ 
430829 Corning Incorporated (NY, 
USA) 
6 well, well plate 
F-bottom 
3516 Costar, Corning Incorporated 
(NY, USA) 
24 well, well plate 662.160 Greiner Bio-one Cellstar 
(Frickenhausen, Germany) 
68Ga Generator  iThemba LABS (Somerset West, 
RSA) 
96 well, well plate (V-
bottom) 
651101 Greiner Bio-one (Frickenhausen, 
Germany) 
   
Mice  C57/BL6 Animal Resources Centre (Perth, 
Australia) 
Atomic absorption 
spectrometer (AAS)  
Varian AA280FS Fast 
Sequential 
Varian (California, USA) 
BD Falcon FACS tubes 352008 BD Biosciences (San Diego, 
USA) 
BD Falcon cell strainer 352360 BD Biosciences (San Diego, 
USA) 
Bovine Serum Albumin A7906-100G Sigma-Aldrich (St. Louis, USA) 
Carbon coated copper grids GYCu200 ProSciTech (Thuringowa, QLD, 
Australia) 
Centrifuge   Allegra X-22 Beckman Coulter (California, 
USA) 
Blood serum biochemical 
immunoassay analyser 
Abbott Architect Plus 
ci4100 
Roche Diagnostics (Melbourne, 
Australia) 
DMEM cell media 11965-092 Gibco® by life technologies™ 
(NY, USA) 
Dotarem® contrast agent for 
MRI 
Batch 14GD008B Guerbet (Aulnay-sous-bois, 
France) 
DPX with colour fast 
mounting media 
11023DPX Fronine (Rivertone, Australia) 
DTPA Anhydride 
(Diethylenetriaminepenta – 
Acetic Acid Anhydride) 
D-6148 Sigma-Aldrich (St. Louis, USA) 
Endotoxins Meter 4108 Charles River Laboratories  
Endosafe-PTS 
72 
 
 Eppendorf Mini Spin Plus 
Centrifuge 
 Eppendorf (Hamburg, Germany) 
FACS Canto™ II Flow 
Cytometer 
V96300723 BD Biosciences (San Jose, CA, 
U.S.A.) 
 
Fetal bovine serum SFBS-F Bovogen Biologicals (Victoria, 
Australia) 
Ficoll®-Paque Premium GE17-5442-02 GE Healthcare Bio-Sciences AB, 
Sweden) 
Fluorescent mounting 
medium 
S3023 Dako Australia Pty Ltd (N.S.W., 
Australia) 
FluoroDishTM (flat bottom 
glass) 
FD35COL World Precision Instruments 
(Sarasota, USA) 
Growth factor 
Murine GM-CSF 
315-03 PeproTech (Rocky Hill, USA) 
Growth factor 
Murine Flt3 
250-31L PeproTech (Rocky Hill, USA) 
Growth factor 
Human GM-CSF 
215-GM R&D Systems (Minneapolis, 
USA) 
Growth factor 
Human IL-4 
204-IL R&D Systems (Minneapolis, 
USA) 
Growth factor 
Human IL-4 
200-04 PeproTech (Rocky Hill, USA) 
Haematocrit capillary tubes 9100175 Hirschmann Laborgerate 
(Eberstadt Germany) 
Haemocytometer Depth 0,100nm 
0,0025 mm2 
Hirschmann EM Techcolor 
(Heilbronn, Germany) 
HEPES 1M Buffer Solution 15630-80 Gibco® by life technologies™ 
(NY, USA) 
Histopathology Tissue 
Processor 
ASP 200 S Leica Biosystems (NSW, 
Australia) 
Incubator – animal cells Heat Force® THF-212-UV Thermoline L+M (NSW, 
Australia) 
Incubator – human cells Heraeus BB15 Thermo Scientific (NSW, 
Australia) 
Lipopolysaccharides L4391-1MG Sigma-Aldrich (St. Louis, USA) 
Magnetic hot plate and 
Stirrer 
CH 2091.001 U-Lab (Eltham, Australia) 
Menzel-Glaser Superfrost® 
Plus Microscope Slides 
(25x75x1.0mm) 
SF41296SP Lomb Scientific Pty Ltd (NSW, 
Australia) 
Microscope Nikon TMS 300 754 Grale Scientific (Melbourne, 
Australia) 
Microscope Cover Glass 
(22x22mm) 
CCS2222100 Mikro-Glass (Australia) 
Microtome RM 2235 Leica Microsystems Nussloch 
GmbH (Germany) 
   
Murine FLT-3 Ligand 250-31L PeproTech (Rocky Hill, USA) 
Murine GM-CSF Ligand 315-03 PeproTech (Rocky Hill, USA) 
Orbital mixer EOM5 Ratek Instruments Pty Ltd 
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 206127780 (Victoria, Australia) 
Penicillin/Streptomycin 15070-063 Gibco (Invitrogen) (Aukland, 
New Zealand) 
Petrie Dish 616201 Greiner Bio-one (Frickenhausen, 
Germany) 
Phosphate Buffered Saline 
(PBS) 
21600-010 Invitrogren Corporation (New 
Zealand) 
Qualtex drying oven Model 70, Serial 3964.1  Watson (Victoria, Australia) 
Radio-isotope Dose 
Calibrator 
CRC-15PET CAPINTEC Inc. (USA) 
Ratek water bath WB20D Ratek Instruments Pty Ltd 
(Victoria, Australia) 
RPMI 1640 cell media 11875-093 Gibco® by life technologies™ 
(NY, USA) 
Sartorius Weigh Scale BP211D Sartorius AG (Gottingen, 
Germany) 
Scanning Electron 
Microscope 
Nova NanoSEM™ FEI (Oregon, USA) 
Small Animal PET Scanner MOSAIC Animal Imaging Philips Healthcare (DA Best, 
The Netherlands) 
Sonicator  00002939 Thermoline Scientific (N.S.W., 
Australia) 
Sterilizer (autoclave)  Siltex (Bentleigh East, Australia) 
Thin layer chromatography 
scanner 
Rita Star TLC-01 
2003123 
Raytest (Straubenhardt, 
Germany) 
Tissue/Wax Embedding 
Centre workstation 
Shandon Histocentre™ 3 Thermo Electron Corporation 
(Madison, USA) 
Transmission Electron 
Microscope 
JEOL 2010 EM 135 003-8 JEOL (Tokyo, Japan) 
Trypan blue solution (1.4%) T8154 Sigma-Aldrich (St. Louis, USA) 
Trypsin-EDTA solution 
(0.25% trypsin, 1 mM 
EDTA) 
25200-056 Gibco® by life technologies™ 
(NY, USA) 
Vacutte with K2EDTA 10ml Greiner Bio-one (Frickenhausen, 
Germany) 
Water bath WB20 D Ratek Instruments (Boronia, 
Australia) 
Weigh scale HR-200 
12304600 
A and D Company (Tokyo, 
Japan) 
X-ray Diffractometer Bruker D8 ADVANCE  Bruker Corporation 
(Massachusetts, USA) 
Whatman® filter paper 1001 090 GE Health Care (Pittsburgh, 
USA) 
Zetasizer Malvern Nano-ZS 
ZENN3600 
MAL1073053 
Malvern Instruments 
(Worcestershire, England) 
 
Table 2.4: A list of tissue culture reagents, drugs and equipment used in the laboratory.  
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2.5 Software for analyses 
 
Software Version Provider 
ImageJ 1.48v National Institutes of Health 
(U.S.A.) 
GraphPad Prism 6.05 GraphPad Software 
Inc.(U.S.A.) 
Microsoft Excel Microsoft Office  
Home & Student 2013 
Microsoft Corporation 
(U.S.A.) 
Table 2.5: A list of software programs used to analyse data throughout this thesis. 
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 2.6 Human Cells 
 
2.6.1 Monocyte derived dendritic cells (Mo-DC) 
 
Monocytes were obtained from peripheral blood mononuclear cells (PBMC).  To isolate the 
PBMC, the buffy coat was separated from whole blood of healthy donors by using a gradient 
centrifugation technique with Ficoll®-Paque Premium (Sigma-Aldrich, St. Louis, USA) 
(described in section 2.6.4).   
A cell count was performed using trypan blue (Sigma-Aldrich, St. Louis, USA) and a 
haemocytometer (Hirschmann EM Techcolor, Heilbronn, Germany).  In a fume hood, 1.5x106 
cells per ml were cultured in complete RPMI 1640 (Gibco® by life technologies™, NY, 
USA) cell media in a 6 well plate (Costar, Corning Incorporated, NY, USA).  A total of 
4.5x106 cells in 3ml were placed in each well and 20ng/ml (w/v) of GM-CSF (R&D Systems, 
Minneapolis, USA) and 20ng/ml (w/v) of IL-4 recombinant cytokines (R&D Systems, 
Minneapolis, USA) were added and placed in an incubator (Heraeus BB15, Thermo 
Scientific, NSW, Australia) at 37 oC and 5% CO2.  At the end of third day, the well plate was 
removed from the incubator, placed in a fume hood and the spent media was carefully 
removed with a sterile pipette.  Fresh complete media and cytokines were added and the well 
plate returned to the incubator where they remained for three further days; making a total of 6 
days.  On the seventh day, the in vitro experimental process commenced with the Mo-DC.  
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 2.6.2 Buffy coat 
 
Ethics approval (Project Number 19/13) was received from the Human Research Ethics 
Committee at RMIT University to approach the Australian Red Cross Blood Service and 
request orders for buffy coats.  Once the order was approved, the buffy coat was collected 
from the Australian Red Cross Blood Service. 
The buffy coat was collected from the Australian Red Cross Blood Service the night before 
the experimental procedure.  The Australian Red Cross Blood Service provided the buffy coat 
(approximate volume of 50 ml) in a plastic collection bag, tagged with record numbers; 
placed in a polystyrene foam package and placed in a cardboard box.  This was kept overnight 
at room temperature, until the experimental process commenced in the morning.  The first 
step was always gradient centrifugation technique with Ficoll®-Paque Premium (GE 
Healthcare Bio-Sciences AB, Sweden), described in Section 2.5.4.  Once the white blood cell 
components were isolated, in vitro experiments were undertaken. 
 
2.6.3 Blood from volunteers 
 
Adult consenting colleagues volunteered to provide a sample of approximately 15 ml of 
whole blood.  Blood was withdrawn by experienced and qualified personnel within the 
Haematology Department, RMIT University.  The date that this occurred and the name of the 
volunteer were recorded in the log book in the Haematology Blood Collection Room.  Whole 
blood was collected in a vacuette (Greiner Bio-one, Frickenhausen, Germany) containing 
K2EDTA to prevent coagulation.  The blood then underwent gradient centrifugation technique 
with Ficoll®-Paque Premium (described in Section 2.5.4) so that the white blood cell 
component was isolated for in vitro experiments.  
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 2.6.4 Separation by Ficoll®-Paque Premium gradient centrifugation   
 
The following gradient density separation technique was used to isolate the white blood cell 
components; from either the buffy coat supplied from the Australian Red Cross Blood Service 
or from whole blood kindly donated by consenting colleagues at RMIT University.    
Either whole blood or buffy coat was transferred into two sterile 50 ml tubes, with equal 
volume of blood in each tube.  A volume of sterile PBS (Invitrogren Corporation, New 
Zealand), equivalent to the volume of whole blood or buffy coat in each tube was added to 
each 50 ml tube.  The contents of one tube (sterile PBS with either whole blood or buffy coat) 
was slowly and carefully transferred (with pipette controller and glass pipette) into another 50 
ml tube that already contained 15ml of Ficoll®-Paque Premium.  This was repeated with the 
other 50 ml tube (containing sterile PBS with either whole blood or buffy coat).  Both of these 
tubes were then removed from the fume hood and placed in a centrifuge (Beckman Coulter, 
California, USA) and spun at 1,500 rpm (433 rcf) for 30 minutes; no brake was used to stop 
the centrifuge spinning at the end of the 30 minute period. 
White blood cells (PBMC) were collected, transferred into a new sterile 50ml tube and 
washed a further two times with sterile PBS (first wash was at 2,000 rpm, 771 rcf, for 15 
minutes and the second wash was at 1,800 rpm, 624 rcf, for 10 minutes).  On completion of 
all washes, the PBMC pellet was resuspended in 10ml of complete media and a cell count 
performed. 
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 2.6.5 Dose response with R-PE tagged dextran coated iron oxide 
nanoparticles 
 
Mo-DC were generated as discussed in Section 2.5.1.  In a 6 well, well plate containing 4.5 x 
106 per 3 ml.  Different concentrations of nanoparticles (200 µg/ml, 100 µg/ml, 50 µg/ml, 20 
µg/ml, and 5 µg/ml) were added.  A control well with no nanoparticles was included for all 
experiments.  Nanoparticles tagged with R-PE (Life Technologies, Carlsbad, USA) were 
sonicated (Thermoline Scientific, NSW, Australia) for 10 minutes, prior to being added to the 
Mo-DC cultures and incubated for 24 hours.   
Following incubation, the supernatant was carefully removed, placed in a labelled microtube 
(Sarstedt, Numbrecht, Germany) and then stored at -80 oC for further cytokine analysis.  Mo-
DCs were removed using sterile PBS to.  Collected Mo-DCs were centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes, the supernatant discarded and resuspended in 0.5% BSA/PBS (w/v).  
Mo-DCs were added to a sterile 96 well v-bottom well plate (Greiner Bio-one) and 
centrifuged at 1,500 rpm (433 rcf) for 5 minutes.   
The supernatant was discarded and 0.5% BSA/PBS (w/v) antibody were added and incubated 
at 4 oC for 30 minutes.  Following incubation, cells were centrifuged at 1,500 rpm (433 rcf) 
for 5 minutes, supernatant discarded and cells resuspended in FACS fix for flow cytometry 
analysis (FACSCanto II, BD Biosciences, San Jose, USA).   
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 2.6.6 Dose response with FITC tagged dextran coated iron oxide 
nanoparticles 
 
Monocyte derived dendritic cells (Mo-DC) were generated as discussed in section 2.5.1.  In a 
sterile 6 well plate containing 4.5 x 106 cells in 3 ml, different conditions of nanoparticles 
(200 µg/ml, 100 µg/ml, 50 µg/ml, 20 µg/ml, and 5 µg/ml) were added.  A control well with no 
nanoparticles was included for all experiments.  Nanoparticles tagged with FITC (Sigma-
Aldrich, St. Louis, USA) were sonicated for 10 minutes, prior to being added to MoDC 
cultures and incubated for 24 hours.   
Following incubation, the supernatant was carefully removed, placed in a labelled micro tube 
and then stored at -80 oC for further cytokine analysis.  MoDCs were removed using sterile 
PBS to lift off any cells adhering to the bottom of each well.  Collected MoDCs were 
centrifuged at 1,500 rpm (433 rcf) for 5 minutes, the supernatant then discarded and 
resuspended in 0.5% BSA/PBS (w/v).  MoDCs were added to a sterile 96-well v-bottom well 
plate and centrifuged at 1,500 rpm (433 rcf) for 5 minutes.  The supernatant was discarded 
and 0.5% BSA/PBS (w/v) antibody were added and incubated at 4 oC for 30 minutes.  
Following incubation, cells were centrifuged at 1,500 rpm (433 rcf) for 5 minutes, supernatant 
discarded and cells resuspended in FACS fix for flow cytometry analysis. 
 
 
2.6.7 Time course with FITC 
 
Monocyte derived dendritic cells (Mo-DC) were generated as discussed in section 2.5.1.  In a 
sterile 6 well plate containing 4.5 x 106 cells in 3 ml, six conditions were established: one well 
served as a control and received no nanoparticles; the remaining wells received 200 µg/ml of 
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 FITC tagged nanoparticles at different time points (24 hours, 18 hours, 6 hours, 4 hours and 1 
hour).  The nanoparticles were sonicated for 10 minutes, prior to being added to MoDC 
cultures and then incubated for 24 hours.   
On completion of the treatment periods, the supernatant was carefully removed, placed in a 
labelled micro tube and then stored at -80 oC for further cytokine analysis.  MoDCs were 
removed using sterile PBS was used to lift off any cells that had adhered to the bottom of each 
well.  Collected MoDCs were centrifuged at 1,500 rpm (433 rcf) for 5 minutes, the 
supernatant discarded and resuspended in 0.5% BSA/PBS (w/v).  MoDCs were added to a 
sterile 96 well v-bottom well plate; 2 x 200 µl from each tube (representing each original 
condition).  Therefore, each original condition (from the flat bottom 24 well plate) was 
divided into two (and placed in a 96 v-bottom well plate).  The 96 well plate was then 
centrifuged at 1,500 rpm (433 rcf) for 5 minutes and the supernatant was then discarded.   
One well of each original condition, was resuspended with 200 µl of cold 0.5% BSA/PBS 
(w/v) and the other corresponding condition was resuspended with 200 µl of cold 0.5% 
BSA/PBS (w/v) that contained antibody.  The 96 well plate was then incubated at 4 oC for 30 
minutes.  Following incubation, cells were centrifuged at 1,500 rpm (433 rcf) for 5 minutes, 
supernatant discarded and cells resuspended in FACS fix for flow cytometry analysis.   
 
 
2.6.8 Human Inflammatory Cytometric Bead Array (CBA) Analyser 
 
Supernatant from specified (dose response and time course) in vitro human experiments were 
stored at -80 oC.  Frozen samples were thawed and used to assess cytokine levels by CBA 
analysis (BD™ Cytometic Bead Array, BD Biosciences, San Diego, USA) as per 
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 manufacturer’s instructions and read on flow cytometry.  The specific cytokines analysed 
were: IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70.   
 
 
2.6.9 Nanoparticle uptake in whole PBMC and peripheral blood dendritic 
cell subsets, in vitro 
 
Blood was withdrawn from volunteers as described in Section 2.5.3 and was then followed by 
Ficoll®-Paque Premium gradient centrifugation as discussed in Section 2.6.4.   
Peripheral blood mononuclear cells (PBMC) were suspended in complete RPMI 1640 media 
and set up in sterile 6 well plates and the following uptake conditions were investigated: 
control (no nanoparticles), 200 µg/ml of R-PE tagged nanoparticles, 100 µg/ml of R-PE 
tagged nanoparticles, 200 µg/ml of FITC tagged nanoparticles and 100 µg/ml of FITC tagged 
nanoparticles; incubated at 37 oC with 5% CO2 for 24 hours. 
Following incubation, the supernatant was carefully removed and stored at -80 oC.  Sterile 
PBS was used to resuspend cells and lift them off the bottom of each well and centrifuged at 
1,500 rpm (433 rcf) for 5 minutes.  The cells were re-suspended in 0.5 % BSA/PBS (w/v) 
with the following conditions: control (no nanoparticles), 200 µg/ml of R-PE tagged 
nanoparticles and 100 µg/ml of R-PE tagged nanoparticles control.  200 µl from each 
condition was placed in 9 wells of a 96 well v-bottom well plate.  The cells in the following 
conditions were resuspended in 400 µl of 0.5 % BSA/PBS (w/v): 200 µg/ml of FITC tagged 
nanoparticles, 100 µg/ml of FITC tagged nanoparticles – and 200 µl from each condition was 
placed in 2 wells of the same 96 well v-bottom well plate.   
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 The 96 well plate was then centrifuged again at 1,500 rpm (433 rcf) for 5 minutes, the 
supernatant discarded and the cells stained with the following antibody combinations: Control 
(no stain), Lin 1, HLA-DR, CD11c, CD123, CD14, mix*, CD80 and CD83.  The mix* 
treatment was composed of Lin 1, HLA-DR, CD11c and CD123.  The antibodies were 
suspended in cold 0.5 % BSA/PBS (w/v).  All stains were from BD Biosciences, San Diego, 
USA. 
The cells were incubated at 4 oC for 30 minutes.  Following incubation, cells were washed in 
PBS and centrifuged at 1,500 rpm (433 rcf) for 5 minutes, fixed in FACS fix buffer and 
analysed by flow cytometry. 
 
 
2.7 Mice 
 
All mice used were approved for experimental use by the RMIT University Animal Ethics 
Committee (AEC1210 and AEC1320).  Female C57/BL6 mice aged between 8 and 12 weeks, 
supplied by Animal Resources Centre (Perth, Australia) were used for all experiments and 
experimental mice were allowed to acclimatise for 48 hours within the RMIT Animal Facility 
before any procedures were performed. 
A maximum of 4 mice were housed in standard sized cages for “tissue mice” used for stem 
cell extraction and subsequent in vitro experiments (AEC 1210); with approval for these mice 
to be killed by CO2 asphyxiation.   
For in vivo experiments (project number AEC 1320), C57BL/6 mice were housed in larger 
cages, at a maximum of 5 mice per cage; with approval for these mice to be killed by the 
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 Vascular Perfusion Technique under strong intraperitoneal anaesthesia provided by sodium 
pentobarbitone. 
 
2.7.1 Method of killing mice approved by RMIT University Animal Ethics 
Committee 
 
RMIT University Animal Ethics Committee (AEC) provided the following approval for 
killing mice.   
For in vitro experiments approved under AEC 1210, tissue mice were killed by CO2 
asphyxiation.  The cage housing 4 mice were collected from the housing room and brought 
into one of the procedure rooms, of the RMIT Animal and Aquatic Facility.  A CO2 cylinder 
was connected to a Perspex box positioned on a bench top.  CO2 was allowed to fill this 
Perspex box.  After several minutes, one of the 4 mouse was collected from the housing cage 
and placed into the CO2 filled Perspex box.  One minute after the mouse stopped moving, paw 
reflexes were tested and signs of breathing cessation were scrutinised.  When no response was 
observed, the mouse was removed from the CO2 filled Perspex box and placed in an opaque 
carrying container.  The mice in the housing cage were not able to observe these events and 
were returned to the housing room.  The killed mouse in the opaque carrying container was 
brought to the laboratory for bone marrow stem cell extraction, as described in Section 2.10. 
For in vivo experiments approved under AEC 1320, C57BL/6 mice were housed in larger 
cages, at a maximum of 5 mice per cage; with approval for these mice to be killed by the 
Vascular Perfusion Technique under strong intraperitoneal anaesthesia provided by sodium 
pentobarbitone.  Anaesthesia was provided by intraperitoneal injection of sodium 
pentobarbitone, 150 mg/kg, using a 25 gauge needle; and the standard method of Vascular 
Perfusion Fixation was performed by an experienced researcher.  Once the mouse appeared 
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 anaesthetised, its reflexes were assessed to ensure that the mouse was fully anaesthetised; and 
the vascular perfusion fixation procedure commenced as described in Section 2.12.2. 
 
 
2.8 Buffers and solutions 
 
The following buffers and solutions were used in various experimentations, in vitro, 
throughout the PhD project. 
 
 
2.8.1 FACS fix buffer 
 
FACS fix is a cell preserving fixative used to suspend cells for analysis by flow cytometry. 
As needed, a total volume of 500ml FACS fix was made using the following substances and 
technique.  10 g of 2 % glucose (Univar Ajax Chemicals, NSW, Australia), 100 mg of 0.02 % 
sodium azide (BDH Ltd, England) and 5 g of PFA (Merck-Schuchardt, Hohenbrunn, 
Germany) were each weighed and placed in a clean laboratory jar.  This jar was filled to the 
500ml indicator mark with PBS (pH of 7.4).  A magnetic stir bar was placed in this jar and a 
clean cap screwed in place.  The jar and contents were placed on a magnetic plate (U-Lab, 
Eltham, Australia) and stirred until dissolved – as determined by visual inspection of no 
particulate matter.    
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2.8.2 Phosphate buffered saline 
 
Phosphate Buffered Saline (PBS) (GIBCO™ Invitrogen Corporation, New Zealand) without 
calcium and magnesium was prepared as per manufacturer’s instructions. 
 
 
2.8.3 0.5% BSA/PBS (w/v) buffer 
 
This buffer was used to wash and suspend cells when preparing them for antibody surface 
staining; for flow cytometry.   
When required, a total volume of 500 ml was prepared.  0.5 % weight per volume of BSA 
(Sigma-Aldrich, St. Louis, USA) was used.  2.5 g ((0.5/100) x 500 ml) of BSA was weighed 
and placed in a clean laboratory jar.  A magnetic stirrer was placed in the jar and a clean cap 
screwed in place.  This jar was filled to the 500 ml indicator mark with PBS (pH of 7.4).  The 
jar and contents were placed on a magnetic plate and stirred until dissolved.  This was 
determined visually when no particulate matter was apparent.    
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 2.8.4 2% PFA/PBS (w/v) 
 
2 % PFA was used for cell preservation and the cells were imaged with confocal microscopy. 
When required, a total volume of 50 ml was prepared.  2 % weight per volume of PFA 
(Merck-Schuchardt, Hohenbrunn, Germany) was used.  One gram ((2/100) x 50 ml) of PFA 
was weighed and placed in a clean laboratory jar.  A magnetic stirrer was placed in this jar 
and a clean cap screwed in place.  This jar was filled to the 50 ml indicator mark with PBS 
(pH of 7.4).  The jar and contents were placed on a magnetic plate and stirred until dissolved.  
This was determined visually when no particulate matter was observed.    
 
2.9 Iron oxide nanoparticles (IONPs) 
 
Following a review of the relevant literature, it was determined that superparamagnetic iron 
oxide nanoparticles (SPIONs) with a coating of low molecular weight dextran (10,000 
Daltons, also referred to as T10) would be suitable; provided that the overall dimension of the 
SPION would not exceed 50 nm.  Vipul Bansal and Jos Campbell from the Department of 
Applied Chemistry at RMIT University were approached for their expertise and such particles 
were manufactured. 
 
 
2.9.1 Synthesis, dextran coating and characterisation 
 
The iron oxide core, magnetite (Fe3O4), were produced using a technique based on that 
published by Park et al and with modifications introduced by Campbell and Bansal.   
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 Iron chloride and sodium oleate were combined in a solution of ethanol, distilled water and 
hexane; to form an iron oleate.  To create the iron oleate, the solution was refluxed for 4 hours 
at 70 oC.  A separatory funnel system was then used to collect the upper organic layer, which 
then was washed and the hexane evaporated away.   
The iron oleate was then dissolved with oleic acid and 1-octadescene and then refluxed under 
nitrogen gas conditions; which occured at 320 oC for 30 minutes and then allowed to cool to 
room temperature.  Ethanol was then added to the room temperature solution and the Fe3O4 
magnetite particles were separated by centrifugation with three ethanol wash cycles.  T10 
dextran was then coated onto the iron oxide nanoparticles by heating them, along with the 
dextran, in an aqueous medium.  The diameter of the iron oxide core was measured at 15 nm 
and together with the T10 dextran coating, the overall dimension of the SPIONs were 20 nm; 
with Transmission Electron Microscopy (TEM).     
 
 
2.9.2 Characterisation 
 
Assessments were performed to characterise these specialty produced IONPs.  Iron content 
quantification was assessed with atomic absorption spectrometer (AAS) (Varian, California, 
USA).  The sample was atomised by flames at a temperature of at least 2,200 oC.  The 
atomiser aerosol contained iron atoms and their electrons were excited to a higher energy state 
by absorbing energy delivered by a known wavelength.  The selectivity of AAS was provided 
by such a wavelength, as it delivered a defined quantity of energy to allow the electrons to 
transition to a higher energy state (in a known element).  The wavelength then continued 
through to monochromators to select and transmit the iron specific wavelength to a detector.  
The Beer-Lambert Law was then used to quantify the iron content of the sample.   
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 X-Ray Diffraction (XRD) spectra were collected at room temperature using a Bruker D8 
ADVANCE X-Ray Diffractometer (Bruker Corporation, Massachusetts, USA).  The sample 
was air dried at room temperature, placed onto the glass sample holder and then irradiated 
with copper k-alpha radiation with a wavelength of 1.5418 nm.  The diffraction patterns were 
measured at 40 kV with 35 mA.  Spectral peaks were determined by computer integration of 
the diffraction patterns. 
To measure the diameter of the iron oxide nanoparticle with the T10 dextran coating, 
transmission electron microscopy (TEM) was performed with a JEOL 2010 TEM (JEOL, 
Tokyo, Japan) that used a lanthanum boron six crystal as its electron source.  In a fume hood, 
ten µl of colloid suspension of the dextran coated iron oxide nanoparticles was pipetted onto 
the carbon coated surface of the 3mm diameter copper holey grid.  The grid was placed onto 
Whatman filter paper (copper surface was in contact with the Whatman filter paper); these 
were placed in one of the wells of a sterile 24 well plate and allowed to dry overnight.  The 
copper grid was loaded into the JOEL2010 TEM as instructed and transmission electron 
microscopy performed. 
To observe the surface of the T10 dextran coating, scanning electron microscopy (SEM) was 
performed using a FEI Nova Nano SEM, (FEI, Oregon, USA).  An aluminum circular 
mounting disc was prepared with a circular double sided sticking carbon tape and twenty µl of 
the colloid suspension of the dextran coated iron oxide nanoparticles was pipetted onto the 
circular double sided sticking carbon tape.  This was allowed to air dry at room temperature 
for 1 hour.  Pressurised air was sprayed onto the prepared surface to dislodge any particles 
that had not adhered to the carbon tape.  The mounting disc was loaded into the vacuum 
chamber and SEM imaging performed.  
The surface charge was assessed with a Malvern Zetasizer Nano (Malvern Instruments, 
Worcestershire, England).  Dextran coated iron oxide nanoparticles were stored under 
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 different conditions and their surface charge determined.  The particles were first sonicated 
for 10 minutes, then transferred to the dedicated cell chamber and inserted into the Zetasizer 
Nano unit.  The feature to read nanoparticle surface charge was selected and the data 
recorded.  On completion, the dedicated cell chamber was removed from the unit and the 
solution containing nanoparticles was discarded.    
The iron oxide nanoparticles were also observed for their behavioural characteristics (in a 
magnetic field environment) in response to a spin echo T2 weighted pulse sequence.  This 
assessment was performed on both a 1.5 T and 3.0 T clinical MRI scanner.  Both scanners 
were made by Siemens (Erlangen, Germany), used the Syngo operating platform and had 
access to the same pulse sequence; referred to as: t2_se_COR_16-echoes.  Different 
concentrations of nanoparticles were suspended in gel, in 15 ml plastic tubes (with screw 
tops).  A plastic tube rack was glued into a rectangular plastic tub.  When MRI scanning took 
place, these 15 ml tubes were positioned into the rack and the rectangular tub was filled with 
water.  This volume of water provided three valuable functions; firstly, it provided sufficient 
MRI signal (hydrogen) to be detected (so that an image could be reconstructed); secondly, it 
provided image contrast adjacent to the 15 ml tubes containing nanoparticles in gel 
suspension, as the image appearance of the gel suspension was expected to change as the TE 
value (in the pulse sequence) increased; and thirdly, the water bath minimised and/or 
eliminated susceptibility artefacts from the air interface with tubes (that contained gel and 
nanoparticles). 
The gel suspension was prepared in the following manner with the following ratio of 
ingredients: 59 % MilliQ water, 29 % iron oxide nanoparticles, 5 % gelatine (Sigma-Aldrich, 
St. Louis, USA), 3 % BISacrylamide (Sigma-Aldrich, St. Louis, USA) and 3 % acrylamide 
(ICN Biomedicals, Irvine, USA).  This made a total volume of 100 ml gel suspension.  Ten 15 
ml plastic tubes were labelled and filled with varied concentrations of iron oxide 
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 nanoparticles.  The preparation procedure was conducted in a fume hood.  Five grams of 
gelatine (G-2500), three grams of BISacrylamide and three grams of acrylamide were 
separately weighed.  MilliQ water (59.333 ml) and 29.666 ml of iron oxide nanoparticles 
(also in MilliQ water) were also obtained.  The MilliQ water was poured into a glass conical 
flask and placed on a magnetic hot plate and the temperature set to 50 oC.  At temperature, a 
magnetic stirring bar was placed in the flask and the gelatine was firstly poured in slowly.  
Once the gelatine was dissolved, the BISacrylamide was added and when this also dissolved 
into the solution, acrylamide was finally added.  When this final ingredient was dissolved, a 
pipette was used to collect a volume of 5 ml and mix (and resuspend) with the nanoparticles 
in the plastic tubes.  The following table lists the volume of gel material and iron oxide 
nanoparticle.  The concentration of nanoparticles was 1,000 µg/ml. 
Percentage 
concentration of 
29% volume for 
iron oxide 
nanoparticles 
Volume of 
iron oxide 
nanoparticles 
(ml) 
Volume of MilliQ 
Water to required to 
reach maximum 29% 
(1.67 ml) of total 
volume of 5 ml 
Gel material 
(ml) 
Total 
volume 
(ml) 
100  1.67 0 3.33 5.0 
90  1.5 0.167 3.33 5.0 
80  1.33 0.331 3.33 5.0 
70 1.17 0.498 3.33 5.0 
60 0.99 0.665 3.33 5.0 
50 0.832 0.832 3.33 5.0 
40 0.665 0.999 3.33 5.0 
30 0.498 1.17 3.33 5.0 
20 0.331 1.33 3.33 5.0 
10 0.164 1.5 3.33 5.0 
 
Table 2.6: Percentages and volumes of materials used to compose the gel phantoms. 
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 Ten concentration points were used, each 10 % apart from one another.  This strategy was 
used in anticipation for ease of generating graphs and determining if T2 decay times would be 
exponential or have a linear component.  A further ten 15 ml tubes were filled with just gel 
material and no iron oxide nanoparticles.  These ten tubes served as controls and were also 
imaged at 1.5 T and 3.0 T with the same pulse sequence.  
The t2_se_COR_16-echoes pulse sequence was a Siemens specific pulse sequence whereby 
the TR was fixed at 3,000 ms and the TE varied from 22 ms to 352 ms with incremental 
values of 22 ms; therefore, generating 16 spin echoes (from 22 ms to 352 ms inclusive).  The 
tubes filled with the combined gel and nanoparticles were imaged and so too were the control 
tubes (tubes filled with only gel and no nanoparticles).  Coronal oriented sections were 
obtained and the contrast changes generated by the nanoparticles were assessed with ImageJ 
software, version 1.48v.  Circular region of interest (ROI) areas (same size) were created and 
placed over the images of the gel (no nanoparticles) and gel with nanoparticles and their MRI 
signal intensity changes (if any) were measured in arbitrary units.  These details were entered 
into a spreadsheet.   
Firstly, T2 decay changes were graphed from the ROI values and as the rate of change from 
one signal intensity (data point) to the next was known (22 ms), a power trendline was 
therefore used to assess the data points and understand the behaviour of the iron oxide 
nanoparticles suspended in gel.  Secondly, from both sets of ROI measurements, calculations 
made using the following T2 signal intensity and relaxivity equation. 
SignalSE = SignalOe(-R2 x TE)   Equation 2.1    
     
Where: 
SignalSE is the spin echo signal (in arbitrary units) intensity that results from a contrast agent; 
thus, the ROI signal intensity measured with ImageJ over the gels with nanoparticles; 
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 SignalO is the signal intensity with no contrast material; thus, the ROI signal intensity 
measured with ImageJ over the gels with no nanoparticles (control tube corresponding to the 
same position in the rack as the tube gel and nanoparticles); 
R2 is the relaxation rate, or relaxivity; which is the inverse if T2 (R2 = 1/T2); and, 
TE is the echo time at which SignalSE and SignalO were measured. 
To calculate a value for R2, Equation 2.1 was solved and transposed as follows: 
SignalSE = SignalOe(-R2 x TE) 
ln(SignalSE) = ln(SignalOe-R2 x TE) 
ln(SignalSE) = lnSignalO + In(e-R2 x TE) 
In(SignalSE) =(InSignalO) − (R2 x TE)  
In(SignalSE) − (InSignalO) = − (R2 x TE) 
(In(SignalSE) − (InSignalO)) / (− TE) = R2 <=> 1 / T2 
R2 = (In(SignalSE) − (InSignalO)) / (−TE) <=> 1 / T2 
  
These calculations were performed for all tube samples that contained iron oxide 
nanoparticles at every TE value ranging from 22 ms to 352 ms inclusive.  The relaxivity, or 
rate of change from one time point to the next, denoted with Δ R2 was also graphed. 
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 2.9.3 Functionalising amine chain on T10 dextran 
 
To facilitate conjugations with FITC, R-PE, DTPA Anhydride (Sigma-Aldrich, St. Louis, 
USA) and radiolabelling with 68Ga, the amine chain on the dextran coating was 
functionalised.   
The process commenced with a stock concentration of 1,000 µg/ml per ml of dextran coated 
iron oxide nanoparticles.  These were sonicated for 10 minutes until well dispersed.  In a fume 
hood, 10 ml of the stock solution was collected and transferred into a sterile 50 ml tube.  This 
was placed in a centrifuge (along with another 50 ml containing water, for balance) at 8,000 
rpm for 10 minutes.  At completion of this centrifugation step, the supernatant was discarded 
and 20 ml of ethanol (99%) was added.  This was then sonicated for 10 min (until well 
dispersed).  2 ml of 28 % aqueous ammonia was then added and also 500 µl of (3-
Aminopropyl) triethoxy-silane (minimum 98%).  The tube was then placed on a rotary shaker 
for 2 hours at room temperature.   
 
 
2.9.4 Conjugating FITC to IONP 
 
At the completion of process described in Section 2.8.3, once the tube had completed two 
hours on the rotary shaker at room temperature; the tube was removed and placed in a 
centrifuge at 8,000 rpm for 10 minutes (along with a balance tube).     
The buffer used to dissolve the FITC powder and to buffer the conjugation reaction was 
provided in the FluoroTagTM FITC Conjugation Kit and prepared, as per manufacturer’s 
instructions (Sigma-Aldrich, St. Louis, USA).  Simply, the contents of one capsule was added 
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 to 50 ml of deionized water and vortexed until dissolved; thus 0.1 M solution of sodium 
carbonate-bicarbonate buffer that had a pH of 9.0 was produced.    
Following 10 minutes of centrifugation, the supernatant was removed, a wash performed with 
0.1 M solution of sodium carbonate-bicarbonate buffer (pH of 9.0) and then placed in a 
sonicator for less than 10 minutes, until well dispersed, as observed visually.  A lesser 
duration of sonication was needed at this point, as the functionalised amine permitted the 
nanoparticles to disperse more readily.  Following sonication, the tube was centrifuged again 
at 8,000rpm for 10 minutes, the supernatant was removed and 2 ml of buffer added (0.1 M 
solution of sodium carbonate-bicarbonate buffer having a pH of 9.0).  This was then sonicated 
for 5 minutes until well dispersed. 
The FITC was then prepared by carefully weighing 1 mg of FITC power and adding 1 ml of 
0.1 M solution of sodium carbonate-bicarbonate buffer (pH of 9.0).  The sample was vortexed 
until the FITC powder dissolved.  IONP dispersed in 2 ml of buffer was then placed on a 
vortex at very low speed and the 1 ml of dissolved FITC solution was added to the 
nanoparticles drop-wise.  The 50 ml tube with the IONP and FITC sample was then covered 
with aluminium foil placed on a gentle stirrer for 2 hours at room temperature.  At the 
completion of that step, the IONP-FITC conjugation was stored at 4 oC until required.   
 
 
2.9.5 Conjugating R-PE to IONP 
 
The amine chain on the T10 dextran coating was functionalised as described in Section 2.8.3.  
The IONP were further prepared as per Section 2.3.4 with the exception of not adding 
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 dissolved FITC; instead, R-PE was added as received from the supplier (Life Technologies, 
Carlsbad, USA) without any modification.      
 
2.9.6 Conjugating DTPA Anhydride 
 
DTPA Anhydride (Sigma-Aldrich, St. Louis, USA) was conjugated to both iron oxide 
nanoparticles that had the T10 amine chain functionalised as per Section 2.8.3 and also to the 
same nanoparticles that had already been conjugated with FITC as described in Section 2.8.4. 
1 mg of DTPA Anhydride was weighed and added to 500 µl of colloid suspension of either 
nanoparticle preparation.  The sample was vortexed until the DTPA Anhydride powder was 
dissolved (less than 30 seconds), was wrapped in aluminium foil and placed on a shaker at 
room temperature for a minimum of two hours.  
 
 
2.9.7 Radiolabelling with 68Ga (IONP + DTPA Anhydride + 68Ga) 
 
Following the methodology discussed in section 2.8.6, IONPs were centrifuged at 14,000 rpm 
for 5 minutes and the buffer supernatant removed and replaced with an equivalent volume of 
0.5 M ammonium acetate (FlukaChemme GmbH, Germany).  This was repeated three times.  
On the third instance, the ammonium acetate supernatant was not replaced.  Next, the gallium 
generator (iThemba LABS, Somerset West, RSA) was prepared.  The lead shield was lowered 
and 3 ml of 5 M hydrochloric acid was used to flush and clean the generator tubes.  This was 
followed with 3 ml of MilliQ water.  Air was then pushed through the tubing to clear it of any 
MilliQ water. Germanium-68 (68Ge) was the parent isotope, with a half-life of 271 days, and 
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 the gallium generator was used to extract 68Ga (a positron emitting isotope) from a sample of 
decaying 68Ge.  5 ml 68Ge was slowly infused through the tubing over a 1 minute period.   
The elution process was then performed.  1 ml of Solution 1, or N1, was infused through the 
tubing and this was followed by 1 ml of Solution 2, or N2 – (N1 was a solution of 80 % 
acetone and 0.15 M of hydrochloric acid in MilliQ water and N2 was a solution of 97.56 % 
acetone and 0.05 M of hydrochloric acid in MilliQ water).  Dislodgement occurred – the 
elution process dislodged 68Ga from 68Ge; along the column that was in between the two 
three-way-taps and that dislodgement process took approximately 2 minutes.   
That process dispensed 68Ga into a glass vial containing 1.5 ml of ammonium acetate and thus 
made gallium acetate.  This occurred at a temperature of approximately 80 oC for about 5 
minutes (to evaporate the acetone) and was performed until condensation was visualised in 
the neck of the glass vial.  The tubing was then cleared by pushing through 3 ml of air.  500 µl 
of liquefied 68Ga was added to the IONP sample and resuspened and placed behind lead 
bricks for an incubation period of 15 minutes.  Thin layer chromatography (TLC) was then 
performed to assess bound 68Ga from free (unbound) 68Ga.   
When radiolabelled (68Ga) dextran coated IONPs were to be administered to humans, an 
endotoxin screen was performed by the Quality Assurance Radio-Chemist with an endotoxins 
meter (Charles River Laboratories).  
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 2.9.8 MTS assay 
 
PBMC were extracted from human buffy coat by using the gradient centrifugation technique 
with Ficoll®-Paque Premium as described in Section 2.6.4.  A cell count was performed using 
trypan blue and a haemocytomter, under microscopy.  PBMC were then suspended in 
complete RPMI 1640 media (10% FBS, 2% HEPES buffer and 1 % Pen/Strep).  Cells were 
seeded at 5.0 x 105 per ml.  A 24 well plate was used to test the PBMC’s response to varying 
concentrations of T10 dextran coated IONPs and a second 24 well plate was used to test the 
PBMC’s response to equivalent concentrations of gadoteric acid, the gadolinium based MRI 
agent in Dotarem® (Guerbet, Aulnay-sous-bois, France).  According to the product label, the 
concentration of gadotreric acid was 279.32 mg/ml.  The equivalent concentrations tested are 
presented in table 2.7. 
 
IONP (µg/ml) 200 100 50 20 5 0 (control) 
Dotarem® (µg/ml) 72 40 20 7 2 0 (control) 
 
Table 2.7: The equivalent doses of each contrast agent tested in µg/ml concentration 
values. 
 
Each concentration of either the IONPs or the Dotaren® tested, was tested three times for each 
experiment, that is, in triplicate or three replicates; as demonstrated in Tables 2.8 and 2.9.  
Each treatment condition had a corresponding well that contained all components of the 
treatment condition minus the PBMCs; this served as the background value to be subtracted 
from the average triplicate values.  This was each performed five times, n = 5.   
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Control 
5.0 x 105 cells 
200 µg/ml  
5.0 x 105 cells 
100 µg/ml  
5.0 x 105 cells 
50 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
5 µg/ml  
5.0 x 105 cells 
Control 
5.0 x 105 cells 
200 µg/ml  
5.0 x 105 cells 
100 µg/ml  
5.0 x 105 cells 
50 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
5 µg/ml  
5.0 x 105 cells 
Control 
5.0 x 105 cells 
200 µg/ml  
5.0 x 105 cells 
100 µg/ml  
5.0 x 105 cells 
50 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
5 µg/ml  
5.0 x 105 cells 
Control 
No cells 
200 µg/ml  
No cells 
100 µg/ml  
No cells 
50 µg/ml  
No cells 
20 µg/ml  
No cells 
5 µg/ml  
No cells 
 
Table 2.8: The arrangement of the well plate for testing the cell viability of PBMC with 
IONPs using the MTS assay.  Total volume in each well is 1 ml, prior to adding 200 ml of 
MTS.  In the fourth row, which served to create a background value from the plate reading, 
the volume to 1 ml was made up with complete media and the vehicle that carried the 
nanoparticles, which in this case was MilliQ water. 
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Control 
5.0 x 105 cells 
72 µg/ml  
5.0 x 105 cells 
40 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
7 µg/ml  
5.0 x 105 cells 
2 µg/ml  
5.0 x 105 cells 
Control 
5.0 x 105 cells 
72 µg/ml  
5.0 x 105 cells 
40 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
7 µg/ml  
5.0 x 105 cells 
2 µg/ml  
5.0 x 105 cells 
Control 
5.0 x 105 cells 
72 µg/ml  
5.0 x 105 cells 
40 µg/ml  
5.0 x 105 cells 
20 µg/ml  
5.0 x 105 cells 
7 µg/ml  
5.0 x 105 cells 
2 µg/ml  
5.0 x 105 cells 
Control 
No cells 
72 µg/ml  
No cells 
40 µg/ml  
No cells 
20 µg/ml  
No cells 
7 µg/ml  
No cells 
2 µg/ml  
No cells 
 
Table 2.9: The arrangement of the well plate for testing the cell viability of PBMC with 
Dotarem® (279.32 mg/ml of gadoteric acid) using the MTS assay.  Total volume in each 
well was 1 ml, prior to adding 200 ml of MTS.  In the fourth row, which served to create a 
background value from the plate reading, the volume to 1 ml was made up with complete 
media and the vehicle that carried the gadoteric acid, which in this case was apyrogenic water 
for injection. 
 
The well plates were placed in an incubator (37 oC and 5% CO2) and at 22 hours incubation, 
MTS (Promega, Madison, USA) added according to the manufacturer’s instructions of a ratio 
of 5:1 to the total well volume; thus 200 ml of MTS was added to each well.  The well plates 
were returned to the incubator for a further 2 hours; completing a total of 24 hours incubation.  
Each plate was then placed into a plate reader and scanned with a wavelength of 490 nm, as 
per the instructions of the MTS manufacturer.   
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2.10 Bone marrow derived murine dendritic cell cultures, in vitro 
 
This section recounts the method of extracting bone marrow stem cells, adding cytokines and 
generating DC.  This was performed in aseptic conditions in a fume hood.  The following 
were sprayed with 70 % ethanol and allowed to air dry: the interior of the fume hood itself, a 
cork board, tube rack, 50 ml tubes, tubes with warmed cell media, tube with red blood cell 
lysis buffer, PIPETTEBOY, glass pipettes tips, pipette and the exterior of three Petrie dishes.  
Dissecting tools (scissors and forceps) were placed in a beaker and soaked in 70 % ethanol. 
The killed mouse was sprayed with 70 % ethanol and pinned to the cork board using sterile 
needles.  Scissors were used to cut the fur layer horizontally across the mouse, above the level 
of the pelvis.  This was then pulled down towards the hind paws so that the pelvis and lower 
limbs were exposed.  The muscle tissue of the lower limbs were then carefully cut away.  
Scissors were used to cut at the ankle joints (separate the paws), knee joints and the hip joints; 
to free the tibia and femur in both lower limbs.  These were then placed for several seconds in 
a Petrie dish which contained 70 % ethanol and then transferred to a second Petrie dish with 
complete RPMI 1640 media (10 %  FBS, 2 %  HEPES buffer and 1 % Pen/Strep).   
The mouse carcass was then placed in a plastic bag and kept in a freezer within the laboratory, 
until ready to return to the university’s animal and aquatic facility for ethical disposal. 
One of the bones (either a tibia or a femur) was transferred to a third Petrie dish that contained 
complete RPMI 1640 media.  With a tibia, scissors were used to make a complete cut/sever 
above the ankle at the lower quarter of the tibia and another complete cut/sever was made at 
the tibial plateau.  With a femur, a complete cut/sever was made at the femoral condyle and at 
the femoral head.  A 26 gauge needle was attached to 3 ml syringe, media from the Petrie dish 
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 was drawn and passed through each bone (one at a time) until all marrow contents were 
removed. 
A sterile Pasteur pipette was used to collect the Petri dish contents (complete media and 
marrow cells) and transfered into a sterile 50 ml tube.  This was centrifuged at 1,200 rpm (277 
rcf) for 4 minutes with acceleration and brake both set at level seven.  The supernatant was 
then discarded and 3 ml of red blood cell lysis buffer was added and the cell pellet re-
suspended and allowed to stand for 5 minutes.  Complete RPMI 1640 media was then added 
to the 25 ml indicator mark.  A new sterile 50 ml tube was obtained and a cell strainer was 
inserted and sterile Pasteur pipette used to add the cells drop-wise onto the cell strainer and 
allowed to drip into the sterile tube.  Once all contents were transferred, the cell strainer was 
removed and the top screwed in place securely and this tube was then centrifuged using the 
same settings as previous.  The supernatant was discarded and 10 ml of complete RPMI 1640 
media was added to the cell pellet and re-suspended.   
A cell count was performed using trypan blue and a haemocytometer.  Ten microliters of the 
cell suspension was placed in a well of a 96 well plate and 10 µl of trypan blue was added to 
the same well and mixed together.  A sample of this was placed under a glass cover slip on 
the haemocytometer and a cell count performed using a microscope.  One million cells per ml 
were added to wells in a 24 well plate (maximum 3 million cells in a 3 ml volume in a well).  
Cytokines (either GM-CSF or Flt3) were added at 20 ng per ml.  The well plate was then 
placed in an incubator with a temperature of 37 oC and 5 % CO2.   
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2.11 In vitro studies 
 
Experimental in vitro studies with murine cells were approved by the RMIT University 
Animal Ethics Committee, AEC Project Number 1210.  Cells were collected as described in 
Section 2.9.  The in vitro experiments described in Sections 2.10.1, 2.10.2, 2.10.3 and 2.10.4 
with both myeloid DC (5 days following the addition of GM-CSF to murine bone marrow 
stem cells) and with combined myeloid and plasmacytoid DC (8 days following the addition 
of IL-4 to murine bone marrow stem cells).   
 
 
2.11.1 Dose response (uptake) 
 
Cells mentioned in Section 2.11 were placed in a sterile 24 well plate with 3 x 106 cells in 3 
ml in each well.  Six conditions were established: one well served as a control and received no 
nanoparticles, the remaining wells received different concentrations of nanoparticles (200 
µg/ml, 100 µg/ml, 50 µg/ml, 20 µg/ml, and 5 µg/ml).  Nanoparticles tagged with FITC were 
sonicated for 10 minutes, prior to being added to cells cultures and incubated for 24 hours.   
Following incubation, the supernatant was carefully removed, placed in a labelled micro tube 
and then stored at -80 oC for further cytokine analysis.  Sterile PBS was used to lift off any 
cells that had adhered to the bottom of each well.  The collected cells from each well were 
placed in labelled tubes and centrifuged at 1,500 rpm (433 rcf) for 5 minutes, the supernatant 
then discarded and cells resuspended with 0.5% BSA/PBS (w/v).  Cells were then added to a 
sterile 96 well v-bottom well plate and centrifuged at 1,500 rpm (433 rcf) for 5 minutes.  The 
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 supernatant was then discarded and cold 0.5% BSA/PBS (w/v) antibody were added and 
incubated at 4 oC for 30 minutes. Following incubation, cells were centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes, supernatant discarded and cells resuspended in FACS fix for. 
 
 
2.11.2 In vitro assessment of maturation marker on in vitro grown DCs 
by flow cytometry  
 
Cells mentioned in 2.11 were placed in a sterile 24 well plate with 3 x 106 cells in 3 ml in 
each well.  Six conditions were established: one well served as a control and received no 
nanoparticles, the remaining wells received different concentrations of nanoparticles (200 
µg/ml, 100 µg/ml, 50 µg/ml, 20 µg/ml, and 5 µg/ml).  Nanoparticles tagged with FITC were 
sonicated for 10 minutes, prior to being added to cells cultures and incubated for 24 hours.   
Following incubation, the supernatant was carefully removed, placed in a labelled micro tube 
and then stored at -80 oC for further cytokine analysis.  Sterile PBS was used to lift off any 
cells that adhered to the bottom of each well.  Collected cells were centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes, the supernatant discarded and resuspended in 0.5% BSA/PBS (w/v).  
Cells were resuspended and each original cell culture (or well) condition was divided into 4 
equal volumes and transferred into a sterile 96 well, v-bottom well plate.  Therefore, each 
original condition (from the flat bottom 24 well plate) was divided into four (and placed in a 
96 v-bottom well plate).  The 96 well plate was centrifuged at 1,500 rpm (433 rcf) for 5 
minutes.  The supernatant was then discarded.   
As each original condition was divided into four; the contents of one well was resuspended 
with 200 µl of cold 0.5% BSA/PBS; the second well was resuspended with 200 µl 0.5% 
BSA/PBS that contained antibody CD86; the third well was resuspended with 200 µl 0.5% 
BSA/PBS that contained combined antibodies CD11c and CD86 and the fourth division was 
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 resuspended with 200 µl 0.5% BSA/PBS that contained combined antibodies CD11c and 
CCR7. 
The 96 well plate was then incubated at 4 oC for 30 minutes, then centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes, the supernatant was then discarded and cells resuspended in FACS fix 
for flow cytometry analysis. 
 
 
2.11.3 In vitro assessment of apoptosis on in vitro grown DC’s by flow 
cytometry 
 
Cells mentioned in 2.11 were placed in a sterile 24 well plate with 3 x 106 cells in 3 ml in 
each well.  Six conditions were established: one well served as a control and received no 
nanoparticles, the remaining wells received different concentrations of nanoparticles (200 
µg/ml, 100 µg/ml, 50 µg/ml, 20 µg/ml, and 5 µg/ml).  Nanoparticles tagged with FITC were 
sonicated for 10 minutes, prior to being added to cells cultures and incubated for 24 hours.   
Following incubation, the supernatant was carefully removed, placed in a labelled micro tube 
and then stored at -80 oC for further cytokine analysis.  Sterile PBS was used to lift off any 
cells that adhered to the bottom of each well.  Collected cells were centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes, the supernatant discarded and resuspended in 0.5% BSA/PBS (w/v).  
Cells were resuspended and each original cell culture (or well) condition was divided into 4 
equal volumes and transferred into a sterile 96 well, v-bottom well plate.  Therefore, each 
original condition (from the flat bottom 24 well plate) was divided into four (and placed in a 
96 v-bottom well plate).  The 96 well plate was centrifuged at 1,500 rpm (433 rcf) for 5 
minutes.  The supernatant was then discarded.   
105 
 
 As each original condition was divided into four; the contents of one well was resuspended 
with 50 µl of binding buffer (provided in the kit); the second well was resuspended with 50 µl 
of binding buffer that contained Annexin V (BD Biosciences, San Diego, USA); the third well 
was resuspended with 50 µl of binding buffer that contained 7AAD (BD Biosciences, San 
Diego, USA); and the fourth well was resuspended with 50 µl of binding buffer with both 
Annexin V and 7AAD. 
The 96 well plate was then wrapped in aluminium foil, placed on a laboratory bench top for 
30 minutes at room temperature, then uncovered and centrifuged at 1,500 rpm (433 rcf) for 5 
minutes.  The supernatant was then discarded and cells resuspended in FACS fix for flow 
cytometry analysis within 30 minutes of this final step.   
 
 
2.11.4 Time course (time dependent uptake) 
 
Cells mentioned in 2.11 were placed in a sterile 6 well plate containing 4.5 x 106 cells in 3 ml, 
six conditions were established: one well served as a control and received no nanoparticles; 
the remaining wells received 200 µg/ml of FITC tagged nanoparticles at different time points 
(24 hours, 18 hours, 6 hours, 4 hours and 1 hour).  The nanoparticles were sonicated for 10 
minutes, prior to being added to cell cultures and then incubated for 24 hours.   
On completion of the treatment periods, the supernatant was carefully removed, placed in a 
labelled micro tube and then stored at -80 oC for further cytokine analysis.  Cells were 
removed using sterile PBS was used to lift off any cells that had adhered to the bottom of each 
well.  Collected cells were centrifuged at 1,500 rpm (433 rcf) for 5 minutes, the supernatant 
discarded and resuspended in 0.5 % BSA/PBS (w/v).  Cells were added to a sterile 96 well v-
bottom well plate; 2 x 200 µl from each tube (representing each original condition).  
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 Therefore, each original condition (from the flat bottom 24 well plate) was divided into two 
(and placed in a 96 v-bottom well plate).  The 96 well plate was then centrifuged at 1,500 rpm 
(433 rcf) for 5 minutes and the supernatant was then discarded.   
One well of each original condition, was resuspended with 200 µl of cold 0.5 % BSA/PBS 
(w/v) and the other corresponding condition was resuspended with 200 µl of cold 0.5 % 
BSA/PBS (w/v) that contained antibody.  The 96 well plate was then incubated at 4 oC for 30 
minutes.  Following incubation, cells were centrifuged at 1,500 rpm (433 rcf) for 5 minutes, 
supernatant discarded and cells resuspended in FACS fix for flow cytometry analysis.   
 
 
2.11.5 Mouse Inflammatory Cytometric Bead Array (CBA) Analyser 
 
Supernatant from specified (dose response and time course) in vitro murine experiments were 
stored at -80 oC.  Frozen samples were thawed and used to assess cytokine levels by CBA 
analysis (BD™ Cytometic Bead Array, BD Biosciences, San Diego, USA) as per 
manufacturer’s instructions and read on flow cytometry.  The specific cytokines analysed 
were: IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70.   
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 2.12 In vivo studies 
 
In vivo studies performed with mice and their tissues were approved by the RMIT University 
Animal Ethics Committee (AEC Project Number 1320). 
 
 
2.12.1 Murine strain and lymph node tracking, in vivo 
 
Female mice, C57BL/6, aged between 8 to 12 weeks were used for all lymph node tracking 
experiments, in vivo.   
 
 
2.12.2 Mouse injections (injection methods and sites) 
 
All mice received unilateral hock injections of iron oxide nanoparticles (coated with dextran 
and tagged with FITC) suspended in saline.  A maximum volume of 100 µl at a concentration 
of 200 µg/ml was administered into the hock, subcutaneously.  The use of a hock injection 
was designed to be more sympathetic and humane (compared to a foot pad injection), while 
still providing lymphatic drainage to the popliteal lymph node.  In addition to the hock 
injections, each mouse received subcutaneous injections into their flanks, on the same side.  
Again, a maximum volume of 100 µl at a concentration of 200 µg/ml was used for these flank 
injections.   
The injection into the flank was used to determine lymphatic drainage into the inguinal lymph 
node. Following the time period to be assessed, either one hour or one day, the mice were 
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 heavily anaesthetised (intraperitoneal injection of sodium pentobarbitone, 150 mg/kg with a 
25 gauge needle) and the standard method of Vascular Perfusion Fixation was performed.  
Once the mouse appeared anaesthetised, its reflexes were assessed to ensure that the mouse 
was fully anaesthetised; an incision across below the rib cage was made, the descending aorta 
was clamped, a needle was inserted through the left ventricle and its tip was positioned in the 
ascending aorta.  The injection or perfusion then took place with heparinised phosphate-
buffered saline to flush out the blood, followed by 4% paraformaldehyde in phosphate 
buffered saline until fixation tremors were noted.  This indicated the point of death.  The 
mouse, thus, died humanely on completion of the Vascular Perfusion Fixation process, under 
anaesthesia.  The mouse was then dissected and the required tissues and organs removed.  The 
inguinal and popliteal lymph nodes were removed from one leg (right leg) and underwent 
further analysis by flow cytometry and confocal microscopy.  The other lymph nodes (left 
side) remained in the mouse for further analysis (imaging with MRI).  Other organs/tissues 
assessed were the liver, spleen, kidneys, heart and lungs; with histological staining 
techniques).  A blood sample (for blood serum biochemical assay) was also taken just prior to 
the commencement of the Vascular Perfusion Fixation process via a retro-orbital sinus.  The 
remainder of the mouse was preserved with 10 % neutral buffered formalin (NBF).   
 
 
2.12.3 Preparation of iron oxide nanoparticles 
 
The dextran coated iron oxide nanoparticles were functionalised as described in Section 2.8.3 
and then conjugated with FITC as stated in Section 2.8.4.  To wash unbound FITC, the 
required volume of particles were centrifuged at 5,000 rpm for 5 minutes and resuspended in 
saline.  This was performed three times.  The mice received injections of FITC tagged 
nanoparticles suspended in saline. 
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2.12.4 Lymph node removal and preparation for FACS flow 
cytometry 
 
Popliteal and inguinal lymph nodes were removed by surgical dissection, post mortem and 
placed in 10% NBF.  To prepare the lymph nodes for flow cytometry, they were placed in 
0.5% BSA/PBS (w/v), fatty tissue surrounding the lymph node was carefully removed and the 
soft rubber end of a syringe plunger was used to rupture the capsule of the lymph node and 
release its capsular contents.  The cellular contents were then collected centrifuged at 4,000 
rpm for 4 minutes and resuspended in 0.5% BSA/PBS (w/v).  Lymph node cells were divided 
into two staining conditions: (1) no antibody (control) and (2) CD11c antibody as per 
manufacturer specification.  Antibody staining was performed at 4 oC for approximately 25 
minutes, after which they were centrifuged at 4,000 rpm for 4 minutes, washed and 
resuspended in FACS fix buffer for flow cytometry.     
 
 
2.12.5 Organ removal for histological analysis 
 
On completion of the Vascular Perfusion Fixation process, all mice were then dissected and 
organs were removed for histological analysis.  Organs included the liver, spleen, kidneys, 
heart and lungs; which were fixed in 10% NBF for further analysis.     
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 2.12.6 Histological analysis 
 
Organs (liver, spleen, kidney, heart and lungs) fixed for histopathological analysis were 
processed using a histopathology tissue processor (Leica ASP200S, NSW, Australia) using a 
protocol specifically designed for rodent tissue.  The automated process included preparing 
these tissues with 10 % NBF, 70 % ethanol, 90 % ethanol, 100 % ethanol and xylene for exact 
durations and temperatures. 
On completion, the tissues were embedded in paraffin wax using an embedding station 
(Shandon Histocentre 3, Thermo Electron Corporation, Madison, USA) and wax blocks 
containg murine organs were created.  4 µm thick sections were cut using a microtome (RM 
2235, Leica Microsystems, Nussloch, Germany)) and placed on Superfrost Plus (positively 
charged) glass microscope slides, then positioned in racks and placed in a drying oven 
(Watson, Victoria, Australia) at 60 oC for one hour. 
 
 
2.12.7 Biochemical analysis of blood serum 
 
A blood sample (for blood serum biochemical assay) was taken just prior to the 
commencement of the Vascular Perfusion Fixation process, while mice were heavily 
anaesthetised, via their retro-orbital sinus.  The blood sample was taken using a haematocrit 
capillary tube (Hirschmann Laborgerate, Eberstadt Germany) transferring blood into a micro 
tube, allowed to clot for at least 1 hour and then centrifuged at 2,000 rpm (771 rcf) for 10 
minutes.  Serum was collected and stored -80 oC for further analysis.  The blood serum 
samples were later analysed for various biochemical parameters at the Department of 
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 Pathology Peter MacCallum Cancer Centre using a blood serum biochemical immunoassay 
analyser (Abbott Architect Plus, ci4100, Roche Diagnostics, Melbourne, Australia).  
 
2.12.8 FACS flow cytometery analyser 
 
All FACS flow cytometry experiments were performed using the FACS Canto™ II Flow 
Cytometer (BD Biosciences, San Jose, USA) located within the RMIT Flow Cytometry 
Facility (RMIT University, Bundoora West Campus, Australia).   
 
 
2.13 MRI imaging studies 
 
MRI imaging of gel phantoms with suspended iron oxide nanoparticles (as set out in section 
2.8.2) were performed with both a 1.5 T Siemens MRI scanner at The Austin Hospital 
(Studley Road, Heidelberg, 3084, Victoria, Australia) and a 3.0 T Siemens at Peter MaCallum 
Cancer Centre, (St. Andrews Place, East Melbourne, Victoria, Australia).  In both instances, a 
head coil was used with the MRI imaging process.  To ensure that the gel phantoms were 
positioned within the isocentre volume of the MRI magnet, and that the imaging plane co-
incided with this, a specially designed foam pad was fashioned to elevate the desired imaging 
plane of the gel phantoms to be within the central horizontal plane (z-direction) of the head 
coil.  
Mice were scanned with a 3.0 T Siemens MRI scanner at Peter MaCallum Cancer Centre.  
The mice were imaged using a wrist coil (an MRI imaging coil designed for imaging the 
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 human wrist).  This coil approximated the dimension of the mice and allowed the mice to be 
as close as possible to the coil, acting as a receiver for the MRI signal emanating from the 
mice); thus maximising SNR.  The mice had been killed by cervical spine dislocation 
immediately prior to MRI imaging. 
2.14 PET imaging studies 
 
For PET imaging, the radiotracer used was 68Ga.  The radiolabelling process was as described 
in section 2.8.7.  For PET imaging in mice, 68Ga was radiolabelled to dextran coated iron 
oxide nanoparticles tagged with FITC and for PET imaging in humans, the 68Ga was 
radiolabelled to dextran coated iron oxide nanoparticles (without FITC). 
Mice were imaged with a Small Animal PET (Philips Healthcare, DA Best, The Netherlands)    
scanner and were anesthetised with 2% isoflurane in medical air (20 % oxygen and 80 % 
nitrogen) with a total flow rate of 0.8 litres per minute.  PET imaging commenced 1 hour after 
the mice received a foot-pad injection of radiolabelled nanoparticles (a volume of 100 µl and 
a nanoparticle concentration of 1,000 micrograms per ml).  
The Human Ethics Committee (Peter MacCallum Cancer Centre) granted approval for 
experimental research in patients diagnosed with prostate cancer. These patients provided 
their consent to this imaging procedure.  They received general anaesthesia, were brought to 
the operating theatre and positioned supine on the operating table with their legs in stirrups.  
An ultrasound machine and rectal probe were used to identify the prostate gland.  The 
radiolabelled nanoparticles – 1,000 µg/ml in a total volume of 1,000 ml – were divided into 8 
equal fractions or doses (125 µl), and directly injected into the prostate by a radiation 
oncologist, using ultrasound guidance.  Four injections were into the peripheral zone of the 
prostate and the remaining four doses were injected into the prostate’s inner zone.  1 hour post 
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 procedure, the patient was brought to the PET/CT scanner for imaging.  The patient was 
positioned supine on the PET/CT imaging table and entered the gantry head-first. 
2.15 Histopathology staining 
 
2.15.1 Haematoxolin and Eosin staining 
 
Organs processed for histopathology analysis were stained with haematoxylin and eosin 
(H&E) according to the following protocol: 
1. Xylene (5 minutes). 
2. Xylene (3 minutes). 
3. Absolute alcohol (2 minutes). 
4. Absolute alcohol (2 minutes). 
5. Rinse in tap water (1 minute). 
6. Haemotoxolin (30 seconds). 
7. Rinse in tap water (20 seconds). 
8. Scott’s tap water (30 seconds). 
9. Rinse in tap water (20 seconds). 
10. Eosin (20 seconds). 
11. Rinse in tap water (20 seconds). 
12. In 70 percent alcohol (1 minute). 
13. Absolute alcohol (1 minute). 
14. Absolute alcohol (1 minute). 
15. Xylene (20 seconds) 
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 16. Xylene.  The Superfrost Plus glass microscope slides remain in this bath until they 
were glass cover-slipped with xylene based DPX colourfast mounting media (Fronine, 
NSW, Australia). 
  
2.15.2 Perls Prussian Blue Staining for Haemosiderin 
 
Organs processed for histopathology analysis were stained with Perls Prussian Blue according to 
the following protocol: 
1. Tissue sections on positively charged microscope slides were dewaxed as per the 
following process: 
a. Xylene (2 minutes) 
b. Xylene (1 minute) 
c. Absolute alcohol (2 minutes) 
d. Absolute alcohol again (1 minute) 
e. 70 percent alcohol (2 minute). 
2. Bring to water 
3. Positively charged microscope slides were dewaxed sections placed n tank with equal 
volume mixture of hydrochloric acid and potassium ferrocyanide (5 minutes) 
4. Washed in distilled water 
5. Counterstained in nuclear fast red (20 minutes) 
6. Washed in tap water (1 minute) 
7. Dehydrated according to the following process: 
a. 70 percent alcohol (2 minutes) 
b. Absolute alcohol (1 minute) 
c. Absolute alcohol again (1 minute) 
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 d. Xylene (2 minutes) 
e. Xylene again (2 minutes) 
8. Cleared and mounted with xylene based DPX colourfast mounting media and glass 
cover slip   
 
2.15.3 Periodic Acid Schiff’s (PAS) reaction staining 
 
The kidney tissue sections processed for histopathology analysis underwent the PAS reaction 
staining protocol as follows: 
1. Tissue sections on positively charged microscope slides were dewaxed as per the 
following process: 
a. Xylene (2 minutes) 
b. Xylene (1 minute) 
c. Absolute alcohol (2 minutes) 
d. Absolute alcohol again (1 minute) 
e. 70 percent alcohol (2 minutes) 
2. Bring to water  
3. Oxidisation with 1 percent periodic acid (10 minutes) 
4. Washed in distilled water (1 minute) 
5. Placed in Schiff’s reagent at room temperature (20 minutes) 
6. Washed well in water (5 minutes) 
7. Counterstained with Mayer’s Haematoxylin (90 seconds) 
8. Placed to blue in Scott’s tap water (30 seconds) 
9. Washed in water 
10. Dehydrated according to the following process 
a. 70 percent alcohol (2 minutes) 
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 b. Absolute alcohol (1 minute) 
c. Absolute alcohol again (1 minute) 
d. Xylene (2 minutes) 
e. Xylene again (2 minutes) 
11. Cleared and mounted with xylene based DPX colourfast mounting media and glass 
cover slip. 
 
 
 
2.16 Generation of graphs and statistical analysis 
 
The following graphs – Figures 3.13 to 3.38, and, Figures 3.41 to 3.66 – presented in Chapter 
3 and in the Appendix 1, were created using Microsoft Excel (Microsoft Corporation, USA).  
The trendlines presented in Figures 3.13 to 3.22 inclusive and Figures 3.41 to 3.50 inclusive 
contain power trendlines because the rate of change in the pulse sequence is known to be 22 
ms from one TE to the next.  The feature of adding a power trendline to a data set is not 
possible with GraphPad Prism 6 (GraphPad Software Inc. USA).  Figures 3.67 and 3.68 are 
3D graphs (data sets presented on a 3D graph) and this feature was also not available with 
GraphPad Prism 6. 
The remaining graphs throughout this thesis were generated using GraphPad Prism 6.  Where 
statistical analysis was performed, the following was applicable. 
• The alpha, α, value (threshold significance level), was set at 0.05 
• As GraphPad Prism was used to generate the graphs and statistical data, their 
statistical terminology and references were used and summarised in Table 2.9. 
• Where no asterisk/s appear on a graph, no statistical significance was identified.  
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P value 
 
Wording Summary 
< 0.0001 Extremely significant **** 
 
0.0001 to 0.001 Extremely significant *** 
 
0.001 to 0.01 Very significant 
 
** 
0.01 to 0.05 Significant 
 
* 
≥ 0.05 Not significant 
 
ns 
 
Table 2.9: The correlation of calculated P value, statistical wording and summary (as 
indicated with asterisk/s) according to GraphPad Prism, version 6.05.  Throughout this 
chapter, when calculated statistical P values conformed to any of the ranges indicated, the 
corresponding wording was used and asterisks were incorporated into the graphs.  
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 3.0 Chapter 3 – Characterisation of iron oxide nanoparticle in the clinical 
magnetic environment, radiolabelling with 68Ga and in vitro cytotoxicity 
 
 
3.1 Introduction 
 
For almost a decade now, there has been progressively increased research efforts into 
exploiting certain attributes of iron oxide nanoparticles for a variety of imaging techniques, 
incorporated with MRI.  These include using iron oxide nanoparticles as MRI contrast agents, 
for cell tracking(208-210), for drug delivery(211, 212) and for hyperthermia therapy(213, 214).  One 
facet of current research interest is the possibility of multimodal imaging flexibility offered by 
nanoparticles that can be radiolabelled with a suitable radionuclide(215, 216).  In this respect, 
recent research activities have turned to designing imaging agents for the hybrid imaging 
modes of PET/MRI.  At this time, no PET/MRI for patients is available in Australia, however, 
there is anticipation that this will soon change in major hospitals offering oncology and 
related surgical services.  For any nanoparticle to be primarily considered as a PET/MRI 
contrast agent, it would need to be radiolabelled with a positron emitting radionuclide. 
Compared to current PET only imaging and to MRI only imaging, a hybrid or multimodal 
approach with a suitable contrast agent offers improved contrast-to-noise ratio amongst 
anatomical structures defined by the spatial resolution offered by MRI.  This would thereby 
improve the specificity of these modalities, particularly MRI; and also provide further 
diagnostic capabilities to referring clinicians for their patients.        
For iron oxide nanoparticles to be utilised as imaging agents, they would need to be designed 
with several favourable characteristics that can be maximised by either MRI or PET or 
combined imaging processes.  For MRI, iron oxide nanoparticles would need to have their 
own magnetic properties, be compatible in the MRI and magnetic field environments, 
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 demonstrate T2 spin-spin relaxation behaviour and respond to pulse sequence directions.  For 
in vivo administration, iron oxide nanoparticles need to; be biocompatible, be evenly 
distributed in a colloidal suspension (no chemical agglomeration or aggregation), and each 
have a consistent size throughout the sample.  
Their size, that is, the physical dimension of nanoparticles, can determine their in vivo 
biodistribution(109).  Iron oxide nanoparticles greater than 50 nm are readily isolated by organs 
of the reticulo-endithelial system (RES), namely the liver and spleen(18, 217).  This is especially 
true when these nanoparticles are administered by an intravascular route and their 
sequestration occurs within minutes.  Commercially available iron oxide nanoparticle 
preparations (such as Resovist® and Endorem™) have been marketed specifically as a 
contrast agent for imaging the liver with MRI.  For improved biodistribution in vivo, iron 
oxide nanoparticles would need to be less than 50 nm, as this would also provide them with a 
greater circulation time throughout the body(18, 56). 
Physical properties of the iron oxide nanoparticles used for the purposes of experiments 
pertaining to this thesis were that they were less than 50 nm, specifically, 20nm, 
approximately.  They were coated with T10 dextran for in vitro and in vivo biocompatibility.  
The biocompatibility or safety profile afforded by T10 dextran is that it is a very low 
molecular weight dextran, as opposed to higher molecular weight dextrans that have been 
shown to induce an IgG response in vivo(218).  Dextran has already proven itself to be a 
successful biocompatible coating in commercially approved iron oxide contrast agents for 
intravenous (Resovist®, Endorem™, Feridex®). 
The iron oxide core itself; if it can be demonstrated that low concentrations of iron oxide 
nanoparticles (with high magnetic properties) can induce a visually noticeable signal intensity 
change on MRI images, then a small quantity would need to be administered in vivo; and if 
such nanoparticles were radiolabelled, this in turn would signify that less ionising 
120 
 
 radiation(219) would be present but still generate PET image data due to PET’s contrast-to-
noise ratio (CNR) sensitivity.  Iron (oxide) is normally found in the human body; and with 
commercially available and FDA approved iron oxide nanoparticle preparations, any risk of 
iron overload in the liver is rendered minimal or negligible(18).  The excretory pathway of iron 
oxide from the human body, however, is well known and understood.  Dextran coated iron 
oxide nanoparticles are incorporated as phagolysosomes within phagocytic cells(18).  From 
here, intracellular dextranase enzymes cleave the dextran from the nanoparticle and the iron 
oxide is solubilized into iron ions, which then progress into the haemoglobin pool, and as with 
endogenous iron, it is eliminated via the RBC cycle and the liver(220).  The safety profile of 
iron oxide nanoparticles have been established at concentrations up to 200 µg/ml and 
concentrations greater than this have demonstrated intracellular toxicity due to high levels of 
reactive oxygen species (ROS)(221).  One method of assessing cytotoxicity of nanoparticles is 
by performing a MTS assay.  MTS is the compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and is combined with an electron 
coupling agent (phenazine ethosulfate; PES).  MTS is bioreduced by cells into a formazan 
product that is soluble in tissue culture medium.  The conversion of MTS into the aqueous 
soluble formazan product is accomplished by dehydrogenase enzymes found in metabolically 
active cells. The absorbance of formazan is measured at a wavelength of 490 nm in a plate 
reader. The quantity of formazan product as measured by the amount of 490nm absorbance is 
directly proportional to the number of living cells in culture(222).  
For in vitro experimentation, the physical size of the iron oxide nanoparticles were also 
critical, as size is one determining factor for ease of ingestion by cells.  The outer surface of 
the T10 dextran coating should be smooth to not restrict or adversely affect ingestion by cells.  
The surface charge of nanoparticles may also be a factor in determining the degree of cell 
internalisation in a variety of cells, particularly in healthy cell and in cancer cell types.   
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 These desired characteristics are also applicable if cell tracking were to be pursued(18, 208, 210), 
that is, cells can be loaded with iron oxide nanoparticles; with features designed specifically 
to facilitate cell entry.  The cells would then be re-administered to their original host and they 
would be imaged with MRI to observe their migration from their administration site to their 
eventual destination, in vivo.  Biocompatibility features, embedded in their fabrication, would 
also ensure no cytotoxity or rejection.   
The principle of withdrawing cells from a patient, adding a feature and then administering 
these cells to the patient; has been a standard practice within the Nuclear Medicine field for 
decades; that is, ex vivo radiolabelling of cells and returned for in vivo imaging applications.  
For example, labelling white blood cells (leukocytes) with Indium-111 (111In) to image acute 
infective process is common-place; whereby a blood sample from a patient is taken, the white 
blood cells isolated, incubated with 111In, re-administered to the same patient and imaging 
then performed.  In a very similar process, radio-active gallium is used to label neutrophils to 
image long-standing infective processes such as osteomyelitis (gallium binds to the 
membrane of neutrophils).  Nuclear Medicine can also image the activity in the liver and 
spleen by radiolabelling technetium (99mTc) to red blood cells; whereby the majority of the 
radio-activity conjugates to haemoglobin, but more specifically, in the beta chain component 
of the globin.  These Nuclear Medicine imaging procedures can encounter challenges that 
limit their clinical utility under certain condition.  For example, patients being medicated with 
heparin would not be suitable candidates for RBC labelling and imaging, as 99mTc will bind to 
heparin rather than RBCs.  Likewise, radiolabelling of lymphocytes(223) and leukocytes(224) 
with 99mTc has been demonstrated to induce chromosomal aberrations.  These limitations can 
be addressed and overcome by radiolabelling nanoparticles, as the nanoparticles (instead of 
cells) will serve as a carrier for the radionuclide.    
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 Further supporting the case for incorporating nanoparticles with Nuclear Medicine is that the 
size of iron oxide nanoparticles are analogous to the size of various antimony sulphide 
colloids already widely used for a number of radionuclide imaging procedures and 
administered to patients.  99mTc antimony sulphide is administered intravenously and targets 
bone marrow in patients experiencing bone marrow related conditions such as avascular 
necrosis of the femoral head and also bone metastases.  In an imaging technique referred to as 
intramammary lymphoscintigraphy, 99mTc antimony sulphide can be used to map lymph 
drainage in patients with breast cancer, prior to surgery for lymph node removal.  99mTc 
antimony sulphide has been measured at less than 100nm and rhenium sulphide is 
approximately 40nm(225).     
 
 The specific aims of this chapter were to: 
1. Assess the physical characteristics of the specially fabricated iron oxide nanoparticles. 
2. Measure the surface charge on the outer T10 dextran coating 
3. Observe the behavioural characteristics of these iron oxide nanoparticles in a clinical 
MRI scanner, at 1.5 T and 3.0 T, namely their spin-spin relaxivity (T2) and behaviour. 
4. Radiolabel 68Ga to the iron oxide nanoparticles. 
5. Perform cell viability (MTS) assays. 
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 3.2 Results 
 
 
3.2.1 Physical characterisation of dextran coated iron oxide nanoparticles 
 
3.2.1.1 Transmission Electron Microscopy (TEM) 
 
A JEOL 1010 TEM operating at an accelerating voltage of 100 kv and a JEOL 2010 HRTEM 
that incorporated a lanthanum boron six crystal as its electron source and operating at an 
accelerating voltage of 200 kv; were used to assess the nanoparticles’ physical characteristics.  
The size and shape of the iron oxide core and the T10 dextran coating were identified and 
measured.  On the TEM images, the iron oxide core appeared to be circular (and not quasi-
cuboid) and of suitable density.  The T10 dextran coating was demonstrated as almost being 
translucent and with an even thickness encompassing the dense, circular iron oxide core.  The 
iron oxide core was measured to be approximately 15 nm, the T10 dextran coating providing 
a coat of approximately 5nm thickness; thus, these particles have an overall diameter of 
approximately 20 nm.   
The TEM images also demonstrate the sample on the carbon coated copper grid to be uniform 
in size and this uniformity was consistent throughout the samples that were imaged, that is, 
the nanoparticles were monodispersed.  Samples of nanoparticles were prepared for TEM 
imaging at the commencement of this project, at the mid-way point and also at the end of this 
research.  This was to ensure that the specifically fabricated nanoparticles maintained their 
physical characteristics throughout this study. 
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Figure 3.1: TEM image of dextran coated iron oxide nanoparticles to ascertain physical 
dimensions post fabrication (40,000 magnification taken in March 2011). 
This micrograph was taken in March 2011 with a JEOL 1010 TEM containing a lanthanum 
boron six crystal as its electron source.  This image forms part of a series of images taken to 
determine the physical dimensions and monodispersity of the laboratory manufactured 
nanoparticles.     
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Figure 3.2: TEM image of dextran coated iron oxide nanoparticles to ascertain physical 
dimensions post fabrication (60,000 magnification taken in March 2011). 
This micrograph image (60,000 magnification) was taken in March 2011 with a JEOL 1010 
TEM containing a lanthanum boron six crystal as its electron source.  This image is from the 
same sample (3mm copper grid with nanoparticles prepared for TEM) as the nanoparticles 
presented in Figure 3.1.   
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March 2011 
Figure 3.3: TEM image of dextran coated iron oxide nanoparticles to ascertain physical 
dimensions post fabrication (150,000 magnification taken in March 2011). 
This micrograph image (150,000 magnification) was taken in March 2011 with a JEOL 1010 
TEM containing a lanthanum boron six crystal as its electron source.  This image is from the 
same sample (3mm copper grid with nanoparticles prepared for TEM) as the nanoparticles 
presented in Figures 3.1 and 3.2.   
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Figure 3.4: TEM image of dextran coated iron oxide nanoparticles to ascertain physical 
dimensions post fabrication (300,000 magnification taken in March 2011). 
This micrograph image (300,000 magnification) was taken in March 2011 with a JEOL 1010 
TEM containing a lanthanum boron six crystal as its electron source and is from the same 
sample (3mm copper grid with nanoparticles prepared for TEM) as the nanoparticles 
presented in Figures 3.1 to 3.3.   
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20nm 
 
Figure 3.5: High resolution TEM of dextran coated iron oxide nanoparticles taken at the 
midway time-point of PhD thesis (350,000 magnification taken in June 2013). 
This micrograph image (350,000 magnification) was taken in June 2013 with a JEOL 2010 
TEM containing a lanthanum boron six crystal as its electron source.  The physical 
dimensions of the dextran coated iron oxide nanoparticles were evaluated for consistency in 
physical dimension and monodispersity at approximately the midway time-point of the 
experiments supporting this PhD thesis.   
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Figure 3.6: TEM of dextran coated iron oxide nanoparticles taken at approximately the 
end time-point of PhD thesis (75,000 magnification taken in November 2014).  This 
image (100,000 magnification) was taken in November 2014 with a JEOL 1010 TEM 
containing a lanthanum boron six crystal as its electron source.  At approximately the end 
time-point of the experiments supporting this PhD thesis, the physical dimensions of the 
dextran coated iron oxide nanoparticles were evaluated for a final time for consistency in 
physical dimension and monodispersity. 
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Figure 3.7: TEM of dextran coated iron oxide nanoparticles taken at approximately the 
end time-point of PhD thesis (100,000 magnification taken in November 2014).  This 
image (100,000 magnification) was taken in November 2011 with a JEOL 1010 TEM 
containing a lanthanum boron six crystal as its electron source and is from the same sample 
(3mm copper grid with nanoparticles prepared for TEM) as the nanoparticles presented in 
Figure 3.6.   
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3.2.1.2 Scanning Electron Microscope 
 
A FEI NovaNano SEM was used to observe the iron oxide nanoparticles from another 
dimension and specifically the outer surface of the T10 dextran coating surrounding the iron 
oxide core.  The nanoparticles displayed a spherical morphology.  The surface coating was 
noted to have a smooth appearance and this was consistent across all samples imaged.  A 
smooth surface (as opposed to an inconsistent exterior) was designed to facilitate ingestion by 
cells when in vitro experiments were conducted.    
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Figure 3.8: SEM image to ascertain physical dimensions post fabrication (approximately 
300,000 magnification, March 2011).  This SEM image was taken in March 2011 with a FEI 
NovaNano to determine the surface characteristic of the laboratory fabricated dextran coated 
iron oxide nanoparticles.   
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Figure 3.9: SEM image of another sample to ascertain physical dimensions post 
fabrication, including dimension measurements (approximately 300,000 magnification, 
taken in March 2011).  This SEM image was taken in March 2011 with a FEI NovaNano 
SEM.  In addition to observing the surface characteristics with SEM, their dimensions were 
also measured under SEM imaging. 
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 3.2.2 Surface charge of dextran coated iron oxide nanoparticles 
 
A Malvern Nano-ZS zetasizer was used to measure the surface charge of the nanoparticles.  
At the commencement of this thesis, a colloid suspension of 1.5 ml of MilliQ water 
containing nanoparticles at a concentration of 100 µg/ml were placed in micro tubes with 
room air and also in nitrogen filled glass vials.  A total of ten micro tubes and ten nitrogen 
filled glass vials were used.  The samples were stored in the following conditions: 
• a standard fridge at 4 oC 
• a standard freezer at -20 oC 
• a long tern storage freezer at -80 oC 
Throughout this thesis, samples were prepared for surface charge readings.  The surface 
charges, measured in millivolts, from the six readings are tabulated and graphed. 
 
Storage Condition Mean Surface Charge 
(millivolt) 
Standard Error 
of the Mean 
Fridge (4 oC) Sample stored 
under air 
-15.62 
 
9.083 
 
Fridge (4 oC) Sample stored 
under nitrogen 
-20.80 
 
8.681 
 
Freezer (-20 oC) Sample stored 
under air 
-30.50 
 
4.300 
 
Freezer (-20 oC) Sample stored 
under nitrogen 
-19.32 
 
3.455 
 
Freezer (-80 oC) Sample stored 
under air 
-23.17 
 
0.8793 
 
Freezer (-80 oC)  Sample 
stored under nitrogen 
-20.50 
 
2.436 
 
 
Table 3.1: The mean of six readings of particle surface charge (millivolts), stored under 
common laboratory or clinical conditions.  The standard error of the mean (SEM) is also 
presented and used as error bars when graphed.    
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As like charges repel each other, consistent like-charges would assist the nanoparticles in 
minimised chemical aggregation and agglomeration.  The nanoparticles selected for use with 
in vitro and in vivo experimentation were from those stored in a standard 4 oC fridge, under 
normal room air, as these had the least negative charge.  
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Figure 3.10: Surface charge (millivolts) of T10 dextran coating on iron oxide 
nanoparticles kept under different storage conditions.  Iron oxide nanoparticles coated 
with T10 dextran were kept under different storage conditions and their surface charge was 
read and recorded with a Malvern Zetasizer (n=6) on six separate occasions throughout this 
thesis.  At each reading, a new sample of particles was prepared and used, from the individual 
storage condition.  The results presented are shown as the mean value of the six readings with 
standard error of the mean as error bars. 
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 3.2.3 IONP gel phantoms in the magnetic environment of clinical MRI 
scanners 
 
The iron oxide nanoparticles were observed for their behavioural characteristics (in a 
magnetic field environment) and their capabilities to provide contrast changes in MRI images; 
in response to a spin echo T2 weighted pulse sequence.  The assessment was performed on 
both a 1.5 T and 3.0 T clinical MRI scanner and with a 12-channel head coil.  Both scanners 
were made by Siemens, used the Syngo operating platform and had access to the same pulse 
sequence; referred to as: t2_se_COR_16-echoes. 
Under clinical conditions, an MRI image contains recorded signal intensity detail directly 
related to the magnetic or proton relaxation of nuclear spins of protons (hydrogen protons of 
water molecules).  To allow the MRI clinical scanner to detect a hydrogen signal and to 
minimise and/or eliminate susceptibility artefacts from the air interface with tubes that 
contained gel and iron oxide nanoparticles, the plastic container (with the securely glued rack 
holding the tubes filled with nanoparticles) was filled with water.  MRI imaging was 
performed with a Siemens clinical MRI scanner at both 1.5 T and 3.0 T and a 12-channel head 
coil was used.  
The strength of a contrast agent and the extent to which it provides a presence within an MRI 
image, is based on the agent's ability to alter either the spin-lattice relaxation time, T1, such as 
gadolinium; or spin-spin relaxation time, T2.  Such factors, which primarily affect the 
performance of all MRI contrast imaging agents, are also applicable to iron oxide 
nanoparticles.  Thus, the resulting relaxation effects of iron oxide nanoparticles are a 
combination of factors; including the iron oxide core, the applied magnetic field strength and 
the local environment or condition or tissue that the iron oxide nanoparticle find themselves 
in.   
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 The addition of nanoparticles, with an iron oxide core, generates a further (localised) 
magnetic field of its own, due to its iron content, induced magnetic field inhomogeneities 
localised to their location.  These induced inhomogeneities lead to an increased transverse 
relaxation rate (a decrease in T2 thus appearing hypo-intense), also known as spin-spin 
relaxation time (T2).  This was observed with an increase in nanoparticle concentration 
(µg/ml) in the prepared gel phantoms resulted in a decrease in MRI signal, hence a hypo-
intense image appearance.  Iron oxide nanoparticles demonstrated relaxation changes that 
would allow them to be classified as a spin-spin relaxation contrast agent. 
Compared to a 1.5 T clinical MRI scanner; a progression to an increased magnetic field 
strength, as with high magnetic field strength clinical MRI scanners, 3.0 T or greater, the 
proton relaxivities of substances become more rapid.  The relaxivity rate 1/T2 at 3.0 T was 
thus more rapid compared to 1.5 T.  The T2 spin echo pulse sequence used was composed of 
16 echoes.  The TE values ranged from 22 ms (echo number 1) to 352 ms (echo number 16) 
inclusive.  All other echoes were 22 ms apart; as presented in Table 3.2. 
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Echo number TE value (ms) 
1 22 
2 44 
3 66 
4 88 
5 110 
6 132 
7 154 
8 176 
9 198 
10 220 
11 242 
12 264 
13 286 
14 308 
15 330 
16 352 
 
Table 3.2: The echo numbers and their corresponding TE values. 
Siemens MRI scanners, 1.5 T and 3.0 T, each used the same spin echo pulse sequence; 
t2_se_COR_16-echoes; and one image at each echo was created.   
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One MRI image at each echo was generated and in each of these images, the signal intensity 
changes at each tube was assessed, therefore, a total of 160 data ROI were created and used to 
calculate graphs that demonstrated the spin-spin relaxation of the iron oxide nanoparticles.   
ImageJ software was used to quantitate (in arbitrary units) the MRI signal intensity changes 
induced by the iron oxide nanoparticles interacting with the magnetic field. These data were 
entered into Excel.  The T2 spine echo contrast intensity change formula; SignalSE = SignalOe(-
R
2
 x TE); was transposed to R2 = (In(SignalSE) − (InSignalO)) / (−TE) <=> 1 / T2; and 
relaxation curved generated.   
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Figure 3.11: Top view of plastic container filled with water and containing plastic tubes 
filled with gel of increasing concentration of iron oxide nanoparticles; scanned at 1.5 T.  
A T2 weighted image generated from a 16 echo spin echo pulse sequence at 1.5 T.  This 
image was acquired with a TE value of 44ms and a TR value of 3,000 ms and a 12-channel 
head coil was used.   
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Figure 3.12: Top view of plastic container filled with water and containing control tubes 
– plastic tubes filled with gel only (no iron oxide nanoparticles); scanned at 1.5 T 
A T2 weighted image generated from a 16 echo spin echo pulse sequence at 1.5 T.  This 
image was acquired with a TE value of 44 ms and a TR value of 3,000 ms and a 12-channel 
head coil was used.   
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 Firstly, the signal intensity changes were calculated for the tubes that contained gel and iron 
oxide nanoparticles.  Secondly, the signal intensity changes were calculated for the tubes that 
contained only gel and no iron oxide nanoparticles.  Thirdly, the values calculated for the gel 
only tubes were used to subtract from the values calculated for the tubes that contained both 
gel and nanoparticle.  This served two purposes.  As both sets of tubes were imaged in the 
same position, the subtraction allowed for any image contract effects due to the gel to be 
eliminated and also, any magnetic field inhomogeneities inherent to the individual scanner 
would also be accounted for; as magnetic field inhomogeneity can accelerate localised de-
phasing of spins and therefore alter local relaxivity.     
The time between each echo (in the 6 echo pulse sequence) is known and thus, power trend 
lines have been applied to graphed measurements.   
The following series of supporting graphs have been inserted in Appendix 1: A series of 
graphs (Figure 3.13 to Figure 3.22) that demonstrate the change in T2 relaxivity, Δ R2 
response (or intensity decay profile), for each concentration sample across the 16 echoes in 
the pulse sequence, at 1.5 T.  The next series of graphs (Figure 3.23 to Figure 3.38) record the 
linear fit to the T2 relaxivity as a function of nanoparticle concentration and each of the 
known 16 TE echoes in the pulse sequence used, at 1.5 T.  The same graphs and calculations 
were produced at 3.0T and are also presented in Appendix 1 (Figure 3.41 to Figure 3.66).  An 
image of the gel phantoms with varying concentrations of iron oxide nanoparticles (Figure 
3.39) and without nanoparticles (Figure 3.40) generated at 3.0T, appears in sequence prior to 
Figure 3.41).   
On the following pages, Figure 3.67 represents the composite of Figures 3.13 to 3.22, Figure 
3.68 represents the composite of Figures 3.41 to 3.50; Figure 3.69 displays the combination of 
Figures 3.23 to 3.38; and Figure 3.70 displays the combination of Figures 3.51 to 3.66.     
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Figure 3.67:  A comparison of the change in R2 relaxivity, intensity-decay profile of all 
iron oxide concentration samples, as determined at 1.5 T.  This 3D graph demonstrates the 
intensity decay profiles of all samples and compares the subtle differences between them 
across all TE values of the spin echo pulse sequence t2_se_COR_16-echoes at 1.5 T.  
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   µg/ml graph equation R2 
16.4 y = 23.635x-0.413 R² = 0.9969 
33 y = 45.607x-0.416 R² = 0.9966 
49.8 y = 68.059x-0.408 R² = 0.9955 
66.5 y = 82.358x-0.394 R² = 0.9914 
83.2 y = 79.628x-0.351 R² = 0.9751 
99.9 y = 101.4x-0.366 R² = 0.9699 
117 y = 119.56x-0.365 R² = 0.977 
133 y = 141.24x-0.386 R² = 0.9884 
150 y = 250.76x-0.486 R² = 0.9394 
167 y = 204.36x-0.443 R² = 0.9669 
    
Table 3.3: A comparison of R2 values of intensity decay profiles of all concentration 
samples at 1.5 T.  Note that as the concentration of nanoparticles increases, the R2 values 
commences to move away from the value of 1, indicating inhomogeneity and dephasing of 
spins, particularly at a concentration of 150 µg/ml. 
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Figure 3.68:  A comparison of the change in R2 relaxivity, intensity-decay profile of all 
iron oxide concentration samples, as determined at 3.0 T.  This 3D graph demonstrates the 
intensity decay profiles of all samples and compares the subtle differences between them 
across all TE values of the spin echo pulse sequence t2_se_COR_16-echoes at 3.0 T. 
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µg/ml graph equation R2 
16.4 y = 29.66x-0.448 R² = 0.9989 
33 y = 48.054x-0.419 R² = 0.9968 
49.8 y = 74.54x-0.417 R² = 0.9967 
66.5 y = 95.261x-0.415 R² = 0.9969 
83.2 y = 90.05x-0.382 R² = 0.9966 
99.9 y = 119.29x-0.386 R² = 0.9901 
117 y = 119.29x-0.386 R² = 0.9901 
133 y = 170.11x-0.413 R² = 0.9845 
150 y = 225.67x-0.466 R² = 0.9756 
167 y = 274.1x-0.478 R² = 0.9701 
 
Table 3.4: A comparison of R2 values of intensity decay profiles of all concentration 
samples at 3.0 T.  Note that as the concentration of nanoparticles increases, the R2 values 
commences to move away from the value of 1, indicating inhomogeneity and dephasing of 
spins, particularly at 133 µg/ml, which is one concentration value less than at 1.5 T, 
confirming the NMR principle of rapid dephasing at higher field strengths. 
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Figure 3.69: Comparison of the linear fit to the T2 relaxivity rates as a function of iron 
oxide nanoparticle concentration, of all samples at 1.5 T.    
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Echo 
number 
TE 
value 
(ms) graph equation R2 
1 22 y = 0.2882x + 4.5173 R² = 0.9779 
2 44 y = 0.221x + 2.9077 R² = 0.983 
3 66 y = 0.1911x + 2.1912 R² = 0.9867 
4 88 y = 0.1735x + 1.7393 R² = 0.9895 
5 110 y = 0.1663x + 1.2965 R² = 0.9889 
6 132 y = 0.1536x + 1.1375 R² = 0.9894 
7 154 y = 0.153x + 0.7817 R² = 0.9886 
8 176 y = 0.1344x + 1.0287 R² = 0.9909 
9 198 y = 0.1316x + 1.0451 R² = 0.9852 
10 220 y = 0.1139x + 1.4566 R² = 0.9877 
11 242 y = 0.112x + 1.5628 R² = 0.9629 
12 264 y = 0.099x + 1.8665 R² = 0.9679 
13 286 y = 0.104x + 1.8328 R² = 0.9244 
14 308 y = 0.0889x + 2.3182 R² = 0.8891 
15 330 y = 0.0846x + 2.7387 R² = 0.8359 
 
Table 3.5: Comparison of R2 of linear fit equations, as a function of nanoparticle 
concentration at 1.5 T.  These figures support the dephasing, and resulting image signal 
intensity changes observed, according to TE values at 1.5 T.  Note that as TE values increase, 
the linear fit becomes less accurate, indicating dephasing effects on the iron oxide 
nanoparticles. 
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Figure 3.70: Comparison of the linear fit to the T2 relaxivity rates as a function of iron 
oxide nanoparticle concentration, of all samples at 3.0 T.    
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Echo 
number 
TE 
value 
(ms) graph equation R2 
1 22 y = 0.3332x + 3.2128 R² = 0.9882 
2 44 y = 0.248x + 2.1639 R² = 0.993 
3 66 y = 0.2082x + 2.0011 R² = 0.9945 
4 88 y = 0.1845x + 1.5138 R² = 0.9945 
5 110 y = 0.1696x + 1.4361 R² = 0.9942 
6 132 y = 0.1587x + 1.1653 R² = 0.9957 
7 154 y = 0.147x + 1.2744 R² = 0.9933 
8 176 y = 0.1419x + 1.0113 R² = 0.9942 
9 198 y = 0.1352x + 1.0715 R² = 0.9911 
10 220 y = 0.1336x + 0.7622 R² = 0.994 
11 242 y = 0.1212x + 1.2905 R² = 0.9719 
12 264 y = 0.1227x + 0.939 R² = 0.9834 
13 286 y = 0.1014x + 1.9394 R² = 0.9285 
14 308 y = 0.1005x + 1.8697 R² = 0.9309 
15 330 y = 0.0932x + 2.1364 R² = 0.8946 
16 352 y = 0.0821x + 2.4585 R² = 0.8817 
 
Table 3.6: Comparison of R2 of linear fit equations, as a function of nanoparticle 
concentration ant 3.0 T.  These figures support the dephasing, and resulting image signal 
intensity changes observed, according to TE values at 3.0 T.  Note that as TE values increase, 
the linear fit becomes less accurate, indicating dephasing effects on the iron oxide 
nanoparticles and this occurs at a much earlier TE values compared with 1.5 T. 
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3.2.4 Radiolabelling of dextran coated iron oxide nanoparticles with 68Ga 
 
At the end of the incubation period with eluted 68Ga, the dextran coated iron oxide 
nanoparticles underwent TLC to determine the level of purity of radiolabelling.  The 
radiolabelling efficiency, as measured by TLC was 87.59 % (n=3); that is, when the 
radiolabelled sample of dextran coated iron oxide nanoparticles is prepared, 87.59% of the 
68Ga was bound to the nanoparticles and 12.41% was free or unbound.  This is summarised in 
Figure 3.69.  An example of the TLC spectral assessment is provided in Figure 3.70. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
  
 
 
 
b o u n d  6 8 G a u n b o u n d  6 8 G a
0
2 0
4 0
6 0
8 0
1 0 0
6 8 G a
S p e c tra l p e a k s
%
 
Figure 3.71: The ratio of 68Ga bound to nanoparticles to unbound 68Ga following the 
radiolabelling process.  The error bars represent the standard error of the mean (n=3).  The 
minimal error indicates that the radiolabelling process is robust and reproducible.  
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
  
 
 
 
 
 
Figure 3.72: A TLC chromatogram of a nanoparticle sample radiolabelled with 68Ga.  
The green coloured peek quantifies the 68Ga in the sample that is bound and the red coloured 
peek identifies the amount of 68Ga that is free or unbound or not labelled; to the T10 dextran 
coated iron oxide nanoparticles. 
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3.2.5 MTS assay of T10 dextran coated iron oxide nanoparticles  
 
FDA approval of commercially available dextran coated iron oxide nanoparticles imply that 
they are biocompatible and safe to administer to humans at the recommended dose per body 
mass.  Published results have demonstrated that, commonly, iron oxide nanoparticles offer a 
very safe profile with signs of cytotoxicity becoming apparent at concentrations greater than 
200 µg/ml, in vitro(221).  To assess the cytocompatibility of the iron oxide nanoparticles 
especially prepared for use throughout this thesis, MTS Cell Proliferation Assays were 
conducted, in vitro, with human peripheral blood mononuclear cells (PBMC), n = 5.    
Figure 3.71 shows the results of the MTS assays performed with PBMCs following a 24 hour 
incubation time with nanoparticle concentrations of 200 µg/ml, 100 µg/ml, 50 µg/ml, 20 
µg/ml and 5 µg/ml.  Each experiment had three replicate values and the average of these 
replicates were compared with control wells (no nanoparticles).  MTS assays were also 
performed with the safest known gadolinium based MRI contrast agent, Dotarem® (gadoteric 
acid)(40, 226-228), n = 5.  These were also structured identically as per the PBMCs and 
nanoparticle experiments; with three replicates for each experiment with PBMCs and 
compared with control wells (no Dotarem®).  The results from both sets of MTS assays, 
nanoparticle and Dotarem®, were compared.    
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Figure 3.73: MTS Cell Proliferation Assay comparison with human PBMCs and T10 
dextran coated IONPs and with human PBMCs and Dotarem®.    
Percentage cell viability of human PBMCs following an incubation time of 24 hours with 
varying concentrations of T10 dextran coated iron oxide nanoparticles and separately with 
Dotarem®.  The data is representative of triplicate assessments, performed five times (n = 5) 
and the error bars are the standard error of the mean. Statistical comparison was performed 
using a two-way ANOVA statistical post-test analysis with the Tukey’s multiple comparison 
test (multiple comparison test comparing each group with the other group).  No statistical 
significance was identified.   
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3.3 Discussion 
 
For the intended purposes of experiments needed to be conducted throughout this thesis, there 
were a number of factors considered to be of equal and of paramount importance.  These 
factors included the composition of the nanoparticle, its size and morphology.  If these 
features are considered at the conception and design stage and followed through with 
incorporation into the fabrication process, such favourable characteristics will allow such 
nanoparticles to be included into a variety of laboratory experimental procedures to support 
the possible or eventual applications to new imaging possibilities. 
At the commencement of this thesis, a review of the literature was performed.  Published 
results identified that of all the possible combinations for nanoparticle composition, the least 
toxic and most biocompatible combination would be a nanoparticle composed with an iron 
oxide core with a dextran coating or outer shell(18, 56, 229).  Further exploration of the published 
revealed that high molecular weight dextrans were linked with allergic reactions and IgG 
responses in some humans(88, 218).  Therefore, a low molecular weight dextran would be more 
appropriate in order to improve biocompatibility.  The overall size of the nanoparticles is also 
critical; to perform in vitro experiments with murine and human cells, the nanoparticles would 
need to be of a size that would allow them to be ingested.  The nanoparticle size becomes 
even more critical when applied in in vivo studies.  It has been established that, in vivo, 
nanoparticles greater than 60nm are readily identified and taken up by the RES(18).  A 
commercially available preparation of low molecular weight dextran coated iron oxide 
nanoparticles, Resovist®, is FDA approved and has been TGA approved, for use as a contrast 
agent specifically for imaging liver with MRI.  Even though Resovist® is composed of iron 
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 oxide core with a dextran coating, it’s overall size is greater than 60nm; meaning that it is 
readily taken up by the Kupffer cells of the liver and other cells of the RES (spleen and bone 
marrow) and provides T2 signal change characteristics on MRI images.  Nanoparticles with a 
lesser size would evade sequestration of the RES and thus increase in vivo circulation time. 
The nanoparticles used throughout this thesis, conformed to these desired characteristics, that 
is, an iron oxide core, low molecular weight dextran coating (T10) and a dimension of 20 nm 
with a smooth surface. The iron oxide core provided suitability for MRI imaging with T2 
characteristics and their 20 nm size allowed for in vivo and in vitro experiments. The low 
molecular weight dextran served two purposes; firstly to improve biocompatibility and 
secondly, to increase the range of imaging possibilities as the dextran’s amine chain could be 
functionalised.  The functionalise amine chain facilitated conjugation with FITC or R-PE and 
also with DTPA Anhydride for radiolabelling with 68Ga.      
Publications regarding the role of nanoparticles surface charge are not all in agreement; it is 
difficult to state with certainty if any statement made with respect to nanoparticles having 
either a positive, neutral or negative surface charge.  It is clear, however, that with the 
different cells that have been examined, the resulting data have demonstrated their own 
preferential uptake of differently charged nanoparticles.  For example, Villanueva et al(230) 
demonstrated that human cervical carcinoma cells (HeLa) preferentially internalised 
negatively charged nanoparticles; compared to the same nanoparticles with a positive or 
neutral charge. The postulation is that there are strong non-specific interactions with the 
plasma membrane, even though plasma membranes are known to be negatively charged.  The 
mechanism of internalisation is believed to occur through nonspecific binding and clustering 
effects of cationic sites on the plasma membrane.  Zhang et al(231) also reported iron oxide 
nanoparticles with a negative surface charge being internalised by both healthy breast 
epithelial cells (MCF10A) and with breast epithelial cancer cells (MCF7) and the 
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 accompanying TEM images identified internalisation via endocytosis.  These investigators 
further suggested that internalisation could be mediated by certain proteins; theorising that 
proteins from the cell culture medium could be located on the nanoparticle surface and induce 
receptor-mediated endocytosis.  To support this theory, Zhang et al referred to studies with 
similar findings and suggestions.  The findings of Koudelka et al(232) are put forward to also 
support for their theory, in that the 54 kD protein found on plasma membranes of both human 
and murine cells could be responsible for mediating the endocytosis of negatively charged 
nanoparticles.   
Human mesenchymal stem cells were shown to internalise approximately equal quantities of 
negative, positive and neutral charged nanoparticles, as reported by Lorenz et al(233).  These 
investigators, in the same publication, also reported that HeLa cells showed internalisation of 
greater amounts of positively charged nanoparticles, which counters the findings reported by 
Villanueva.  Thiele et al(234) reports that positively charged FITC-tagged nanoparticles tend to 
remain stuck to the outer cell membranes of human derived macrophages and human dendritic 
cells and purports that the phagocytic activity of positively charged particles, by these cells, is 
attributable to multiple factors such as the bulk material that both the particles and cells are 
held in, in addition to the size, charge and coating of the particles.  BSA in the cell culture 
medium was attributed to the continuing phagocytic activity of these cells.  They confirmed 
this by using trypan blue to quench the FITC of the particles adhered to the outer cell 
membrane, prior to performing flow cytometry.   
Similar findings were supported by Foged et al(235) where immature DC (derived from human 
mononuclear cells) demonstrated greater uptake of negatively charged particles (100 nm) 
compared to positive charged particles, over a 4 hour incubation time; and assert further that 
negatively charged particles of a smaller size could offer superior interactions with immature 
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 DC, compared to positive charged particles, as the negative charged particles will have less 
non-specific interactions with other cells. 
Two commercially available iron oxide preparation, FDA approved for intravenous 
administration, have a dextran coating (Feridex®) and a carbodextran coating (Resovist®) 
and are both anionic.  The nanoparticles used for this thesis had a negative charge, in the order 
of -15.62 ± 9.083 mV.  Results of in vitro studies presented in the following chapters will 
demonstrate that these nanoparticles are internalised by both murine and human cells in vitro 
and in vivo.  
It has been conclusively established that iron oxide nanoparticles demonstrate T2 
characteristics on MRI images; which is directly attributable to the iron oxide core(1, 2).  In the 
magnetic field environment of a clinical MRI scanner, the iron oxide core can behave 
analogous to a small magnet.  At the nano scale, considering the surface area-to-volume ratio, 
collectively, the iron oxide cores can generate large scale imaging signal changes.   
During the imaging process, under the application of a pulse sequence, the recovery to the 
magnetic equilibrium state (for iron oxide nanoparticles) is via the T2 process of spin-spin 
relaxation; that is, the signal loss in the transverse plane.  In the region where iron oxide 
nanoparticles are located (analogous to a contrast agent at a site of pathology, or the different 
concentrations of iron oxide nanoparticles suspended in gel), the presence of such particles 
creates an additional magnetic field.  This, in turn, induces local magnetic field 
inhomogeneities which increase the rate of transverse relaxation (T2) of proton adjacent and 
nearby protons.  This rapid decrease of T2 is demonstrated on an MRI image as a region of 
hypo-intensity, or darker that the surrounding biological tissue.  
This physics principle has been adequately demonstrated by the specially fabricated dextran 
coated iron oxide nanoparticles.  Ten gel samples were prepared with different concentrations 
of particles (as described in chapter two, section 2.12) and imaged with a spin echo, T2 
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 weighted, pulse sequence with 16 TE values.  MRI imaging performed at both 1.5 T and 3.0 T 
demonstrated that these particles behave as desired in the magnetic field environments of 
these clinical MRI scanners.  For all nanoparticle concentrations, their change in R2 relaxivity, 
Δ R2, or intensity-decay profile were graphed for 1.5 T and for 3.0 T.  Also, the linear fit to 
the T2 relaxivity rate, 1/T2, as a function of iron oxide nanoparticle concentration, at each TE 
value was also graphed at both 1.5 T and at 3.0 T.  The signal intensity changes demonstrate 
rapid loss of T2, particularly at 3.0 T compared to 1.5 T.  These signal intensity changes 
render imaging changes contributed by these nanoparticles readily identifiable, therefore, 
demonstrating these nanoparticles’ capabilities as suitable T2 contrast agent at both 1.5 T and 
3.0 T 
MRI imaging also confirmed the even distribution of nanoparticles, as a contrast agent, within 
the gel suspension.  In addition to visually comparing MRI signal intensities of the gel and 
nanoparticle filled tubes, quantitative analysis was conducted with their DICOM images being 
imported to ImageJ software program, and the signal intensity changes resulting from the 
presence of the nanoparticles were assessed.  From this information graphs were generated 
demonstrating the capabilities of these nanoparticles across the 16 TE values.  The control gel 
samples were also imaged and quantitated with the same method and subtracted from the 
values recorded for the corresponding nanoparticle-gel tubes; to account for magnetic field 
variations at those spatial locations and, important, to remove any signal contribution that 
may be attributed to the gel itself.   
Imaging modalities that can complement one another are able to deliver more clinically useful 
imaging information than either modality can provide individually.  PET and MRI are two 
such modalities that, when combined, the united advantages overcome their individual 
limitations.  The use of nano-radiotracers is under development by many research groups with 
some success being published, and are designed for specific applications, using a variety of 
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 nanoparticle composites and radionuclides to target the relevant biochemical process under 
investigation.  Multimodal molecular imaging techniques (incorporating nanotechnology and 
radionuclides) are now seen as essential tools in translational and preclinical studies to 
evaluate new techniques(236, 237).  Clinical molecular imaging is seen as offering earlier 
detection, improve the accuracy of disease characterisation and also assess treatment efficacy 
earlier (and alter and improve treatment if necessary).  
Even though MRI demonstrates excellent soft tissue definition with high levels of spatial 
interpretation, still, with certain available iron oxide nanoparticle preparations, the volume 
required to generate noticeable signal changes on MRI images has been reported to vary from 
2 mg and 20 mg of iron per kilogram body mass(219).  The addition of a suitable radionuclide, 
such as 68Ga (a PET agent) – as PET offers a higher order of magnitude in detection 
sensitivity (compared to MRI), – thus, the use of lower concentrations or volumes per 
kilogram of body mass of iron oxide nanoparticles would be needed – and together – 
molecular information can be provided with less ionising radiation. 
Nanoparticles, therefore, can allow for creative opportunities for molecular imaging.  
Publications inform us that required capabilities can be engineered at the fabrication stage or 
(also at the synthesis stage) conjugated certain functional elements to the outer surface of 
nanoparticles.  For this thesis, 68Ga labelled iron oxide nanoparticles were prepared and 
evaluated with a TLC (to ascertain radiochemical purity) for bound and unbound 68Ga.  TLC 
results demonstrated a very high average radiolabelling yield of 87.59 %.  This result was at 
the pre-wash stage; that is, immediately on completion of the incubation period of 68Ga with 
dextran coated iron oxide nanoparticles.  From here, the radio-active sample was centrifuged, 
the supernatant (containing as much unbound 68Ga as possible) was removed and then 
resuspended in saline for in vivo administration.  Interestingly, unbound or free 68Ga results in 
corresponding activity being identified with PET imaging, in the liver, spleen, bone marrow 
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 and kidneys, in vivo, and these same organs are responsible for collecting iron oxide 
nanoparticles, if their size are greater than 60 nm. 
PET/MRI, with a radiolabeled nanoparticle can overcome limitations of both modalities and 
exploit the advantages of both; which are, using the radionuclide to maximise CNR on PET 
and using the nanoparticle to maximise both SNR and spatial resolution with MRI.  
Importantly, PET will provide functional information and MRI will contribute structural and 
anatomical detail(238).  Therefore, radiolabeled nanoparticles can be designed to target 
biochemical activity as well as demonstrate maximum soft tissue spatial definition with 
MRI(239).  Combining nanotechnology and molecular imaging and thus open new imaging 
possibilities and provide greater benefits to patients. 
In vivo, Resovist® is a commercially available dextran coated iron oxide nanoparticle contrast 
agent specifically marketed as a liver imaging agent with MRI.  It has an excellent safety 
profile, is well tolerated by patients, and is FDA approved.  At one point, Resovist® was 
available in Australia.   
To determine if the iron oxide nanoparticles would have severe deleterious effects on cells in 
vitro, MTS cell proliferation assays were performed using human PBMCs incubated for 24 
hours with T10 dextran coated IONPs, in vitro, and also PBMC incubated for 24 hours with 
Dotarem®, in vitro.  Of all the commercially available gadolinium based MRI contrast agents, 
Dotarem® has the highest level of human safety profile with no recorded incidence of NSF 
attributed to it(226).  Its comparatively safer profile has been attributed to its macrocyclic 
arrangement of gadolinium in relation to the chelating agent(40, 45, 227, 228).  The two datasets 
were graphed and compared; the justification being that as the ultimate intention was for the 
IONPs to be administered to human subjects, then they would need to be tested with human 
cells and compared with the safest known gadolinium MRI contrast agent (as also tested with 
the same type of human cells under the same in vitro conditions).  The post-test analysis was 
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 conducted with a two-way ANOVA and Tukey’s multiple comparison test.  No statistical 
significance could be found between any of the conditions treated with Dotarem®, nor could 
any statistical significance difference be found between the conditions treated with the T10 
dextran coated IONPs; and importantly, no statistical significance was identified between any 
of the treatment conditions with nanoparticles when compared with any of the treatment 
conditions with Dotarem®.  There was also no statistical difference between any of the 
treatment conditions and the control conditions.  These comparisons suggest that both of these 
contrast agents have the same effect on the human cells tested, in vitro, and under the 
conditions of the experiment.  Therefore, both the concentrations of the tested nanoparticles 
and Dotarem® do not impede cell viability of the human PBMC tested over a 24 hour 
incubation period, in vitro.     
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 3.4 Conclusion 
 
The aims of this chapter were addressed and experimental results lead to the following 
conclusions.    
1. The dimensions and morphology of the specially fabricated dextran coated iron oxide 
nanoparticles were assessed.  Their overall dimension was measured to be 
approximately 20 nm with TEM.  Assessment with SEM demonstrated their 
morphology to be spherical and the dextran coating was smooth.  Measurements taken 
with SEM also confirm the dimension of these nanoparticles to be approximately 20 
nm. 
 
2. The surface charge of these nanoparticles were demonstrated to be in the negative 
millivolt range for all storage conditions tested.  The storage condition that provided 
the least negative millivolt charge was from nanoparticles stored in a standard 
refrigerator (4 oC) under room air.  Nanoparticles stored under air in a standard freezer 
(-20 oC) revealed the greatest negative millivolt surface charge. 
 
 
3. The T2 characteristic behaviour of these nanoparticles were imaged using a spin echo 
pulse sequence with 16 TE values at both 1.5 T and 3.0 T (clinical MRI scanners).  It 
was demonstrated graphically and also with phantom gel images, that the 
nanoparticles exhibited well defined imaging behaviour under T2 weighted condition; 
generating readily identifiable and measurable signal intensity changes; thus making 
these nanoparticles viable as T2 contrast imaging agents (MRI). 
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 4. The radiolabelling process, in total, from completion of DTPA incubation to 
completion of 68Ga incubation time, was between 2 hours and 2 ½ hours.  The process 
resulted in high levels of radiolabelling effectiveness (87.59 %).  This established the 
likely possibility of using this radiolabelled nanoparticle preparation as a dual modal 
(PET and MRI) contrast agent. 
 
 
5. The cytotoxicity results, through the MTS cell viability assays, demonstrate that the 
tested concentrations of T10 dextran coated iron oxide nanoparticles and of Dotarem® 
do not reduce viability in human PBMCs compared to the control conditions.  
Importantly, there was no statistical significance between the effect that the 
nanoparticle preparation had on the human PBMCs compared to the effect that 
Dotarem® (the safest known gadolinium based MRI contrast agent) had on the 
PBMCs under the same experimental conditions, in vitro.  
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 4.0 Chapter 4 – Characterisation of Iron Oxide Nanoparticle Uptake by 
Murine Derived Dendritic Cells, in vitro.   
 
 
4.1 Introduction 
 
Murine dendritic cells (DCs) were first identified and described by Steinmen and Cohn in 
1973(197).  Since then, our understanding of DCs has increased to the point where DCs are 
being used for cancer immunotherapy experiments with potential translational possibilities.  
The commonly accepted definition of DCs is based on their function; that is, DCs have the 
unique capabilities to internalise, process and present antigens(198) to naïve T cell 
lymphocytes(199) (and B cell lymphocytes) and prime an immune response(200, 201).  Further, 
DCs are also defined by phenotype as being lacking in certain lineage specific markers (Lin-) 
and expressing elevated levels of Major Histocompatibility Complex (MHC) molecules (class 
II); this phenotype is represented as -HLA-DR+ (198).   
From a progenitor cell perspective, DCs can be categorised into two main groups or 
originating from either one of two lineages: conventional DCs (cDC) and plasmacytoid DC 
(pDC)(202).  cDC are also referred to as myeloid DC (mDC)(203).  DC progenitor cells originate 
in the bone marrow and are carried by blood to lymphoid organs and peripheral tissue; where, 
in situ; they develop into mDC(202).  pDC develop or differentiate in the bone marrow first and 
then subsequently colonise lymphoid organs(202).  pDC precursors produce significant 
quantities of type I interferons, such as IFN-α and IFN-β(204).  A further distinction is that 
mDCs are progressively migrating from their peripheral tissue base to the corresponding 
region’s draining lymph node (LN), while DCs originating from lymphoid organs remain 
localised there throughout their cell life cycle.    
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 DCs can also be categorised as either immature DCs or mature DCs.  Commencing from their 
progenitor cell origins, the presence of GM-CSF and the Flt3 ligand, allow these progenitor 
cells to become immature DCs, in vitro.   Immature DCs (iDCs) continually sample their 
immediate environment and have a high phagocytic capacity.  If iDCs ingest a pathogen, or in 
the presence of other relevant stimulants, iDC enter a phase of developing maturity.  This 
triggers a maturity signal and a complex interplay of chemicals is orchestrated.  Prior to this 
maturity signal, however, iDC (murine) are identified as having the following phenotype and 
attributes:  
• Low expression levels of costimulatory markers: CD80, CD86, CD40 and CD83 
• Low secretion levels of IL-12 cytokine 
CD, or cluster of differentiation, are proteins found on cells and these proteins provide a 
costimulatory signal necessary for T cell activation.  Low expression levels of certain CD 
signify that iDC have not been activated or have not received a maturation signal.  IL-12 is a 
cytokine, a small protein; affecting the migration of iDCs to its destination, as it matures and 
affecting the subsequent behaviour of T cells (once the iDCs become mDCs and meet with T 
cells).  Chemokines, interferons and interleukins are classified as cytokines. 
As DCs mature, their physical chemotaxic transition into, and through, afferent lymphatic 
vessels requires cytokine stimulation and induction of the CCR7 chemokine receptor(201).  The 
expression of CCR7 is triggered when immature DCs become activated.  Activation of DCs 
result in up regulation of CCR7 and down regulation of inflammatory cytokine receptors to 
facilitate chemotaxis migration to draining lymph nodes(200). 
Following the maturation signal and as iDCs evolve to mDCs, they will migrate to their 
destination site (such as lymph nodes or sites of infection).  mDCs (murine) have been 
identified with the following phenotype and expression levels: 
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 • High expression levels of  CD80, CD86, CD40, CD25 and CD83 
• High secretion levels of IL-12 cytokine 
 
Mature DCs that have migrated to secondary lymphoid organs (such as the lymph nodes or 
spleen) are also characterised has having a very minimal capacity for phagocytosis, 
(compared to iDC), thus, alternatively, a lower capacity to capture antigens; however, they 
develop capability to efficiently present antigen material to naïve T cells to stimulate an 
immune response – hence, their potential pivotal role in immunotherapy.  
DCs can also be triggered to migrate to lymph nodes by indirect methods. Firstly, under 
normal physiological conditions and in the immunological steady state, the normal movement 
of lymph fluid along afferent lymphatic vessels is by gentle pulsatile motion(200); secondly, 
signals originating from B-cells located from within activated lymph nodes can initiate a 
migration of DCs(200).   
The migration(207) of iDCs from their initial environment to the high endothelial venules 
(HEV) and the T cell zone (within lymph nodes), together with the simultaneous transition 
from immature to mature; is a rather complex series of events.  pDC enter lymph nodes 
directly with the blood supply, whereas other types of DCs enter lymph nodes via the afferent 
lymphatic vessel(201).  It is this afferent lymphatic vessel that drains nearby tissue and thus 
providing the physical migratory pathway.   
DC precursor cells originate in bone marrow and migrate to all areas of the body where they 
can exist in an immature state, sampling their immediate environment and awaiting 
antigens(200).  Upon stimulation with a suitable antigen, iDCs commence a sentinel function to 
home to secondary lymphoid organs and structures, especially lymph nodes, where they 
interact with naïve T cells and also central memory T cells(200).   
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 Chemokines are mediators of iDC migration, whereby, intracellular signalling pathways are 
triggered to commence cell migration and activation to maturity(200).  Chemokine and 
chemokine receptors are pivotal in shifting DCs to LNs through afferent lymphatic vessels 
and also from blood(200).  Via afferent lymphatic vessels, DCs enter the subcapsular sinus and 
then migrate to the T-cell zone of the LN cortex.  DCs from the blood stream enter the HEV 
and then migrate from the HEV, through the endothelial wall, and into the T-cell zone for 
efficient and effective interaction with naïve T cells. 
Along with DCs antigen presenting characteristics, comes their unique talent to encourage an 
immune response from T cells.  This is the broad and guiding principle of Dendritic Cell 
Immunotherapy (DCI)(207).  DCs also provide a link between the innate (non-specific) and 
adaptive (acquired) immune systems.  
Cellular MRI is a method of detecting cells in vivo, after they have been labelled ex vivo with 
a contrast agent, commonly IONP.  This technology and methodology has been applied by 
researchers to generate iDC from bone marrow progenitor cells, incubate iDC with IONP 
preparations, then administer these loaded cells into a live specimen and observe their 
migration and subsequent fate with MRI, in vivo.  The advantages offered by cellular MRI 
include that it is non-invasive imaging to live specimens, it uses non-ionising radiation and 
produces images of exquisite image quality.   
DCs and cellular MRI are both central in experimental techniques for cancer immunotherapy 
– where an individual’s immune cells and system can be activated to combat cancer cells.  
Tumours can be targeted with the use of antigen-specific vaccine; that is, DCs are loaded with 
cancer vaccines with tumour specific antigen (peptides or proteins) and used to initiate an 
anti-tumour response(20).  For DC-based cancer immunotherapy to be considered effective, 
DCs would need to migrate to secondary lymph organs such as lymph nodes and the spleen.  
Early attempts were not wholly successful; as the methodology used to attempt to load 
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 antigens into DCs and have them try to migrate to secondary lymph organs to commence and 
immune reaction were not efficient.  Essentially, tumour antigen and adjuvant were 
introduced in vivo by either intradermal, subcutaneous or intramuscular injection; from here, 
local DCs were supposed to internalise the antigen, process it and migrate to lymph nodes.  
This was not successful because tumours can release immunosuppressive substances and also 
self-tolerance to the tumour antigen can exist; combined together, these can inhibit an 
effective immune response.  At present, researchers are overcoming this is with an ex vivo 
approach – iDCs are generated in vitro from haematopoietic precursor cells in non-
immunosuppressed conditions, then loaded with antigen and then administered into the live 
specimen.   
Upon activation, DCs commence a migratory progression to lymph nodes and during this 
migration process, DCs process uptaken antigens, place these on their cell surface (along with 
MHC molecules) for presentation to T cell lymphocytes and upregulate costimulatory 
markers.  These costimulatory markers are expressed as the DCs transition from an immature 
to mature state and also facilitate interaction with T cell lymphocytes(204); as only mature DCs 
are capable of activating T cell lymphocytes.  T cells require three different signals in order to 
be effectively and efficiently activated.  Firstly, the T cell receptors must recognise and accept 
the antigen presented by the DC (together with MHC molecules).  Secondly, T cells require 
the costimulatory molecules that have been upregulated and presented with mature DCs.  
Thirdly, a paracrine (cell-to-cell) signal from soluble molecules in the form of cytokines 
and/or chemokines produced by the mature DCs(204).   
For experiments pertaining to this thesis, murine DCs were generated from bone marrow 
precursors, in vitro, by incorporating the GM-CSF cytokine.  A DCs progression to a mature 
state can be identified phenotypically by its expression of costimulatory proteins such as 
CD86 (and MHC class II)(204, 240), CD80 and CD83(205).  By culturing murine bone marrow 
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 cells with the Flt3-ligand, murine pDC precursors can be generated similar to human cells(204).  
Plasmacytoid pre-dendritic cells or type 1 interferon (IFN)-producing cells (IPCs), in both 
humans and mice, display a plasmacytoid morphology and have the capacity to produce large 
amounts of type 1 IFN in response to viral and bacterial stimulation(240).  Murine IPCs readily 
produce IL-12 in response to viruses or bacteria(240).  Human IPC do not have the ability to 
produce IL-12p70(240). 
Are IONPs, as an introduced foreign substance to DCs, capable of being internalised by DCs 
and do they initiate maturation and migratory signals?  A proprietary Cytometric Bead Array 
(CBA) Mouse Inflammation Kit can be used to test for the six most common cytokines that 
are known to be involved with an immune response to stimulus, the maturation process and 
migratory chemotaxis.  This assessment techniques holds some advantages over the ELISA 
technique such as: a lesser supernatant volume is needed to perform the CBA assay 
(approximately one-sixth of the volume is required as the CBA assay can detect six cytokines 
in one sample), results from performing one CBA assay would be equivalent to performing 
six conventional ELISAs, the CBA assay is comparatively quicker and less expensive to 
perform. The CBA assay does, however, have a known limitation, which is, it may have a 
reduced sensitivity to murine MCP-1. 
 
 
 
 
 
 
172 
 
 These following cytokines are protein molecules, secreted by DCs and used for signalling 
cellular activities, can be identified and quantified with a CBA assay (mouse), and it was 
these cytokines which were quantified by flow cytometry in conjunction with a proprietary 
CBA Mouse Inflammation Kit. 
 
Mouse IL-6  (also known as B cell stimulating factor) 
This is a general pro-inflammatory cytokine and also has a role in the final differentiation of 
B cells.  IL-6 is also known to have a regulatory role of a tumour’s microenvironment 
regulation(241).  It has also been identified that patients with advanced metastatic cancer 
patients have higher levels of IL-6 in their blood.  One example of this is pancreatic cancer, 
with noted elevation of IL-6 present in patients and unfortunately correlating with poor 
survival rates(242).  Hence, there is an interest in developing anti-IL-6 agents as therapy against 
many of these diseases(243, 244).  As an anti-inflammatory cytokine, it is mediated through its 
inhibition of TNF-α and IL-1 and its activation of IL-1a and IL-10(245).  Il-6 has also been 
documented to stimulate inflammatory and auto-immune responses in patients with various 
pathologies including: prostate cancer, diabetes, atherosclerosis, Alzeimer’s disease, multiple 
myeloma and rheumatoid arthritis(243). 
 
Mouse IL-10 
This is an anti-inflammatory cytokine produced by monocytes, lymphocytes and subsets of T 
and B cells.  IL-10 inhibits the synthesis of pro-inflammatory cytokines such as  INF-γ, IL-2, 
IL-3, TNF-α and GM-CSF, thereby supressing the ability of DCs to present antigens to T cells 
It also down regulates MHC II antigens and co-stimulatory molecules on macrophages. 
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 Mouse MCP-1, monocyte chemo-attraction protein 1   
(also known as CCL2, chemokine Ligand 2) 
This is secreted by DCs, monocytes and macrophages to augment anti-tumour activity by 
monocytes themselves.  MCP-1 can also direct DCs, (and memory T cells and monocytes to a 
lesser extent) to sites of inflammation.  Whether it be tumour or inflammation, MCP-1 has a 
role in the chemotaxis of DCs.  It has also been identified with the positive regulation of 
eradicating apoptotic cells. 
 
Mouse IFN-γ  (interferon-γ) 
This cytokine holds important functions in both the innate and adaptive immunity systems.  It 
is known to be produced by NK and NK T cells as part of the innate immune response and is 
also well known for its ability to activate macrophages.  IFN-γ is secreted by myeloid cells, 
DCs and macrophages as a cell self-activation process during the onset period of infection.  It 
also has anti-tumour, anti-viral and immune-regulatory properties. 
 
Mouse TNF (tumour necrosis factor, TNF-α, also known as cachexin) 
This is a monocyte derived cytotoxin that is implicated in tumour regression.  It is 
predominately produced by activated macrophages but also by CD4+ lymphocytes, NK cells 
and neutrophils.  Its functions include: to regulate immune cells, induce apoptotic cell death 
and inhibit tumourigenesis and viral replication.  TNF will acts together with IL-1 and IL-6 to 
respond to sepsis.  Prolonged periods of low concentrations of TNF has known to lead to 
cachexia (wasting syndrome seen in cancer patients). 
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 Mouse IL-12p70 
Murine DCs produce IL-12p70 in response to antigen stimulation.  This, in turn, stimulates 
production of IFN-γ and TNFα from T-cells (and NK cells).  Interestingly, IL-12p70 can also 
reduce IL-4 mediated suppression of IFN-γ and can inhibit angiogenesis, the formation of 
new blood vessels, by increasing IFN-γ. 
 
Apoptosis is the programed cell death in multicellular organisms while necrosis is a form of 
traumatic cell death that results from acute cellular injury.  Foreign substances, such as IONP, 
can induce apoptosis.  Cells have their own tolerances to foreign material according to their 
dose and exposure duration.  The TNF cytokine is the major extrinsic mediator of apoptosis.  
The apoptotic process and sequence is characterized by specific processes and morphologic 
traits.  These include the loss integrity of the cell plasma membrane, progressive destruction 
and loss of cytoplasm and nucleus, and inter-nucleosomal separation of DNA.   
The earliest detectable feature of cells in apoptosis is the loss of plasma membrane.  
Phospholipid phosphatidylserine (PS), found in the inner aspect of the cell membrane 
becomes exposed to the cell’s external environment.  Annexin V binds to cells with exposed 
PS as it has a high affinity for PS at this early stages of apoptosis.  Successful cell staining 
with Annexin V occurs prior to the complete loss of cell membrane integrity which takes 
place at the end stages of apoptotic or necrotic cell death processes.  To identify compromised 
integrity to the cell membrane from these events and stages, cell staining is also performed 
with 7-Amino-Actinomycin (7-AAD), a vital cell dye; which indicates cells in early 
apoptosis.  Cells with a viable and intact membrane will be negative for 7-AAD, however, 
cells with a disrupted membrane (either damaged or dead) will allow 7-AAD to enter.  
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 The specific aims of this chapter were: 
1. To determine dose dependent uptake of IONPs by GM-CSF and Flt-3 derived murine 
BM-DCs, in vitro. 
2. To determine time dependent uptake of IONPs by GM-CSF and Flt3 derived murine 
BM-DCs, in vitro. 
3. To determine the potential maturation effect of IONPs on GM-CSF and Flt3 derived 
murine BM-DCs, in vitro.  
4. To determine the apoptotic effect of IONPs on GM-CSF and Flt3 derived murine BM-
DCs, in vitro.   
5. To identify increased cytokine release by GM-CSF and Flt3 derived murine BM-DCs 
after exposure to IONPs, in vitro.  
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 4.2 Results 
 
 
4.2.1 Dose dependent uptake of FITC tagged IONPs by murine BM-DCs, 
in vitro 
 
Bone marrow stem cells from female C57BL/6 mice were cultured with either GM-CSF or 
Flt3 as described in Section 2.10 and incubated with FITC tagged IONPs as stated in Section 
2.11.1 and dose dependent uptake studies performed, in vitro.  Flow cytometry was used to 
measure the uptake of FITC tagged IONPs by observing the fluorescence of the FITC and the 
granularity of the cells.   
 
4.2.1.1 Dose dependent uptake of FITC tagged IONPs by GM-CSF 
grown murine BM-DCs, in vitro 
 
Uptake of FITC tagged IONPs by CD11c+ (membrane protein of DCs) GM-CSF grown 
murine BM-DCs demonstrated an almost dose-dependent effect with statistical analysis 
identifying no statistical significance beyond an IONP concentration dose of 50 µg/ml (Figure 
4.1A).  The Fold Increase in MFI from the FITC itself (tagged to the IONPs) was at 
maximum statistical significance with an IONP concentration of 100 µg/ml (Figure 4.1B).   
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 4.2.1.2 Dose dependent uptake of FITC tagged IONPs by Flt3 derived 
BM-DCs, in vitro 
 
Uptake of FITC tagged IONPs by CD11c+ (membrane protein of DCs) Flt3 grown murine 
BM-DCs demonstrated no statistically significant difference between adjacent treatment 
conditions.  There was no statistical significance between the control mean and treatment 
conditions where the IONP concentration used was 50 µg/ml or less (Figure 4.2A).  
Statistically significant uptake occurred with 100 µg/ml and 200 µg/ml (Figure 4.2A).  The 
Fold Increase in MFI graph (Figure 4.2B) demonstrated no statistical significance between the 
control mean and any of the treatment conditions (Figure 4.2B).   
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 4.2.2 Time dependent uptake of FITC tagged IONPs by BM-DCs, in vitro 
 
Bone marrow stem cells from female C57BL/6 mice were cultured with Flt3 as described in 
Section 2.10 and incubated with FITC tagged IONPs as stated in Section 2.11.4 to perform 
time dependent uptake studies.  Flow cytometry was used to measure the uptake of FITC 
tagged IONPs of each treatment condition by observing the fluorescence of the FITC and the 
granularity of the cells.   
 
4.2.2.1 Time dependent uptake of FITC tagged IONPs by GM-CSF 
grown BM-DCs, in vitro 
 
CD11c+ (membrane protein of DCs) GM-CSF grown murine BM-DCs demonstrated the 
level of uptake of FITC tagged IONPs at 1 hour incubation time was statistically comparable 
to the uptake at 24 hours incubation time, in vitro, and, there was very significant statistical 
difference between the control mean and the mean of each treatment condition (Figure 4.3A).  
There was no statistical significance of the Fold Increase in MFI between the treatment 
conditions, however, there was statistical significance between the mean value of the control 
condition and the mean value of the 24 hour incubation time treatment condition (Figure 
4.3B).   
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 4.2.2.2 Time dependendent uptake of FITC tagged IONPs by Flt3 
grown BM-DCs, in vitro 
 
 
CD11c+ (membrane protein of DCs) murine BM-DCs demonstrated that compared to the 
mean of the control condition, the level of uptake of FITC tagged IONPs became statistically 
significant (and thus noticeable) at 18 hours incubation time (Figure 4.4A).  There was no 
statistical significance of the Fold Increase in MFI between the treatment conditions, nor 
between the control condition and any of the incubation time treatment conditions (Figure 
4.4B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
183 
 
  
 
 
 
B 
A Fig
ur
e 
4.
4:
 T
im
e 
de
pe
nd
en
t u
pt
ak
e 
(A
, p
er
ce
nt
ag
e 
up
ta
ke
 a
nd
 B
, M
FI
) o
f F
IT
C
 ta
gg
ed
 I
O
N
Ps
 b
y 
Fl
t3
 d
er
iv
ed
 B
M
-D
C
, 
in
 v
itr
o.
  C
57
B
L/
6 
de
riv
ed
 D
M
-D
C
s 
w
er
e 
gr
ow
n 
fo
r 8
 d
ay
s 
w
ith
 F
lt3
 a
nd
 in
cu
ba
te
d 
w
ith
 2
00
 µ
g/
m
l o
f F
IT
C
 ta
gg
ed
 IO
N
Ps
 fo
r 
24
 h
ou
rs
, i
n 
vi
tro
.  
U
pt
ak
e 
by
 C
D
11
c+
 c
el
ls
 w
as
 q
ua
nt
ita
te
d 
by
 f
lo
w
 c
yt
om
et
ry
 a
nd
 a
na
ly
se
d 
us
in
g 
FA
C
SD
iv
a 
so
ftw
ar
e 
(B
D
 
B
io
sc
ie
nc
es
), 
n=
3.
  R
es
ul
ts
 a
re
 s
ho
w
n 
as
 th
e 
m
ea
n 
pe
rc
en
ta
ge
 s
ur
fa
ce
 e
xp
re
ss
io
n 
w
ith
 s
ta
nd
ar
d 
er
ro
r o
f t
he
 m
ea
n 
as
 e
rr
or
 b
ar
s. 
 
O
ne
-w
ay
 A
N
O
V
A
 s
ta
tis
tic
al
 a
na
ly
si
s 
w
ith
 p
os
t-t
es
t 
an
al
ys
is
 w
as
 c
on
du
ct
ed
 w
ith
 t
he
 T
uk
ey
’s
 t
es
t 
(m
ul
tip
le
 c
om
pa
ris
on
 t
es
t 
co
m
pa
rin
g 
ea
ch
 g
ro
up
 w
ith
 th
e 
ot
he
r 
gr
ou
ps
) 
fo
r 
tre
at
m
en
ts
 b
et
w
ee
n 
co
lu
m
ns
.  
Th
e 
D
un
ne
tt’
s 
te
st
 w
as
 u
se
d 
to
 c
om
pa
re
 th
e 
co
nt
ro
l g
ro
up
 w
ith
 e
ac
h 
tre
at
ed
 g
ro
up
.  
W
he
re
 n
o 
as
te
ris
ks
 a
re
 d
is
pl
ay
ed
, n
o 
st
at
is
tic
al
 s
ig
ni
fic
an
ce
 w
as
 f
ou
nd
.  
Fi
gu
re
 4
.4
A
;  
 
Pe
rc
en
ta
ge
 u
pt
ak
e 
by
 C
D
11
c+
 c
el
ls
.  
Fi
gu
re
 4
.4
B
; T
he
 M
FI
 fr
om
 th
e 
FI
TC
 (t
ag
ge
d 
to
 th
e 
IO
N
Ps
) f
ro
m
 th
e 
pe
rc
en
ta
ge
 u
pt
ak
e 
by
 C
D
11
c+
 c
el
ls
.  
  
184 
 
 4.2.2.3 Comparison of results of GM-CSF grown murine BM-DCs and 
Flt3 grown murine BM-DCs time dependent uptake studies 
 
For improved comparision and understanding of time dependent uptake between GM-CSF 
grown and Flt3 grown murine BM-DCs, the results presented Section 4.2.2.1 (Figure 4.3) and 
Section 4.2.2.2 (Figure 4.4) were sumarised and tabulated (Table 4.1 and Table 4.2).  Flt3 
grown murine BM-DCs demonstrated less percentage up take , at all time points, compared to 
GM-CSF grown murine BM-DCs; and thus, the percentage up take of Flt3 grown murine 
BM-DCs were expressed as a percentage of the percentage uptage of GM-CSF grown murine 
BM-DCs. 
 
Incubation 
Time 
% Uptake Flt3       
murine DC 
% Uptake GM-CSF 
murine DC 
% of GM-CSF 
24 hours 42.70 71.08 60.07 
18 hours 36.45 73.18 49.80 
4 hours 19.90 64.35 30.92 
1 hour 7.65 57.60 13.28 
 
Table 4.1: Comparison of percentage uptake of FITC tagged IONPs by GM-CSF and 
Flt3 murine derived DCs and their corresponding differences according to incubation 
time, in vitro. 
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Incubation 
Time 
FI in MFI Flt3        
murine DC 
FI in MFI GM-CSF 
murine DC 
% of GM-CSF 
24 hours 1.54 3.40 45.29 
18 hours 1.34 1.90 70.53 
4 hours 1.26 2.50 50.4 
1 hour 1.23 2.65 46.42 
 
Table 4.2: Comparison of FI in MFI of FITC tagged IONPs by GM-CSF and Flt3 
murine derived DCs and their corresponding differences according to incubation time, 
in vitro. 
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 4.2.3 Dose dependent maturation of murine BM-DCs, in vitro 
 
In vitro experiments were performed to determine if the FITC tagged IONPs induced cellular 
maturity in GM-CSF generated murine BM-DCs.  A co-staining technique was used with 
flow cytometry.  CD11c (protein membrane identified with DCs) positive cells were 
identified for CD86 (a protein that can stimulate T cells) and also CCR7 (associated with the 
chemotaxis of murine DCs to LNs).  Both CD86 and CCR7 are associated with maturing 
DCs.   
 
4.2.3.1 Dose dependent maturation of GM-CSF grown murine BM-
DCs, in vitro 
 
There was no statistical significance of CD86 expression across the concentration dose 
treatment conditions or between the control mean and these same treatment conditions (Figure 
4.5A); indicating that at the concentration doses tested, these BM-DCs offer no or minimal 
potential stimulation to T cells via CD86 expression.    The corresponding Fold Increase in 
MFI did identify significant statistical difference between the intensity of the detectable FITC 
from the IONPs and the control mean , but no other (Figure 4.5B).   
The surface expression of CCR7 (Figure 4.6A) and the corresponding Fold Increase in MFI 
(Figure 4.6B) was not statistically significant compared to the control means and there was 
also no significance identified between treatment conditions; thus minimimal or no LN 
migration capability could be induced in these BM-DCs under these tested conditions.     
The level of CD86 and CCR7 expressions, compared to their control means, signify that these 
BM-DCs remain in a relatively immature state following 24 hours incubation with FITC 
taggd IONPs.  The surface expression of CCR7 was approximately half the value of the 
surface expression of CD86 (Figure 4.7A). 
187 
 
  
 
 
Figure 4.5: Dose dependent maturation of GM-CSF BM-DC grown over 6 days, in vitro.  
C57BL/6 derived BM-DCs were grown with GM-CSF for 6 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours.  Co-staining of CD86 and CCR7 with 
CD11c+ was quantitated by flow cytometry and analysed using FACSDiva software (BD 
Biosciences), n=3.  One-way ANOVA statistical analysis with post-test analysis was 
conducted with the Tukey’s test (multiple comparison test comparing each group with the 
other group) for treatments between columns.  The Dunnett’s test was used to compare the 
control group with each treated group.  Where no asterisks are displayed, no statistical 
significance was found.  Figure 4.5A: % surface expression of CD86 by CD11c+ cells.  The 
results are shown as the mean percentage surface expression with standard error of the mean 
as error bars.  Figure 4.5B: The results are shown as the mean fold increase in MFI with 
standard error of the mean as error bars.  Figure 4.5C: A representative flow cytometry dot-
plot of cells from the 100 µg/ml treatment condition is shown.  Figure 4.5D: A representative 
flow cytometry histogram from the 100 µg/ml treatment condition, corresponding with the 
dot-plot presented in Figure 4.5C is shown.  
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Figure 4.6: Dose dependent maturation of GM-CSF BM-DC grown over 6 days, in vitro.  
C57BL/6 derived BM-DCs were grown with GM-CSF for 6 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours.  Co-staining of CD86 and CCR7 with 
CD11c+ was quantitated by flow cytometry and analysed using FACSDiva software (BD 
Biosciences), n=3.  One-way ANOVA statistical analysis with post-test analysis was 
conducted with the Tukey’s test (multiple comparison test comparing each group with the 
other group) for treatments between columns.  The Dunnett’s test was used to compare the 
control group with each treated group.  Where no asterisks are displayed, no statistical 
significance was found.  Figure 4.6A: % surface expression of CCR7 by CD11c+ cells.  The 
results are shown as the mean percentage surface expression with standard error of the mean 
as error bars.  Figure 4.6B: The results are shown as the mean fold increase in MFI with 
standard error of the mean as error bars.  Figure 4.6C: A representative flow cytometry dot-
plot of cells from the 100 µg/ml treatment condition is shown.  Figure 4.6D: A representative 
flow cytometry histogram from the 100 µg/ml treatment condition, corresponding with the 
dot-plot presented in Figure 4.6C is shown.  
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Figure 4.7: Comparison of CD86 and CCR7 surface expressions in GM-CSF grown BM-
DCs, in vitro.   Figure 4.7A compares the % surface expression of both CD86 and CCR7 
expression and Figure 4.7B compares the Fold Increase in MFI of both CD86 and CCR7 
expressions.   Two-way ANOVA statistical analysis with post-test analysis was conducted 
with the Tukey’s test (multiple comparison test comparing each group with the other group) 
for treatments between columns.  The Dunnett’s test was used to compare the control group 
with each treated group.  Where no asterisks are displayed, no statistical significance was 
found.  In Figure 4.5B, a significant statistical difference was noted between the fold increase 
in MFI (corresponding to % surface expression of CD86 by CD11c+ cells) between the 
control condition and 200µg/ml of FITC tagged T10 dextran coated IONPs; this has also been 
indicated in Figure 4.7B.  
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4.2.3.2 Dose dependent maturation of Flt3 grown BMDCs, in vitro 
 
There was statistical significance in the % surface expression of CD86 of the 200 µg/ml 
treatment condition mean compared to the control mean.  There was no further statistical 
difference between the control mean and any other treatment condition mean.  Amongst the 
treatment conditions, the only statistical sigficance was found between the means of the 100 
µg/ml and 5 µg/ml treatment groups (Figure 4.8A).  Figure 4.8A suggests that at the 
concentration doses tested, these Flt3 derived murine BM-DCs offer some potential 
stimulation to T cells via CD86 expression pathway, namely at an IONP concentration of 200 
µg/ml.  The corresponding Fold Increase in MFI (Figure 4.8B) was not statistically significant 
compared to the control mean and there was also no significance identified between treatment 
conditions. 
The surface expression of CCR7 (Figure 4.9A) and the corresponding Fold Increase in MFI 
(Figure 4.9B) was not statistically significant compared to the control means and there was 
also no significance identified between treatment conditions; thus minimimal or no LN 
migration capability could be induced in these Flt3 derived murinbe BM-DCs, under these 
tested conditions.  The level of CD86 and CCR7 expressions, compared to their control 
means, signify that these BM-DCs remain in a relatively immature state following 24 hours 
incubation with FITC taggd IONPs.  The surface expression of CCR7 was approximately half 
the value of the surface expression of CD86 (Figure 4.10A). 
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Figure 4.8: Dose dependent maturation of Flt3 BM-DC grown over 8 days, in vitro.  
C57BL/6 derived BM-DCs were grown with GM-CSF for 8 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours.  Co-staining of CD86 and CCR7 with 
CD11c+ was quantitated by flow cytometry and analysed using FACSDiva software (BD 
Biosciences), n=3.  One-way ANOVA statistical analysis with post-test analysis was 
conducted with the Tukey’s test (multiple comparison test comparing each group with the 
other group) for treatments between columns.  The Dunnett’s test was used to compare the 
control group with each treated group.  Where no asterisks are displayed, no statistical 
significance was found.  Figure 4.8A: % surface expression of CD86 by CD11c+ cells.  The 
results are shown as the mean percentage surface expression with standard error of the mean 
as error bars.  Figure 4.8B: The results are shown as the mean fold increase in MFI with 
standard error of the mean as error bars.  Figure 4.8C: A representative flow cytometry dot-
plot of cells from the 100 µg/ml treatment condition is shown.  Figure 4.8D: A representative 
flow cytometry histogram from the 100 µg/ml treatment condition, corresponding with the 
dot-plot presented in Figure 4.8C is shown.  
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Figure 4.9: Dose dependent maturation of Flt3 BM-DC grown over 8 days, in vitro.  
C57BL/6 derived BM-DCs were grown with GM-CSF for 8 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours.  Co-staining of CD86 and CCR7 with 
CD11c+ was quantitated by flow cytometry and analysed using FACSDiva software (BD 
Biosciences), n=3.  One-way ANOVA statistical analysis with post-test analysis was 
conducted with the Tukey’s test (multiple comparison test comparing each group with the 
other group) for treatments between columns.  The Dunnett’s test was used to compare the 
control group with each treated group.  Where no asterisks are displayed, no statistical 
significance was found.  Figure 4.9A: % surface expression of CCR7 by CD11c+ cells.  The 
results are shown as the mean percentage surface expression with standard error of the mean 
as error bars.  Figure 4.9B: The results are shown as the mean fold increase in MFI with 
standard error of the mean as error bars.  Figure 4.9C: A representative flow cytometry dot-
plot of cells from the 100 µg/ml treatment condition is shown.  Figure 4.9D: A representative 
flow cytometry histogram from the 100 µg/ml treatment condition, corresponding with the 
dot-plot presented in Figure 4.9C is shown.  
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Figure 4.10: Comparison of CD86 and CCR7 surface expressions in Flt3 grown BM-
DCs, in vitro.   Figure 4.10A compares the % surface expression of both CD86 and CCR7 
expression and Figure 4.10B compares the Fold Increase in MFI of both CD86 and CCR7 
expressions.   Two-way ANOVA statistical analysis with post-test analysis was conducted 
with the Tukey’s test (multiple comparison test comparing each group with the other group) 
for treatments between columns.  The Dunnett’s test was used to compare the control group 
with each treated group.  Where no asterisks are displayed, no statistical significance was 
found. 
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4.2.7 Apoptosis studies of murine BM-DCs, in vitro 
 
BM-DC survival in the presence of FITC tagged IONPs, in vitro, was investigated to gather 
knowledge for considering the possibility of later in vivo studies; in keeping with a long term 
goal for extending research in this area.  Apoptosis, programmed cell destruction and death, 
can occur when cells experience exceedingly stressful, harmful or toxic conditions.  Apoptosis 
studies, with a double stained technique were performed using a readily available proprietary 
kit was used.  7-Aminoactinomycin D (7-AAD), a fluorescent marker for cellular DNA, does 
not traverse an intact cell membranes; therefore, BM-DCs with compromised membranes will 
stain with 7 AAD.  Annexin V, a cellular protein, was incorporated to identify BM-DCs that 
have expressed on their surface membranes markers for apoptosis which include 
phosphatidylserine (PS) and phosphatidlethanolamine (PE).  Flow cytometry was used, in 
conjunction with the propriety apoptosis kit and Figure 4.11 is a representation of how cell 
populations are identified or allocated quadrants according to their health status. 
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Figure 4.11: A representative dot-plot of apoptosis data from flow cytometry with GM-
CSF grown murine BM-DC, in vitro.  This is a representative example of a dot plot 
generated from flow cytometry analysis showing cells expressing viable/living cells (Q3-2), 
dead cells (Q1-2), early apoptotic (Q4-2) and late apoptotic cells (Q2-2).    
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4.2.7.1 Apoptosis studies of GM-CSF grown murine BM-DCs with 
FITC tagged IONPs, in vitro  
 
Bone marrow stem cells from female C57BL/6 mice were cultured with GM-CSF as 
described in Section 2.10 and incubated with FITC tagged IONPs as stated in Section 2.11.1 
and apoptosis studies were performed as reported in Section 2.11.3.  There was uniform BM-
DC population mean values present in each quadrant, contributed by a statistically even 
distribution BM-DC population across each treatment condition; being consistent with the 
control BM-DC population mean (Figure 4.12).  No statistical difference between the mean 
value of the BM-DC control means and the treatment means could be identified, and there 
was also no statistical significance amongst the BM-DC population means of each treatment 
conditions; in each quadrant that represents the BM-DC health status as tested, in vitro.   
As the population within each quadrant can be considered rather homogenous (only one point 
of statistical variation in Q2, Figure 4.12B), the average percentage mean values of each 
quadrant was graphed and compared (Figure 4.13).  The largest overall BM-DC population 
was found in quadrant 3, therefore, viable/healthy, and the lowest population of these cells 
was found in quadrant 1, the dead cell quadrant (Figure 4.13).  Figure 4.14 represents the dot-
plots of these BM-DCs as identified using flow cytometry from an apoptosis study. 
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Figure 4.12:  IONP induced apoptosis of GM-CSF derived BM-DCs, in vitro.  C57BL/6 
derived BM-DCs were grown with GM-CSF for 6 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours. Stages of cell health were quantitated by 
flow cytometry and analysed, (n=3).  The apoptosis study was performed with Annexin V and 
7AAD.  The results are shown as the mean percentage of cell population within an apoptotic 
quadrant with standard error of the mean as error bars.  Two-way ANOVA statistical analysis 
with post-test analysis conducted with Tukey’s test (multiple comparison test comparing each 
group with all other groups).  Where no asterisks are displayed, no statistical significance was 
found.  Figure 4.12A: Percentage of cells that were found in quadrant one, dead or necrotic.  
Figure 4.12B: Percentage of cells that were found in quadrant two, late stage apoptosis.  
Figure 4.12C: Percentage of cells that were found in quadrant three, viable or healthy.  
Figure 4.12D: Percentage of cells that were found in quadrant four, early stage apoptosis.    
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Quadrant  
(from FACS) 
Definition of 
Quadrant 
Average Percentage 
of Cell Population 
(GM-CSF) 
Q1 Dead 10 % 
Q2 Late Apoptosis 32 % 
Q3 Alive / Viable 39 % 
Q4 Early Apoptotic 20 % 
 
Table 4.3:  Average percentage figures (rounded up to nearest whole number) of GM-
CSF induced murine DCs in varying stages of apoptosis, death or viability.  From Figure 
4.12, this table was composed, demonstrating the average percentage figures of cells in 
varying stages of apoptosis, death or viability as identified by the apoptosis double staining 
technique and flow cytometry and analysed using FACSDiva software (BD Biosciences) and 
shown here, (n=3).   
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Figure 4.13: The average mean percentage figures of GM-CSF grown BM-DCs 
population from the quadrants representing the stages of cell health.   As there was no 
statistical variation of the individual components (control means and treatment means) within 
each quadrant, the average percentage mean values of each quadrant is represented here and 
statistically compared.  A two-way ANOVA with Tukey’s multiple comparison test was used 
to compare each quadrant with one another. 
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Figure 4.14:  IONP induced apoptosis of GM-CSF derived BM-DCs, in vitro.  C57BL/6 
derived BM-DCs were grown with GM-CSF for 6 days and incubated with varying 
concentrations of FITC tagged IONPs for 24 hours. Stages of cell health were quantitated by 
flow cytometry and analysed, (n=3).  The apoptosis study was performed with Annexin V and 
7AAD.  The dot-plots shown are representative of   cells        in the four identified stages of 
apoptosis, ranging from dead or necrotic cells (quadrant one), late stage apoptosis (quadrant 
two), viable or healthy cells (quadrant 3) and early stage apoptosis (quadrant four).  Figure 
4.14A: Representative dot-plot of apoptosis study of cells in the control condition, following 
24 hours incubation.  Figure 4.14B: Representative dot-plot of apoptosis study of cells 
incubated with 200 µg/ml of FITC tagged IONP for 24 hours.  Figure 4.14C: Representative 
dot-plot of apoptosis study of cells incubated with 100 µg/ml of FITC tagged IONP for 24 
hours.  Figure 4.14D: Representative dot-plot of apoptosis study of cells incubated with 50 
µg/ml of FITC tagged IONP for 24 hours.  Figure 4.14E: Representative dot-plot of 
apoptosis study of cells incubated with 20 µg/ml of FITC tagged IONP for 24 hours.  Figure 
4.14F: Representative dot-plot of apoptosis study of cells incubated with 5 µg/ml of FITC 
tagged IONP for 24 hours.   
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4.2.7.2 Apoptosis studies of Flt3 grown BM-DCs with FITC tagged 
IONPs, in vitro 
 
Bone marrow stem cells from female C57BL/6 mice were cultured with Flt3 as described in 
Section 2.10 and incubated with FITC tagged IONPs as stated in Section 2.11.1 and apoptosis 
studies were performed as reported in Section 2.11.3.  Again, there was uniform BM-DC 
population mean values present in each quadrant, contributed by a statistically even 
distribution BM-DC population across each treatment condition; being consistent with the 
control BM-DC population mean (Figure 4.15).  No statistical difference between the mean 
value of the BM-DC control means and the treatment means could be identified, and there 
was also no statistical significance amongst the BM-DC population means of each treatment 
conditions; in each quadrant that represents the BM-DC health status as tested, in vitro.   
As the population within each quadrant can be considered rather homogenous (only one point 
of statistical variation in Q3, Figure 4.15C), the average percentage mean values of each 
quadrant was graphed and compared (Figure 4.16).  The largest overall Flt3 grown murine 
BM-DC population was found in quadrant 3, therefore, viable/healthy, and the lowest 
population of these cells was found in quadrant 4, the early apoptotic quadrant (Figure 4.16).  
Figure 4.17 represents the dot-plots of these BM-DCs as identified using flow cytometry from 
an apoptosis study. 
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Figure 4.15:  IONP induced apoptosis of Flt3 derived BM-DCs, in vitro.  C57BL/6 
derived BM-DCs were grown with Flt3 for 8 days and incubated with varying concentrations 
of FITC tagged IONPs for 24 hours. Stages of cell health were quantitated by flow cytometry 
and analysed, (n=5).  The apoptosis study was performed with Annexin V and 7AAD.  The 
results are shown as the mean percentage of cell population within an apoptotic quadrant with 
standard error of the mean as error bars.  Two-way ANOVA post-test analysis was conducted 
with the Tukey’s test (multiple comparison test comparing each group with the other group).  
Where no asterisks are displayed, no statistical significance was found.  Figure 4.15A: 
Percentage of cells that were found in quadrant one, dead or necrotic.  Figure 4.15B: 
Percentage of cells that were found in quadrant two, late stage apoptosis.  Figure 4.15C: 
Percentage of cells that were found in quadrant three, viable or healthy.  Figure 4.15D: 
Percentage of cells that were found in quadrant four, early stage apoptosis.   
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Quadrant  
(from FACS) 
Definition of 
Quadrant 
Average Percentage 
of Cell Population 
(Flt3) 
Q1 Dead 19 % 
Q2 Late Apoptosis 20 % 
Q3 Alive / Viable 49 % 
Q4 Early Apoptotic 12 % 
 
Table 4.4:  Average percentage figures (rounded up to nearest whole number) of Flt3 
induced murine DCs in varying stages of apoptosis, death or viability.  From Figure 4.15, 
this table was composed, demonstrating the average percentage figures of cells in varying 
stages of apoptosis, death or viability as identified by the apoptosis double staining technique 
and flow cytometry and analysed using FACSDiva software (BD Biosciences) and shown 
here, (n=5).   
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Figure 4.16: The average mean percentage figures of Flt3 grown BM-DCs population 
from the quadrants representing the stages of cell health.   As there was no statistical 
variation of the individual components (control means and treatment means) within each 
quadrant, the average percentage mean values of each quadrant is represented here and 
statistically compared.  A two-way ANOVA with Tukey’s multiple comparison test was used 
to compare each quadrant with one another. 
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Figure 4.17:  IONP induced apoptosis of Flt3 derived BM-DCs, in vitro.  C57BL/6 
derived BM-DCs were grown with Flt3 for 8 days and incubated with varying concentrations 
of FITC tagged IONPs for 24 hours. Stages of cell health were quantitated by flow cytometry 
and analysed, (n=5).  The apoptosis study was performed with Annexin V and 7AAD.  The 
dot-plots shown are representative of   cells in the four identified stages of apoptosis, ranging 
from dead or necrotic cells (quadrant one), late stage apoptosis (quadrant two), viable or 
healthy cells (quadrant 3) and early stage apoptosis (quadrant four).  Figure 4.17A: 
Representative dot-plot of apoptosis study of cells in the control condition, following 24 hours 
incubation.  Figure 4.17B: Representative dot-plot of apoptosis study of cells incubated with 
200 µg/ml of FITC tagged IONP for 24 hours.  Figure 4.17C: Representative dot-plot of 
apoptosis study of cells incubated with 100 µg/ml of FITC tagged IONP for 24 hours.  Figure 
4.17D: Representative dot-plot of apoptosis study of cells incubated with 50 µg/ml of FITC 
tagged IONP for 24 hours.  Figure 4.17E: Representative dot-plot of apoptosis study of cells 
incubated with 20 µg/ml of FITC tagged IONP for 24 hours.  Figure 4.17F: Representative 
dot-plot of apoptosis study of cells incubated with 5 µg/ml of FITC tagged IONP for 24 
hours.   
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 4.2.7.3 Comparison of results of GM-CSF grown murine BM-DCs and 
Flt3 grown murine BM-DCs apoptosis studies 
 
Compared to GM-CSF grown murine BM-DCs, Flt3 grown murine BM-DCs appear to better 
tolerate the FITC tagged IONPs at the completion of 24 hours incubation time with the 
nanoparticle concentrations tested.  This was demonstrated by approximately 49% of the Flt3 
grown murine BM-DC population identified in the quadrant 3 (viable) by flow cytometry; and 
thereby having the remainder of their cell population in non-viable quadrants (dead, late 
apoptosis and early apoptosis).  GM-CSF grown murine BM-DCs had 39% of their cell 
population in the viable quadrant and their remaining cell populations were in the non-viable 
quadrants, as determined with flow cytometry.  Statistically, however, there was no 
significance between the values of average cell populations of GM-CSF grown murine BM-
DCs and Flt3 grown murine BM-DCs found in each quadrant.  
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Figure 4.18: Comparison average mean values of cell populations from apoptosis 
studies.  The average percentage mean values of each quadrant from both the GM-CSF grown 
BM-DC and Flt3 grown DC apoptosis in vitro are represented here and statistically compared.  
A two-way ANOVA with Tukey’s multiple comparison test was used to compare each 
quadrant with one another.  A two-way ANOVA with Tukey’s multiple comparison test was 
used to compare each quadrant with one another.  Where no asterisks are displayed, no 
statistical significance was found. 
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 4.2.8 Dose dependent cytokine secretion of murine BM-DC following 
incubation with FITC tagged IONPs for 24 hours, in vitro        
 
To ascertain if the presence of FITC tagged IONPs triggered an inflammatory response from 
GM-CSF grown and Flt3 grown, murine BM-DCs, a readily available propriety cytometric 
bead array kit was used to detect the expression of inflammatory cytokines the supernatant 
from in vitro dose dependent uptake experiments.  The kit was able to detect the following 
cytokines: IL-p70, TNF, IFN-γ, MCP-1, IL-10 and IL-6.  The supernatant from dose 
dependent studies tested, in vitro, only three cytokines were expressed in elevated levels:  
TNF, MCP-1, and IL-6.   
For both types of murine BM-DCs, the cytokine expressions were not dependent upon the 
concentration of FITC tagged IONPs tested, following 24 hours incubation, in vitro (Figures 
4.19 and 4.20).  The expression levels of the TNF, MCP-1, and IL-6 cytokines found in the 
supernatant of dose dependent in vitro studies from Flt3 grown murine BM-DCs was 
approximately half the value expressed by GM-CSF grown murine BM-DCs. 
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Figure 4.19: Dose dependent cytokine expression of GM-CSF grown BM-DC following 
incubation with FITC tagged IONPs for 24 hours, in vitro.  C57BL/6 derived BM-DCs 
grown with GM-CSF for 8 days were incubated with varying concentrations of FITC tagged 
IONPs for 24 hours, in vitro.  Supernatants were collected and stored at -80 oC for future 
cytokine analysis.  Cytokine expression was quantitated using the CBA Murine Inflammatory 
Kit (BD Biosciences) and analysed using flow cytometry, n=3.  Cytokine levels are shown as 
mean values with standard error of the mean represented as error bars.  One-way ANOVA 
(nonparametric) multiple comparison test (as a post-test analysis) was performed with the 
Tukey’s multiple comparison test.  Where no asterisks are displayed, no statistical 
significance was found. 
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 Figure 4.20: Dose dependent cytokine expression of Flt3 grown BM-DC following 
incubation with FITC tagged IONPs for 24 hours, in vitro.  C57BL/6 derived BM-DCs 
grown with Flt3 for 8 days were incubated with varying concentrations of FITC tagged 
IONPs for 24 hours, in vitro.  Supernatants were collected and stored at -80 oC for future 
cytokine analysis.  Cytokine expression was quantitated using the CBA Murine Inflammatory 
Kit (BD Biosciences) and analysed using flow cytometry, n=3.  Cytokine levels are shown as 
mean values with standard error of the mean represented as error bars.  One-way ANOVA 
multiple comparison test (as a post-test analysis) was performed with the Tukey’s multiple 
comparison test.  Where no asterisks are displayed, no statistical significance was found. 
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 4.3 Discussion 
 
Murine DCs were generated from bone marrow precursors, in vitro, by incorporating either 
the GM-CSF or Flt3 cytokine or growth factor, as described in Section 2.1.  Following an 
incubation period of 24 hours with IONPs at 5 % CO2 at 37 oC, Figure 4.1A demonstrates that 
GM-CSF BM-DCs, uptake FITC tagged IONP in a dose dependent fashion, also known as a 
titration effect or response.  Reviewing the post-test statistical analysis with the Tukey’s test 
(to identify any statistical significance between treatment groups), there was very significant 
(**, P = 0.001 to 0.01) statistical difference between the means of the cells exposed to 50 
µg/ml and 20 µg/ml concentrations.  There was no statistical difference (ns, P ≥ 0.05) 
recorded with the remaining cell population means, graphically positioned adjacent to each 
other; that is, there was no statistical difference recorded between cell populations incubated 
with 200 µg/ml and 100 µg/ml; between 100 µg/ml and 50 µg/ml; and between 20 µg/ml and 
5 µg/ml.  Therefore, even though a concentration of 50 µg/ml is more than double that of 20 
µg/ml, these cells manage to respond and internalise the FITC tagged IONPs.  As there is no 
statistical difference identified beyond this concentration (50 µg/ml); it can be deduced that 
this concentration is at or near the maximum capabilities of the cells (BM cells seeded at 3 x 
106 cells in 3 ml in each well).  An increase to either 100 µg/ml or 200 µg/ml results in no 
statistically significant greater uptake of IONP by the cells.   
The corresponding graph depicting Fold Increase in MFI (Figure 4.1B) from the GM-CSF 
stimulated murine DCs, again, show no statistical difference between the FITC tagged IONPs 
concentrations of 100 µg/ml or 200 µg/ml; closely reflecting the uptake findings of Figure 
4.1A at these two higher doses.  Across the range of concentrations tested, graphically, the 
treatment means also visually demonstrate a dose dependent effect.  For both the control and 
200 µg/ml conditions, there was extremely significant (****, P < 0.0001) statistical difference 
identified by the Dunnett’s test; denoting that the GM-CSF induced murine DCs successfully 
212 
 
 had uptaken FITC tagged IONPs.  The Tukey’s test resulted in no statistical significance 
between means of adjacent treatment conditions; that is, there was no significance between 5 
µg/ml and 20 µg/ml, between 20 µg/ml and 50 µg/ml, between 50 µg/ml and 100 µg/ml, and 
so on.  This response further supports a dose dependent effect and that the GM-CSF induced 
murine DCs are capable of internalising the FITC tagged IONPs.  
The dose uptake experiments performed with the Flt3 induced murine DCs (Figure 4.2A) also 
demonstrate a dose dependent effect, however, the uptake by Flt3 is approximately 75% to 
that of the GM-CSF DCs.  For example, at a concentration of 200 µg/ml, the mean uptake by 
GM-CSF DCs is 80 %, whereas at this same concentration, the uptake by Flt3 DCs is 60 % 
(60 % is ¾ of 80 %).  This pattern is followed throughout the remaining concentration levels.  
The Tukey’s test demonstrates that there was no statistical significance (ns, P ≥ 0.05) between 
the means of adjacent treatment conditions; that is there was no significance between 5 µg/ml 
and 20 µg/ml, between 20 µg/ml and 50 µg/ml, between 50 µg/ml and 100 µg/ml, and so on.  
The Dunnet’s test cannot identify any statistical significance (ns, P ≥ 0.05) between the 
control mean and the 50 µg/ml concentration mean and less, for Flt3 primed murine DCs; 
therefore, statistically noticeable percentage uptake commences with a FITC tagged IONP 
concentration of 100 µg/ml (*, statistically significant, P = 0.01 to 0.05) and continued to very 
significant (**, P = 0.001 to 0.01) between control and 200 µg/ml; at 24 hours incubation.   
Figure 4.2B, demonstrates Fold Increase in MFI for the Flt3 murine DCs.  The Fold Increase 
in MFI values identified with Flt3 murine DCs is approximately 57 % compared with GM-
CSF murine DCs.  At the FITC tagged IONP concentration of 200 µg/ml, for instance, a mean 
value of 1.9 is recorded for Flt3 murine DCs and approximately 3.5 for GM-CSF murine DCs 
(2.0 is 57 % of 3.5).  This, for Flt3 murine DCs, corresponds with its reduced uptake 
identified in Figure 4.2A, compared with GM-CSF murine DCs (Figure 4.1A).  Tukey’s test 
for treatments between columns, resulted in no statistical significance (ns, P ≥ 0.05) between 
adjoining treatment concentration means.  Dunnett’s test was used to compare the control 
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 group with each treated group; resulted in no statistical significance (ns, P ≥ 0.05) between the 
control condition and all treatment conditions.   
The maximum concentration of 200 µg/ml of FTC tagged IONP, as tested during the dose 
uptake studies, was used to perform time course experiments with both GM-CSF and Flt3 
murine DCs.  With GM-CSF murine DCs (Figure 4.3A), the Tukey’s test was unable to 
identify any statistical significance between any of the treatment groups, meaning that uptake 
of IONPs by GM-CSF murine DCs at 24 hours offered no statistical difference compared to 
the minimum incubation period tested of 1 hour.  Therefore, the level of IONP uptake at 1 
hour is comparable to that at 24 hours, thus, no real advantage was offered by the addition 23 
hours of incubation.  The Dunnett’s test, however, did recognise a very significant (**, P = 
0.001 to 0.01) statistical significance between the control mean and the mean of each 
treatment condition.  The corresponding Fold Increase in MFI graph plotted in Figure 4.3B, 
was assessed with the Tukey’s test and no statistical significance (ns, P ≥ 0.05) was found 
between treatment conditions.  The Dunnett’s test identified a significant statistical difference 
(*, P = 0.01 to 0.05) between the control and highest concentration (200 µg/ml) means.  This 
same test (Dunnet’s) reported no statistical significance (ns, P ≥ 0.05) between the control 
mean and the means of the remaining treatment conditions.  Therefore, there was a benefit to 
the 24 hour incubation period, which was that it allowed the maximum difference between 
control and the highest concentration treatment in terms of Fold Increase in MFI; and with 
respect to percentage uptake, the 24 hour and 18 hour time points were considered 
approximately equivalent and both were statistically very significant (**, P = 0.001 to 0.01) 
compared to the control.   
With Flt3 murine DCs, the percentage uptake pattern (Figure 4.4A) visually appeared to be 
time dependent, that is, as the incubation time increased, so too did the percentage uptake.  
The Tukey’s statistical assessment discerns that there was statistical significance (*, P = 0.01 
to 0.05) between the mean values of the 24 hour and 1 hour time points and no statistical 
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 significance (ns, P ≥ 0.05) between all other combinations of treatment time points.  The 
Dunnett’s test identified significant (*, P = 0.01 to 0.05) statistical difference between control 
and 24 hour and between control and 18 hour time points.  Accordingly, therefore, with Flt3 
murine DCs, statistically suitable percentage uptake was identified at 18 hours of incubation 
with IONPs; whereas with GM-CSF murine DCs the equivalent occurred at the 1 hour 
incubation time point.     
Compared to GM-CSF, the actual percentage values of uptake of IONPs by Flt3 murine DCs 
were lower, as presented in Table 4.1.  These tabulated and calculated figures also 
demonstrate that even at 1 hour incubation of GM-CSF murine BM-DCs with IONPs, a 
greater percentage of these cells (71.08 %) had uptaken IONPs compared to Flt3 murine DCs 
at completion of the longest incubation time tested of 24 hours (42.7 %).  The Fold Increase 
in MFI graphs revealed findings of a similar nature, that is, the Fold Increase in MFI of the 
Flt3 murine BM-DCs (Figure 4.4B) are at a level lesser than the GM-CSF and are tabulated in 
Table 4.2.  
To determine if the FITC tagged IONP triggered a maturation signal in either the GM-CSF or 
Flt3 induced murine DCs, maturation experiments were performed.  Cells that were positive 
for CD11c, a protein associated with dendritic cells, were also assessed for CD86 and CCR7 
expressions.  CD86 is a protein expressed by many DCs and is known to facilitate activation 
for T-cell lymphocyte proliferation by providing costimulatory signals; thus, an indicator of 
DC maturation.  CCR7 is expressed by lymphoid cells, such as DCs, and is considered as a 
migratory marker – it stimulates and controls the co-ordinated movement of memory T-cell 
lymphocytes to lymph nodes and other secondary lymph organs.  It directs responding cells to 
traverse the endothelial wall of the HEV and transition to the T-cell zone of lymph nodes.  
CCR7 also has the ability to stimulate maturation of DCs.   
215 
 
 CD11c positive murine DCs arising from GM-CSF stimulation, demonstrated levels of CD86 
that graphically appeared elevated, compared to its expression of CCR7 (Figure 4.6A).  The 
CD86 surface expression, demonstrated a dose dependent effect (graphically) with respect to 
treatment with IONP at concentrations from 5 µg/ml to 50 µg/ml and plateauing or peaking at 
100 µg/ml.  CCR7 also demonstrated a dose dependent effect, however, expressed in lesser 
quantities; approximately half the value compared to CD86; for all treatment conditions and 
also with control conditions (Figure 4.7).  The data contributing to Figure 4.7 was assessed 
and no statistical significance was identified between CD86 and CCR7 for all treatment 
conditions; in relation to percent surface expression (Figure 4.7A) and Fold Increase in MFI 
(Figure 4.7B).  It can be argued that, visually, according to the graph presented, there could 
possibly be a dose-dependent effect, however, more importantly, no statistical significance 
was found between treatment conditions.  Significant (*, P = 0.01 to 0.05) statistical 
difference was identified, however, in fold increase in MFI between control and the level of 
CD86 expressed in response to 200 µg/ml of FITC tagged IONP (Figure 4.5B).  The only 
possible explanation that can be offered for this was the maximum possible presence of FITC 
(in the 200 µg/ml treatment group) compared with no FITC (in the control group). 
The expression of CD86 by Flt3 murine DCs demonstrated a dose-dependent response 
between 5 µg/ml to 50 µg/ml (Figure 4.8).  The levels of CCR7 expressed was approximately 
between one-quarter to one-third of the CD86 expression, across the treatment concentrations.  
When these results are compared to those of GM-CSF derived murine DCs, the secretion of 
CD86 is approximately at 40 %.  The corresponding Flt3 murine DCs Fold Increase in MFI 
(Figure 4.8B), reflected the percentage surface expression; confirming a titration or dose-
dependent effect.  Therefore, from these results, under these experimental conditions, the 
IONP have a greater maturation and migratory effect on GM-CSF murine DCs than on Flt3 
murine DCs.  
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 Apoptosis, programmed cell destruction and death, can occur when cells experience 
exceedingly stressful, harmful or toxic conditions.  Apoptosis studies, with a double stained 
technique, was performed as described in Section 2.11.3 using a proprietary kit containing PE 
Annexin V, 7AAD and Annexin Binding Buffer.  Following a 24 hour incubation period with 
FITC tagged IONPs, the apoptosis studies (n = 3) identified average GM-CSF murine cell 
populations to be in the following stages of apoptosis (Table 4.3).   
Table 4.3 is a tabulated representation of the graphs presented in Figure 4.12 and Table 4.4 is 
representative of Figure 4.15.  Flt3 derived DCs can better tolerate FITC tagged IONPs at 
these tested concentrations at the completion of the 24 hour incubation period.  Comparing the 
two murine DC populations (GM-CSF and Flt3 derived), approximately half (49 %) of the 
Flt3 murine DCs remained alive and viable rather than 39 % of GM-CSF murine DCs (Figure 
4.18).  With respect to quadrants 1 (dead cells); 19 % of the Flt3 derived murine DCs were 
identified as dead, whereas, about half this figure, 10 % of GM-CSF murine DCs were 
deceased.   GM-CSF murine DCs had a greater percentage of cells in both early apoptosis 
(quadrant 4), 20 % and in late apoptosis (quadrant 2), 32 % - while Flt3 murine DCs had 12 % 
and 20 % of their cell populations in these apoptotic states, respectively.  With respect to 
quadrants 1 (dead cells), 2 (late apoptotic) and 3 (early apoptotic); there were a combined 62 
% of the GM-CSF murine DC cell population experiencing these apoptotic stages and a 
combined 51 % of Flt3 murine DCs. In summary, while Flt3 derived murine DCs had a 
greater population percentage as dead cells, overall, there was a greater percentage of viable 
cells as fewer cells were in early and late apoptosis; thus Flt3 murine DCs demonstrated 
greater survival capabilities under these treatment conditions.   
A number of possible reasons can be offered to explain these differences.  Firstly, the 
apoptosis studies were performed 3 times with GM-CSF murine DCs, as opposed to 5 times 
with Flt3 murine DCs.  As the replicates are different for these to cell types, there is a greater 
long-term averaging of n = 5 replicates compared to n = 3 replicates.  Secondly, the large 
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 error bars for both cell types, could indicate that the response to treatment conditions are 
variable.  Thirdly, and perhaps more logically, the plasmacytoid component of the Flt3 
murine DCs may be contributing to the greater viability of Flt3 murine DCs and being lesser 
of them in early and late apoptosis.  GM-CSF murine DCs are considered to be myeloid DCs, 
whereas, Flt3 murine DCs are considered to have myeloid and plasmacytoid aspects.  Overall, 
therefore, and average of 39% of the GM-CSF derived dendritic cell population are viable and 
healthy following 24 hours incubation with IONPs; compared with a value of 49 % of 
dendritic cells generated with Flt3 (viable and healthy following the same incubation period 
and treatment conditions).    
For both derivations of murine DCs (GM-CSF and Flt3 generated), a proprietary cytometric 
bead array Mouse Inflammation Kit was used to simultaneously identify the secretion of pro-
inflammatory cytokines IL-12p70, TNF, IFN-γ, MCP-1, IL-6 and an anti-inflammatory 
cytokine IL-10; as secreted in their cellular supernatants following exposure to FITC tagged 
IONP.   
The IL-12p70 cytokine is secreted by DCs due to antigen stimulation, it initiates production 
of IFN-γ and TNF.  IL-12p70 can also stop oncologic angiogenesis, the development of new 
blood vessels to supply tumours, by triggering high secretion of IFN-γ. 
TNF, produced by lymphoid cells, acts as a cytotoxin for tumour regression and also induces 
apoptotic cell death, however, its actions are inhibited by elevated levels of IL-6.  TNF has a 
clinical association with oncology patients reaching cachexia; as demonstrated by elevated 
blood serum levels of TNF.   
IFN-γ is released by DCs, myeloid cells and macrophages.  It plays an important role for both 
innate and adaptive immunity with respect to immune-regulation, it has anti-tumour 
properties and may also be involved with cell self-activation at the onset of infection.  
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 MCP-1, secreted by DCs to an inflammatory response, is significant for establishing a 
chemotaxic effect and establishing a chemical gradient that directs migration of DCs to their 
destination to interact with T cells. 
IL-6 has an inhibiting consequence on TNF and can activate IL-10; and interestingly is an 
inflammatory cytokine and an anti-inflammatory myokine.  
IL-10 is an anti-inflammatory cytokine that can suppress production of pro-inflammatory 
cytokines, namely INF-γ and TNF (and also IL-2 and IL-3) and can also suppress the antigen 
presenting capabilities of DCs, in general.   
Figures 4.19 and 4.20 both demonstrate that murine myeloid DCs (GM-CSF induced) and 
murine myeloid/plasmacytoid DCs (Flt3 induced) respond similarly to experimental 
conditions with elevated in vitro secretion of TNF, MCP-1 and IL-6.        
For both cell types, when the secretion of TNF, MCP-1 and IL-6 in the presence of various 
concentrations of FITC tagged IONPs is compared to control conditions, there is no statistical 
difference (Figure 4.19 and Figure 4.20).  Therefore, it can be surmised that the IONPs tested 
do not appear to induce a notable inflammatory response; and thus, there is no statistical 
difference in cytokine secretion between the treatment and control conditions.     
Flt3 generated murine DCs, having myeloid and plasmacytoid characteristics, showed release 
of the same cytokines (TNF, MCP-1 and IL-6) but at approximately half the values to that of 
GM-CSF derived DCs (measured in pg/ml).  These lower secretions of TNF and IL-6 could 
explain why there were 51 % of the Flt3 population in a combined state early apoptosis, late 
apoptosis and death; compared with GM-CSF murine DCs.  For these Flt3 murine DCs, and 
considering the results from apoptosis studies, Flt3 murine DCs can better tolerate and survive 
these experimental treatment conditions compared to GM-CSF murine DCs. 
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 What cannot be explained by these results for both cell types is that while IL-6 is being 
secreted, it does not appear to have an inhibiting effect on TNF.  This may be dues to that 24 
hours may be insufficient time for both IL-6 and IL-10 to fully respond and have an impact on 
the TNF release levels.  For both cell types, IL-10 is also being released, but at very low, but 
detectable levels.   
When the data from the apoptosis and CBA studies are reviewed with the respective 
maturation data; together, it can be argued that the Flt3 derived murine DCs are maturing 
either at a slower rate or in less numbers, compared to GM-CSF induced murine DCs.  
Therefore, the GM-CSF DCs are progressing through their cell-cycle towards death, at a 
faster rate, when incubated with IONPs under the treatment conditions presented here.  
Comparatively, there are less GM-CSF DCs alive or viable; greater numbers in early and late 
apoptosis; and the secreted cytokine data supports the apoptotic data, which, in turn, supports 
the maturation data – for both cell types. 
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 4.4 Conclusion 
 
The aims of this chapter have been addressed and the experimental results lead to the 
following conclusions: 
1. GM-CSF derived BM-DCs demonstrated a dose-dependent response to the IONPs 
concentrations tested.  Of the nanoparticle concentrations tested, 50 µg/ml is the 
concentration that is at or near the maximum capabilities of the GM-CSF stimulated 
murine DCs.  An increase to either 100 µg/ml or 200 µg/ml resulted in no statistically 
significant (ns, P ≥ 0.05) greater uptake of IONP by the cells when compared to 50 
µg/ml concentration.  When compared to the control condition, 5 µg/ml concentration 
resulted in no statistical (ns, P ≥ 0.05) significance; whereas with all other 
concentrations, these DCs demonstrated percentage uptake that was statistically 
extremely significant (****, P < 0.0001) compared to control.  Flt3 derived BM-DCs 
(myloid/plasmacytoid type DCs) demonstrated a dose-dependent response to the 
IONPs concentrations tested.  At the nanoparticle concentrations tested, these DCs 
showed percentage uptake equivalent to approximately 75 % to the percentage uptake 
shown by GM-CSF generated murine DCs.  Following 24 hours incubation, 
statistically noticeable (*, P = 0.01 to 0.05) percentage uptake occurred at 100 µg/ml 
(compared to control condition) and an increase to 200 µg/ml resulted in very 
significant (**, P = 0.001 to 0.01) statistically difference compared to control 
conditions.  
2. GM-CSF induced BM-DCs (myeloid type DCs) time course experiments were 
performed.  These DCs demonstrated maximum uptake of IONPs at 1 hour incubation 
with 200 µg/ml of IONPs.    Time course studies with Flt3 generated BM-DCs 
(myloid/plasmacytoid type DCs) demonstrated that maximum uptake occurred at 4 
hours incubation with 200 µg/ml of IONPs. 
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 3. GM-CSF was used to generate myeloid type DCs and Flt3 used to generate 
myloid/plasmacytoid type DCs.  GM-CSF generated BM-DCs expressed CD86 at 
twice the level that it expressed CCR7.  Flt3 generated BM-DCs secreted CCR7 at a 
level that was 25 % to 30 % to their expression levels of CD86; or alternatively, these 
cells expressed CD86 at a level that was 3 to 4 times greater than their expression of 
CCR7.  Flt3 derived BM-DCs secreted CD86 at a value that was about 40 % 
equivalent to the level of CD86 expressed by GM-CSF derived BM-DCs.  In vitro, 
under these experimental conditions, the IONPs had a stimulatory effect on both cell 
types, however, the effect was greater on GM-CSF derived BM-DCs, resulting in 
greater expression of maturation and migratory markers from GM-CSF derived BM-
DCs than from Flt3 derived BM-DCs.  
4. Apoptosis, programmed cell death, studies were performed with GM-CSF generated 
BM-DCs (myeloid type DCs) and also with Flt3 generated BM-DCs 
(myloid/plasmacytoid type DCs).  Under these experimental conditions; 
approximately half (49%) of the Flt3 murine DCs remained alive and viable compared 
to 39 % of GM-CSF murine DCs.  GM-CSF murine DCs had a greater percentage of 
cells in both early apoptosis (quadrant 4), 20 % and in late apoptosis (quadrant 2), 32 
% - while Flt3 murine DCs had 12 % and 20 % of their cell populations in these 
apoptotic states, respectively.  Therefore, combined, 62 % of the GM-CSF murine DC 
cell population experienced these apoptotic stages and a combined 51 % of Flt3 
murine DCs.  19 % of the Flt3 derived murine DCs were identified as dead, whereas, 
about half this figure, 10 % of GM-CSF murine DCs were deceased.  From the results, 
Flt3 derived murine DCs can better tolerate FITC tagged IONPs at these tested 
concentrations at the completion of the 24 hour incubation period; while Flt3 derived 
murine DCs had a greater population percentage as dead cells, overall, there was a 
greater percentage of viable cells as fewer cells were in early and late apoptosis; thus 
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 Flt3 murine DCs demonstrated greater survival capabilities under these treatment 
conditions.   
5. The supernatant from dose uptake experiments were assessed using a CBA Murine 
Inflammatory Kit.  Murine myeloid DCs (GM-CSF induced) and murine 
myeloid/plasmacytoid DCs (Flt3 induced) respond similarly to experimental 
conditions with elevated in vitro secretion of TNF, MCP-1 and IL-6.  The ratio of 
released TNF and IL-6 by GM-CSF murine DCs across all IONP concentrations 
demonstrated an almost dose dependent expression effect and pattern of secretion 
levels of TNF and IL-6 were almost visually identical.  Flt3 generated murine DCs, 
having myeloid and plasmacytoid characteristics, showed secretion of the same 
cytokines as GM-CSF induced DCs (TNF, MCP-1 and IL-6) but at approximately half 
the pg/ml values to that of GM-CSF derived DCs.  For both cell types, a migratory 
stimulus response is occurring to the presence of IONP, in vitro, as MCP-1 has been 
noticeably released, GM-CSF murine DCs at twice the secretion level as Flt3 murine 
DCs.  For both cell types, IL-10 is also being released, but at very low, but detectable 
levels.   
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 5.0 Chapter 5 – Characterisation of Iron Oxide Nanoparticle Uptake by 
Human Monocyte Derived Dendritic Cells, in vitro   
 
 
5.1 Introduction  
 
Cellular magnetic resonance imaging (cMRI) is the imaging cells in vivo, with MRI(20).  The 
cells commonly used in cMRI are DCs – which have been either extracted from a patient and 
labelled with IONPs, ex vivo, and then returned to the patient; or; precursor cells from a 
patient have been used to generate DCs, in vitro, then labelled with IONPs and then returned 
to the patient(196).  The need for detailed understanding of cellular interactions is leading to 
innovative research activity and new knowledge gained is rapidly being applied to DCs in 
preclinical strategies for diagnosing and treating a variety of human disease.  Once immature 
DCs are triggered with a “maturation/danger” signal, they commence migration to secondary 
lymphoid organs(203).  This process is also in response to certain necessary chemokines and as 
the immature DCs migrate, they become mature DCs upon arrival at their destination.  The 
mature DCs then present antigen material to naïve T cells.  
The two main lineages of DCs, plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) have 
their own identifiable phenotypes.  pDCs are known to be CD123+ (and CD11c) and mDCs 
are CD11c+ (CD123-).   CD11c+ DCs have characteristics similar to immature DCs; having 
low expressions of costimulatory molecules (CD80, CD86), maturation marker (CD83), and 
chemokine receptor CCR7 (migration marker)(203, 246, 247).  To study human DCs, monocytes 
are isolated from peripheral blood mononuclear cells and DCs generated with the addition of 
recombinant cytokines, in vitro.  This is currently the most common method used.  In human 
blood, DC progenitor cells only account for approximately 0.1 % of cells and have the 
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 potential to differentiate into immuno-stimulatory DCs if cultured in vitro with GM-CSF, IL-
4 and TNF-α(206).  For the experiments performed in this thesis, this method was used to 
generate DCs, in vitro,as described in Section 2.6.1.   
DCs can actually be extracted from human peripheral blood, by a process known as either 
haemapheresis, apheresis or leukopheresis ; however, due to their significantly low numbers, 
their isolation by haemapheresis in sufficient numbers for clinical or research applications can 
be overwhelmingly laborious(206, 248).  Therefore, in vitro generation of DCs from peripheral 
blood monocytes is currently the preferred method used to collect DCs in sufficient numbers 
for clinical or research use(206, 249).  Monocytes are cultured with GM-CSF and IL-4 to develop 
into CD11c+ DCs. These DCs have a phenotypic expression similar to immature DCs, having 
low expression levels of CD80, CD83, CD86 and MHC-II (induced by IFN-γ).  Also, like 
other immature DCs, these in vitro generated DCs are capable of antigen uptake(206).  The 
lymphoid lineage shows characteristics that distinguish them from myeloid DCs.  
Plasmacytoid DCs (pDCs) can secrete high levels of type I interferon (IFN) and also have an 
important role within the innate immune system(250).  pDCs migrate to the LNs through blood 
and HEV pathways and are comparatively inefficient at taking up exogenous microbes and 
are more adept to presenting viral antigens.  pDCs can be distinguished by their expression of 
CD123(251).  The migration of DCs from peripheral tissues or organs into their respective 
draining LNs is key for the adaptive immune system to respond(206). 
DCs also have the ability to modify their function as they mature.  For example, immature 
DCs have a high capacity for phagocytosis, they can carry out micropinocytosis and express 
surface receptors that mediate endocytosis.  Immature DCs have greater capabilities to 
internalise exogenous reagents compared to mature DCs(252). 
Upon uptake of antigens, DCs undergo a maturation process.  From here, the maturation 
process can be recognised by changing surface expression levels of MHC-I, MHC-II; and the 
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 CD80 and CD86 costimulatory markers(206) and IL-12 is also secreted in larger quantities(253).  
Furthermore, maturation also includes a reduced capacity for antigen uptake and an increase 
in the expression of CCR7 (also referred to as CD197), a chemokine receptor to facilitate 
migration to secondary lymphoid tissue(254, 255).   
Mature DCs become resistant to the immunosuppressive effects of IL-10; a tumour derived 
cytokine(256).  Mature DCs are more potent than their immature counterparts in inducing 
CD8+ cytolytic T-lymphocyte responses in vitro, and they are resistant to the 
immunosuppressive effects of tumour-derived IL-10. 
A variety of immune cells exist in human blood.  Of relevance to this thesis are the common 
myeloid progenitor and common lymphoid progenitor which both arise from multi-potential 
haematopoietic stem cells.  One of the lineages descending from the common myeloid 
progenitor cell line, is the myeloblast.  The myeloblast can differentiate into basophils, 
neutrophils and eosinophils (collectively known as granulocytes) and also monocytes.  These 
monocytes can further differentiate into either macrophages or myeloid DCs.  The common 
lymphoid progenitor can differentiate into lymphocytes and lymphoid DCs.  These collective 
lymphocytes are comprised of small lymphocytes (B cell and T cell lymphocytes) and large 
granular lymphocytes (natural killer cells)(257). 
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Figure 5.1:  Schematic representation of haematopoiesis of human blood cells.  This 
representation does not depict the complete haematopoiesis of human blood cells, but rather 
only the summary of that relevant to the experimental processes of this thesis(258, 259). 
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 To identify and quantitate the relevant sub-sets of immune cells, multi-colour assays were 
performed; using a variety of fluorophores and flow cytometry.  Collectively, DCs are 
phenotypically defined as Lin- HLA-DR+ cells; with a heterogenous DC population mix.  The 
strategy behind a multi-colour assay is to identify lymphoid DCs which are CD123+ and 
myeloid DCs which are CD11c+.  As   CD123+ and CD11c+ are not specific to only DCs, 
additional markers are used; HLA-DR and Lineage Cocktail 1 which combines CD3, CD14, 
CD16, CD19, CD20 and CD56(260). 
CD11c is also expressed by monocytes, as well as DCs; and CD123 is expressed by 
monocytes, granulocytes and lymphocytes, in addition to DC(260)s.  Both DCs types express 
high levels of HLA-DR and low levels of markers for monocytes, lymphocytes and large 
granular lymphocytes (natural killer cells) all of which are contained within the Lineage 
Cocktail 1.  Basophils can be identified by the lack of HLA-DR expression(260).  Hence, the 
relevant cell population sub-sets within a heterogeneous population of human PBMC 
monocyte derived DC preparations, can be identified by multi-colour assay with flow 
cytometry.  In this case, the Lineage Cocktail 1 marker used the FITC fluorophore; and 
therefore, the IONPs used were tagged with R-PE as outlined in Section 2.9.5.  CD123 used 
the APC fluorophore, while HLA-DR used APC-CY™ and the fluorophore for CD11c was 
PE-CY™7. 
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 Supernatant from dose uptake and time course were collected and stored at -80 oC for later 
experimental requirements.  This supernantant was used with a Cytometric Bead Array (CBA) 
Inflammation Kit to identify the levels of cytokine secretion.  A proprietary Cytometric Bead 
Array (CBA) Human Inflammation Kit can be used to test for the six most common cytokines 
that are known to be involved with an immune response to stimulus, the maturation process 
and migratory chemotaxis.  These following cytokines are protein molecules, secreted by DCs 
and used for signalling cellular activities, can be identified and quantified with a CBA assay 
(human);IL-8, IL-1β,  IL-6, IL-10, TNF and IL-12p70.  The IL-6, IL-10, TNF and IL-12p70 
cytokines were described in Section 4.1 and that content is applicable here.   
IL-8 
Macrophages are known to secrete the IL-8 chemokine cytokine in in response to 
inflammation(261).  The IL-8 cytokine is also known to induce chemotaxis in target cells, 
triggering migration to infection sites where the target cells then perform phagocytic 
activity(262).  In oncology patients, IL-8 plays a role in promoting angiogenesis for tumour 
expansion and metastases(263). 
IL-1β (also known as Catabolin) 
The IL-1β cytokine is produced by monocytes and activated macrophages(264) and is engaged 
with cell proliferation(265), differentiation(266) and apoptosis(267); as well as being a mediator of 
inflammatory response(264).   
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 To image DCs, in vivo, there are currently two main approaches taken by researchers.  The 
first is to observe the priming kinetics of DC interactions with T-cell lymphocytes within 
lymph nodes; and the second is imaging of antigen activated DCs for therapeutic applications, 
from their site of administration to their eventual destination, from a whole body or 
anatomical region perspective. 
The imaging of DC and T cell interactions within the lymph node micro-environment is 
commonly performed with two-photon microscopy in small animals, in vivo(206, 268, 269).  The 
second approach has been imaged using either nuclear medicine techniques or with MRI – in 
both animals and in human trials(268).  For humans, the alternative of non-ionising and high 
imaging sensitivity provided by MRI, affords safe, non-invasive imaging, along with ongoing 
data acquisition being permissible.  With current technology, Nuclear Medicine imaging 
techniques such as PET and SPECT provide the highest contrast resolution available, whereas 
MRI can deliver superior spatial resolution.  Current literature suggests that both nuclear 
medicine imaging techniques and MRI are not routinely being used during DC-based 
immunotherapy to image migration of DCs.  The main reason for limited nuclear medicine 
imaging is it currently cannot overcome the major disadvantage of the need for a radio-
isotope with a sufficient half-life that will allow periodic imaging of DCs for several days(206).  
Another disadvantage is that the spatial resolution offered by either SPECT or PET(270) cannot 
compete with two-photon microscopy and MRI.  Two of the most common and applicable 
radio-isoptes have short half-lives, which makes then capable for observing migrating DCs for 
less than on day; rather than the much needed two days(206).  Imaging agents; such as 18F, only 
has a half-life of 110 minutes.  Also, 18F can become unstable, in vivo, and provide 
contaminated signal detection from the kidneys and urinary bladder; thus making the 
interpretation of image data difficult(206). 
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 In addition to the highest spatial resolution possible from current non-invasive imaging 
modalities, using MRI to image DC migration, also allows capabilities for serial or dynamic 
imaging along with anatomical detail.  MRI is currently in wide-spread clinical use, and 
therefore, any successful imaging of DC migration at trial stages, can easily become 
translational(205, 206, 271).  Iron oxide nanoparticles, with their T2 MRI image contrast 
capabilities, presently offers the most sensitive and practicable imaging agent, in both animal 
and human applications(206).  For the purpose of in vitro loading of DCs and then imaging 
their migration in vivo, the innovative use of IONPs together with MRI have not been fully 
realised.  The current benefits, with translation possibilities, are that at certain dosages, IONPs 
can be non-toxic to DCs; once IONPs are internalised by DCs, they are compartmentalised in 
vesicles(205), and as IONPs become concentrated in these vesicles, they can induce a quite 
large local magnetic field and thus generate a relatively high image contrast with MRI(206); 
and this, in turn, can provide detectable ease against lymph node tissue.  The in vitro 
preparation of DCs with IONPs can take advantage of the high phagocytic capacity of 
immature DCs(272). 
When PET/MRI becomes available in Australia, radio-labelled IONPs may offer a new 
avenue for imaging DC migration which can merge the advantages of PET (high image 
contrast) and MRI (high spatial resolution) and overcoming PET imaging’s individual 
disadvantages.  This author envisages that 68Ga can be detected with PET and once there is no 
detectable gamma-radiation, then MRI can be used to continue serial imaging by detecting the 
IONPs. 
For the experiments pertaining to this chapter, monocyte derived DCs were generated from 
adherent peripheral blood mono-nuclear cells, from donor blood, as described in Section 
2.6.1.  This now seems to be the preferred starting point for commencing cell-mediated 
immunotherapy with DCs(246, 249, 257).  In this approach, DCs are isolated from cancer patients 
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 and incubated with exogenous and specific tumour antigens in vitro, and the antigen loaded 
DCs are then administered to the patient to enhance the immune response against tumour 
targets.  DCs can be isolated from human peripheral blood monocytes. The relative number of 
DCs in vivo is low compared with most other cell lineages; thus their extraction in sufficient 
numbers for clinical use or for research can be difficult(206). Therefore, the majority of 
applications currently rely on in vitro generation of DCs from peripheral blood monocytes(206, 
270, 273). Given their purity and abundant yield, these are the most commonly used precursor 
cells for generating human DCs in clinical study. Monocytes are induced to generate CD14– 
CD11c+ DCs after treatment with GM-CSF and IL-4(20, 273), have characteristics similar to 
immature DCs through their low expression of CD83, CD80, CD86 and MHC-II(20, 206) and 
display efficient antigen-uptake capability(206, 274). 
In addition to tracking DCs, nanoparticle-based MRI can also be used for tracking other 
relevant cells such as stem cells, progenitor cells, monocytes, and granulocytes(20, 206, 268, 270, 
275).  MoDCs can be labelled and then matured, in vitro.  Haematopoietic precursor cells from 
murine bone marrow or monocytes from human peripheral blood, when treated with GM-CSF 
and IL-4, can differentiate into iDCs.  These cells can then be incubated with imaging agents 
such as iron oxide nanoparticles (MRI) or per-fluorocarbon emulsions, 19F (PET) before 
further differentiation to mature DC (maturation cytokines can be used)(20).  The translational 
application of DC-based therapy can be supported greatly through molecular imaging. New 
discoveries on DC migration and behaviour in vivo will lead to new advances in the treatment 
of a broad range of cancers. 
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The specific aims of this chapter were: 
1. To determine the dose dependent uptake of R-PE tagged IONPs by human MoDC, in 
vitro. 
2. To determine the dose dependent uptake and time dependent uptake of FITC tagged 
IONPs by human MoDC, in vitro. 
3. To determine the dose dependent uptake of R-PE tagged IONPs by human peripheral 
blood DC subsets, in vitro.    
4. To determine the dose dependent uptake of R-PE tagged IONPs and also FITC tagged 
IONPs by human peripheral blood cells (PBMC, lymphocytes and 
granulocytes/monocytes), in vitro.   
5. To determine cytokine release by human MoDC after incubation with tagged IONPs, 
in vitro.  
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 5.2  Results 
 
5.2.1 Dose dependent uptake of human monocyte CD14+ cells and CD11c+ 
myeloid DCs, in vitro 
 
Cells were prepared as described in Section 2.6.1 and the in vitro experiments established as 
per Section 2.6.5 and 2.6.6.  A cellular staining technique was used to prepare cells for flow 
cytometry detection, identification and analysis. 
 
5.2.1.1 Dose dependent uptake of human monocyte CD14+ cells and 
CD11c+ myeloid DCs, with R-PE tagged IONPs, in vitro 
 
The uptake of R-PE tagged IONPs by CD14+ cells (Figure 5.2A) showed no statistical 
significance between any of the concentration of nanoparticles tested, meaning that CD14+ 
cells internalised the tested concentrations of IONPs equally.  CD11c+ were also capable of 
internalising the R-PE tagged IONPs to the same extent, statistically, as CD14+ cells, at each 
concentration dose (treatment condition) tested (Figure 5.3); however, there was statistical 
significance between the higher concentrations (200 µg/ml and 100 µg/ml) and the lower 
concentrations (20 µg/ml and 5 µg/ml) tested within the CD11c+ in vitro experimental group 
alone.  The statistical difference is due to the CD11c+ cell populations means having a lesser 
SEM (except the 20 µg/ml CD11c+ population) compared with the CD14+ cells; indicating 
that the CD11c+ cells could be more efficient or consistent at internalising the R-PE tagged 
IONPs (compared with CD14+ cells).  
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Figure 5.2: Dose dependent uptake of human monocyte CD14+ cells and CD11c+ 
myeloid DCs with R-PE tagged IONPs, in vitro.  Dose dependent uptake studies were 
performed with cultured human Mo-DC.  CD14 is expressed by DCs and also monocytes that 
are capable of differentiating into DCs.  CD11c is expressed by human DCs but also by 
monocytes.  CD14+ cells (Figure A, Figure B) and CD11c+ myeloid DCs (Figure C, Figure 
D) positive for R-PE uptake (tagged to IONP) after being incubated for 24 hours with varying 
concentrations of IONPs, were identified by flow cytometry, n=3.  One-way ANOVA with 
the Tukey’s multiple comparison test (comparing each treated condition with other treated 
conditions) and the Dunnett’s text comparing the control mean with the treatment condition 
means were used to statistically analyse the data.  Where no asterisks are displayed, no 
statistical significance was found. 
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Figure 5.3: Comparison of human monocyte CD14+ and CD11c+ myeloid DC 
population by dose dependent uptake performed with R-PE tagged IONPs, in vitro.  
Dose dependent uptake studies were performed with cultured human Mo-DC.  CD14 is 
expressed by DCs and also monocytes that are capable of differentiating into DCs.  CD11c is 
expressed by human DCs but also by monocytes.  Both CD14+ and CD11c+ myeloid DCs 
positive for R-PE uptake (tagged to IONP) after being incubated for 24 hours with varying 
concentrations of IONPs, were identified by flow cytometry, n=3.  Two-way ANOVA was 
used with the Tukey’s multiple comparison test, to statistically analyse the data.  Where no 
asterisks are displayed, no statistical significance was found. 
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5.2.1.2 Dose dependent uptake of human monocyte CD14+ cells and 
CD11c+ myeloid DCs, with FITC tagged IONPs, in vitro 
 
CD14+ cells demonstrated almost maximum uptake of FITC tagged IONPs across all dose 
concentrations tested, thus displaying efficient internalisation of these nanoparticles.  CD11c+ 
cells demonstrated a classic dose dependent uptake pattern with a significant statistical 
difference between each adjacent treatment condition (except between 50 µg/ml and 20 
µg/ml).  When the uptake of nanoparticles by these two cell types are compared (Figure 5.5), 
the maximum (or near maximum) possible uptake shown by CD14+ cells and the dose 
dependent uptake of CD11c+ cells, are together responsible for the statistical differences seen 
at 50 µg/ml, 20 µg/ml and 5 µg/ml.  
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Figure 5.4: Dose dependent uptake of human CD14+ cells and CD11c+ cells with FITC 
tagged IONPs, in vitro.  Dose dependent uptake studies were performed with cultured human 
Mo-DC.  CD14 is expressed by DCs and also monocytes that are capable of differentiating 
into DCs.  CD11c is expressed by human DCs but also by monocytes.  Both CD14+ cells 
(Figure A, Figure B) and CD11c+ myeloid DCs (Figure C, Figure D) positive for FITC 
uptake (tagged to IONP) after being incubated for 24 hours with varying concentrations of 
IONPs, were identified by flow cytometry, n=3.  One-way ANOVA was used with the 
Tukey’s multiple comparison test (comparing each treated condition with other treated 
conditions) and the Dunnett’s text comparing the control mean with the treatment condition 
means to statistically analyse the data.  Where no asterisks are displayed, no statistical 
significance was found.   
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Figure 5.5: Comparison of human monocyte CD14+ and CD11c+ myeloid DC 
population by dose dependent uptake performed with IONPs tagged with FITC.  Dose 
dependent uptake studies were performed with cultured human Mo-DC.  CD14 is expressed 
by DCs and also monocytes that are capable of differentiating into DCs.  CD11c is expressed 
by human DCs but also by monocytes.  Both CD14+ and CD11c+ myeloid DCs positive for 
FITC uptake (tagged to IONP) after being incubated for 24 hours with varying concentrations 
of IONPs, were identified by flow cytometry, n=3.  Two-way ANOVA was used with the 
Tukey’s multiple comparison test to statistically analyse the data.   
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5.2.2 Time dependent uptake of human monocyte CD14+ cells and CD11c+ 
myeloid DCs, in vitro 
 
Cells were prepared as described in Section 2.6.1 and the in vitro experiments established as 
stated in Section 2.6.7.  A cellular staining technique was used to prepare cells for flow 
cytometry detection, identification and analysis. 
 
5.2.2.1 Time dependent uptake of human monocyte CD14+ cells and 
CD11c+ myeloid DCs, with FITC tagged IONPs, in vitro    
 
Both CD14+ cells (Figure 5.6A) and CD11c+ cells (Figure 5.6B) demonstrated maximum 
uptake of FITC tagged IONPs, indicating that maximum uptake was identified at 1 hour 
incubation; being the shortest incubation time tested.  Comparing the uptake of both cell types 
(Figure 5.7), CD11c+ cells required at least 6 hours incubation time to reach maximum 
(100%) uptake, equivalent to CD14+ cells.   
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Figure 5.6: Time dependent uptake of human CD14+ cells and CD11c+ cells with FITC 
tagged IONPs.  Time dependent uptake studies were performed with cultured human Mo-
DCs, incubated with 200µg/ml of FITC tagged IONPs, over varying time periods.  CD14 is 
expressed by DCs and also monocytes that are capable of differentiating into DCs.  CD11c is 
expressed by human DCs but also by monocytes.  Both CD14+ (Figure A, Figure B) and 
CD11c+ myeloid DCs (Figure C, Figure D) positive for FITC uptake (tagged to IONP), were 
identified by flow cytometry, n=3.  One-way ANOVA with the Tukey’s multiple comparison 
test (comparing each treated condition with other treated conditions) and the Dunnett’s text 
comparing the control mean with the treatment condition means was used to statistically 
analyse the data.  Where no asterisks are displayed, no statistical significance was found. 
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Figure 5.7: Comparison of human monocyte CD14+ and CD11c+ myeloid DC 
population by time dependent uptake performed with IONPs tagged with FITC.  Time 
dependent uptake studies were performed with human Mo-DC.  CD14 is expressed by DCs 
and also monocytes that are capable of differentiating into DCs.  CD11c is expressed by 
human DCs but also by monocytes.  Both CD14+ and CD11c+ myeloid DCs positive for 
FITC uptake (tagged to IONP) after being incubated for 24 hours with varying concentrations 
of IONPs, were identified by flow cytometry.  This was performed three times, n=3.  Two-
way ANOVA was used to statistically analyse the data with the Tukey’s multiple comparison 
test.   
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5.2.3 Dose dependent uptake of R-PE tagged IONPs by human peripheral 
blood DCs, in vitro 
 
Cells were prepared as described in Section 2.6.1 and the in vitro experiments established as 
specified in Section 2.6.9.  A cellular staining technique was used to prepare cells for flow 
cytometry detection, identification and analysis. 
 
5.2.3.1 Dose dependent uptake of R-PE tagged IONPs by human 
peripheral blood DCs; CD123+ plasmacytoid DCs and CD11c+ myeloid 
DCs, in vitro 
 
CD123+ lymphoid DCs demonstrated statistically equivalent capabilities at internalising the 
tested nanoparticles (Figure 5.8A), however, there was a significant statistical difference 
between how these same two nanoparticle concentrations were internalised by CD11c+ 
myeloid cells (Figure 5.8C).  When the uptake of both cell types are compared at each 
individual concentration of nanoparticle tested (Figure 5.9), no statistical significance could 
be identified.   
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Figure 5.8: Dose dependent uptake of human peripheral blood DCs; CD123+ 
plasmacytoid DCs and CD11c+ myeloid DCs, positive for R-PE tagged IONPs, in vitro.  
Dose dependent uptake studies were performed with human peripheral blood DCs.  Both 
CD123+ plasmacytoid DCs (Figure A, Figure B) and CD11c+ myeloid DCs (Figure C, 
Figure D) positive for R-PE uptake (tagged to IONP) after being incubated for 24 hours with 
varying concentrations of IONPs, were identified by flow cytometry, n=5.  One-way ANOVA 
with the Tukey’s multiple comparison test (comparing each treated condition with other 
treated conditions) and the Dunnett’s text comparing the control mean with the treatment 
condition means was used to statistically analyse the data.  Where no asterisks are displayed, 
no statistical significance was found. 
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Figure 5.9: Comparison of dose dependent uptake of human peripheral blood DCs; 
CD123+ plasmacytoid DCs and CD11c+ myeloid DCs, positive for R-PE tagged IONPs.  
Dose dependent uptake studies were performed with human peripheral blood DCs.  Both 
CD123+ plasmacytoid DCs and CD11c+ myeloid DCs positive for R-PE uptake (tagged to 
IONP) after being incubated for 24 hours with varying concentrations of IONPs, were 
identified by flow cytometry, n=5.  Two-way ANOVA was used with the Tukey’s multiple 
comparison test to statistically analyse the data.  Where no asterisks are displayed, no 
statistical significance was found. 
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5.2.4 Dose dependent uptake of FITC tagged IONPs and R-PE tagged 
IONPs by PBMCs, lymphocytes and granulocytes/monocytes, in vitro 
 
Cells were prepared and the in vitro experiments established as specified in Section 2.6.9.  A 
cellular staining technique was used to prepare cells for flow cytometry detection, 
identification and analysis.  To determine if other cell types; known to have a role in 
immunity and thus broadening the potential for immunotherapy or cMRI with IONPs; could 
be identified from multi-coloured flow cytometry assay. 
 
5.2.4.1 Dose dependent uptake of FITC tagged IONPs and R-PE 
tagged IONPs by PBMCs, in vitro 
 
There was no statistical difference between the internalisation of the FITC tagged IONPs at 
the two concentrations tested (Figure 5.10A).  Like-wise can be stated with the same cell 
ctype and R-PE tagged IONPs (Figure 5.10C).  When the uptake of both differently tagged 
IONPs by PBMCs are compared (Figure 5.11) at the same two concentrations, no statistical 
difference could be identified; thus, the PBMCs performed equally, in vitro, and this was in 
keeping with their known phagocytic capabilities.  
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Figure 5.10: Dose dependent uptake of IONPs by human PBMC, in vitro.  Whole PBMCs 
were incubated with no, 200 µg/ml and 100 µg/ml of FITC tagged IONPs (Figure A, Figure 
B) and R-PE tagged IONPs (Figure C, Figure D) separately for 24 hours and fluorescence 
was determined by flow cytometry, n=5.  % uptake and fold increase in mean fluorescence 
intensity were determined for all experimental conditions.  One-way ANOVA with the 
Tukey’s multiple comparison test (comparing each treated condition with other treated 
conditions) and the Dunnett’s text comparing the control mean with the treatment condition 
means was used to statistically analyse the data.  Where no asterisks are displayed, no 
statistical significance was found. 
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Figure 5.11: Comparison of dose dependent uptake of tagged IONPs by human PBMCs, 
in vitro.  Dose dependent uptake studies were performed with whole PBMCs and assessed 
with flow cytometry following 24 hours incubation with varying concentrations of R-PE and 
FITC tagged IONPs, separately; n=5.  Two-way ANOVA was used to statistically analyse the 
data with the Tukey’s multiple comparison test.  Where no asterisks are displayed, no 
statistical significance was found. 
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5.2.4.2 Dose dependent uptake of FITC tagged IONPs and R-PE 
tagged IONPs by lymphocytes, in vitro 
 
The lymphocytes demonstrated no statistical difference in the uptake of FITC tagged IONPs 
at the two concentrations tested (Figure 5.12A) and the same occurred with R-PE tagged 
IONPs (Figure 5.12C).  When the uptake of both nanoparticle varieties are compared at each 
treatment condition (Figure 5.13), there was no statistical difference; denoting that 
lymphocytes were able to internalise both nanoparticles similarly and could be identified as 
lymphocytes with flow cytometry. 
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Figure 5.12: Dose dependent uptake of IONPs by human lymphocytes, in vitro.  Whole 
PBMCs were incubated with no, 200 µg/ml and 100 µg/ml of FITC tagged IONPs (Figure A, 
Figure B) and R-PE tagged IONPs (Figure C, Figure D), separately, for 24 hours and 
fluorescence was determined by flow cytometry, n=5.  Lymphocytes were identified using a 
staining technique with flow cytometery and % uptake and fold increase in mean fluorescence 
intensity were determined for all experimental conditions.  One-way ANOVA with the 
Tukey’s multiple comparison test (comparing each treated condition with other treated 
conditions) and the Dunnett’s text comparing the control mean with the treatment condition 
means was used to statistically analyse the data.  Where no asterisks are displayed, no 
statistical significance was found. 
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Figure 5.13: Comparison of dose dependent uptake of IONPs by lymphocytes, in vitro.  
Dose dependent uptake studies were performed with whole PBMCs and human lymphocytes 
were identified and assessed with flow cytometry following 24 hours incubation with varying 
concentrations of R-PE and FITC tagged IONPs, separately; n=5.  Two-way ANOVA was 
used to statistically analyse the data with the Tukey’s multiple comparison test.  Where no 
asterisks are displayed, no statistical significance was found. 
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5.2.4.3 Dose dependent uptake of FITC tagged IONPs and R-PE 
tagged IONPs by granulocytes/monocytes, in vitro 
 
The granulocytes/monocytes demonstrated no statistical significance in the uptake of FITC 
tagged IONPs at the two concentrations tested (Figure 5.14A) and the same occurred with R-
PE tagged IONPs (Figure 5.14C).  Interestingly, when the uptake of both nanoparticle 
varieties are compared at each treatment condition (Figure 5.15), the granulocytes/monocytes 
responded differently, in vitro.  Granulocytes/monocytes could internalise greater quantities 
of the R-PE tagged IONP variety, demonstrating an extremely significant statistical difference 
between both nanoparticle varieties at each concentration tested, in vitro.   
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Figure 5.14: Dose dependent uptake of IONPs by human granulocytes/monocytes, in 
vitro.  Whole PBMCs were incubated with no, 200 µg/ml and 100 µg/ml of FITC tagged 
IONPs (Figure A, Figure B) and R-PE tagged IONPs (Figure C, Figure D), separately, for 
24 hours and fluorescence was determined by flow cytometry, n=5.  Granulocytes/monocytes 
were identified using a staining technique with flow cytometery and % uptake and fold 
increase in mean fluorescence intensity were determined for all experimental conditions.  
One-way ANOVA with the Tukey’s multiple comparison test (comparing each treated 
condition with other treated conditions) and the Dunnett’s text comparing the control mean 
with the treatment condition means was used to statistically analyse the data.  Where no 
asterisks are displayed, no statistical significance was found. 
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Figure 5.15: Comparison of dose dependent uptake of IONPs by human 
granulocytes/monocytes with, in vitro.   Dose dependent uptake studies were performed 
with whole PBMCs and human granulocytes/monocytes were identified and assessed with 
flow cytometry following 24 hours incubation with varying concentrations of IONPs, n=5.  
Two-way ANOVA was used to statistically analyse the data with the Tukey’s multiple 
comparison test.  Where no asterisks are displayed, no statistical significance was found. 
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5.2.5 Human cytokine analysis of supernatants from dose dependent and 
time dependent studies with PBMC and FITC tagged IONPs, in vitro                 
 
To determine and identify if FITC tagged IONPs trigger an inflammatory response in 
PBMCs, in vitro, the supernatant from dose dependent and time dependent studies were tested 
with a Cytometric Bead Array kit that could test six cytokines commonly involved in an 
inflammatory and immune response.   
With the supernatant from the dose dependent studies; in Figures 5.17B to F inclusive, there 
was no statistical difference between the treated conditions and the control condition; and also 
no statistical difference between the treated conditions themselves except for Figure 5.17B 
(cytokine TNF), where there was a significant statistical difference between the 200 µg/ml 
and 5 µg/ml treatment groups.  Figure 5.15 demonstrated that the secretion of the IL-12p70 
cytokine is almost dose dependent, under the conditions tested; thus, the cytokine release of 
IL-12p70 increased with increased concentration of IONPs. 
With the supernatant from the dose dependent studies; Figures 5.18B to F inclusive revealed 
that there was no statistical difference between the treated conditions and the control 
conditions; and also no statistical difference between the treated conditions themselves except 
for Figure 5.17E (cytokine IL-1β), where a significant statistical difference between the 
treatment groups at 6 hours and 1 hour was identified.   
Figure 5.18A (cytokine IL-12p70) identified a significant statistical difference between the 
control mean and the 24 hours incubation mean; the control mean and the 4 hours incubation 
mean; and the control mean and the 1 hour incubation time mean.  There was very significant 
statistical difference between the control mean and the 18 hours incubation time mean as well 
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 as the control mean and the 6 hour time point mean.  There was no statistical significance 
between the treatment groups at any of the time points tested, implying that the secretion level 
of cytokine IL-12p70 was the same from 1 hour to 24 hour incubation times.  The level of IL-
12p70 release was greater than the level secreted by the same cell types under control 
conditions.    
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 Figure 5.16: Cytokine secretion by human PBMCs after incubation with FITC tagged 
IONPs, from dose dependent experiments, in vitro.  Human PBMCs were incubated with 
varying concentrations of FITC tagged IONPs for 24 hours, in vitro, and supernatants were 
collected for cytokine analysis by flow cytometry using cytometric bead analysis, n=3.  One-
way ANOVA was used to statistically analyse the data with the Tukey’s multiple comparison 
test comparing treatment groups with each other and the Dunnett’s test was used to compare 
the control group with the treatment groups.  Where no asterisks are displayed, no statistical 
significance was found. 
C D 
E F 
A B 
257 
 
  
Figure 5.17:  Cytokine secretion by human PBMCs after incubation with FITC tagged 
IONPs, from time dependent uptake experiments, in vitro.  Human PBMCs were 
incubated with 200 µg/ml of FITC tagged IONPs at various time points, in vitro, and 
supernatants were collected for cytokine analysis by flow cytometry using cytometric bead 
analysis, n=3.  One-way ANOVA was used to statistically analyse the data with the Tukey’s 
multiple comparison test comparing treatment groups with each other and the Dunnett’s test 
was used to compare the control group with the treatment groups.  Where no asterisks are 
displayed, no statistical significance was found. 
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5.3 Discussion 
 
Cellular imaging can be defined as the visualisation of specific cells in a living organism.  
Delivery of biodegradable IONP to APCs, especially DCs, has potential for immunotherapy.  
For cellular therapies to be successful, specific cells would need to be delivered to their 
intended destination.  Uniquely; a cell therapy approach to stimulating an immune response 
would require DCs migrate to the regional lymph nodes of interest.  Extending from this, 
researchers have used MRI to image the migration path of magnetically labelled DCs, in 
humans.  Not only can MRI detect the magnetically labelled DCs, image their migration path, 
but also demonstrate all this in relation to a patient’s own anatomy in multiple imaging 
planes.  In one study(276), autologous DCs were labelled with a clinically available 
superparamagnetic iron oxide formulation or the radio-active tracer 111In-oxine and were co-
injected into the lymph nodes using ultrasound imaging guidance in melanoma patients.  MRI 
demonstrated superior assessment of the DC migration path (inter- and intra-nodal cell 
migration patterns) compared with scintigraphy.  MRI cell tracking using iron oxides appears 
safe and well suited to monitor cellular therapy in humans.  Such an approach takes advantage 
of the high phagocytic capabilities of immature dendritic cells.  Thus, immature DCs have 
been used by cell therapy researchers together with FDA approved nanoparticle preparations 
and the labelling occurred with high efficiency without compromising iDC function.   
Figure 5.2 presented results showing the percentage of cells that internalised R-PE tagged 
IONPs, as quantitated with flow cytometry, by cells that were CD14+ (Figure 5.2A) and cells 
that were CD11c+ (Figure 5.2C).  In relation to the literature, it is noted that human DCs and 
monocytes (capable of differentiating into DCs) are known to be CD14+ and human myeloid 
dendritic cells are CD11c+, but also, approximately, 90 % of monocytes circulating in the 
bloodstream are CD11c+(277).  Human myeloid DCs are negative for CD14 and their 
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 proportion in circulating human blood has been recorded to be approximately 5 % of the 
PBMC population; and that the majority of circulating monocytes (CD14+) also demonstrate 
higher levels of phagocytosis but lower cytokine secretion(257).  Statistical analysis of Figure 
5.2A identified no statistical significance (ns, P ≥ 0.05) between treatment conditions and 
extremely significant (*** P = 0.0001 to 0.001 and **** P < 0.001) statistical difference 
between the control condition and any of the treatment conditions.  These imply that CD14+ 
monocytes have the capability to internalise the varying concentrations of R-PE tagged 
IONPs as tested, in vitro, equally well.  Also, the level or quantity of R-PE tagged IONPs 
internalised by these same CD14+ monocytes in the treatment groups was, compared to the 
control CD14+ monocytes, extremely significant; thus confirming their high level of 
phagocytic activity, consistent with the available literature(275).  Results of dose dependent 
experiments with CD11c+ DCs and R-PE tagged IONPs following 24 hours incubation was 
presented in Figure 5.2C and statistically analysed.  There was statistical significance (*, P = 
0.01 to 0.05) between the CD11c+ DCs incubated with 200 µg/ml of R-PE tagged IONPs and 
20 µg/ml and also with 5 µg/ml concentrations.  There was also statistical significance (*, P = 
0.01 to 0.05) between the CD11c+ DCs incubated with 100 µg/ml of R-PE tagged IONPs and 
5 µg/ml concentration.  Figure 5.3 compares the percentage dose dependant uptake of cells 
that are CD14+ and CD11c+, side by side, and there is no statistical significance between the 
CD14+ monocytes and CD11c+ myeloid DCs at each corresponding concentration of R-PE 
tagged IONP as well as under control conditions, demonstrating that both are equally capable 
of internalising the tested nanoparticles under the experimental conditions tested.   
The same experimented was repeated with FITC tagged IONPs and results presented in 
Figures 5.4 and 5.5.  Figure 5.4C demonstrated a classic dose dependent uptake effect with 
significant statistical significance between adjacent treatment conditions (except for between 
50 µg/ml and 20 µg/ml).  Significant statistical (*, P = 0.01 to 0.05) difference was recorded 
between CD11c+ myeloid DCs under control condition compared to both the 20 µg/ml and 50 
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 µg/ml treatment conditions and a very significant (**, P = 0.001 to 0.01) statistical 
significance was noted between CD11c+ cells in the control state and CD11c+ cells incubated 
with 100 µg/ml of FITC tagged IONP and also control conditions and 200 µg/ml 
concentration.  Results provided in Figure 5.5 demonstrate that all CD14+ cells were healthy, 
viable and highly effective at internalising the FITC tagged IONP (compared to the CD11c+ 
cells) and thus, consistent with published literature(275).      
Time dependent uptake experiments were also performed with human CD14+ monocytes and 
human CD11c+ dendritic cells, together with FITC tagged IONPs, and results presented in 
Figure 5.6.   Of the time points tested, together with statistical analysis, maximum uptake of 
FITC tagged IONP occurred by the one hour incubation time point for both CD14+ 
monocytes and CD11c+ DCs.  Therefore, statistically, there was no additional advantage 
gained in extending the incubation time to 24 hours; for each cell type.  Figure 5.7 compared 
the time dependent uptake of both cell types.  It was noted here that there was no statistical 
significance between the control conditions, 24 hour and 18 hour time points.  There was, 
however, a significant (*, P = 0.01 to 0.05) statistical difference between the CD14+ 
monocytes and the CD11c+ DCs at the 6 hour time point and also at 4 hours incubation time.  
The greatest statistical significance (***, P = 0.0001 to 0.001) between these two cell types 
occurred at the one hour time point, thus indicating that CD14+ monocytes can perform 
phagocytosis of the tested nanoparticles more efficiently compared to CD11c+ DCs over the 
first 6 hours of incubation, with the greatest efficiency being demonstrated at the tested one 
hour time point; meaning thatCD11c+ cells required at least 6 hours incubation time to 
achieve maximum nanoparticle uptake equivalent to CD14+ cells.   
 Human peripheral blood contains CD123+ lymphoid DCs and these are also considered to be 
CD11c-(247).  CD11c+ DCs are not only present in human blood, but myeloid CD11c+ DCs 
can also be found in peripheral lymphoid tissue and germinal centres(260).  Such differences in 
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 DC phenotype and their localisation in lymphoid organs had led researchers to suggest that 
distinct and different functional activities for CD123+ and CD11c+ DCs(198, 278).   
Figure 5.8 presented results showing the percentage of cells that internalised R-PE tagged 
IONPs in dose dependent experiments, as quantitated with flow cytometry, by cells that were 
CD123+ (Figure 5.8A) and cells that were CD11c+ (Figure 5.8C).  The two highest 
concentrations of IONPs previously used in dose uptake studies were tested, 200 µg/ml and 
100 µg/ml.  With Figure 5.8A, statistical assessment revealed no statistical significance in 
uptake between these two concentrations of R-PE tagged IONPs for CD123+ lymphoid DCs.  
There was significant (*, P = 0.01 to 0.05) statistical significance between the CD123+ cells 
in the control condition and those that internalised nanoparticles in the 200 µg/ml 
concentration treatment.  There was no statistical significance between CD123+ cells in the 
control group and those incubated with 100 µg/ml.  Statistical evaluation of Figure 5.8C, 
myeloid CD11c+ cells, showed significance (*, P = 0.01 to 0.05) statistical difference in the 
uptake of R-PE tagged IONPs cells incubated with 200 µg/ml and 100 µg/ml of nanoparticles.  
There was also significant (*, P = 0.01 to 0.05) statistical significance between the CD11c+ 
cells in the control condition and those that internalised nanoparticles in both the 200 µg/ml 
and 100 µg/ml concentration treatments.  Figure 5.9 compared the percentage up of 
nanoparticles by both CD123+ and CD11c+ alongside each other at each treatment condition 
as well as under control conditions.  Statistical analysis demonstrated no statistical difference 
between CD123+ and CD11c+ cells under these tested conditions.  
Apart from DCs, other cells that have variable roles in immune responses and processes were 
assessed with both FITC tagged IONPs and R-PE tagged IONPs and results presented in 
Figures 5.10 to 5.15 inclusive.  The cells experimented with were PBMCs, Lymphocytes and 
Granulocytes/Monocytes.  With PBMCs, statistical evaluation of the treatment conditions in 
Figures 5.10A and 5.10C resulted in no significant (ns, P ≥ 0.05) difference when dose 
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 depended studies were conducted with either FITC tagged IONPs or R-PE tagged IONPs.  
When the PBMCs in the control condition are statistically compared with those incubated 
with nanoparticles for 24 hours, it is found that there was a very significant (**, P = 0.001 to 
0.01) statistical difference between PBMC control cells and those treated with FITC tagged 
IONPs and there was an extremely significant (***, P = 0.0001 to 0.001) statistical difference 
between control PBMCs and those treated with R-PE tagged IONPs.  When both of these 
projects were compared alongside each other, Figure 5.11, it was found that there were no 
statistical significance between how PBMCs behaved when incubated with either FITC 
tagged IONPs or R-PE tagged IONPs. 
Results of dose dependent uptake studies with lymphocytes were presented in 5.12 and 5.13.  
Statistical evaluation of the treatment conditions in Figures 5.12A and 5.12C resulted in no 
significant (ns) difference when dose depended studies were conducted with either FITC 
tagged IONPs or R-PE tagged IONPs.  When the lymphocytes in the control condition are 
statistically compared with those incubated with nanoparticles for 24 hours, it was discovered 
that there was a very significant (**, P = 0.001 to 0.01) statistical difference (100 µg/ml) and 
extremely significant (***, P = 0.0001 to 0.001) statistical difference (200 µg/ml) between 
lymphocyte control cells and those incubated with FITC tagged IONPs.  When the same dose 
dependent experiments were performed with R-PE tagged IONPs, there was a significant 
(***, P = 0.0001 to 0.001, with 100 µg/ml) and very significant (****, P < 0.05, with 
200µg/ml) statistical difference between control lymphocytes and those treated with R-PE 
tagged IONPs.  When both of these experimental processes were compared alongside each 
other, Figure 5.13, it was found that there were no statistical significance between how 
lymphocytes behaved when incubated with either FITC tagged IONPs or R-PE tagged IONPs. 
Results of dose dependent uptake studies with granulocytes/monocytes were presented in 5.14 
and 5.15.  Statistical evaluation of the treatment conditions in Figures 5.14A and 5.14C 
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 resulted in no significant (ns, P ≥ 0.05) difference when dose depended studies conducted 
with either FITC tagged IONPs or R-PE tagged IONPs.  When the granulocytes/monocytes in 
the control condition are statistically compared with those incubated with nanoparticles for 24 
hours, was extremely significant (****, P < 0.0001) statistical difference between 
granulocytes/monocytes under control conditions and those incubated with FITC tagged 
IONPs.  The statistical response occurred with control granulocytes/monocytes and those 
treated with R-PE tagged IONPs, (****, P < 0.0001, with both 100 µg/ml and 200µg/ml).  
When both of these experimental processes were compared alongside each other, Figure 5.15, 
it was found that there was extremely significant (****, P < 0.0001) statistical significance 
between how granulocytes/monocytes behaved when incubated with either FITC tagged 
IONPs or R-PE tagged IONPs. 
A proprietary CBA Human Inflammatory Cytokine Kit was used to analyse the supernatant of 
in vitro dose dependent (Figure 5.16) and time dependent (Figure 5.17) studies with human 
immune cells and IONPs.  Statistical analysis demonstrates that for the cytokines graphed in 
Figures 5.18B to F inclusive, there was no statistical difference between the treated conditions 
and the control condition and there was also no statistical difference between the treated 
conditions themselves except for Figure 5.16B (cytokine TNF), where there was a significant 
(*, P = 0.01 to 0.05) statistical difference between the 200 µg/ml and 5 µg/ml treatment 
groups.  With the graph presented in Figure 5.16A (cytokine IL-12p70), there was significant 
(*, P = 0.01 to 0.05) statistical difference between 200 µg/ml and 5 µg/ml, 100 µg/ml and 50 
µg/ml, and 100 µg/ml and 20 µg/ml; and very significant (**, P = 0.001 to 0.01) statistical 
difference between 100 µg/ml and 5 µg/ml treatment groups.  When the control mean was 
compared to the mean of the treatment groups, it was found that there was significant (*, P = 
0.01 to 0.05) statistical difference between control and 200 µg/ml and control and 50 µg/ml 
treatment means; there was very significant (**, P = 0.001 to 0.01) statistical difference 
between control and 100 µg/ml treatment mean.  Figure 5.16 thus demonstrates that the 
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 secretion of the IL-12p70 cytokine is almost dose dependent, under the conditions tested; 
thus, the cytokine release of IL-12p70 increased with increased concentration of IONPs. 
Statistical analysis was also performed for the graphs presented in Figure 5.17, analysis of 
cytokine production from in vitro time dependent studies.  Statistical analysis of Figures 
5.17B to F inclusive revealed that there was no statistical difference between the treated 
conditions and the control conditions and there was also not statistical difference between the 
treated conditions themselves except for Figure 5.17E (cytokine IL-1β), where there was a 
significant (*, P = 0.01 to 0.05) statistical difference between the treatment groups at 6 hours 
and 1 hour.  Statistical analysis of Figure 5.17A (cytokine IL-12p70) identified that there was 
significant (*, P = 0.01 to 0.05) statistical difference between the control mean and the 24 
hours incubation mean, the control mean and the 4 hours incubation mean and also the control 
mean and the 1 hour incubation time mean.  There was very significant (**, P = 0.001 to 0.01) 
statistical difference between the control mean and the 18 hours incubation time mean as well 
as the control mean and the 6 hour time point mean.  There was no statistical significance (ns, 
P ≥ 0.05) between the treatment groups at any of the time points tested, implying that the 
secretion level of cytokine IL-12p70 was the same from 1 hour to 24 hour incubation times.  
The level of IL-12p70 secretion was greater than the level secreted by the same cell types 
under control conditions.    
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 5.4 Conclusion 
 
The aims of this chapter have been addressed and the experimental results lead to the 
following conclusions: 
1. CD14+ and CD11c+ cells were able to be identified and their dose dependent uptake 
of R-PE tagged IONPs showed no statistical difference, following 24 hours incubation, in 
vitro, for the concentration of IONPs tested; thus both CD14+ and CD11c+ cells are both 
equally capable of internalising the tested nanoparticles under the presented experimental 
conditions.   
2. CD14+ and CD11c+ cells were able to be identified and their dose dependent uptake 
of FITC tagged IONPs showed no statistical difference (ns, P ≥ 0.05), following 24 hours 
incubation, in vitro, for the concentration of IONPs tested; thus both CD14+ and CD11c+ 
cells are both equally capable of internalising the tested nanoparticles under the presented 
experimental conditions.  The time dependent in vitro studies demonstrated that maximum 
uptake of FITC tagged IONP occurred by the one hour incubation time point for both CD14+ 
and CD11c+ cells.  Therefore, statistically, there was no additional advantage gained in 
extending the incubation time to 24 hours; for each cell type 
3. CD11c+ and CD123+ cells were identified with the multi-coloured flow cytometry 
assay.  There was no statistical difference (ns, P ≥ 0.05) between the uptake demonstrated by 
CD11c+ and CD123+ cells for the concentrations of IONPs tested under the experimental 
conditions presented. 
4. The use of FITC tagged IONPs and R-PE tagged IONPs were used to identify 
PBMCs, lymphocytes, and granulocytes/monocytes.  PBMCs demonstrated no statistical 
difference (ns, P ≥ 0.05) in the uptake of either FITC tagged IONPs or R-PE tagged IONPs; at 
the concentrations tested and experimental conditions presented, in vitro.  Lymphocytes 
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 demonstrated no statistical difference (ns, P ≥ 0.05) in the uptake of either FITC tagged 
IONPs or R-PE tagged IONPs; at the concentrations tested and experimental conditions 
presented, in vitro.  Granulocytes/monocytes demonstrated extremely significant (****, P < 
0.0001) statistical difference in the uptake of R-PE tagged IONPs compared with FITC tagged 
IONPs; at the concentrations tested and experimental conditions presented, in vitro; the 
uptake of R-PE tagged IONPs was greater than the uptake of FITC tagged IONPs. 
5. Assessment of the supernatant from dose effect studies identified that five (TNF, IL-
10, IL-6, IL-1β, IL-8) of the six cytokines were secreted at levels statistically equivalent to the 
control condition.  The release of the IL-12p70 cytokine is almost dose dependent, under the 
conditions tested; thus, the cytokine secretion of IL-12p70 increased with increased 
concentration of IONPs.  Assessment of the supernatant from time dependent studies 
identified that secretion of five (TNF, IL-10, IL-6, IL-1β, IL-8) of the six cytokines were 
secreted at levels statistically equivalent to the control condition.  The level of IL-12p70 
secretion was greater than the level released by the same cell types under control conditions.  
The secretion level of cytokine IL-12p70 was the same from 1 hour to 24 hour incubation 
times with no statistical difference (ns, P ≥ 0.05) between the incubation times tested across 
the 24 hours.   
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 6.0 Chapter 6 – Application of Iron Oxide Nanoparticles In Vivo 
 
 
6.1 Introduction 
 
As first discussed in Section 1.6, lymphoscintigraphy with gamma emitting radio-active nano-
colloids, together with blue vital dye; are the current clinical approaches used to identify the 
SLN and other draining lymph nodes(279).  This is then followed by surgery where the lymph 
nodes are exposed and a hand held gamma probe is used to identify those emitting gamma 
radiation.  Once these lymph nodes are excised, they are treated to histopathological 
evaluation and based on such findings, any metastasis is staged and the corresponding 
treatment options considered accordingly.  CT also offers a role in imaging lymph nodes and 
staging of cancer; by way of a series of acquisitions; firstly without iodinated intravenous 
contrast media and then with iodinated contrast media (arterial and venous phase aquisitions).  
On CT images, the overall size and shape of lymph nodes are noted and any changes from 
normal (from less than 1 cm diameter and oval shaped to greater than 1 cm diameter and 
circular shaped in cross-section) are related to metastatic spread and staging.  The three major 
concerns regarding CT imaging of lymph nodes are that CT imaging cannot identify the SLN 
itself; it is unable to detect occult metastatic lymph nodes and it is unable to offer any imaging 
detail about the flow of lymph fluid(160).   
99mTc, a nano-sized radio-colloid, was first introduced clinically in the 1960’s for Nuclear 
Medicine imaging(280).  Since then, a variety of radio-tracers have been introduced for 
investigating functional organ processes and pathologies.  Imaging molecular interaction with 
PET is considered to be the most sensitive and specific method available, in vivo, for 
humans(160).  18F-FDG is the most commonly used PET radio-tracer and has been successfully 
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 used to identify the increased glycolytic consumption of cancer cells (compared to normal 
healthy cells)(281).  To date, the clinical application of this potential approach, to identify 
metastatic cells in lymph nodes, has not been realised.  One drawback of using 18F-FDG is 
that it is not a selective radio-tracer as other cells and organs in the body demonstrate active 
glucose uptake rather than just tumour cells(282); such as the heart, brain, kidney and urinary 
bladder.  Another limitation of 18F-FDG and PET is the limited spatial resolution of PET 
images themselves; that is, 18F-FDG will not be able to demonstrate lesions that are less than 
the dimension of the PET images’ spatial resolution(282) which is in the order of 2.3mm(283) 
and is inferior to CT and MRI(284).  There is a need therefore, to improve upon such existing 
techniques.  Iron oxide nanoparticles, together with MRI, can overcome the current 
limitations to lymph node imaging with CT, SPECT and of spatial resolution inherent to PET 
imaging.  Iron oxide nanoparticles offer opportunities for creative solutions and flexibility for 
imaging lymph nodes.  They can be superparamagnetic, meaning that a low concentration can 
be used to generate obvious signal changes on MRI images.  They can be administered 
intravenously and also by conventional interstitial (subcutaneous or intradermal) means; to 
reach the lymph nodes.  Furthermore, they have a safety profile that allows them to be loaded 
into immune cells that are known to migrate to lymph nodes.  MRI also offers the added 
benefit of greater spatial and contrast resolution than CT and further still, MRI does not 
operate with ionising radiation.  68Ga is a positron emitter with a higher energy value than 18F, 
thus providing greater contrast resolution on PET imaging(285).  By having a shorter half-life 
than 67Ga, 68Ga offers the advantages of a quicker uptake time leading to better defined 
biodistribution(286).  The dosimetric advantage of 68Ga also allows easier patient management; 
as upon completion of imaging, there is very little ionising radiation remaining – allowing 
immediate patient discharge and also public safety.  The physical dimensions of iron oxide 
nanoparticles used in this thesis and commercially available isosulfan blue (vital blue dye 
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 used in conjunction with lymphoscintigraphy) are both 20 nm, while 99mTc labelled sulphur 
colloid is approximately 220 nm (287). 
Intravenous administration of iron oxide nanoparticles can migrate to lymph nodes; by 
moving through the vascular wall, into the interstitial environment where they are internalised 
by macrophages and then these macrophages pass through the lymph vessel walls; where they 
then migrate to the lymph node.  As early as 2000, Moore et al, investigated dextran coated 
iron oxide nanoparticles for use in a gliosarcoma rodent model (four rats) and tabulated that 
25 % of the iron content of intravenously administered dose was to be found in lymph nodes; 
compared to 0.11 % accumulation into the brain tumour they were investigating(288).  The 0.11 
% (equating to 0.26 µg of iron relative to the injected dose) was sufficient to be detected on 
MRI with 1.5 T.  All imaging was performed 24 hours after administration.  They also 
successfully radio-labelled these particles with Iodine-125 (125I), however, this radio-isotope 
is a relatively low energy gamma emitter with a half-life of 59 days.  Bumb et al, 
demonstrated that a foot pad injection into nude mice using silica coated iron oxide 
nanoparticles, the draining lymph nodes could be successfully imaged with MRI and also with 
optical imaging(289).  At post mortem, microscope evaluation of H&E and Prussian blue iron 
stains confirmed that the particles migrated passively to the draining lymph nodes without 
macrophage uptake. 
The successful migration of nanoparticles to lymph nodes has also been proven to be size-
dependent.  Zubris et al, assessed polymeric nanoparticles ranging from 50 nm to 120 nm in 
diameter by subcutaneous injection into the breast of Yorkshire pigs(290).  Images were taken 
24 hours later with a Near Infra-Red (NIR) imaging system and 50 nm sized nanoparticles 
were observed as being capable of migrating over a distance of 20 cm from their injection site 
(breast) to the corresponding sentinel lymph node.  This was also confirmed with surgical 
excision of sentinel lymph node, its histological analysis and accompanying microscopy 
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 imaging.  All other larger sized nanoparticles did not demonstrate migration capabilities to the 
corresponding sentinel lymph node.  Zhou et al demonstrated that even smaller particles; 10 
nm core sized iron oxide nanoparticles and 24 nm overall hydrodynamic size when 
conjugated with NIR830 dye; in female nude mice via a foot pad injection were capable of 
migrating to the draining lymph nodes(291).  The MRI (3.0 T) and NIR image findings were 
also confirmed with vital blue dye staining.  Tseng et al used lipid-calcium phosphate 
nanoparticles of two dimensions, 25 nm and 67 nm; both radio-labelled with 111In and 
injected into the tail vein of both C57BL/6 and nude mice(292).  SPECT/CT imaging was 
performed at 2 hours, 4 hours and 24 hours post tail vein injection.  Their results also showed 
a sized dependent effect; the 25 nm sized particles performed better than the 67 nm particles.  
The 25 nm particles convincingly entered the lymphatic system and congregated within 
lymph nodes.  Not only did Tseng et al attribute this success to the physical size of the 
particles, but also their slightly negative surface charge of -20 mV of the PEGlygated lipid 
coating; which allowed long blood circulating times and deep tissue penetration to accumulate 
in lymph nodes.  Tseng et al also stated that the negative charge allowed the particles to travel 
as individual particles and not agglomerate.  At the 2 hour and 4 hour time point, there was 
some activity noted in the liver and spleen (indicating uptake by the RES), however, the 
majority of radio-activity was found to be in the heart and the adjoining major blood vessels 
indicating that the radio-labelled nanoparticles were still in circulation at those time points.  
At 24 hours, radio-activity was noted to accumulate in the lymph nodes throughout the mice 
in a symmetrical arrangement; demonstrating even biodistribution, in vivo. 
The possibility of iron oxide nanoparticles inducing adverse effects on mice, in vivo, need to 
be established.  In general, iron oxide nanoparticles have a very good safety profile, in vivo, 
with patients.  FDA approved preparations are available.  Any immediate adverse effects on 
mice can be ascertained with biochemistry analysis of their blood serum.  Blood serum 
biochemical analytes have been found to vary according to gender and age, even within the 
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 same mouse strain and between three different mice strains.  Mazzaccara et al performed 
biochemical serum analysis on three readily available mice strains, including C57BL/6(293).  
Blood was extracted via the retro-orbital sinus under anaesthesia from the same mice at 1 to 2 
months, then at 3 to 8 months and finally at 9 to 12 months.  Male and female mice were 
used; 15 of each gender.  The mice used for biochemical serum analysis in this thesis were 8 
weeks (2 months) old and the blood sample was also retrieved from the retro-orbital sinus; 
therefore the majority of the findings of Mazzaccara et al can be used as a comparison.  
Further still, the same blood serum analyte has been found to provide different values based 
upon the blood collection method; as published by Schnell et al with an age and gender 
matched study and using the following blood collection methods; retro-orbital sinus, cardiac 
puncture, inferior vena cava and the tail vein(294).   
Histology assessment must also be performed for two very important reasons; but also, it 
must be kept in mind that biochemical evaluations can vary considerably.  Firstly, if any 
changes seen in murine biochemistry are genuine, they can be linked to structural or physical 
changes in the corresponding tissue.  Secondly, histology assessment is performed to identify 
if cellular integrity is maintain or adversely affected.  Generalised structural changes in cell 
architecture are identified with a H&E stain; a Perl stain is used to identify iron content in 
cells (that can presumably be attributed to the iron from the nanoparticles based on size) and a 
PAS reaction stain can be performed to specifically observe the basement membrane of 
kidney tissue samples (as this is the first structure to visually fail and demonstrate signs of 
structural demise)(295). 
Iron oxide nanoparticles have been given consideration as MRI contrast agents since the mid 
1980’s(22).  The first publication documenting use of iron oxide nanoparticles in a clinical trial 
to image lymph nodes in humans, dates to 2003(165).  Eighty male patients (40 in the USA and 
40 in The Netherlands) with diagnosed prostate cancer and undergoing surgical resection of 
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 the prostate gland and/or pelvic lymph nodes; were administered (by intravenous drip infusion 
over a 20 to 30 minute time frame) with 2.6 mg of iron (from iron oxide nanoparticles) per kg 
of body mass.  MRI at 1.5T was performed prior to nanoparticle administration and again 24 
hours post administration.  All MRI images were correlated with H&E histology assessment 
of surgically resected lymph nodes.  The MRI images, taken in isolation, demonstrate 
conclusively that healthy and diseased lymph nodes can be differentiated from one another 
with the addition of iron oxide nanoparticles.  Overall, the proposed technique/method, has 
some practical challenges that may limit its implementation as a routine clinical procedure 
and may not be entirely robust.  These include scanning the patient pre and post nanoparticle 
administration and any associated difficulty in ensuring that both sets of images are equivalent 
or comparable or the patient can be positioned identically.  Also, 24 hours may not be 
sufficient in some patients to have the nanoparticles reach all the relevant lymph nodes; as 
some authors report the need to scan at 36 hours post administration(296).  Importantly, if a 
number of lymph nodes demonstrate signal intensity for metastases, then this method cannot 
identify the actual sentinel lymph node.  This published methodology relies on iron oxide 
nanoparticles permeating from the blood vessels into the interstitium and macrophages 
ingesting them and then the macrophages entering afferent lymphatic vessels leading to 
lymph nodes. 
Iron oxide nanoparticles have also been used without MRI to successfully identify lymph 
nodes.  Winter et al has recently published their results of a prospective pilot study where iron 
oxide nanoparticles were used, without MRI, to identify draining lymph nodes from the 
prostate(297).  In their study, 20 patients with prostate cancer scheduled for open radical retro-
pubic prostatectomy with pelvic lymph node dissection were injected with 2 ml of iron oxide 
nanoparticles (concentration not reported) directly into the prostate; 20 hours (average) before 
surgery.  At surgery, a hand held magnetometer (by SentiMag®, CE certified as a Class IIa 
medical device) was used to identify lymph nodes containing iron oxide nanoparticles, 
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 Sienna+® (60 nm in diameter).  The Sienna+® nanoparticles, together with the SentiMag® 
magnetometer, were used analogous to 99mTc nanoscale radio-colloid and hand held gamma 
ray detector.  The imaging aspect has been removed (with gamma emitting 99mTc radio-
colloid there is lymphoscintigraphy SPECT imaging performed); no MRI was performed with 
the Sienna+® particles.  Upon surgical excision of lymph nodes (containing Sienna+® 
particles and detected with the SentiMag® magnetometer), histology confirmation was 
conducted with H&E and Perl’s Prussian blue staining.  The most important feature offered 
by this methodology is that that no ionising radiation at all is incorporated which is of benefit 
to patients and life-long health care professionals.  The major negative here is the 20 hour 
time frame from injection to detection at surgery, which is significantly greater than current 
clinically available techniques.  No further testing was reported if a shorter duration was 
viable while attaining similar results; as currently nano-sized radio-colloids migrate from 
injection site to the draining lymph node in approximately one hour.   
Ravizzini et al also correctly identify the limitations of current clinical practice of combining 
nano-sized radio-colloid with vital isosulfan blue dye; and offer the possibility of gadolinium 
labelled nanoparticles as an alternative to overcome the known limitations with established 
techniques(287).  The nanoparticle is in effect a carrier of the gadolinium agent.  The possibility 
offered by gadolinium-labelled nanoparticles, following interstitial injection, is that we have 
known MRI imaging pulse sequences that can be readily used with gadolinium and we have 
an established understanding of the image appearance of gadolinium.  Also, there is no 
ionising radiation with MRI.  The nanoparticles presented in Ravizzini et al were also coated 
with materials such as Cy5.5 to allow for Near Infra-Red (NIR) optical imaging of the lymph 
nodes.  This approach also offers functional capabilities so that the sentinel lymph node can 
be recognised.  The major downfall of this technique, as also recognised by the authors 
themselves, Ravizzini et al, is the possibility of gadolinium disassociating from the 
nanoparticle.  The strength of the chemical bond between the gadolinium and the nanoparticle 
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 may well be the key to the success of this technique.  The authors also remind us that NSF is 
an interstitial fibrosis disease (and the gadolinium nanoparticles are injected interstitially).  
In 2008, Heesakkers et al, offered the results of a multi-centre study of 375 consecutive 
patients (over a two year period) with prostate cancer where patients were imaged with iron 
oxide nanoparticles and MRI and these imaging findings were compared to multi-detector CT 
(MDCT)(298).  Patients enrolled in the study had been diagnosed with prostate cancer by tissue 
biopsy and were scheduled for pelvic lymph node dissection.  MDCT was performed with 
oral contrast media and iodinated intravenous contrast media.  MRI imaging was performed 
24 to 36 hours following drip infusion of the iron oxide nanoparticle, Sinerem®.  Their 
findings included that MRI imaging of lymph nodes resulted in higher sensitivity than MDCT 
for detecting lymph node metastases and that their post-test data analysis determined that the 
probability of prostate cancer lymph node metastases not appearing on MRI was low enough 
to omit pelvic lymph node dissection, thereby removing the need for surgery and associated 
mortality and morbidity risks.   
To the knowledge of this PhD candidate, there are currently no publications of a possible 
PET/MRI contrast agent specifically used to diagnose the draining lymph nodes from the 
prostate gland in human patients.  There have been such experiments performed in mice that 
have been published.  The possibility of a PET/MRI contrast agent, that is, an iron oxide 
nanoparticle radoio-labelled with a positron emitting radio-nuclide, used for identifying 
draining lymph nodes from prostate gland, offers the potential to overcome limitations of 
current techniques (nano-sized radio-colloid with blue dye) and proposed techniques (of just 
magnetic nanoparticles; waiting between 20 to 36 hours).  IONP radiolabeled with a positron 
emitter and injected directly interstitially, can allow for MRI imaging with greater image 
quality and non-ionising radiation compared to CT, detection by PET in approximately 1 hour 
post administration. 
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The specific aims of this chapter were to: 
1. Inject iron oxide nanoparticles (coated with dextran and tagged with FITC) into the 
hock and flank of C57BL/6 mice and evaluate if they drained to the popliteal and 
inguinal lymph nodes, respectively, and quantitate this with flow cytometry. 
2. Perform biochemistry assessment on the blood serum of mice undergoing step 1 
above. 
3. Remove organs (heart, lung, liver, kidney and spleen) of mice in experimental process 
in step 1 above and perform H&E, Perl’s Prussian Blue and PAS to correspond with 
any biochemical findings. 
4. Image mouse separately with PET and then with MRI, after being injected with iron 
oxide nanoparticles (coated with dextran and tagged with FITC) and radio-labelled 
with 68Ga following footpad injection; then removed radio-active positive lymph node 
and perform uptake study on flow cytometry. 
5. Remove lymph node positive for radio-activity (in step 4 above) and prepare for 
confocal microscopy. 
6. Inject iron oxide nanoparticles (coated with dextran and radio-labelled with 68Ga) into 
human patients and perform PET imaging (PET/CT) to observe migration from 
prostate gland to draining lymph nodes. 
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 6.2 Results 
 
 
6.2.1 Subcutaneous injection of T10 dextran coated IONPs tagged with 
FITC and quantitation with flow cytometry. 
 
A total of ten mice, each received subcutaneous injection of 200 µl of dextran coated iron 
oxide nanoparticles tagged with FITC, at a concentration of 100 µg/ml, into their hocks.  A 
hock injection is a humane method (alternative to foot pad) to ascertain if these specially 
prepared nanoparticles had the capability to migrate to the popliteal lymph node.  These same 
mice also received the same volume and concentration of the same nanoparticles injected 
subcutaneously at their flanks, to ascertain drainage to the inguinal lymph node.  One hour 
post injection, all mice were killed under anaesthesia when performing the vascular perfusion 
fixation technique.  Please refer to Chapter 2, Materials and Methods, Sections 2.7 and 2.12.    
A further 10 mice received the same volume and concentration of nanoparticles, injected at 
the same sites.  Methodology followed was as described for the one hour time point, however, 
these ten mice, were killed under vascular perfusion fixation at 24 hours post injection. 
At post mortem, the popliteal and inguinal lymph nodes were excised and prepared for flow 
cytometry as described in Section 2.12.4. 
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Figure 6.1: Uptake of FITC tagged IONPs by total lymph node cells extracted from the 
popliteal and inguinal lymph node cells, 1 hour and 24 hours post subcutaneous 
injection, in vivo.  Eight week old female C57BL/6 mice were injected subcutaneously 
with FITC tagged IONPs in either the hock or flank and popliteal and inguinal lymph nodes 
were collected respectively, at 1 hour (10 mice) and 24 hours (10 mice) after subcutaneous 
injection, in vivo.  Cells were collected from each lymph node and % uptake of total lymph 
node cells extracted that were positive for FITC tagged IONPs were assessed by flow 
cytometry and analysed using FACSDiva software (BD Biosciences) and shown here with 
error bars representing standard error of the mean.  Statistical analysis was performed using 
GraphPad Prism 6.05.  Two way ANOVA was used to statistically analyse the data with the 
Bonferroni multiple comparison test.  There was no statistical difference between the popliteal 
and inguinal lymph nodes at each time point and there was also no statistical difference 
between each time points for either lymph nodes.       
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Figure 6.2: Uptake (fold increase in mean fluorescent intensity) of FITC tagged IONPs 
by total lymph node cells extracted from the popliteal and inguinal lymph node cells, 1 
hour and 24 hours post subcutaneous injection, in vivo.  Eight week old female C57BL/6 
mice were injected subcutaneously with FITC tagged IONPs in either the hock or flank and 
popliteal and inguinal lymph nodes were collected respectively, at 1 hour (10 mice) and 24 
hours (10 mice) after subcutaneous injection, in vivo.  Cells were collected from each lymph 
node and % uptake of total lymph node cells extracted that were positive for FITC tagged 
IONPs were assessed by flow cytometry and analysed using FACSDiva software (BD 
Biosciences) and this graph demonstrates the mean fluorescent intensity (MFI) from the FITC 
(tagged to the IONPs), quantitated by flow cytometry and analysed using FACSDiva software 
(BD Biosciences) and shown here (popliteal lymph nodes, n=10 and inguinal lymph nodes, 
n=10).  The results are shown as fold increase (compared to control) in mean fluorescent 
intensity with error bars representing the standard error of the mean.  Statistical analysis was 
performed using GraphPad Prism 6.05.  Two way ANOVA was use to statistically analyse the 
data with the Bonferroni multiple comparison test.  No statistical significance (ns) could be 
detected between the cells from either lymph node or from either time point.       
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Figure 6.3: Uptake of FITC tagged IONPs by popliteal and inguinal lymph node cells, 1 
hour and 24 hours post subcutaneous injection, in vivo.  Eight week old female C57BL/6 
mice were injected subcutaneously with FITC tagged IONPs in either the hock or flank and 
popliteal and inguinal lymph nodes were collected respectively, at 1 hour (10 mice) and 24 
hours (10 mice) after subcutaneous injection, in vivo.  Cells were collected from each lymph 
node and % uptake of CD11c positive cells that were also positive for FITC tagged IONPs 
were assessed by flow cytometry and analysed using FACSDiva software (BD Biosciences) 
and shown here with error bars representing standard error of the mean.  Statistical analysis 
was performed using GraphPad Prism 6.05.  Two way ANOVA was used to analyse the data 
with the Bonferroni multiple comparison test.  An adjusted P value of 0.0180 between the 
popliteal lymph nodes between 1 hour and 24 hours indicates a significant statistical 
difference ( * ).  The Source of Variation for this statistical difference is the time span 
between the two collection points with a P value summary of 0.0067 ( ** ).  There was no 
statistical difference between the inguinal lymph nodes between these two same time points; 
and no statistical significance between the popliteal and inguinal lymph nodes at 1 hour; and 
also no statistical difference between these same two lymph node groups at 24 hours.       
 
 
 
 
280 
 
  
1  H o u r 2 4  h o u r s
0
1
2
3
4
5
C D 1 1 c +  C e lls
T im e  P o s t S u b c u ta n e o u s  In je c tio n
F
o
ld
 I
n
c
re
a
s
e
 i
n
 M
F
I
P o p lite a l L y m p h  N o d e s
In g u in a l L y m p h  N o d e s
 
Figure 6.4: Uptake (fold increase in mean fluorescent intensity) of FITC tagged IONPs 
by popliteal and inguinal lymph node cells, 1 hour and 24 hours post subcutaneous 
injection, in vivo.  Eight week old female C57BL/6 mice were injected subcutaneously with 
FITC tagged IONPs in either the hock or flank and popliteal and inguinal lymph nodes were 
collected respectively, at 1 hour (10 mice) and 24 hours (10 mice) after subcutaneous 
injection, in vivo.  Cells were collected from each lymph node and % uptake of CD11c 
positive cells that were also positive for FITC tagged IONPs were assessed by flow cytometry 
and analysed using FACSDiva software (BD Biosciences) and this graph demonstrates the 
mean fluorescent intensity (MFI) from the FITC (tagged to the IONPs), quantitated by flow 
cytometry and analysed using FACSDiva software (BD Biosciences) and shown here 
(popliteal lymph nodes, n=10 and inguinal lymph nodes, n=10).  The results are shown as fold 
increase (compared to control) in mean fluorescent intensity with error bars representing the 
standard error of the mean.  Statistical analysis was performed using GraphPad Prism 6.05.  
Two way ANOVA was used to statistically analyse the data with the Bonferroni multiple 
comparison test.  No statistical significance (ns) could be detected between the cells from 
either lymph node and no Source of Variation could be detected.   
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 6.2.2 Biochemistry assessment on the blood serum of mice undergoing 
subcutaneous injection of T10 dextran coated IONPs tagged with FITC  
 
While mice were under anaesthesia and just prior to performing the vascular perfusion 
fixation technique, haematocrit capillaries were used to retrieve blood samples from the retro-
orbital sinus.  The blood serum was attained from blood sample as described in Section 2.12.7 
and biochemical analysis was performed. 
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 Mean Value  
(n=10) 
Mean Value  
(n=10) 
 
 1 hour post 
injection of FITC 
tagged IONP 
24 hours post 
injection of FITC 
tagged IONP 
Units 
    
AlbG 2.93 2.61 g/L 
AlkP 198.6 196.6 U/L 
ALT 35.4 47.7 U/L 
Amy 1236.9 946.6 U/L 
BiliT 0.152046784 0.192982456 µmol/L 
CreaC 0.393413776 0.350678733 µmol/L 
GGT < 4 < 4 U/L 
TP 5.15 4.57 g/L 
Urea 137.52 132.12 mmol/L 
 
Table 6.1: Biochemical analyte values obtained from murine blood serum under 
experimental conditions.  The mice used were female C57BL/6 and 8 weeks old.  The 
abbreviations represent the following terms: AlbG (albumin globulin), AlkP (alkaline 
phosphatase), ALT (alanine aminotransferase), Amy (amylase), BiliT (Bilirubin Total), CreaC 
(creatinine clearance or glomerular filtration rate (GFR)), GGT (gamma-glutamyl 
transferase), TP (total protein) and Urea (urea). 
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 Averages  
(n=10) 
Averages  
(n=10) 
Averages  
(n=15) 
Averages  
(n=15) 
 
 1 hour post 
injection of FITC 
tagged IONP 
1 day post 
injection of FITC 
tagged IONP 
Mazzaccara  
et al 
Schnell et al Units 
      
AlbG 2.93 2.61 Not available 3.9 ± 0.48 g/L 
AlkP 198.6 196.6 221 
(214 – 246) 
125 ± 19.3 U/L 
ALT 35.4 47.7 51 
(46 – 54) 
59 ± 34 U/L 
Amy 1236.9 946.6 Not available 2008 ± 449.9 U/L 
BiliT 2.7 3.3 6.8 
(3.4 – 6.8) 
5.13 ± 0 * 
 
µmol/L 
CreaC 34.6 31 35.4 
(26.5 – 35.3) 
79.56 ± 
26.52* 
µmol/L 
GGT < 4 < 4 9.5 
(8 – 10) 
Not available U/L 
TP 5.15 4.57 Not available 4.9 ± 0.57 g/L 
Urea 137.52 132.12 7.1 
(5.7 – 8.5) 
25 ± 4.5 mmol/L 
 
Table 6.2: Blood serum biochemical analyte values from the experimental process and 
compared with published values.  Comparison was made with obtained experimental results 
and those published by Mazzaccara et al(293) (mice at 2 months of age) and Schnell et al(294) 
(mice at 6 months of age).  All mice were femail C57BL/6.  The asterisk ( * ) denotes that the 
figure was calculated to convert the units from mg/dl to µmol/L. 
 
 
 
 
 
 
 
 
 
284 
 
 6.2.3 Histopathological Evaluation 
 
On completion of vascular perfusion fixation, organs that may succumb to possible adverse 
events/reactions to contrast media (in this case dextran coated iron oxide nanoparticles tagged 
with FITC) were removed from the mice. These organs were the liver, kidney, spleen heart 
and lungs.  They were preserved, embedded in wax blocks, a microtome used to cut tissue 
samples and set on microscope slides as described in Section 2.12.6. 
H&E, Perls Prussian Blue and PAS staining were performed.  The H&E stain was designed to 
observe the generalised cellular architecture and condition, the Perls Prussian Blue was 
performed to observe any iron deposits and a PAS stain was used to identify if there was any 
disruption to the basement membrane of the kidney tissue (as this is the first site of renal 
injury in response to toxicity). 
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Figure 6.5: Periodic acid Schiff (PAS) stain (A and B) of paraffin embedded murine kidney sections 
and of known positive control tissue sections (C and D).  Representative micrographs of PAS stained 
murine kidney sections from mice receiving iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel 
B) time points, post subcutaneous injections (hock and flank); both at 400x magnification.  Panel C (100x 
magnification) and panel D (200x magnification) are known positive control tissue samples placed in the 
same rack as the murine kidney tissue sections and have undergone the PAS stain process simultaneously.  
All of the observed murine kidney sections were clear of iron deposits.    
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Figure 6.6: Haematoxylin and eosin (H & E) stain (A and B) and Perls Prussian blue stain (C and D) of 
paraffin embedded murine kidney sections and Perls Prussian blue stain of known positive control 
tissue sections (E and F).  Representative micrographs of H & E stained murine kidney sections from mice 
receiving iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel B) time points post subcutaneous 
injections (hock and flank); both at 400x magnification.  Panels C and D (both at 400x magnification) are 
representative micrographs of Perls Prussian blue staining of murine kidney sections, also 1 hour and 1 day 
post subcutaneous injections and panels E (100x magnification) and F (200x magnification) are known 
positive control tissue samples placed in the same rack as the murine kidney tissue sections and have 
undergone the Perls Prussian blue stain process simultaneously. 
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Figure 6.7: Haematoxylin and eosin (H & E) stain (A and B) and Perls Prussian blue stain (C and D) of 
paraffin embedded murine liver sections and Perls Prussian blue stain of known positive control tissue 
sections (E and F).  Representative micrographs of H & E stained murine liver sections from mice receiving 
iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel B) time points post subcutaneous injections 
(hock and flank); both at 400x magnification.  Panels C and D (both at 400x magnification) are representative 
micrographs of Perls Prussian blue staining of murine liver sections, also 1 hour and 1 day post subcutaneous 
injections and panels E (100x magnification) and F (200x magnification) are known positive control tissue 
samples placed in the same rack as the murine liver tissue sections and have undergone the Perls Prussian 
blue stain process simultaneously.   
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Figure 6.8: Haematoxylin and eosin (H & E) stain (A and B) and Perls Prussian blue stain (C and D) of 
paraffin embedded murine spleen sections and Perls Prussian blue stain of known positive control 
tissue sections (E and F).  Representative micrographs of H & E stained murine spleen sections from mice 
receiving iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel B) time points post subcutaneous 
injections (hock and flank); both at 400x magnification.  Panels C and D (both at 400x magnification) are 
representative micrographs of Perls Prussian blue staining of murine spleen sections also at 1 hour and 24 
hour time points post subcutaneous injections and panels E (100x magnification) and F (200x magnification) 
are known positive control tissue samples placed in the same rack as the murine spleen tissue sections and 
have undergone the Perls Prussian blue stain process simultaneously. 
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Figure 6.9: Haematoxylin and eosin (H & E) stain (A and B) and Perls Prussian blue stain (C and D) of 
paraffin embedded murine cardiac sections and Perls Prussian blue stain of known positive control 
tissue sections (E and F).  Representative micrographs of H & E stained murine cardiac sections from mice 
receiving iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel B) time points post subcutaneous 
injections (hock and flank); both at 400x magnification.  Panels C and D (both at 400x magnification) are 
representative micrographs of Perls Prussian blue staining of murine cardiac sections, also at 1 hour and 24 
hour time points post subcutaneous injections and panels E and F (both at 200x magnification) are known 
positive control tissue samples placed in the same rack as the murine cardiac tissue sections and have 
undergone the Perls Prussian blue stain process simultaneously. 
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Figure 6.10: Haematoxylin and eosin (H & E) stain (A and B) and Perls Prussian blue stain (C and D) 
of paraffin embedded murine lung sections and Perls Prussian blue stain of known positive control 
tissue sections (E and F).  Representative micrographs of H & E stained murine lung sections from mice 
receiving iron oxide nanoparticles at 1 hour (panel A) and 24 hour (panel B) time points post subcutaneous 
injections (hock and flank); both at 400x magnification.  Panels C and D (both at 400x magnification) are 
representative micrographs of Perls Prussian blue staining of murine lung sections, also at 1 hour and 24 hour 
time points post subcutaneous injections and panels E (100x magnification) and F (200x magnification) are 
known positive control tissue samples placed in the same rack as the murine liver tissue sections and have 
undergone the Perls Prussian blue stain process simultaneously.   
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 6.2.3.1 Comparison of Perls Prussian Blue stain for iron (Fe3+) content 
in murine spleen and murine liver  
 
For all mice used in the experimental process described in Section 2.12.2, the RES organs 
(spleen and liver) removed post mortem were compared for iron (Fe3+) deposit by using the 
Perls Prussian blue stain as described in Section 2.15.2.  This direct comparison was 
performed because no mice were used as controls for the Perls Prussian blue (please refer to 
discussion in Section 6.3) and also because unbound iron (Fe3+) is normally found in the 
spleen.  If iron (Fe3+) from the IONPs disassociated and were responsible for iron (Fe3+) 
deposits in the spleen, they would also be present in the liver.  The logical reasoning is that if 
no unbound Fe3+ can be identified by Perls Prussian blue staining in the liver (presumably 
from the IONPs), then any positive Perls Prussian blue staining in spleen cannot be attributed 
to the IONPs.  Further, the dimension of one iron oxide nanoparticle is 20 nm and therefore 
the iron (Fe3+) component would be less than 20 nm; thus, if any iron (Fe3+) did disassociate, 
it would be doubtful if it would be visible with the resolving power (400x magnification) of 
the light microscope used to image these stained sections.   
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Figure 6.11: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 1 (A and 
B), 2 (C and D) and 3 (E and F) in the first group of mice.  These mice were killed 1 hour 
post injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels A, C and 
E are Perls Prussian blue stained spleen sections and panels B, D and F are Perls Prussian blue 
stained liver sections from the same mice.  All representative micrographs presented here are 
at 400x magnification.  A known positive control tissue sample placed in the same rack as 
these murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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Figure 6.12: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 4 (G and 
H) and 5 (I and J) in the first group of mice.  These mice were killed 1 hour post injection 
of IONPs, their organs removed, fixed, sectioned and stained.  Panels G and I are Perls 
Prussian blue stained spleen sections and panels H and J are Perls Prussian blue stained liver 
sections from the same mice.  All representative micrographs presented here are at 400x 
magnification.  A known positive control tissue sample placed in the same rack as these 
murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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Figure 6.13: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 1 (A and 
B), 2 (C and D) and 3 (E and F) in the second group of mice.  These mice were killed 1 
hour post injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels A, C 
and E are Perls Prussian blue stained spleen sections and panels B, D and F are Perls Prussian 
blue stained liver sections from the same mice.  All representative micrographs presented here 
are at 400x magnification.  A known positive control tissue sample placed in the same rack as 
these murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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Figure 6.14: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 4 (G and 
H) and 5 (I and J) in the second group of mice.  These mice were killed 1 hour post 
injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels G and I are 
Perls Prussian blue stained spleen sections and panels H and J are Perls Prussian blue stained 
liver sections from the same mice.  All representative micrographs presented here are at 400x 
magnification.  A known positive control tissue sample placed in the same rack as these 
murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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Figure 6.15: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 1 (A and 
B), 2 (C and D) and 3 (E and F) in the third group of mice.  These mice were killed 24 
hours post injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels A, 
C and E are Perls Prussian blue stained spleen sections and panels B, D and F are Perls 
Prussian blue stained liver sections from the same mice.  All representative micrographs 
presented here are at 400x magnification.  A known positive control tissue sample placed in 
the same rack as these murine spleen and liver tissue sections and have undergone the Perls 
Prussian blue stain process simultaneously (not presented here).   
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Figure 6.16: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 4 (G and 
H) and 5 (I and J) in the third group of mice.  These mice were killed 24 hours post 
injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels G and I are 
Perls Prussian blue stained spleen sections and panels H and J are Perls Prussian blue stained 
liver sections from the same mice.  All representative micrographs presented here are at 400x 
magnification.  A known positive control tissue sample placed in the same rack as these 
murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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Figure 6.17: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 1 (A and 
B), 2 (C and D) and 3 (E and F) in the fourth group of mice.  These mice were killed 24 
hours post injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels A, 
C and E are Perls Prussian blue stained spleen sections and panels B, D and F are Perls 
Prussian blue stained liver sections from the same mice.  All representative micrographs 
presented here are at 400x magnification.  A known positive control tissue sample placed in 
the same rack as these murine spleen and liver tissue sections and have undergone the Perls 
Prussian blue stain process simultaneously (not presented here).   
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Figure 6.18: Perls Prussian blue stain of paraffin embedded murine spleen sections and 
corresponding Perls Prussian blue stain of liver sections from mouse number 4 (G and 
H) and 5 (I and J) in the fourth group of mice.  These mice were killed 24 hours post 
injection of IONPs, their organs removed, fixed, sectioned and stained.  Panels G and I are 
Perls Prussian blue stained spleen sections and panels H and J are Perls Prussian blue stained 
liver sections from the same mice.  All representative micrographs presented here are at 400x 
magnification.  A known positive control tissue sample placed in the same rack as these 
murine spleen and liver tissue sections and have undergone the Perls Prussian blue stain 
process simultaneously (not presented here).   
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 6.2.4 PET and MR imaging of mice after being injected with T10 dextran 
coated IONPs + FITC and radio-labelled with 68Ga following footpad 
injection. 
 
The radio-labelling method described in Section 2.8.7 was used to radio-label 68Ga to the 
dextran coated iron oxide nanoparticles tagged with FITC.  The mice were imaged 1 hour 
after a foot pad injection with a SA PET scanner while under GA. 
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 On completion of PET imaging, the mice were killed by anaesthetic overdose.  MRI was then 
performed, at 3.0 T, with Gradient Echo and Spin Echo pulse sequences. 
 
 
Figure 6.20: MRI images taken at 3T demonstrating identifying the popliteal lymph 
node (red circle) with signal intensity pattern characteristic of iron oxide nanoparticles.  
These images demonstrate that, with MRI, the iron oxide nanoparticles have migrated from 
the foot pad subcutaneous injection site to the popliteal lymph node (red circle).  Importantly, 
also noted are the inhomogeneity imaging effects and the hypo-intense signal change; both 
characteristic of iron oxide nanoparticles accumulation in the popliteal lymph node.  These 
images are of the same mouse, taken at slightly different coronal imaging levels. 
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 The popliteal lymph nodes that appeared as hot spots on PET imaging were excised and 
prepared for flow cytometry as also described in Section 2.12.4.  
 
Figure 6.21: Flow cytometry histogram (A) and data (B) indicating that 53.7% of cells 
extracted from the popliteal lymph node were positive for FITC and increased 
granularity from the iron oxide nanoparticles.  On this one occasion, as a proof of concept 
and principle, a C57BL/6 mouse received a footpad injection of 68Ga radio-labelled IONPs 
tagged with FITC and following 1 hour, this mouse was killed, the popliteal lymph node 
removed, cells extracted and prepared for flow cytometry analysis.     
 
 
 
 
 
# Event % Expression MFI 
5,606 53.7 1,786 
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 6.2.5 Remove lymph node positive for 68Ga radio-activity and prepared for 
confocal microscopy. 
 
On completion of PET imaging, the mice were killed by anaesthetic overdose.  The popliteal 
lymph nodes that appeared as hot spots on PET imaging were excised and prepared for 
confocal microscopy. 
 
Figure 6.22: Confocal microscopy image produced with bright field and FITC laser 
demonstrating FITC tagged nanoparticles within cells.  A C57BL/6 mouse received a 
footpad injection of 68Ga radio-labelled IONPs tagged with FITC and following 1 hour, this 
mouse was killed and the popliteal lymph node was removed, sectioned and mounted on a 
positively charged microscope slide.  Confocal microscopy imaging was performed; the 
fluorescent green appearance is representative of FITC and the increased black or dark 
regions are representative of nanoparticle accumulation within cells. 
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Figure 6.23: Confocal microscopy image produced with a FITC laser demonstrating 
FITC fluorescence from nanoparticles within cells.  This image was produced from the 
same microscope slide used to produce Figure 6.22.  A popliteal lymph node was removed 
from a C57BL/6 mouse, sectioned and mounted on a positively charged microscope slide.  
The fluorescent green appearance is representative of FITC and they appear to fill a 3D 
volume, presumably the internal dimensions of cells. 
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 6.2.6 Iron oxide nanoparticles radio-labelled with 68Ga injected into human 
patients and perform PET imaging (PET/CT) to observe migration from 
prostate gland to draining lymph nodes 
 
The iron oxide nanoparticles were radio-labelled with 68Ga as described in Section 2.8.7.  
Patients with diagnosed prostate cancer and undergoing gold seed fiducial marker 
implantation consented to receive the nanoparticle-68Ga preparation while under general 
anaesthesia.  Eight syringes were prepared, each with a volume of 200 µl and radioactivity 
ranging from between 2.5 MBq to 3.2 MBq (as measured by a dose calibrator), of which, 4 
were injected into the inner prostate zone and 4 injected into the outer prostate zone. 
 
 
 
Figure 6.24: PET image co-registered with CT of a male patient following 
administration of nanoparticles radio-labelled with 68Ga directly into the prostate gland 
and one hour later demonstrating radio-activity in a right sided draining lymph node (as 
well as the urinary bladder).  The red colour signifies the greatest intensity of radio-activity 
by 68Ga.  The fused or co-registered CT image (Figure 16.24A) is a transverse slice through 
the pelvis at the level of the ischial spines.  Figure 16.24B is the CT image only (the same as 
Figure 16.24A), with no overlay of PET imaging data.  
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Figure 6.25: PET image (co-registered with CT) of a male patient following 
administration of nanoparticles radio-labelled with 68Ga directly into the prostate gland 
and one hour later demonstrating radio-activity in a small left sided draining lymph 
node (as well as the urinary bladder).  The red colour signifies the greatest intensity of 
radio-activity by 68Ga.  The fused or co-registered CT image (Figure 16.25A) is a transverse 
slice through the pelvis at the level of the ilia and lower sacrum.  Without the overlay of 
radio-activity of 68Ga obtained with PET, it would not be possible to identify this draining 
lymph node based on CT image (Figure 16.25B) alone.  
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Figure 6.26: PET image (co-registered with CT) of a male patient following 
administration of nanoparticles radio-labelled with 68Ga directly into the prostate gland 
and one hour later demonstrating radio-activity in a small para-aortic draining lymph 
node.  The red colour signifies the greatest intensity of radio-activity by 68Ga.  The fused or 
co-registered CT image (Figure 6.26A) is a transverse slice through the lower abdomen, at a 
level superior to the iliac crests and inferior to the lower poles of the kidneys.  Without the 
overlay of radio-activity of 68Ga obtained with PET, it would not be possible to identify this 
draining lymph node based on the CT image (Figure 6.26B) alone as it is some distance 
(superiorly) from the prostate gland. 
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Figure 6.27: PET image (co-registered with CT) of a male patient following 
administration of nanoparticles radio-labelled with 68Ga directly into the prostate gland 
and imaged one hour later demonstrating radio-activity in the draining lymph nodes.  
These images are of the same patient, taken at two different levels, demonstrating 
radioactivity from 68Ga (radio-labelled to dextran coated IONPs) collecting in the draining 
lymph nodes of the prostate gland.  Figure 6.27A demonstrates a draining lymph node nearby 
the prostate gland.  Figure 6.27B shows more of the typical and expected draining lymph 
nodes adjacent to the prostate gland and, importantly, the left superficial inguinal lymph node 
(white arrow), which is atypical of lymphatic drainage from the prostate gland. 
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Figure 6.28: PET image (co-registered with CT) of the same male patient in Figure 6.17 
following administration of nanoparticles radio-labelled with 68Ga directly into the 
prostate gland and imaged one hour later demonstrating radio-activity in the draining 
lymph nodes.  These PET/CT images are of the same patient, taken at two different levels, 
through the mid-abdomen (Figure 6.28A) and the mid thoracic cavity (Figure 6.28B), 
demonstrating radioactivity from 68Ga (radio-labelled to dextran coated IONPs) collecting in 
lymph nodes draining from the prostate gland.   
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 6.3 Discussion 
 
There are numerous publications concerning a variety of nanoparticle preparations and in vivo 
murine studies.  The results presented in Section 6.2 will be discussed relative to the most 
applicable publications performed with iron oxide nanoparticles, with translational potential 
for SLN imaging (from the prostate gland); specifically with iron oxide nanoparticles of 
approximately 20 nm in diameter, radiolabelled for PET imaging and also capable of imaging 
with MRI.  Iron oxide nanoparticles have been observed, by many different imaging or 
detection methods, migrating from their injection site to their target site or destination.  The 
most common imaging or detection methods includes MRI, optical imaging or luminescence 
(such as NIR), SPECT (if radio-labelled to a gamma emitter) and PET (for positron emitting 
radionuclides).  The results presented in Section 6.2 demonstrate that when the iron oxide 
nanoparticles have reached their lymph node target in vivo (murine), they can be clearly 
identified with flow cytometry (when tagged with FITC) and with PET (when radio-labelled 
with 68Ga) and also simply with MRI.  Where the murine studies advance the knowledge 
presented in the current literature is with quantitation via flow cytometry and radio-labelling 
with 68Ga; as no publications can be found with flow cytometry and FITC tagged iron oxide 
nanoparticles and no publications exist of 68Ga being radio-labelled to these same 
nanoparticles.  Interestingly, in December 2013, one publication was presented where 68Ga 
was radio-labelled to PSMA ligands(299).  This publication was identified by this PhD 
candidate in October 2014.  The laboratory notebook of this PhD candidate shows that work 
in this area (radio-labelling 68Ga to iron oxide nanoparticles) commenced in July 2013 and 
was perfected in December 2013; unaware of the publication by Afshar-Oromieh et al(299).   
Figures 6.1 and 6.2 each compare the detectable FITC (tagged to the iron oxide nanoparticles) 
and the granularity of cells extracted from popliteal and inguinal lymph nodes after 1 hour and 
24 hours from the time of injection.  At one hour post injection, 40 % of total lymph node 
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 cells from the popliteal lymph node are positive for FITC and 45 % of inguinal lymph node 
cells.  At 24 hours (1 day) post injection, the total lymph node cells, from mice in that specific 
experimental group, present a comparatively lesser value than the mice in the one hour 
experimental group.  At 24 hours post injection, 30 % of total lymph node cells from the 
popliteal lymph node are positive for FITC and 40 % of inguinal lymph node cells.  An 
explanation offered for these lesser values could be that following 24 hours, a portion of the 
FITC tagged nanoparticles would have transitioned through the sentinel lymph nodes (either 
popliteal or inguinal) and made their way to other parts of the lymphatic system.  It is 
noteworthy that at both time points the mean and standard deviation range of the data from 
the inguinal lymph node is greater than that obtained from the popliteal lymph node.  The 
most plausible explanation that can be offered to rationalise the greater mean value would be 
that the nanoparticles have less distance to travel when migrating from the flank subcutaneous 
injection site to the inguinal lymph node when compared to the hock injection site and 
nanoparticle migration to the popliteal lymph node.  The nanoparticles used for these 
injections were all from the same preparation.  No publications can be identified with similar 
or same experimental study and thus the findings presented here cannot be compared to 
others.  The corresponding fold increase in MFI of the FITC (tagged to the nanoparticles and 
internalised by the cells) from the total lymph node cells also represent, and thus confirm, the 
same pattern observed with percentage surface expression.  That is, at 1 hour post injection 
(Figure 6.2), the fold increase in MFI of the total lymph node cells extracted from the inguinal 
lymph node (fold increase of 2) is greater than the cells from the popliteal lymph node (fold 
increase of 3).  The 50 % in fold increase (from 2 to 3), again, can, in probability, be 
attributed to the shorter distance that the nanoparticles need to migrate from the subcutaneous 
flank injection site to its draining inguinal lymph node.  This same pattern is seen at 24 hours 
(Figure 6.2).  CD11c+ cells were also specifically identified with flow cytometry from the 
total lymph node cell population and such cells include lymphocytes, NK cells and certain 
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 macrophage populations – all found within lymph nodes and capable of internalising 
nanoparticles.  The flow cytometry data, by percentage surface expression, revealed that at the 
1 hour time point, twice as many CD11c+ cells from the popliteal lymph node internalised the 
FITC tagged nanoparticles compared to CD11c+ cells from the inguinal lymph node (Figures 
6.3 and 6.4).  The same figures also show that the spread of data points, the standard 
deviation, for CD11c+ cells from the popliteal lymph node is greater compared to CD11c+ 
cells from the inguinal lymph node.  At the 24 hour (1 day) time point, the CD11c+ cells from 
both the popliteal and inguinal lymph nodes are approximately equivalent with 0.8 % and 0.7 
% uptake, respectively (Figure 6.3).  The correlative fold increase in MFI data (Figures 6.4) 
for the one hour time point differs from the percentage surface expression data.  The fold 
increase in MFI from CD11c+ cells from the popliteal lymph node is lesser than those from 
the inguinal lymph node; even though by percentage surface expression, the value arising 
from CD11c+ cells was twice as those from the inguinal lymph node.  The shorter distance 
from the flank to the inguinal lymph node (compared with the hock injection site to the 
popliteal lymph node destination) may also explain the greater fluorescence intensity 
captured.  With respect to CD11c+ cells at the 24 hour (1 day) time point, the fold increase in 
MFI is relatively equal with 2.5 and 2.25 arbitrary units.  One published study measured iron 
content in gliosarcoma brain tumours of four rats from dextran coated iron oxide 
nanoparticles 24 hours after intravenous administration.  The iron content was found to be 
0.26 µg of iron relative to the injected dose or 0.11 % of the injected nanoparticle dose(288), 
however, this was, presumably, the average iron content value detected in the gliosarcoma 
tumour, regardless of tumour size or the number of tumour cells in each of the four rats.     
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Histological tissue staining is capable of providing insight to the integrity of certain 
structures.  Haematoxylin and eosin (H&E) stain can provide information about general 
cellular architecture.  The H&E staining of kidney (Figure 6.6A and B), liver (Figure (6.7A 
and B), spleen (Figure 6.8A and B), heart (Figure 6.9A and B) and lung (Figure 6.10A and B) 
were assessed by an experienced and suitably qualified academic and researcher and has 
determined that the structural integrity of these tissue samples observed are sound and 
microscopically appear to be normal.  A Perls Prussian blue stain identifies iron deposits; 
thus, with iron oxide nanoparticles, this staining technique can be used to determine if iron 
from the iron oxide nanoparticles was present (panels A and B in Figures 6.6 to 6.10 
inclusive).  It should be noted that in spleen tissue samples, naturally occurring iron deposits 
(due to the highly vascular nature of the spleen) can be demonstrated with Perls Prussian blue 
stains.  Therefore, a Perls Prussian blue stain may not be the most appropriate method for 
assessing if iron present in splenic tissue samples have arisen from iron oxide nanoparticles.  
In the experimental process for this thesis, the nanoparticles were administered to mice 
subcutaneously and not intravascularly (venous or arterial).  Iron deposits that could be 
attributed to the 15 nm iron oxide core from the nanoparticles were not able to be identified 
microscopically at 400x magnification, in the tissue samples.  A Periodic Acid Schiff (PAS) 
stain was used specifically to detect any disruption to basement membrane (or basal laminae) 
of the kidneys (Figure 6.5).  Tissue samples from the murine kidneys did not demonstrate any 
loss of integrity of the basement membrane.  All tissue samples produced for H&E (kidney, 
liver, spleen, heart and lung), Perls Prussian blue (kidney, liver, spleen, heart and lung) and 
PAS (kidney) stains were obtained from all mice in the 1 hour and 24 hour experimental 
groups and therefore are considered to be representative. 
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 When observing the murine spleen images (Perls Prussian blue stain) in figures 6.11 to 6.18, 
there are signs of haemosiderin (brown appearance) and unbound iron, Fe3+, (blue 
appearance)(300-303).  Both presentations are normal and either are found located randomly in 
the spleen’s white pulp, red pulp, nodule or a combination of these locations.  The 
haemosiderin, pigment from red blood cells, infers that ferritin protein and iron (Fe3+) are 
bound together; as haemosiderin is regarded as an iron storage complex(304-306).  Ferritin 
protein can be found within certain blood cells, and when bound to iron, the iron remains 
stored within these cells(305, 307).  Ferritin protein can also be found, unbound, in serum and in 
cells from the RES (liver, spleen and bone marrow)(307, 308). 
The reason for this comparison (Perls Prussian blue staining of spleen and liver) is because no 
control mice were incorporated into the experiment design for this.  Performing Perls Prussian 
blue and PAS stains was suggested by other researchers from RMIT University after all mice 
approved by the university ethics committee had been killed.  The original intention was to 
only perform H&E staining and thus, the original experiment design included this in the 
following manner (to minimise the number of mice used).  For each mouse, the same leg 
(drainage to the popliteal LN) and flank (drainage to the inguinal LN) received injection of 
IONPs (as described in Section 2.12.2.  The contra-lateral side was not injected; therefore, 
each mouse served as its own control, with respect to popliteal and inguinal lymph nodes.  
This approach was specifically used to minimise the number of mice needed and also because 
the literature that was reviewed indicated that H&E staining would be sufficient to identify 
any damage to overall tissue architecture(295, 309).  It was only later, following consultation 
with other researchers and experts, that conducting additional histopathological stains; Perls 
Prussian blue and PAS (for kidney only) was considered.  This was performed from preserved 
tissue specimens.   
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 It is now acknowledged that this was not the best approach to take and that control mice 
specifically for Perls Prussian blue and PAS stains should have been added.  
 
Results of imaging mice, in vivo, with PET and with MRI, following a footpad injection of 
iron oxide nanoparticles radio-labelled with 68Ga was presented in Section 6.2.  PET imaging 
occurred one hour post injection and on completion, the mouse was killed by anaesthetic 
overdose and then MRI scanning performed.  PET image clearly demonstrates the draining 
lymph node from the foot pat injection site as a hot spot of increased radio-activity (Figure 
6.19).  From the foot pad, the popliteal lymph node is the primary draining lymph node, 
followed by the inguinal lymph node.  The inguinal lymph node, however, receives better 
lymph drainage from the flank, with murine anatomy in vivo, as the main site.  With the 
murine, in vivo, imaging data, the potential clinical utility of a positron emitter such as 68Ga 
can be clearly noted, compared to 18FDG that can accumulate in the urinary bladder and may 
disguise any hot spot radio-activity within nearby nodes draining from the foot pad injection 
site.  Further still, the MRI image (Figure 6.20) is comparable with that published by Zhou et 
al(291) who used 10 nm core diameter iron oxide nanoparticles, injected into the footpad and 
imaging with MRI demonstrated iron oxide nanoparticles at the popliteal lymph node and 
confirmation performed with vital blue dye.  Mori et al also published MRI images of iron 
oxide nanoparticles migrating to the popliteal lymph node following foot pad subcutaneous 
injection in the same strain of mice used in this thesis project, C57BL/6(310).  There were four 
differences tough; firstly Mori et al use male mice, secondly the MRI scanner had a field 
strength of 11.7 T, thirdly, their smallest sized nanoparticles were 50 nm and fourth, their 
injection site was the foot pad and not the hock.  Mori et al also confirmed the presence of 
their nanoparticles in the popliteal and inguinal lymph nodes by histological means with 
Prussian blue staining.  Despite these difference, the MRI images from this thesis and those 
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 published by Zhou et al and Mori et al all demonstrate that, fundamentally, iron oxide 
nanoparticles will migrate to the draining lymph nodes, in vivo, and are able to be imaged 
with MRI.    
 
Further to the discussion regarding flow cytometry and internalisation by cells within the 
lymph nodes, for this thesis, confirmation of nanoparticle presence within the lymph nodes 
and internalised by cells within the lymph node, when nanoparticles were tagged with FITC 
and radio-labelled with 68Ga, the popliteal lymph node was also extracted and prepared for 
flow cytometry.  53.8 % of cells from the popliteal lymph node were positive for FITC from 
the nanoparticle preparation (IONP+FITC+ 68Ga); thereby confirming the localisation of 
radio-labelled nanoparticles within the popliteal lymph node.  Visually, this was also 
demonstrated with confocal microscopy video footage; from which, static images are 
provided in Figures 6.22 and 6.23. 
Results presented in Figures 6.1 to 6.4 inclusive demonstrate unequivocally that FITC tagged 
iron oxide nanoparticles can migrate from hock and flank subcutaneous injection sites to the 
popliteal and inguinal lymph nodes, respectively.  Results from Figures 6.19 to 6.21 further 
confirm that when the same nanoparticles are also radio-labelled with 68Ga, they are also 
capable of reaching the draining lymph node (and imaged with PET and MRI).  The iron 
oxide nanoparticle preparation with FITC and 68Ga now provide four methods of assessment.  
Firstly, PET imaging can be performed due to the presence of 68Ga; secondly, MRI 
information can be ascertained from the location of the iron oxide nanoparticles and, the FITC 
can be used for either flow cytometry (thirdly) or for confocal microscopy (Figures 6.22 and 
6.23) imaging (fourth) or both.  This can be considered a ground breaking achievement, as 
there is only one published study incorporating 68Ga for PET imaging with mice, in vivo, 
specifically addressing the needs of prostate cancer(299).  
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 The use of 68Ga as a PET agent is progressively being considered to be superior to other 
existing PET radio-nuclides for oncology applications and specifically, prostate cancer.  The 
most common PET tracer, 18FDG, has been known to be recorded with cells, other than 
cancer cells, that have a high metabolic rate or show high levels of activity (heart, liver and 
urinary bladder)(311) and has low imaging specificity(312).  Comparatively, SPECT imaging, 
which is currently used with gamma emitting radio-nuclides for lymphoscintigrahy, has lesser 
image quality (spatial resolution)(160).   
Biochemical analysis of murine blood serum was also performed to correlate any findings 
with tissue stains.  Blood was extracted from 8 week old C57BL/6 female mice from the 
retro-orbital sinus with a capillary haematocrit.  Only one published study could be found that 
studied blood serum biochemistry in the same strain, gender and age mice(293).  Another study 
was identified that performed blood serum biochemistry in the same strain and gender of 
mice, however, their age was far more advanced at 6 months (approximately 24 weeks)(294).  
In both of these publications, there is some variability with the biochemistry analyte values, 
thus making certain comparison difficult.   
The analytes observed were markers for liver, kidney and pancreas and general systemic 
wellness.  Albumin (a serum protein, AlbG) was observed and this helped evaluate the murine 
hydration status as well as the presence of any haemorrhage, intestinal, liver or kidney 
disease.  Values for alkaline phosphatase (AlkP) were next recorded, as an elevation of this 
analyte may indicate liver damage or active bone growth or Cushing’s disease.  To identify 
any immediate injury to the liver, the alanine aminotransferase (ALT) was analysed.  This is a 
known and sensitive indicator of active liver damage, however, it cannot indicate the source 
of current injury to the liver and thus, any change to this analyte should be considered with 
the experimental process that the mouse has undergone and should also be compared with 
other relevant liver anayltes.  The amylase (Amy) assessment reflects the health of the 
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 pancreas.  Elevations in amylase can be an indicator of pancreatitis, however, kidney disease 
also cannot be excluded as an elevated amylase figure may indicate kidney this.  Elevation in 
the total bilirubin (BiliT) level also signals liver disease (and also haemolytic conditions), bile 
duct pathology (cancer or obstruction) and can also point to anaemia.  The creatinine 
concentration (CreaC) levels also provides an understanding of how well the kidneys are 
functioning.  The importance of observing the creatinine level is that is helps to discern if the 
cause of elevated urea levels are related to the kidneys or not.  Another analyte that provided 
insight to liver health was gamma-glutamyl transferase (GGT).  The total protein (TP) levels 
found in blood serum also provided further appreciation of the murine hydration status and 
could be also used to further understand or confirm involvement of the liver and kidneys if 
they were experiencing infectious diseases.  The urea, or the blood urea nitrogen (BUN), 
denoted the quality of kidney function.  Of note was that an increased level of total protein 
(azotemia) could be due to a variety of causes and can signify involvement of one or more 
organs.  Elevated total protein levels could be caused by the kidneys, liver, or heart disease 
and could also be due to urethral obstruction, shock or dehydration. 
The most appropriate comparison of the thesis experimental biochemistry data can be made 
with the results published by Mazzaccora et al(293), as both sets are matched for strain and 
gender and closely matched for murine age as well.    In general, the liver and kidneys would 
be the organs most likely to suffer any acute adverse effects from contrast agents administered 
intravascularly; however, under the experimental process described in this thesis, the mice 
received subcutaneous injections of nanoparticles.  With respect to the liver, an elevated 
alanine aminotransferase level defines acute injury and this is not the case at either 1 hour or 
24 hours, as both these values are less than the value published by Mazzacora et al(293) and 
Schnell et al(294).  Other analytes that indicate liver health also were not elevated; these were 
alkaline phosphatase (no liver damage), total bilirubin (no active liver disease) and gamma-
glutamyl transferase thus confirming good general liver health.  Mazzacorra et al did not 
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 provide values for the following analytes that also provide insight into liver health and 
therefore, data was compared to that published by Schnell et al; albumin levels indicate no 
liver disease present and the degree of total protein recorded also indicated no liver infection.  
Analytes to assess kidney well-being were also recorded, of which, some were assessed in 
combination with the liver indicators.  The value recorded for albumin specifies no kidney 
disease was present at the time and the amount of amylase revealed no kidney infection.  The 
total protein value observed also parallels the value published by Schnell et al and supports 
the amylase result of no infection of the kidney.  The quality of kidney function was assessed 
by the blood serum creatinine concentration and the urea (or blood urea nitrogen) quantities.  
The creatinine figure is compliant with that published by Mazzaccara et al, implying that the 
quality of kidney function is normal.  This is, however, countered by the amount of urea 
identified; approximately 19 times more than the value reported by Mazzaccara et al and 
about 5 times more than Schnell et al, however, the PAS stain of all the kidney tissue samples 
of all mice demonstrate no disruption to the integrity of the basement membrane.  Therefore, 
the value of urea recorded is confounding in these circumstances and also in relation to other 
kidney associated analyte values of a comparably normal range.  Furthermore, as analytes 
change greatly with age, some increase while others decrease(293), it is difficult to arrive at a 
confident understanding. 
The results of in vivo (murine and human) imaging presented in this thesis, when assessed 
collectively, offer the potential of a PET/MRI imaging agent in the form of iron oxide 
nanoparticles radiolabelled with 68Ga.  Murine, in vivo, PET imaging provided valuable 
insight to the possibility of iron oxide nanoparticles being used as a carrier for the 68Ga radio-
isotope; as well as exploring potential as a combined PET/MRI imaging agent.  This is in 
keeping with publications in this field.  A recent publication by Bal et al, focussing solely on 
PET imaging for early detection of small tumour lesions within the prostate gland and early 
metastatic spread to draining lymph nodes, discuss the need for more sensitive and specific 
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 positron emitting PET radiotracers along with improved PET spatial resolution with pixel 
sizes of 2 mm (along with resolution recovery and time-of-flight image reconstruction)(312).  
Bal et al, however, do not discuss in depth the superior spatial resolution capabilities offered 
by MRI, either through fusion of images or through hybrid imaging in the form of PET/MRI.  
MRI can easily achieve voxel dimensions of 1 mm3. 
Thorek et al creatively modified existing FDA approved ferumoxytol (17 nm to 35 nm in 
diameter), Feraheme™, and radio-labelled it with 89Zr and referred to these particles as 89Zr-
ferumoxytol(279).  These radio-labelled nanoparticles were laparoscopically inoculated into the 
prostate gland of Hi-Myc transgenic mice.  PET/CT was performed 6 hours later and this was 
followed with MRI.  Their results demonstrated that the PET component of PET/CT can 
detect the radio-activity from 89Zr and that MRI can identify the signal intensity changes from 
the presence of Feraheme™. 
With respect to prostate cancer, detailed imaging, can provide additional benefits to patients 
and clinicians compared with currently available techniques.  These include early diagnosis, 
correct staging and monitoring of treatment.  Since 2008, there have been a number of 
publications advocating the need for improved PET imaging techniques in relation to prostate 
cancer(313-316).  Currently, the most widely used PET radiotracer is 18F-FDG, is not entirely 
suitable for localising primary tumour lesions within the prostate gland due to low tumour 
uptake (specifically, primary prostate cancer) of  18F-FDG, low specificity and imaging 
interference from high radio-activity of 18F-FDG accumulating and emanating from the 
urinary bladder. 
The first publication of a multi-centre prospective clinical trial of patients using iron oxide 
nanoparticles to image lymph nodes with MRI was published in 2003(317).  To this date, there 
is no FDA or TGA approved nanoparticle preparation for lymph node imaging with MRI and 
there is also no FDA or TGA approved single contrast agent for combined PET/MRI imaging.   
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 In relation to prostate cancer, the combined imaging results from this thesis demonstrates 
successful migration from the prostate gland to the draining lymph nodes in 4 consecutive 
patients.  The radio-activity of between 2.5 MBq to 3.2 MBq (per injection into the prostate 
gland and there was a total of 8 injections (4 into the inner prostate zone and 4 into the outer 
prostate zone) from the 68Ga (approximately 1 hour post administration) was capable of being 
identified with PET imaging within the draining lymph nodes.  The imaging results with 
developed platform of iron oxide nanoparticles with 68Ga, has demonstrated translational 
potential for imaging the draining lymph node from the prostate gland in patients.  Figures 
6.24 to 6.28 inclusive, PET/CT images, demonstrated that the IONPs radiolabelled with 68Ga 
that had been injected into the prostate gland, were capable of migrating to the immediate 
draining lymph nodes.  Figures 6.24 to 6.27 were taken at one hour post injection and the 
lymph nodes that typically drain the prostate gland were readily visualised.  Figure 6.27B, 
specifically, and importantly, demonstrated the left superficial inguinal lymph node.  This 
lymph node is not routinely resected for metastatic stagging as it is outside of the extended 
pelvic lymphadenectomy surgical region(318), however, for this patient, it would be of benefit 
to do so as this lymph has an association with lymphatic drainage of the prostate gland.  From 
the prostate gland, lymphatic drainage is considered to be along a lateral pathway to the 
obturator lymph nodes and from there, metastases can progress to the middle and external 
iliac lymph nodes(319).  Metastatic positive lymph nodes in other regions are considered to be 
rare, however, published literature has been steadily emerging that challenges this established 
idea.  In 2007, Weckermann et al stated that by excluding surgical sampling of lymph nodes 
from the pre-sacral, common iliac and retroperitoneal regions, the missed rate of metastatic 
detection can be as much as 63%(320).  A study by Mattei et al, in 2008, identified the 
superficial inguinal lymph to be positive for metastases in 0.6% of cases(321); while in 2010, 
Ganswindt et al published their imaging findings, which observed the superficial inguinal 
lymph nodes to receive lymphatic drainage from the prostate gland in 0.3% of cases with 
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 SPECT(322).  Independently of each other, Briganti et al (in 2012) and Joniau et al (in 2013) 
identified metastatic positive lymph nodes in the para-aortic and inferior vena cava regions in 
up to 15% of cases in patients positive for prostate cancer.   
At two hours post injection, Figures 6.26A, 6.28A and 6.28B demonstrated that distant lymph 
nodes in the abdomen and in the mediastinum/thoracic cavity could be identified (using 
PET/CT and the T10 dextran coated IONPS radiolabelled with 68Ga.  As the lymphatic 
drainage pathway is variable and unique with each patient, the process presented here (T10 
Dextran IONPs radio-labelled with 68Ga, injected into the prostate gland and imaged with 
PET/CT) proved that a definite gain in understanding was achieved, regarding the identified 
lymph nodes involved with lymphatic drainage of the prostate gland – the typical and atypical 
lymph nodes as well as those geographically near to the prostate gland and also distant.  This, 
therefore, introduces the realistic possibility of improving the efficacy of lymphadenectomy 
for metastatic staging, individualised for each patient.  Thus, the imaging data collected with 
PET/CT allows at least three key points to be realised.  Firstly, the draining lymph nodes from 
the prostate gland can be identified with the PET imaging component of a PET/CT scanner.  
Secondly, the time frame of one hour (from injection to PET imaging) is sufficient to allow 
the 68Ga radio-labelled nanoparticles to migrate from the prostate gland to the draining lymph 
node.  Thirdly, the radio-activity used is appropriate as it is readily detected by PET. 
Two studies have been published using a prostate specific membrane antigen (PSMA) radio-
labelled with 68Ga demonstrating localised tumour lesions within the prostate gland.  One of 
these studies, directly compared 68Ga  with 18F-FECH as PET imaging agents for prostate 
cancer in the same patient (with elevated PSA and clinical suspicion of prostate cancer) and 
that PET imaging with 18F-FECH was unable to detect a tumour lesion within the prostate 
gland(323) whereas PET imaging with 68Ga radio-labelled to PSMA was capable of identifying 
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 a tumour lesion within the prostate gland, at the peripheral zone, adjacent to the urinary 
bladder(299); thereby demonstrating the clinical utility of 68Ga (with PSMA) over 18F-FECH.   
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 6.4 Conclusion 
 
The aims of this chapter have been addressed and the experimental results lead to the 
following conclusions.    
1. Dextran coated iron oxide nanoparticles tagged with FITC migrate from their 
subcutaneous site of injection to the regional lymph nodes; from the hock to the popliteal 
lymph node and from the flank to the inguinal lymph node; in vivo, in C57BL/6 female mice.  
The amount of nanoparticles at these lymph nodes has been assessed with flow cytometry an 
quantitated by percent surface expression and also by fold increase in mean fluorescence 
intensity; in lymph node cells and also in CD11c+ cells from these lymph node cells.   
2. Biochemical analysis of blood serum showed that all analytes that were measured, 
signified healthy functioning and no acute physiological distress.  There was, however, on 
confounding value – elevated urea was recorded, however, other analytes indicate the mice 
had normal functioning kidneys with no disease or infection present at the time.  
3. H&E and Perls Prussian blue stain demonstrate sound cellular integrity of heart, lung, 
liver, kidney and spleen tissue at 200X magnification.  PAS stain of kidney tissue 
demonstrates an intact basement membrane, at 400X magnification.  The PAS stain also 
reveals PAS positive staining of the brush border within the proximal tubules most likely due 
to PFA being delivered under pressure during the VPF procedure.  This cannot explain the 
elevated urea level because the VPF was performed after the blood sample was taken from the 
mice.  
4. Murine, in vivo, PET imaging, one hour post foot pad injection with dextran coated 
iron oxide nanoparticles tagged with FITC and radio-labelled with 68Ga, demonstrates 
drainage to the popliteal lymph node.  Flow cytometry quantitated the FITC coated 
nanoparticles in cells extracted from the popliteal lymph node.   
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 5. Confocal microscopy confirms FITC coated nanoparticles are within cells from the 
popliteal lymph node.   
6. Dextran coated iron oxide nanoparticles radio-labelled with 68Ga that was injected into 
the prostate gland of 4 patients diagnosed with prostate cancer, with their consent and with 
human ethics approval from the hospital, demonstrated drainage to the sentinel lymph node 
and nearby lymph nodes as imaged with PET/CT. 
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 7.0 Chapter 7 – Conclusions and Future Directions 
 
 
7.1 Summary 
 
This thesis has presented information pertaining to the assessment and imaging applications 
of iron oxide nanoparticles.  A literature review, applicable to this project, identified how 
nanoparticles, together with MRI, are being used in novel and innovative ways to potentially 
improve patient health outcomes by advancing diagnostic imaging capabilities; thus aiding 
clinicians and patients determining the most appropriate treatment options and any such 
treatment options can be tailored and specific to individual patient circumstances.   
For this thesis, IONP were produced, coated with T10 dextran, suspended in gel at different 
concentrations and MRI T2 characteristics were assessed with 1.5 T and 3.0 T clinical MRI 
scanners.  At the cellular level, in vitro experiments were performed with murine and human 
immune cells to ascertain the effect of these IONPs with cell viability, dose dependent uptake 
and time dependent uptake.  The amine chain of the T10 dextran coating functionalised with 
aqueous ammonia to facilitate conjugation with either FITC or R-PE so that flow cytometry 
quantitation could be determined.  The cytokine expression by the cells tested, in vitro, was 
also studied.  
In vivo experiments were also performed with C57/BL6 mice and most valuably with patients 
diagnosed with prostate cancer.  A series of in vivo murine experiments involved 
subcutaneous injections of FITC tagged IONPs and flow cytometry evaluation of popliteal 
and inguinal lymph nodes, biochemical analysis of blood serum (from the retro-orbital sinus) 
and histopathological stains (H&E and Perls Prussian Blue) of their liver, spleen, heart and 
lung.  The kidneys were also analysed with a PAS stain in addition to H&E and Perls Prussian 
Blue.  The gamma emitting radio-iosotope, 68Ga, was radio-labelled to the functionalised T10 
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 dextran coating of the IONPs and also radiolabelled to the FITC tagged IONPs.  Further 
murine in vivo experiments were conducted with the IONPs tagged with FITC and 
radiolabelled with 68Ga; they were administered into the footpad and later imaged with a SA 
PET and then with 3.0T MRI.  The non-FITC 68Ga radio-labelled IONPs were directly 
injected into the prostate gland of prostate cancer patients (using ultrasound imaging guidance 
while the patients were under GA for radiation therapy gold seed implantation) and imaged 
with PET/CT.  The importance of this procedure (performed in four patients) was to 
determine that the lymph nodes draining the prostate gland were able to be identified and 
imaged; the radio-labelling of 68Ga remained intact with the IONPs while travelling in vivo 
and that the intensity of the radio-activity (the gamma radiation decay) was able to be 
identified and imaged using the PET imaging component of the PET/CT scanner (no 
PET/MRI scanner is currently available in Australia).        
 
 
7.2 Overview 
 
In determining and classifying metastatic staging, the relevant lymph nodes are always 
assessed, either with imaging or with surgical removal or both.  When surgically excised, the 
lymph nodes undergo histopathological evaluation.  Various imaging modalities and their 
unique techniques are designed to each add their own dimension to the overall diagnosis of a 
cancer and its metastasis.  An obvious progression and benefit would be to devise and 
introduce a methodology or technique that will provide the advantages of many of the multi-
layered imaging techniques into one; thereby saving time and money within the healthcare 
sector and assisting clinicians more timely and with more relevance.  The inclusion of T10 
dextran coated IONPs radio-labelled with 68Ga with either PET alone or MRI alone or 
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 PET/MRI combined, can provide an improved role in identifying lymph nodes, in vivo.  
Previously, cellular MRI (cMRI) demonstrated promise in understanding cell-to-cell 
interaction during cancer research, patient trial and pre-clinical stages; however, currently 
some limitations exist which may be overcome by the T10 dextran coated IONPs radio-
labelled with 68Ga preparations.  Therefore, the clinical utility of nanoparticles, PET imaging, 
MRI and cellular MRI is becoming more crucial in understanding the cellular interactions 
involving cancer metastases and the path that cancer cells take, and can take, through the 
human body; in particular, correctly recognising all draining lymph nodes, including those 
distant from the primary site. 
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 7.2.1 Characterisation of IONPs in the clinical magnetic environment, 
radiolabelling with 68Ga and in vitro cytotoxicity 
 
A review of the available literature allowed this author to determine ideal composition and 
dimension needed for nanoparticles to be used as intended for experimental processes.  IONPs 
were manufactured in a chemistry laboratory within RMIT University, containing an iron 
oxide core and T10 dextran coating.  The dextran coated contained amine chains that could be 
functionalised with aqueous ammonia to facilitated conjugation with either FITC or R-PE or 
68Ga, or, FITC and 68Ga together; thereby increasing their innovative applications. 
The physical characteristics of the T10 dextran coated IONPs were assessed with TEM and 
SEM.  Their surface charge (mV) wase also measured, after being stored under a variety of 
laboratory storage conditions.  T2 relaxometry data was generated with the same T2 weighted 
spine echo pulse sequence incorporating 16 echo times (TE) each spaced at 22 ms intervals, 
performed at 1.5 T and 3.0 T.  Graphs were produced that represented this data in a unique 
manner and graphs of these kind have not been available in the current literature.  Firstly, as 
the echoe times within the pulse sequence are known to be separated by a time of 22 ms, a 
power trendline can be used as a line of best fit; where as in the literature a mono-exponential 
decay is almost always assumed and an exponential decay line added.  Secondly, T2 decay of 
the tested IONPs was presented on three dimensional graphs, the y-axis showing Δ T2, the x-
axis showing the TE times and the z-axis showing the IONPs concentration suspend in gel.  
One of these graphs was generated for data obtained at 1.5 T and another graph for data from 
3.0 T.  These graphs informed this author how to be optimise MRI parameters to maximise 
image contrast and also which concentration of IONPs would provide the best possible image 
contrast due to contrast material (inhomogeneity effect).   
It was also demonstrated that 68Ga could be radio-labelled to functionalised IONPs, thereby 
providing further imaging opportunities in addition to MRI, namely PET.  This also presented 
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 the real possibility of dual modality contrast agent; PET/MRI; and this principle was 
demonstrated with in vivo murine experiments.   
The cell viability of T10 coated IONPs was assessed with the Promega CellTiter96® AQueous 
One Solution Cell Proliferation Assay.  The IONPs were tested with murine and human 
immune cells; and also compared with the known safest gadolinium based MRI contrast agent 
currently available, using human PBMCs. 
 
 
7.2.2 Characterisation of IONP uptake by murine derived DCs, in vitro  
 
Bone marrow stem cells from C57/BL6 mice were collected and incubated with GM-CSF (a 
protein that acts as a cytokine) to generate immature DCs.  GM-CSF cells; mimic or behave 
like myeloid DC, which is a conventional type of DC.  It has a myeloid lineage, most 
abundant of the DCs, they take up antigen, activate T cells and migrate to lymph nodes.  Flt3 
(also a protein with cytokine effects) was used with C57/BL6 to also develop an immature 
type of DC, however, these DCs are known to mimic in vivo DC and appear to possess 
characteristics of both myeloid and plasmacytoid DC (they mimic or behave like human DCs 
in vivo).  The understanding gathered from in vitro studies with these two types of DCs 
provided knowledge in preparation for in vitro studies with human DCs.   
Dose dependent in vitro experiments were conducted to assess the level of internalisation of 
FITC tagged IONPs by GM-CSF induced and Flt3 induced, murine DCs; while time 
dependent uptake experiments identified the time point (between 1 hour and 24 hours) at 
which these DCs internalised FITC tagged IONPs to maximum capacity (from a 
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 concentration of 200µg/ml); as measured with flow cytometry by identifying the granularity 
of cells containing FITC.  
Once IONPs were internalised by these DCs, investigations measured specific cell 
developmental process and activity.  The cell maturation process was tested; to determine if 
the immature DCs were made to mature in the presence of IONPs.  once the DCs internalised 
the IONPs, apoptosis investigations identified the population of DCs that were healthy and 
viable and those that were in either early or late stage apoptosis and the DCs population that 
had become non-viable (dead or necrotic).  The supernatant from the dose dependent in vitro 
experiments were collected and the secretion of inflammatory cytokines by DCs in the 
presence of IONPs, were measured using a Mouse Inflammation Kit BD™ Cytometric Bead 
Array (CBA) kit.   
 
 
7.2.3 Characterisation of IONP uptake by human derived DCs, in vitro   
 
Blood samples from volunteers were collected and the PBMC extracted by using a gradient 
separation technique (Ficoll®-Paque Premium gradient centrifugation).  When the PBMCs 
placed in vitro, 60 minutes later, the “adherence step” was performed; that is, monocyte cells 
would adhere to the bottom of the well plate, the remainder of the cells and media collected 
and discarded and fresh media added.  Cytokines were added to the adhered monocytes to 
convert them to DCs, hence, Mo-DCs.  Dose dependent and time dependent experiments with 
FITC tagged IONPs and also R-PE tagged IONPs were performed and quantitated with flow 
cytometry, using a multicolour assay technique to identify Mo-DCs.   
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 Dose dependent experiments of related immune cells that partake in an immune response 
were also performed and assessed with flow cytometry and with the multicolour assay 
technique.  These immune cells were PBMCs, lymphocytes and granulocytes/monocytes. 
The supernatant from the in vitro Mo-DC dose dependent and time dependent experiments 
were collected and the secretion of inflammatory cytokines by DCs in the presence of IONPs, 
were measured using a Human Inflammation Kit BD™ Cytometric Bead Array (CBA) kit.   
 
 
7.2.4 Application of IONPs, in vivo 
 
In vivo assessment of the prototype T10 dextran coated IONPs (tagged with FITC; or tagged 
with both FITC and 68Ga; or tagged with 68Ga) was performed in C57BL/6 mice and in 
human patients diagnosed with prostate cancer. 
Murine subjects received a subcutaneous injection of T10 dextran coated IONPs tagged with 
FITC, subcutaneously, into the hock to evaluate lymphatic drainage to the popliteal lymph 
node and another subcutaneous injection to the flank to ascertain lymphatic drainage to the 
inguinal lymph node.  Under anaesthesia, blood was obtained from the retro-orbital sinus, 
then centrifuged to obtain the serum for biochemical analysis.  At death, the heart, lungs, 
liver, spleen and kidneys were removed, preserved, embedded in paraffin wax, set onto 
positively charged glass microscope slides and stained for histopathological observation.  
Two samples from all organs were stained; one with H&E and the second with Perls Prussian 
Blue.  A third sample from the kidneys was prepared with the PAS stain.   
In vivo PET imaging was performed with mice that received a foot pad injection of T10 
dextran coated IONPs tagged with both FITC and 68Ga.  Mice were then killed by cervical 
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 spine dislocation, placed in a volume head coil and scanned with MRI at 3.0 T.  This process 
was designed to identify the gamma ray emission provided by the 68Ga and to image the 
inhomogeneity effect of the iron oxide, albeit, separately, as no combined PET/MRI scanner 
is currently available in Australia.  The lymph nodes were removed and prepared for flow 
cytometry and for confocal microscopy, to determine the presence of FITC.   
To determine if T10 dextran coated IONPs radiolabelled with 68Ga could reach the lymph 
nodes draining the prostate gland, human patients undergoing implantation of gold seed 
markers into the prostate (under general anaesthesia and with ultrasound guidance) also 
consented to receive these IONPs.  In vivo imaging was conducted with a PET/CT scanner, 
with the PET component detecting the gamma emissions from 68Ga and this being co-
registered with the cross-sectional CT images.  The draining lymph nodes were identified.   
 
 
7.3 Key findings and results 
 
This thesis commenced with six aims.  The first aim was to manufacture and characterise iron 
oxide nanoparticles (IONP).  This aim was successfully achieved, noting that the IONPs were 
manufactured in one of the chemistry laboratories at RMIT University, according to a criteria 
that was informed by a review of the relevant literature.  The IONPs were approximately 20 
nm in total diameter; the iron oxide was approximately 14 nm to 15 nm and the T10 dextran 
coating added a further 4 nm or 5 nm.  The T10 dextran provided a smooth surface which can 
facilitate internalisation by cells.  These physical characteristics were confirmed with TEM, 
SEM.  A zetasizer measured the surface charge of these IONPs, stored under different 
conditions.  Relative to the cells used for in vitro and in vivo experiments for this thesis, 
importantly, the IONPs used were stored at 4 oC, under room air and had a surface charge of – 
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 15.62 mV ± 9.083 (n = 6).  A comprehensive assessment of how these IONPs behaved in a 
clinical MRI environment (1.5 T and 3.0 T) was presented in Section 3.3.3; demonstrating 
their change in R2 (relaxivity intensity decay profile) and the linear fit to the T2 relaxivity (as 
a function of IONP concentration).  These data informed the optimisation of pulse sequences 
when mice were scanned following subcutaneous injection of these IONPs.   
Any toxicity effects were assessed in the form of cell viability MTS assays; conducted with 
human PBMC, comparing these fabricated IONPs and the gadolinium based MRI contrast 
that has the best known safety profile.  At the concentrations tested, there was no difference in 
statistical significance between the two contrast agents.      
The second aim was to characterise IONP uptake and toxicity in murine dendritic cells in 
vitro.  This was achieved through a series of in vitro experiments.  The maximum uptake of 
IONPs by the myeloid-type GM-CSF derived DCs occurs with a IONP concentration of 50 
µg/ml.  Flt3 derived IONPs (myeloid/plasmacytoid type DC) displayed a dose dependent 
response to the various IONP concentrations tested.  The uptake of IONPs by Flt3 derived 
DCs was approximately 75 % to that of GM-CSF derived DCs.  Time course experiments 
identified that maximum uptake of IONPs occurred at 1 hour for GM-CSF derived DCs and at 
4 hours with Flt3 derived DCs.  Experiments relating to cell maturation and co-stimulation 
showed that both DC types expressed CD86 and CCR7.  When the expression levels of CD86 
and CCR7 of the two DC types were compared with each other; the IONPs had a stimulatory 
effect on both cell types, however, the effect was greater on GM-CSF derived BM-DCs, 
resulting in greater expression of maturation and migratory markers from GM-CSF derived 
BM-DCs than from Flt3 derived BM-DC.  Apoptosis, programmed cell destruction and death, 
was assessed.  The Flt3 generated DCs better tolerated the IONPs and demonstrated greater 
survival capabilities (under the treatment conditions) with a greater population of viable and 
healthy cells compared to GM-CSF derived DCs.  Both dendritic cell types secreted TNF, 
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 MCP-1 and IL-6 cytokines at levels greater than baseline or control.  The secretion by Flt3 
derived DCs was approximately half that of GM-CSF derived DCs.  For both cell types, a 
migratory stimulus response occurred to the presence of IONP, in vitro, as MCP-1 had been 
noticeably released, in particular, GM-CSF derived murine DCs demonstrated twice the 
expression level of Flt3 derived murine DCs. 
The third aim of the thesis was to characterise the migration of IONP in vivo with C57BL/6 
mice.  T10 dextran coated IONPs tagged with FITC migrated from their subcutaneous site of 
injection to the regional lymph nodes; from the hock to the popliteal lymph node and from the 
flank to the inguinal lymph node; in vivo, in C57BL/6 female mice.  This was confirmed and 
quantitated with flow cytometry techniques (identification of FITC) in cells extracted from 
lymph nodes techniques and also imaged with confocal microscopy (FITC); when the radio-
labelled (68Ga) version of these same IONPs were used with mice in vivo, the migration from 
injection site to the draining lymph node was confirmed with PET imaging and then with 
MRI.  Biochemical analysis of the murine blood serum showed that all measured analytes 
signified the mice were healthy functioning and not experiencing acute physiological distress.  
Elevated urea levels were recorded, which could not be explained in the context of other 
analytes and mice having access to water, therefore, unlikely that dehydration due to lack of 
water could not be a factor.  The tissue staining techniques, H&E and Perls Prussian blue, 
demonstrated sound cellular integrity of the heart, lung, liver, kidney and spleen tissue.  PAS 
stain of kidney tissue demonstrated an intact basement membrane, however, there was PAS 
positive staining of the brush border within the proximal tubules most likely due to PFA being 
delivered under pressure during the VPF procedure.  This also cannot explain the elevated 
urea level because the VPF was performed after the blood sample was taken from the mice.  
The fourth aim of the thesis was to characterise IONP uptake and toxicity in human cells in 
vitro.  CD14+ and CD11c+ cells were identified and their dose dependent uptake of R-PE 
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 tagged IONPs showed no statistical difference, following 24 hours incubation, in vitro, for the 
concentration of IONPs tested; thus both CD14+ and CD11c+ cells are equally capable of 
internalisation of IONPs.  This was also applicable when FTC tagged IONPs were used.  The 
time dependent in vitro studies demonstrated that maximum uptake of FITC tagged IONP 
occurred by the one hour incubation time point for both CD14+ and CD11c+ cells.  A multi-
colour technique flow cytometry assay identified CD11c+ and CD123+ cells with no 
statistical difference between the uptake demonstrated by CD11c+ and CD123+ cells for the 
concentrations of IONPs tested.  The FITC tagged IONPs and R-PE tagged IONPs were used 
to identify PBMCs, lymphocytes, and granulocytes/monocytes.  A CBA assessment of the 
supernatant from dose dependent studies and time dependent studies with human PBMCs 
identified that five (TNF, IL-10, IL-6, IL-1β, IL-8) of the six cytokines were expressed at 
levels statistically equivalent to the control condition.  The expression of IL-12p70 increased 
with increased concentration of IONPs in the dose dependent studies and with the time 
dependent experiments, maximum expression IL-12p70 occurred at the 1 hour time point.     
The fifth aim of this thesis was to radio-label the IONPs with 68Ga.  The radio-labelling 
efficiency of 68Ga to the T10 dextran IONPs was measured by TLC to be at 87.59 % (n=3); 
that is, the technique used resulted in 87.59 % of the 68Ga bound to the IONPs and 12.41% 
was free or unbound.  The in vivo studies with murine and human subjects, followed with 
PET image, demonstrated that the radio-labelled IONPs were able to reach draining lymph 
nodes and behaved as particulate matter, providing evidence that the 68Ga remained radio-
labelled in vivo.  With murine in vivo studies, the mice were also imaged with MRI and the 
lymph nodes demonstrating the image contrast effects due to iron oxide, co-incided with the 
lymph nodes that showed enhancement due to 68Ga.  
The sixth and final aim of this thesis was to perform in vivo studies with T10 dextran coated 
IONPs radio-labelled with 68Ga.  Human patients diagnosed with prostate cancer received 
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 these radio-labelled IONPs while undergoing gold seed fiducial markers (used to later identify 
the prostate for external beam radiation therapy treatment) under ultrasound guidance.  
Imaging with PET/CT easily identified the nearby draining lymph nodes, as typically 
expected; however, very enlightening, the lymph nodes not routinely associated with draining 
the prostate gland and not routinely surgically removed for metastatic staging, also were 
positive for 68Ga.  These included the left superficial inguinal lymph node and also a lymph 
node in the mediastinum in one specific patient.  The significance of these findings, which 
must not be under-estimated, is that these 68Ga radio-labelled IONPs can be used to map the 
lymph nodes along the lymphatic drainage for each individual patient and clinicians can 
become aware of the path that the prostate cancer may take when metastasising along the 
lymphatic pathway in individual patients.  This will also assist with determining correct 
metastatic staging.  As demonstrated in four patients, the role in identifying the lymph nodes 
draining the prostate gland (with the tested T10 dextran coated IONPs radio-labelled with 
68Ga) is extremely valuable; as the typically geographically adjacent lymph nodes were 
identified and most importantly, the distant and atypical lymph nodes were also identified.           
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 7.4 Discussion and future directions 
 
Further optimisation of T2 pulse sequences for imaging the effects of the IONPs would need 
to be conducted, as there are a multitude of pulse sequences; some are common across 
manufactures while others are unique to individual manufacturers.  This would need to be 
repeated at both 1.5 T and 3.0 T, as these are the two most common magnetic field strengths 
found clinically.  MRI scanners found in dedicated research facilities have higher field 
strengths and individualised pulse sequences; and this would add further complexity.   
Correctly identifying lymph nodes that drain a tumour site is vitally important in properly 
staging metastases and evaluating suitably available treatment options.  The results presented 
throughout this body of work demonstrates that the IONPs behaved ideally in an MRI clinical 
magnetic environment, at both 1.5 T and 3.0 T,  providing excellent image contrast; thus, 
suitable as a potential alternative MRI contrast agent.  When combined with 68Ga, these 
IONPs collected in the lymph nodes draining the prostate gland in human patients; imaged 
with PET (from a PET/CT scanner).  After reviewing the available literature, this author 
considers the work presented in this thesis (with respect to radio-labelling 68Ga to T10 dextran 
coated IONPs and using these to identify lymph nodes draining the prostate gland in patients 
diagnosed with prostate cancer) as the first successful demonstration of this approach/method, 
clinically.  This can potentially provide an immediate health care imaging application and can, 
of course, lead to improved health outcomes for patients by identifying the LNs along their 
own lymphatic drainage pathway.  In principle, this can also provide an improvement over 
current lymphoscintigraphy imaging, as PET imaging is more sensitive to 68Ga compared 
with current gamma emitters used for lymphoscintigraphy with sentinel lymph node imaging 
such as 99mTc.  The preparation presented here, of T10 dextran coated IONPs radio-labelled 
with 68Ga, also presents the possibility of being applied to other body regions such as breast 
cancer metastasis assessment to draining lymph nodes.  The most promising possibility of the 
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 T10 dextran coated IONP radio-labelled with 68Ga and translational aspiration is that, from 
the work presented in this thesis, the logical progression would be to develop and optimise 
this preparation as a dedicated PET/MRI contrast agent for when PET/MRI scanning arrives 
in Australia.   
The results presented in this thesis also allows for the reconsideration of, and advanced 
improved approach to, cellular MRI with DCs.   DCs can be either isolated from a patient or 
developed in vitro in the laboratory from a patient’s own precursor cells, then loaded in vitro 
with a nanoparticle preparation and then returned to the patient for in vivo cellular PET/MRI.  
In principle, the T10 dextran coated IONP radio-labelled with 68Ga presents an innovative 
alternative to monitor cellular interactions from an imaging perspective. DCs, or DC 
progenitor cells, can be isolated from a patient, then at an appropriate stage of development, 
they can be loaded with T10 dextran coated IONPs radio-labelled with 68Ga in vitro under 
controlled laboratory conditions and then returned to the patient for in vivo imaging with 
PET/MRI.  These same nanoparticle preparations can assist with improving the role that 
cellular MRI can provide in understanding the interactions of immune cells in cancer 
processes, perhaps even introducing a new frontier of cellular PET/MRI, cPET/MRI?  The 
T10 dextran coated IONP radio-labelled with 68Ga can potentially solve current limitations 
with cMRI; the first several hours (post administration) can be imaged with the PET 
component (of a PET/MRI scanner); which can monitor DCs loaded with T10 dextran coated 
IONP radio-labelled with 68Ga until the gamma radiation is depleted.  From here, MRI can 
monitor the movement of cell groups by imaging the contrast effects of the iron oxide content.  
Up until now, imaging difficulty has occurred with using just IONPs alone or with a gamma 
emitting radio-isotope alone.  If this can be successful, in vivo, it will increase our 
understanding of DC kinematics; migration and T-cell zone of LNs.  Cellular MRI with these 
nanoparticle preparations can also be incorporated with other cells of interest for other 
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 research applications and specific clinical use, thereby increasing the scope for considering 
the use of cellular MRI in humans.   
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 8.0 Appendices     
 
8.1 Appendix 1 – Change in R2 relaxivity, and, T2 relaxivity rate; at 1.5T 
and 3.0T (to support gel phantom studies presented in Section 3.2.3)      
 
 
 
 
 
Figure 3.13: The change in R2 relaxivity, intensity-decay profile of 16.4 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 16.4 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5T.  
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Figure 3.14: The change in R2 relaxivity, intensity-decay profile of 33.0 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 33.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.15: The change in R2 relaxivity, intensity-decay profile of 49.8 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 49.8 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.16: The change in R2 relaxivity, intensity-decay profile of 66.5 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 66.5 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.17: The change in R2 relaxivity, intensity-decay profile of 83.2 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 83.2 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.18: The change in R2 relaxivity, intensity-decay profile of 99.9 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 99.9 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.19: The change in R2 relaxivity, intensity-decay profile of 117.0 µg/ml sample 
as determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 117.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.20: The change in R2 relaxivity, intensity-decay profile of 133.0 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 133.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.21: The change in R2 relaxivity, intensity-decay profile of 150.0 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 150.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.22: The change in R2 relaxivity, intensity-decay profile of 164.0 µg/ml sample as 
determined at 1.5 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  The R2 value from the graph equation 
demonstrates that the curve fit is excellent.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 164.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 1.5 T.  
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Figure 3.23: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 22 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.24: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 44 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.25: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 66 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.26: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 88 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.27: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 110 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.28: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 132 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.29: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 154 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.30: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 176 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.31: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 198 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.32: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 220 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
 
 
 
 
 
 
 
 
 
 
362 
 
  
 
 
 
 
 
 
Figure 3.33: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 242 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.34: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 264 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.35: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 286 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.36: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 308 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.37: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 330 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.38: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 352 ms at 1.5 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.39: Top view of plastic container filled with water and containing plastic tubes 
filled with gel of increasing concentration of iron oxide nanoparticles; scanned at 3.0 T. 
A T2 weighted image generated from a 16 echo spin echo pulse sequence scanned at 3.0 T.  
This image was acquired with a TE value of 44 ms and a TR value of 3,000 ms and a 12-
channel head coil was used.   
 
 
 
 
 
 
369 
 
  
 
 
 
 
 
 
Figure 3.40: Top view of plastic container filled with water and the control tubes – 
plastic tubes filled with gel only (no iron oxide nanoparticles); scanned at 3.0 T 
A T2 weighted image generated from a 16 echo spin echo pulse sequence at 3.0 T.  This 
image was acquired with a TE value of 44 ms and a TR value of 3,000 ms and a 12-channel 
head coil was used.   
 
 
 
 
 
 
 
370 
 
  
 
 
 
 
 
 
The series of graphs from Figure 3.39 to Figure 3.48 exhibit the change in T2 relaxivity, Δ R2 
response (or intensity decay profile), for each concentration sample across the 16 echoes in 
the pulse sequence, at 3.0 T.  The next series of graphs (Figure 3.41 to Figure 3.65) 
documents the linear fit to the T2 relaxivity as a function of nanoparticle concentration and 
each of the known 16 TE echoes in the pulse sequence used, at 3.0 T.   
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Figure 3.41: The change in R2 relaxivity, intensity-decay profile of 16.4 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 16.4 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
 
 
 
 
 
 
 
 
 
372 
 
  
 
 
 
 
 
 
Figure 3.42: The change in R2 relaxivity, intensity-decay profile of 33.0 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 33.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.43: The change in R2 relaxivity, intensity-decay profile of 49.8 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 49.8 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.44: The change in R2 relaxivity, intensity-decay profile of 66.5 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 66.5 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.45: The change in R2 relaxivity, intensity-decay profile of 83.2 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 83.2 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.46: The change in R2 relaxivity, intensity-decay profile of 99.9 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 99.9 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.47: The change in R2 relaxivity, intensity-decay profile of 117.0 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 117.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.48: The change in R2 relaxivity, intensity-decay profile of 133.0 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 113.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.49: The change in R2 relaxivity, intensity-decay profile of 150.0 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 150.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.50: The change in R2 relaxivity, intensity-decay profile of 167.0 µg/ml sample as 
determined at 3.0 T, of the dextran coated iron oxide nanoparticles has been graphed 
according to equation 2. A power trend line was fitted to the 16 echo data points as they were 
known to be exactly 22 ms apart from one another.  This curve was created by plotting the T2 
response of iron oxide nanoparticles at a concentration of 167.0 µg/ml to the pulse sequence 
t2_se_COR_16-echoes at 3.0 T.  
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Figure 3.51: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 22 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.52: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 44 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.53: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 66 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.54: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 88 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.55: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 110 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.56: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 132 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.57: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 154 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.58: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 176 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
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Figure 3.59: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 198 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration. 
 
 
 
 
 
 
 
 
 
 
390 
 
  
 
 
 
 
 
 
Figure 3.60: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 220 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.61: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 242 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.62: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 264 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.63: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 286 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.64: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 308 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.65: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 330 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Figure 3.66: The linear fit to the T2 relaxivity rate as a function of iron oxide 
nanoparticle concentration, at a TE of 352 ms at 3.0 T.  A linear trend line was fitted to the 
plotted values of the increasing 10 concentration samples, as there is a linear dependence of 
the relaxation rate on concentration.   
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Mandarano G, Lodhia J, Ferris N, Eu P, Davidson R, Cowell C, Development and use of iron 
oxide nanoparticles: Part 2 - The application of iron oxide contrast agents in Magnetic 
Resonance Imaging (MRI), Biomedical Imaging and Intervention Journal. 2010; 6(2):e13. 
Lodhia J, Mandarano G, Ferris N, Eu P, Cowell C. Development and use of iron oxide 
nanoparticles: Part 1 - The Synthesis of Iron Oxide Nanoparticles for Magnetic Resonance 
Imaging, Biomedical Imaging and Intervention Journal. 2010; 6(2):e12. 
 
8.2.2 Oral Presentations 
 
Mallia A, Mandarano G, Pouniotis D, Cullinane C, Hicks R, Eu P; A Fluorescent PET/CT 
Lymphoscintigraphic Agent for Sentinel Lymph Node Imaging and Detection;  Annual 
Congress of the European Association of Nuclear Medicine, 18-22 September, 2014, 
Gothenburg, Sweden 
Mandarano G; Lodhia J; Pouniotis D, Eu P; Ferris N; Davidson R; Cowell S; The continued 
development of iron oxide based nanoparticles for clinical MRI scanning; International 
Society of Radiographers and Radiologic Technologists, 9th to 12th September, 2010, Gold 
Coast Convention and Exhibition Centre 
Conference, CSM 2009 (October), Combined Scientific Meeting of four professional bodies 
(Royal Australian and New Zealand College of Radiologists, Australian Institute of 
Radiography, Faculty of Radiation Oncology, Australasian College of Physical Scientists and 
Engineers in Medicine).  Two oral presentations, with their abstracts published. Details 
below: 
Mandarano G, Lodhia J, Eu P, Ferris N, Cowell S, Davidson R; The possibility of a general 
purpose contrast agent for MRI based on iron oxide nanoparticles; Journal of Medical 
Imaging and Radiation Oncology; Volume 53; Supplement 1; October 2009; p. A36; Wiley-
Blackwell; ISSN 1754-9477 
Lodhia J, Mandarano G, Campbell J, Eu P, Ferris N, Cowell S; The synthesis, evaluation and 
future role of iron oxide nanoparticles in MRI; Journal of Medical Imaging and Radiation 
Oncology; Volume 53; Supplement 1; October 2009; p. A116; Wiley-Blackwell; ISSN 1754-
9477 
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